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 “The main aim of my life has been to free man from the bonds which bind him to the surface, 
allowing him to escape from his natural limits, breathe in an unbreathable atmosphere and 
withstand increasingly great pressures. Just not place man in this new atmosphere but to adapt him 
teaching to explore it, to subsist, to survive and to study what lies around him.” 
 
Jacques Ives Cousteau, The Living Sea 1964. 
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RESUMO 
 
 
A utilização dos métodos da biologia molecular na investigação epidemiológica – designada de 
epidemiologia molecular – tem enorme potencial para o estabelecimento de associações entre 
patologias oncológicas e exposição ambiental relacionada com estilos de vida, ocupação profissional 
ou poluição ambiental.  
A biomonitorização humana consiste, por um lado, na pesquisa e identificação de condições 
ambientais perigosas e, por outro, na estimação do risco de desenvolvimento de cancro por exposição 
a estas condições. Dado que a carcinogénese é um processo prolongado, os biomarcadores a que se 
tem recorrido para reconhecer eventos biológicos anormais têm sido desenvolvidos no âmbito de 
estudos epidemiológicos moleculares. Estes biomarcadores são quantificáveis e permitem a 
identificação da progressão de condições biológicas normais para anormais ao nível molecular. De 
uma forma geral, subdividem-se em biomarcadores de exposição, de efeito e de susceptibilidade 
genética. Os biomarcadores de genotoxicidade são um caso particular de biomarcadores de efeito e 
utilizam-se na avaliação de efeitos genómicos provocados por exposição, ambiental ou ocupacional, 
sendo em geral considerados preditores de desenvolvimento cancerígeno.  
Duas técnicas importantes são utilizadas neste estudo – o ensaio dos micronúcleos por bloqueio da 
citocinese (CBMN) e o comet assay. O CBMN é uma das técnicas mais sensíveis para detecção de dano 
no DNA, sendo amplamente utilizada na investigação de efeitos genotóxicos de uma ampla variedade 
de agentes químicos, físicos e biológicos. O comet assay, permite a quantificação de dano no DNA de 
células individuais. Grande parte das lesões detectadas por esta técnica podem não ser 
posteriormente corrigidas pelos mecanismos normais de reparação do DNA, não se detectando, 
portanto, alterações genéticas que sejam necessariamente permanentes. A combinação destes dois 
ensaios genotóxicos é recomendada para a monitorização de populações com exposição crónica a 
agentes genotóxicos, sendo considerados os testes de genotoxicidade que, a curto prazo, são os mais 
promissores na avaliação de risco em humanos.  
Factores como a idade, género e estilos de vida, tais como o consumo de tabaco e álcool, são variáveis 
que devem ser alvo de avaliação em estudos de biomonitorização pela sua capacidade para gerar 
confundimento no estabelecimento de associações. Também com relevância crescente, como factor 
capaz de condicionar a resposta a agentes genotóxicos, encontram-se os hábitos alimentares. Através 
da aplicação de técnicas de biologia molecular, pode-se investigar a interacção funcional entre o 
genoma e macro e micronutrientes, quer a nível molecular, quer celular e sistémico. A nutrigenética 
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estuda a resposta a padrões alimentares específicos e a forma como os genes e polimorfismos 
genéticos podem influenciar a bioavaliabilidade dos micronutrientes e dos cofactores enzimáticos 
envolvidos na reparação e metabolismo do DNA.  
Os laboratórios são importantes locais de exposição ocupacional, uma vez que se manipula uma 
panóplia de agentes químicos que conferem um risco permanente de exposição por parte dos 
trabalhadores. Neste estudo, foram investigadas as consequências genómicas de exposição de 
trabalhadores a dois tipos particulares de químicos usados em meio laboratorial – o formaldeído e os 
citostáticos.   
O formaldeído está classificado pela International Agency for Research on Cancer (IARC) como 
carcinogénico para humanos (grupo 1), baseado na evidência existente de associação com a incidência 
de cancro nasofaríngeo e, mais recentemente de leucemia mielóide. Relativamente aos citostáticos, 
são um grupo de fármacos cada vez mais utilizados, quer no tratamento de neoplasias quer no de 
doenças não malignas. São um grupo heterogéneo que compreende diversos agentes não 
relacionados mas que têm em comum a capacidade de inibir o crescimento celular, afectando, directa 
ou indirectamente, o genoma. A IARC classifica como carcinogénico para humanos (grupo 1) a 
ciclofosfamida e o paclitaxel, não considerando carcinogénico para humanos o 5-fluoracil (grupo 3).   
É objectivo desta investigação contribuir para o desenvolvimento de um programa de 
biomonitorização da genotoxicidade destas substâncias que contemple biomarcadores de 
susceptibilidade e estilos de vida, nomeadamente dieta e nutrição.  
O planeamento experimental aqui utilizado pode ser descrito como um estudo caso-controlo. Em cada 
um de dois contextos ocupacionais estudados – um para formaldeído, outro para citostáticos – foram 
constituídas duas amostras. Uma de trabalhadores expostos (os casos) e outra de não expostos (os 
controlos), tendo sido quantificados vários biomarcadores moleculares de genotoxicidade e avaliado o 
risco danos genómicos nos expostos por comparação com os controlos.  
O estudo do formaldeído compreendeu 56 trabalhadores de seis laboratórios de Anatomia Patológica 
da região de Lisboa e Vale do Tejo e 85 trabalhadores da Escola Superior de Tecnologia da Saúde 
(ESTeSL) sem exposição a este agente químico (controlos). No contexto ocupacional de exposição a 
citostáticos foram reunidos 46 trabalhadores expostos a citostásticos das unidades de Farmácia, 
Hospital de dia e Pediatria de dois hospitais da região de Lisboa e Vale do Tejo e o grupo de controlo 
foi igualmente formado por 46 indivíduos da ESTeSL. Todos os participantes preencheram um termo 
de consentimento informado acerca da participação no estudo e na recolha das amostras, 
assegurando princípios de confidencialidade. Foi preenchido um questionário para caracterização de 
dados demográficos e de possíveis variáveis de confundimento, tais como exposições na sua ocupação 
laboral e/ou de tempos livres que pudessem enviesar os resultados, contacto com terapias 
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antineoplásicas, entre outros. Foi também preenchido um questionário que permitisse caracterizar os 
hábitos alimentares dos participantes.  
A avaliação da genotoxicidade foi realizada com recurso ao ensaio CBMN e ao comet assay. Ambas as 
técnicas foram realizadas em linfócitos recolhidos e isolados de sangue periférico recolhido por 
venipunctura. Para avaliar os biomarcadores de susceptibilidade individual, nomeadamente os 
polimorfismos dos genes de reparação de DNA (XRCC3 e OGG1), enzimas metabólicas (ADH5) e do 
receptor da vitamina D (VDR), foi realizado PCR em Tempo Real após extracção de DNA pelas técnicas 
de fenol-clorofórmio e por mancha de sangue. A quantificação de vitaminas A e E no soro humano foi 
realizada por HPLC e da vitamina D feita por ensaio imunológico (ELISA). 
Nos dois contextos ocupacionais encontraram-se diferenças estatisticamente significativas entre 
trabalhadores expostos e não expostos (p <0.05), indicando que a exposição é um factor de risco para 
o aumento dos biomarcadores de genotoxicidade avaliados pelo CBMN. O comet assay, aplicado no 
estudo da exposição ocupacional a citostáticos, não apresentou diferenças estatisticamente 
significativas entre expostos e não expostos. 
No que respeita aos biomarcadores de susceptibilidade individual, o estudo da exposição a 
formaldeído encontrou associações estatisticamente significativas entre os genótipos XRCC3 e 
protusões nucleares, nomeadamente entre XRCC3 Met/Met (OR = 3.975, IC=1.053-14.998, p=0.042) e 
XRCC3 Thr/Met (OR = 5.632, IC=1.673-18.961, p=0.005) comparativamente com o genótipo XRCC3 
Thr/Thr. Para os genótipos do VDR BsmI foi encontrada uma associação significativa no grupo dos 
expostos (p=0.041, teste Mann-Whitney), em que os portadores do genótipo CT+T apresentaram 
maior média de micronúcleos em linfócitos comparativamente com o genótipo CC. Não foram obtidos 
resultados significativos para os polimorfismos do ADH5. Não foi encontrada também qualquer 
associação significativa entre os genótipos OGG1 e os biomarcadores quantificados pelo CBMN e pelo 
comet assay no estudo da exposição a citostáticos. 
Os resultados referentes ao estudo nutricional indicam, de forma geral, que a vitamina A actua como 
factor de risco e a vitamina E como protector. Especificamente no estudo do formaldeído, a vitamina 
A obteve uma correlação positiva com as pontes nucleoplásmicas (r=0.557, p <0.01) e a vitamina E 
diminui a média de protusões nucleares (r=-0.297, p<0.05). No estudo dos citostáticos, a vitamina A 
está positivamente correlacionada com o aumento de dano oxidativo no DNA, enquanto a vitamina E 
revelou uma correlação negativa (p <0.05) com os micronúcleos. O folato e a vitamina B12 funcionam 
como factores protectores, ao contrário do ferro. 
Os dados obtidos permitem concluir que é exequível e necessário implementar um programa de 
biomonitorização humana em contextos de exposição ocupacional. Este deve integrar biomarcadores 
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de exposição, efeito, genotoxicidade e susceptibilidade. Hábitos de vida, com particular ênfase na 
nutrição, devem ser incluídos, uma vez que têm influência sobre os biomarcadores estudados.  
 
 
Palavras-Chave: Biomonitorização, genotoxicidade, exposição ocupacional, nutrigenética. 
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ABSTRACT 
 
 
Cytokinesis blocked micronucleus (CBMN) assay and comet assay are the most promising short-term 
genotoxicity assays for human risk assessment and their combination is recommended to monitor 
populations chronically exposed to genotoxic agents. Nutrition is recognized to be an important lifestyle 
factor that influences cancer risk, and should be taken into account at an individual level.  
Laboratories are occupational settings where chemical agents are handled and workers are exposed. 
Formaldehyde and cytostatic drugs, in particular, are chemical agents handled in laboratories that are 
considered carcinogenic for humans and special protective measures should thus be adopted against 
them.  
The aim of this investigation is to contribute to the development of a biomonitoring programme that 
includes genotoxicity assessment related with genetic susceptibility biomarkers, and lifestyle factors, 
namely nutrition. The experimental planning used was a case-control blinded study. Four separated 
samples were formed comprising two samples of subjects exposed (n = 56 for formaldehyde; n = 46 for 
cytostatics), and two samples of non-exposed controls (n = 85 and n = 46, respectively). Participants filled-
in a personal and a food frequency questionnaires. CBMN and comet assays were used to assess 
genotoxicity. Individual susceptibility was investigated by Real Time PCR. Measurements of serum vitamins 
A and E were performed by HPLC, and vitamin D by ELISA. The risk of genotoxicity in those exposed was 
then compared with the risk in the controls, allowing for the quantitative measurement of association 
between exposure and genotoxicity.   
In both occupational settings, the genotoxicity biomarkers were significantly higher in the exposed than in 
the non-exposed controls (p<0.05). In the formaldehyde occupational context, significant associations 
were found between XRCC3 genotypes and nuclear buds; but that was not the case either for ADH5 or 
VDR. Comet assay did not identify significant differences between those exposed to cytostatics and 
controls, and the same lack of association applies to the OGG1 genotypes. Micronutrients association to 
the genotoxicity biomarkers was controversial; we have found positive correlations for vitamin A and 
negative ones for vitamin E.  
Our findings emphasize the need for the implementation of a regular biomonitoring programme of 
personnel occupationally exposed to drugs like formaldehyde and cytostatics.  
 
 
Keywords: Biomonitoring, genotoxicity, occupational exposure, nutrigenetics. 
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1. GENERAL INTRODUCTION 
 
Molecular epidemiology intends to provide reliable and specific information regarding the 
etiology and mechanism of disease processes, which can be associated with environmental 
exposures related to lifestyle, occupation, or ambient pollution, in order to achieve prevention 
at the community level; molecular epidemiology employs laboratory methods to document 
the molecular basis and preclinical effects of environmental carcinogenesis (Portier & Bell, 
1998; Vainio, 1998; Bartsch, 2000; Dusinska & Collins, 2008). 
The possibility to use a biomarker to substitute classical endpoints, such as disease incidence 
or mortality, is the most promising feature and one that is most likely to affect public health. 
Resorting to events that are on the direct pathways from the initiation to the occurrence of 
disease as surrogates for disease incidence is a very appealing approach, being investigated in 
different fields (Bonassi & Au, 2002). The ultimate goal of molecular epidemiology is the 
prevention of disease, and particularly cancer.  
Human biomonitoring consists in the search for specific biomarkers in biological samples, with 
the goal of preventing the harmful accumulation of dangerous substances (Sexton et al., 2004; 
Bertazzi & Mutti, 2008; Manno et al., 2010). Biological monitoring has applications in exposure 
assessment and in occupational health; by measuring human exposure to chemical substances 
and providing unequivocal evidence that both exposure and uptake of chemical or physical 
substances have been taken place (Sexton et al., 2004; Angerer et al., 2007). In order to 
predict disease risk and/or to monitor the effectiveness of control procedures aimed at 
avoiding exposure to genotoxic chemicals in occupational and environmental settings, 
biomarkers of effect, specifically of genotoxicity, have been used (Manno et al., 2010). The 
most frequently used endpoints in human biomonitoring studies have been the cytogenetic 
biomarkers (Barrett et al., 1997; Battershill et al., 2008).  
Major goals of many of the research programmes on biomonitoring are the development and 
validation of biomarkers that reflect specific exposures and predict the risk of disease in 
individuals and in population groups (Watson & Mutti, 2004). From an individual point of 
view, it has long been speculated that genetically determined susceptibility may predispose 
some workers to occupational disease whereas others in the same environment seem to be 
unaffected. Recognition of the role of genetic factors in disease (both occupationally and non-
occupationally related disease) presents new opportunities for detection, prevention, and 
treatment (U.S. Congress, 1990; Vähäkangas, 2008).  
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For environmentally induced diseases, biomarkers of susceptibility play a key role in 
understanding the relationships between exposure to toxic environmental chemicals and the 
development of chronic diseases as well as in identifying individuals at increased risk. They 
may also inform about inter-individual variation in response to a variety of factors (Dusinska & 
Collins, 2008; Vähäkangas, 2008).  
 
Dietary habits are recognized to be an important modifiable environmental factor influencing 
cancer risk and tumour behaviour, being estimated that about 30-40% of all cancers are 
related to dietary habits (Strickland & Groopman, 1995; Davis & Milner, 2007; Sutandyo, 
2010). Nutrition science has evolved into a multidisciplinary field that applies molecular 
biology and integrates individual health with epidemiologic investigation at the population 
level (Go et al., 2003). 
In laboratory context, there are many chemical agents that are handled occupationally by a 
wide range of workers. The International Agency for Research on Cancer (IARC) classifies two 
important chemical agents handled in occupational settings as being human carcinogens 
(group 1): formaldehyde (IARC, 2006) and cytostatics drugs (IARC, 1981; 1987).  
Formaldehyde is a colourless gas that has been considered carcinogenic to humans, making it 
a subject of major environmental concern, namely in occupational settings where employees 
in industrial and medical areas, in particular anatomists and medical students may be highly 
exposed to formaldehyde gas (Gulec et al., 2006). Epidemiological studies linked 
formaldehyde exposure to higher risk of nasopharyngeal, lung, brain, pancreas, prostate, 
colon, and lymphohematopoietic cancers (Walrath & Fraumeni, 1983; Hall et al., 1991; 
Hauptmann et al., 2004; Pinkerton et al., 2004; Orsière et al., 2006; Freeman et al., 2009; 
Hauptmann et al., 2009; Zhang et al., 2009a, 2010; NTP, 2011) in the industry, for embalmers, 
pathologists and anatomist workers. 
Cytostatics drugs allow the inhibition of tumour growth by disrupting cell division and killing 
actively growing cells, being for that reason widely used in the treatment of cancer and in 
some non-neoplasic diseases too. Nevertheless, have been proved to be also mutagens, 
carcinogens and teratogens (Fucic et al., 1998; Burgaz et al., 1999; Sessink & Bos, 1999; 
Bouraoui et al., 2011; Gulten et al., 2011; Buschini et al., 2013).  
Epidemiological studies (NIOSH, 2004) have related cytostatic workplace exposure health 
effects such as skin rashes, hair loss, irritation, hypersensitivity, headaches, spontaneous 
abortions, malformations, infertility, and possibly leukemia, as well as other cancers 
(Kolmodin-Hedman et al., 1983; Stücker et al., 1990; Froneberg, 2006; Harrison, 2006; 
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Fransman et al., 2007; Hedmer et al., 2008; Kopjar et al., 2009; Chu et al., 2011; Stover & 
Achutan, 2011).  
 
 
2. RESEARCH QUESTION 
The main purpose of the research herein presented was to address the following question: 
Is it possible to implement a human biomonitoring programme using genotoxicity, 
susceptibility, and nutrigenetic biomarkers to assess occupational health? 
 
 
 
3. OBJECTIVES 
 
 
3.1. GENERAL OBJECTIVE 
 
The main objective of this investigation was the development of biomonitoring methodologies 
for genotoxicity assessment of chemical agents in occupational settings with exposure to 
formaldehyde and to cytostatic drugs. For that purpose, genotoxicity biomarkers and 
oxidative damage in DNA were studied, as well as how they relate to genetic susceptibility 
biomarkers and lifestyle factors, such as tobacco habits, alcohol consumption and diet.  
 
3.2. SPECIFIC OBJECTIVES 
 
To achieve the general objective and address the investigation question, more specific 
objectives have been established: 
 
1. Determine genotoxicity by cytokinesis-blocked micronucleus assay, measuring 
micronuclei, nucleoplasmic bridges, and nuclear buds in peripheral  blood lymphocytes and 
the micronucleus test in exfoliated cells from buccal mucosa; 
 
2. Determine DNA damage and DNA oxidative damage (8-hydroxydeoxyguanine) by 
comet assay in peripheral blood lymphocytes; 
 
3. Investigate the association between genomic damage measured by the previous 
biomarkers, and genetic polymorphisms in DNA repair genes (XRCC3, OGG1), genes of 
metabolic enzymes (ADH5)  and vitamin D receptor (VDR) by Real Time PCR; 
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4. Verify if antioxidants such as vitamins A, D and E, measured in human serum by HPLC 
and ELISA, reflect differences in the effect biomarkers measured; 
 
5. Substantiate the association between the vitamins quantified (Vitamin D) and genetic 
polymorphisms; 
 
6. Investigate the influence of dietary intake of calories, vitamins A, D, E, B12, folate, 
iron, and selenium assessed by food frequency questionnaire, upon the genotoxicity 
biomarkers measured. 
 
The conduction of these objectives is intended to contribute for the building of a battery of 
biomarkers to be considered in human biomonitoring programmes.  
 
4. THESIS ORGANIZATION  
 
The thesis is organized in VIII sections: I. Introduction, II. State of the art, III. Methodology, IV. 
Results, V. Discussion, VI. Conclusions and Perspectives, VII. References, and VIII. Annexes.  
The Introduction provides a general contextualization of the study focusing in the adequacy 
and relevance of this, and of the questions that will be addressed later.  
The state of the art section is divided in nine chapters, each providing background to 
understand and contextualize corresponding topics in this study, namely: Molecular 
epidemiology, Human biomonitoring, Biomarkers, Genomic instability, Genotoxicity 
assessment methods, Individual susceptibility, Nutritional research, Formaldehyde, and 
Cytostatics. 
The section on Methods presents the study design, describes how samples were collected and  
processed, which variables were measured, as well as the statistical methods used.  
Since there are two distinct occupational contexts under study, the Results section is divided 
into chapter 1 for the formaldehyde occupational setting, and chapter 2 for the cytostatics 
setting.  
The same structure was used in the Discussion section, as it was divided by chemical agent. 
Finally, Conclusions and Future perspectives are presented in section VI. Questionnaires, 
informed consent, and publications are in the Annexes (section VIII), right after the References 
(section VII).  
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II. STATE OF THE ART 
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CHAPTER 1 - MOLECULAR EPIDEMIOLOGY 
 
 
1. CLASSICAL EPIDEMIOLOGY 
 
Traditional epidemiology has always been the hallmark approach to demonstrate associations 
between exposure to hazardous substances and development of disease. When disease is 
cancer, the endpoints for such investigations are usually mortality and disease incidence. 
However, such traditional approach is beset by limitations. For example, the results are meant 
to translate into the implementation of measures of disease prevention to an entire 
community, with little or no regard for inter-individual variations in response to the exposure. 
Since such variations play a significant role in determining who is more likely to be affected, 
they should be taken into account if we are to improve our predictions regarding 
environmental disease. Furthermore, with increasingly stringent regulations on environmental 
exposure and with the automation of hazardous processes, namely in the workplace, the 
exposure concentrations and availability of exposed individuals may become too small to 
conduct meaningful traditional epidemiological investigations (Bonassi & Au, 2002).  
Classical epidemiology studies have made seminal contributions to identifying the etiology of 
the most common types of cancer and have had substantive public health impact. The IARC 
evaluated the cancer-causing potential of more than 900 likely candidate items, placing them 
into the following groups: Group 1 (carcinogenic to humans), Group 2A (probably carcinogenic 
to humans), Group 2B (possibly carcinogenic to humans), Group 3 (unclassifiable as to 
carcinogenicity in humans) and Group 4 (probably not carcinogenic to humans) (IARC, 1989).  
Although there has been growing recognition for the need to incorporate complex 
interactions between environmental exposures together with genetic factors, in order to fully 
understand cancer causation, the molecular tools to explore these associations were yet to be 
developed. There is now growing recognition that environmental challenges not only interact 
with genes but may also modulate genetic effects and influence phenotypes. It is also 
increasingly recognized that environmental exposures may not only damage DNA but 
additionally may alter gene expression through epigenetic mechanisms that could be 
reversible (Spitz & Bondy, 2010).  
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2. MOLECULAR EPIDEMIOLOGY 
The term “molecular epidemiology” made its appearance in the literature in the early 1980s. It 
was originally conceived as an extension of traditional (classical) epidemiology to incorporate 
biomarkers (biochemical and molecular) with conventional questionnaire data, in order to 
further our understanding of mechanisms of carcinogenesis and of events throughout the 
continuum between exposure and cancer development (Hussain & Harris, 1998; Vineis & 
Perera, 2007; Spitz & Bondy, 2010).  
Molecular biology is a potentially useful tool in epidemiological studies as it can be used to 
strengthen the identification of cancers associated with environmental exposures related to 
lifestyle, occupation, or ambient pollution. In molecular epidemiology, laboratory methods are 
employed to document the molecular basis and preclinical effects of environmental 
carcinogenesis ( Portier & Bell, 1998; Vainio, 1998; Bartsch, 2000; Dusinska & Collins, 2008).  
A major objective of molecular epidemiological investigations is to provide reliable and 
specific information regarding the etiology and mechanism of disease processes in order to 
achieve disease prevention. The possibility to use a biomarker to substitute classical 
endpoints, such as disease incidence or mortality, is the most promising feature and one that 
is most likely to affect public health. The use of events that are on the direct pathways from 
the initiation to the occurrence of disease as surrogates for disease incidence is a very 
appealing approach, being investigated in different fields (Bonassi & Au, 2002).  
The ultimate goal of molecular epidemiology is the prevention of cancer. Various lines of 
evidence indicate that the great majority of cancers are, in principle, preventable because the 
factors that determine cancer incidence are largely exogenous. This evidence comes mainly 
from epidemiologic studies and includes: (i) time trends in cancer incidence and mortality; (ii) 
geographic variations and the effects of migration; (iii) the identification of specific causative 
factors such as cigarette smoking, occupational and environmental chemicals, radiation, 
dietary factors and viruses; and (iv) the observation that the majority of human cancers do not 
show simple patterns of inheritance. Genetic factors are clearly important in terms of 
influencing individual susceptibility to carcinogens; and in certain rare forms of human cancer, 
hereditary factors play a decisive role. However, external factors represent also the greatest 
opportunity for primary prevention. This is an optimistic message because it means that the 
development of cancer is not an inherent consequence of the aging process de per se, and the 
human species is not inevitably destined to suffer a high incidence of cancer. This awareness 
has lent greater urgency to the search for more powerful tools for primary prevention, for 
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early warning systems to identify causal environmental agents and flag risks well before the 
malignant process is entrenched (Perera & Weinstein, 2000).  
Molecular epidemiology has the advantage of being directly relevant to human risk, unlike 
animal or other experimental models that require extrapolation to humans. In contrast to 
traditional epidemiology that relies on cancer incidence or mortality as the endpoint, 
molecular epidemiology has the potential to give early warnings by flagging the preclinical 
effects of exposure and increased susceptibility, thus signalling opportunities to avert cancer 
through timely intervention. Moreover, biomarker data on the distribution of procarcinogenic 
changes and of susceptibility factors in the population can improve the estimation of cancer 
risk from a given exposure. However, molecular epidemiology is also subject to many of the 
limitations of epidemiology, such as the vulnerability to confounding factors that give rise to 
misleading results (Perera, 1996).  
Molecular epidemiology has become a major field of research, leading to considerable 
progress in the validation and application of biomarkers. One of its greatest contribution has 
been the insight provided into inter-individual variation in human cancer risk and into the 
complex interactions between environmental factors and host susceptibility factors, both 
inherited and acquired, throughout the multistage process of carcinogenesis (Perera, 1996; 
Bartsch, 2000; Perera & Weinstein, 2000; Weis et al., 2005). Figure 1 compiles the 
multiplexicity of human cancer risk assessment using molecular epidemiology tools 
(interligation between internal exposure assessment and susceptibility), and bioethical issues 
associated and intervention strategies. Increasingly, molecular epidemiology studies are 
incorporating panels of biomarkers relevant to exposure, preclinical effects and susceptibility, 
using samples of blood cells, exfoliated cells, tissues and body fluids. These biomarkers are 
now being widely used in cross-sectional, retrospective, prospective and nested case-control 
epidemiologic studies, with the aim of improving our understanding of the causes of specific 
human cancers ( Perera & Weinstein, 2000; Au, 2007).  
Many of the biomarkers used in molecular epidemiologic studies require further validation 
(Perera & Weinstein, 2000) as it will be discussed in the Biomarkers chapter. 
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Figure 1 - Paradigm of human cancer risk assessment and bioethical issues associated with molecular 
epidemiology and human cancer. Adapted (Hussain & Harris, 1998). 
 
 
2.1. CAPABILITIES OF MOLECULAR EPIDEMIOLOGY 
Molecular epidemiology has many capabilities, namely the delineation of a continuum of 
events between exposure and disease, the identification of exposures and dose 
reconstruction, the identification of events earlier in the natural history of disease, the 
reduction of variable misclassification, the indication of mechanisms, and the enhanced 
individual and group risk assessment (Spitz & Bondy, 2010).  
Using different combinations of biomarkers, molecular epidemiology has reinforced prior 
evidence that risk from carcinogenic exposures can vary significantly with ethnicity, age or 
stage of development, gender, pre-existing health impairment and nutritional factors. 
Biologically based inter-individual variation in only a few susceptibility factors can lead to a 
significant increase in population risk over what would be expected based on the assumption 
of uniform susceptibility, possibly by an order of magnitude or more (Perera, 2000; Perera & 
Weinstein, 2000; Weis et al., 2005).   
The availability of risk estimates based on the frequency of a biomarker in healthy individuals 
would be a formidable tool for any cancer prevention initiative and is the reason that justifies 
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the interest of molecular epidemiologists in prospective human cohort studies. The validation 
of candidate biomarkers for long-term risk prediction is a priority with special attention given 
to those biomarkers – as in the case of micronuclei that are possibly affected by the presence 
of the disease, i.e. the so called “reverse causality”; in this case, cohort studies are preferable 
for biomarker validation (Bonassi & Au, 2002) as all individuals are known to be disease-free at 
the time of biomarker evaluation, with disease eventually arising thereafter.    
 
There has been dramatic progress in the application of biomarkers to studies of cancer 
causation in humans. Progress has been made in the development and validation of 
biomarkers that are directly relevant to the carcinogenic process and that can be used in 
large-scale epidemiologic studies. Study designs have become increasingly complex, with 
greater attention to the need to incorporate appropriate controls and account for potential 
confounders. A number of longitudinal or nested case-control studies have been undertaken 
to establish the predictive value of biomarkers. However, as knowledge of mechanisms in 
carcinogenesis has evolved, the available armamentarium of biomarkers is no longer 
sufficient. The majority of the available biomarkers used in molecular epidemiology studies 
relate to agents that cause DNA damage and are mutagenic (Perera & Weinstein, 2000).  
A recent trend that brings together cancer researchers interested in cancer epidemiology, 
chemoprevention and therapy is the increasing recognition that biomarkers developed in the 
field of molecular epidemiology may also be useful as early or intermediate endpoints in 
studies of cancer prevention by identifying “at risk” populations and then assessing the 
efficacy of various types of intervention (Perera & Weinstein, 2000).  
The field of molecular epidemiology is especially relevant to the very promising and rapidly 
expanding field of cancer chemoprevention, i.e. the use of specific, synthetic or naturally 
occurring compounds to inhibit the carcinogenic process before the development of 
malignant tumours (Perera & Weinstein, 2000). The molecular epidemiology approach, 
measuring molecular or cellular biomarkers as indicators of disease risk or of exposure to 
causative or preventive factors, has applications in studies of environmental and occupational 
exposure, disease etiology, nutrition, lifestyle and others.  
It is a valuable adjunct to conventional epidemiology, and has the advantage that it requires 
far fewer subjects and much less time (being therefore more cost-effective) than the 
traditional approach. In addition, the biomarkers, if carefully chosen, can give useful 
information about molecular mechanisms involved in disease etiology, like for example if they 
reflect an early stage in disease progression (Collins & Dusinska, 2009).  
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
14 
 
In conclusion, the potential benefits of biomarkers and molecular epidemiology in cancer 
prevention justify a major commitment to the further development and use of this approach 
and to addressing the ethical concerns involved in its application to cancer prevention (Perera 
& Weinstein, 2000).  
 
 
3. CANCER EPIDEMIOLOGY 
Most cancers results from man-made and natural environmental exposures (such as tobacco 
smoke; chemical pollutants in air, water, food, drugs; radon; and infectious agents) acting in 
concert with both genetic and acquired characteristics of an individual (Perera, 1996, 2000). It 
has been estimated that without these factors, cancer incidence would be dramatically 
reduced, by as much as 80%-90%. Cancer risk from these environmental carcinogens is 
strongly influenced by many factors, including genetics, age, ethnicity, gender, immune 
function, pre-existing disease, and nutrition (Perera, 1996; Wild, 2009). The majority of cancer 
epidemiology studies were limited to assessing possible causative associations between two 
types of events: exposure to potential causative “environmental” agents (i.e. cigarette smoke, 
specific chemicals in the workplace, dietary factors, etc.) and disease outcome (i.e. clinically 
apparent cancer incidence or cancer mortality). In the past, the modulation of environmental 
factors by host susceptibility was rarely evaluated, but in recent years the interaction between 
environmental factors and host susceptibility has become a very active area of research 
(Perera & Weinstein, 2000). 
 
3.1. MECHANISMS IN CARCINOGENESIS 
Cancer is a multistage process that results from an accumulation of multiple genetic changes. 
The concept that genetic susceptibility to development of cancer is related to genomic 
instability was initially supported by rare disorders such as ataxia telangiectasia and 
xeroderma pigmentosum, which are associated with in vivo and in vitro chromosomal 
instability and defective DNA repair capacity. It is now established that maintaining the 
integrity of the genome is essential for normal cell function and any disruption in the process 
can lead to either cell death or cancer development (El-Zein et al., 2011).  
Carcinogenesis would thus be a sequence of more or less stochastic transitions including gene 
mutations and cell proliferation. In addition, carcinogenesis would be a multifactorial process, 
i.e., different external exposures would be able to affect it and few of them, if any, would be 
necessary (Vineis & Porta, 1996). As a consequence, confounding, (i.e., the interplay of 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
15 
 
multiple concurrent exposures in the interpretation of cause-effect relationships) is 
necessarily required to be considered in any study of carcinogenesis (Vineis & Porta, 1996). 
The carcinogenic process was pictured as an orderly progression of the cell through three 
distinct stages: initiation by exposure to genotoxic agents; tumour progression by agents that 
stimulated the initiated cell to proliferate and expand clonally to form a benign tumor; and 
progression, in which the accumulation of additional genetic damage in the expanding 
population of initiated cells caused the tumor to become malignant. This simplified model has 
been modified by the discovery that cancer results from a succession of genetic and 
epigenetic events whose order may vary. Carcinogens are now understood to be remarkably 
versatile, able to derail gene function by inducing mutations or by disrupting gene expression 
or both. So-called “nongenotoxic” agents, such as chlorinated organic compounds, hormones, 
and asbestos, are known to indirectly damage the genes via a number of different 
mechanisms, including alterations in gene expression and oxidant formation  (Perera, 1996; 
Waters et al., 1999).  
The current paradigm holds that cancer results from the accumulation of changes in the 
structure or expression of certain key genes by mechanisms as varied as point mutation 
induced by carcinogen-DNA binding, gene amplification, translocation, chromosomal loss, 
somatic recombination, gene conversion, or variation in DNA methylation patterns. At the 
center of the paradigm are the oncogenes and tumor suppressor genes that code for proteins 
serving as “relays” in the regulatory circuitry of the cell. Damage to these target genes can 
result in altered protein products or abnormal amounts of normal proteins, leading to 
deregulation of cell growth and differentiation (Perera, 1996).   
 
4. RISK ASSESSMENT 
 
Risk assessment has been the traditional tool to derive acceptable tolerable levels of exposure 
to environmental chemicals. It entails the evaluation of available scientific information on the 
biological, epidemiological and toxicological properties of an agent leading to an informed 
judgement about the potential for adverse effects in humans under defined exposure 
conditions (Greim et al., 1995; Di Marco et al., 1998). Effectively linking molecular 
epidemiology to risk assessment and health policy formulation will, in most cases, require 
additional research to confirm and to further elucidate many of the reported interactions 
between specific environmental exposures and susceptibility factors (e.g. gene-environment, 
gene-gene-environment, and gene-nutrition-environment interactions). But the data, taken 
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together, have bearing on fundamental principles of risk assessment (WHO, 1995; Perera, 
2000).  
 
Risk assessment aims to quantify the probability that a specific agent or chemical will give rise 
to an adverse effect. The principal factors that affect this include the chemical itself, its use 
and exposure levels; and susceptibility of exposed individuals. Even very toxic substances may 
not pose any significant risk to human health if exposure levels are negligible or the number of 
exposed and susceptible subjects is very low. On the other hand, even substances with low 
toxicity may cause serious concern when exposure is at levels sufficient to give rise to 
biologically effective doses and involves a high number of susceptible individuals (Mutti, 1999; 
Watson & Mutti, 2004).  
 
The carcinogenic process involves the accumulation of genetic changes that can be facilitated 
by many susceptibility factors that render individuals vulnerable (Perera, 1996). However, 
conventional risk assessment methods may underestimate the individual’s risk for exposures 
to environmental carcinogens because of the default assumption that all individuals within a 
certain population possess equal susceptibility to a specific carcinogen dose (Perera, 1996; 
Ketelslegers et al., 2008). An individual’s risk for developing cancer depends on both inherited 
and environmental factors; exposure to specific carcinogens is clearly related to increased 
cancer risk. Individual susceptibility varies greatly, however, and may be the factor that 
determines who will develop cancer (Vainio, 1998).  
 
Occupational risk assessment may be defined as the qualitative and quantitative 
characterization of an occupational risk, i.e. the probability that an adverse health effect may 
result from human exposure to a toxic agent which is present in the occupational setting. It 
has three fundamental tools: environmental monitoring, health surveillance and biological 
monitoring. Risk assessment is meant to quantify the likelihood that a quantitatively defined 
occupational exposure of an individual (or group of individuals) to a chemical might result in 
adverse health effects. The level of probability essentially depends on three elements: the 
intrinsic potency/characteristics of the risk factor itself (hazard identification/assessment), the 
level/type/duration of exposure (dose-response/exposure assessment) and the degree of 
individual susceptibility, as represented by the following simple equation (Di Marco et al., 
1998; Perera, 2000): 
Risk = Hazard x Exposure x Susceptibility 
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Each of the three components must be different from zero. It also indicates that the same 
level of risk may be achieved by various associations of different levels of each of the three 
components. Highly intrinsically toxic chemicals, including carcinogens, at low levels of 
exposure and/or susceptibility may provide a similar level of risk as would less toxic ones at 
higher levels of exposure and/or susceptibility (Perera, 2000).  
Exposure assessment is much more complex in epidemiologic studies because human 
exposure does not occur in controlled conditions. Focusing on improving exposure assessment 
in human studies is worthwhile because, although human studies are usually more difficult to 
conduct, they provide valuable additional information to the risk assessment process. 
Typically, human studies substantially decrease the uncertainties of human risk assessment 
(Pirkle & Sampson, 1995).  
In occupational situations, the number of individuals is usually relatively small, and therefore 
the main determinant is the exposure level. However, for environmental exposures a large 
number of individuals might receive a biologically effective dose resulting from relatively low 
exposure levels, and individual susceptibility may represent the main risk determinant 
(Watson & Mutti, 2004).  
Major gains in cancer prevention should stem from theoretically important strategies, namely 
regulations, public education programs, health surveillance, behaviour modification, and 
chemoprevention programs and other interventions that adequately protect these groups 
from environmental carcinogens (Perera, 1996, 2000).  
Despite eventual weaknesses and methodological liabilities, molecular biomarkers studies are 
likely to provide valuable tools for risk assessment and the prevention of environmental 
cancer (Husgafvel-Pursiainen, 2002).   
Regarding risk assessment, other than the concept of susceptibility it is also worth mentioning 
the possible existence of very vulnerable sub-populations who are embedded in the main 
population. Certain groups (those with genetic, ethnic, or gender-related traits conferring 
susceptibility, the young; the elderly; and persons with pre-existing disease or immunologic or 
nutritional deficits) are likely to be at greater risk than other members in the population who 
are similarly exposed (Perera, 1996; Ketelslegers et al., 2008).  
Risk estimates may become seriously inflated when such subgroups comprise an important 
proportion of the main population (Hines et al., 2010a).   
Molecular epidemiology and biomonitoring studies have provided mechanistic data on 
carcinogens that have been used in risk assessment and in some cases regulation of these 
same carcinogens. The Monographs on the Evaluation of Carcinogenic Risks to Humans have 
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been published by the IARC since 1971 as a guide to regulatory and public health agencies in 
their decision making. Since 1997 (Monograph 54), mechanistic evidence, including biomarker 
data in humans or animals, has been used to “upgrade” or “downgrade” the classification of 
carcinogens (Vineis & Perera, 2007). Future research will improve the current assays used by 
molecular epidemiology, making them simpler, cheaper, and more reliable, but these are only 
tools needed for human biomonitoring (Albertini et al., 1996).  
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CHAPTER 2 - HUMAN BIOMONITORING 
 
1. BIOMONITORING 
Human biomonitoring has its roots in the analysis of biological samples, aimed at looking for 
markers of pharmaceutical compounds and occupational chemicals, in an effort to prevent the 
harmful accumulation of dangerous substances (Sexton et al., 2004). Biological monitoring is 
defined as the repeated, controlled measurement of chemical or biochemical markers in 
fluids, tissues or other accessible samples from subjects exposed (or exposed in the past or to 
be exposed) to chemical, physical or biological risk factors in workplace and/or the general 
environment (Bertazzi & Mutti, 2008; Manno et al., 2010). Major goals of many of the 
research programmes on biomonitoring are to develop and validate biomarkers that reflect 
specific exposures and to predict the risk of disease in individuals and in population groups 
(Watson & Mutti, 2004).  
Biomonitoring has many advantages over traditional methods. For example, biological 
samples reveal the integrated effects of repeated exposure. Also, this approach documents all 
routes of exposure – inhalation, absorption through the skin and ingestion, including hand-to-
mouth transfer in children. Such specimens also reflect modifying influences in physiology, 
bioavailability and bioaccumulation, which can magnify the concentrations of some 
environmental chemicals enough to raise them above detection thresholds. Perhaps most 
importantly, these tests can help establish correlations between exposure and subsequent 
illness in individuals – which is often the key observation to prove whether or not a link exists 
between both (Sexton et al., 2004; Angerer et al., 2007). The advantages of human 
biomonitoring for the individuals being studied include: identification of exposure, 
identification of environmental mutagens/carcinogens, and determination of the possible 
range of susceptibility of humans to specific mutagens and carcinogens (Valverde & Rojas, 
2009). In summary, nowadays human biomonitoring of dose and biochemical effect has 
tremendous utility providing an efficient and cost effective means of measuring human 
exposure to chemical substances providing unequivocal evidence that both exposure and 
uptake have been taken place (Sexton et al., 2004; Angerer et al., 2007). Human 
biomonitoring considers all routes of uptake and all sources which are relevant making it an 
ideal instrument for risk assessment and risk management. It can identify new chemical 
exposures, trends and changes in exposure, establish distribution of exposure among the 
general population, identify vulnerable groups and populations with higher exposures and 
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identify environmental risks at specific contaminated sites with relatively low expenditure 
(Angerer et al., 2007). 
 
1.1. BIOLOGICAL MONITORING IN OCCUPATIONAL CONTEXT 
Biological monitoring has applications in exposure assessment and in occupational health. The 
term “biological monitoring” has come into use as a natural adaptation of the term 
environmental monitoring, i.e. the periodic measurement of the level or concentration of a 
chemical, physical or biological risk factor in the workplace environment, which is traditionally 
used as an indirect measure of human exposure. Measurements of the concentration of 
substances or their metabolites in urine, for example, can provide useful information to assess 
inadvertent ingestion, but only in conjunction with measurements of exposure by other 
relevant routes such as inhalation and/or dermal. When compared with environmental 
monitoring, biological monitoring provides additional information which can be effective in 
improving occupational risk assessment at the individual and/or group level (Manno et al., 
2010).  
Biological monitoring of workers has three main goals: the first is individual or collective 
exposure assessment, the second is health protection, and the ultimate objective is 
occupational health risk assessment. It consists of standardized protocols aiming to the 
periodic detection of early, preferably reversible, biological signs which are indicative, if 
compared with adequate reference values, of an actual or potential condition of exposure, 
effect or susceptibility, possibly resulting in health damage or disease. These signs are referred 
to as biomarkers (Manno et al., 2010).  
Another important application of biological monitoring, besides exposure assessment, is the 
use of biomarkers, at either individual or group level, for the correct interpretation of doubtful 
clinical tests. These are usually performed as part of occupational health surveillance program 
when exposure assessment data are unavailable or are deemed unreliable. Biomarkers are 
usually more specific and sensitive than most clinical tests and may be more effective, 
therefore, for assessing a causal relationship between health impairment and chemical 
exposure when a change is first detected in exposed workers (Valverde & Rojas, 2009a; 
2009b; Manno et al., 2010).   
Experience in biological monitoring gained in the occupational setting has often been applied 
to assess (the effects of) human exposure to chemicals in the general environment. The use of 
biological fluids/tissues for the assessment of human exposure, effect or susceptibility to 
chemicals in the workplace represents, together with the underlying data (e.g. personal 
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exposure and biological monitoring measurements), a critical component of the occupational 
risk assessment process, a rapidly advancing science (Manno et al., 2010). In environmental 
epidemiological studies, biological measures of exposure should be preferred, if available, to 
environmental exposure data, as they are closer to the target organ dose and provide greater 
precision in risk estimates and in dose-response relationships (Manno et al., 2010).  
Based on the recognition that certain disease can be caused by exposure to environmental 
contaminants, the movement for prevention of environmental disease has gained broad-
based public support for decades and, the public and the regulatory agencies are demanding 
more reliable information on health risk from environmental contaminants (Au et al., 1998).  
Au et al. (1998) advise on putting more emphasis upon monitoring populations which are 
known to be exposed to hazardous environmental contaminant and on providing reliable 
health risk evaluation. The information can also be used to support regulations on protection 
of the environment. Two issues are crucial in the application of predictive biomarkers to public 
health policies. The first is dealing with the meaning of altered levels of predictive biomarkers 
at individual level. A conservative and traditional approach is that of considering risk 
predictions valid only at group level. This interpretation allows cutting down the effect of 
inter-individual variability and reduces the variability due to technical parameters. On the 
other hand, variability is a fundamental source of information. In addition, differences among 
individual should not be viewed as a nuisance but should be seen as useful hints in the 
hypothesis generation and as an enhanced possibility to apply preventive measures in subsets 
of high risk subjects. The second is crucial aspect is the validation issue. A biomarker must be 
validated before it can be used for health risk assessment, especially as far as regulatory 
aspects are involved. Despite the characterization of valid biomarkers is a leading priority in 
environmental research, defining validity is troublesome. Validity is a general concept that 
refers to a range of characteristics of the biomarker, and an impressive amount of literature 
has been published on the concept of biomarker validity and the various aspects of the 
validation process (Bonassi & Au, 2002).  
The International Labour Organization (ILO) has recommended that occupational health goals 
for industrial nations focus on the hazards of new technology among which pharma and 
biopharma products are leaders. Their unchecked growth cannot continue without parallel 
commitment to the health and safety of workers encountering these “high tech” hazards. 
Improving the present state therefore requires: (i) recognizing healthcare as a “high-hazard” 
employment sector; (ii) fortifying voluntary safety guidelines to the level of enforceable 
regulation; (iii) “potent” inspections; (iv) treating hazardous pharmaceuticals like the chemical 
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toxicants they are; and (v) protecting health care workers at least as well as workers in other 
high-hazard sectors (McDiarmid, 2006).  
 
2. HUMAN GENOME-ENVIRONMENT 
The relative contribution of genetics versus the environment to human illness has been 
debated for decades. The importance of environmental exposures has been supported by 
geographic differences in incidence of disease, by variation in incidence trends over time, and 
by studies of disease patterns in immigrant populations (Olden & Guthrie, 2001).  
Genetic polymorphisms (changes in DNA sequence) often affect the function of a gene but 
some may change the level of expression of a gene or change the activity of the gene product, 
for example, an enzyme. Genetic polymorphisms that are functionally significant are quite 
important when the gene controls the response of an organism to environmental hazards 
(Barrett et al., 1997). Given that a large number of genes are involved in responses to 
environmental hazards and that a large number of polymorphisms exist in these genes, 
genetic differences are important susceptibility factors in environmental responses (Barrett et 
al., 1997).  
There is an important difference between individuals with genetic alterations that lead to 
disease susceptibility and individuals with genetic susceptibility to environmental factors. 
Individuals who inherit a mutation in a disease susceptibility gene have a high risk of 
developing that disease regardless of environmental exposures, although environmental 
factors may increase the incidence or rate of disease development (Barrett et al., 1997).  
Conceptually, the relationship between genes and the environment can be described as a 
loaded gun and its trigger. A loaded gun by itself causes no harm; it is only when the trigger is 
pulled that the potential for harm is released or initiated. Likewise, one can inherit a 
predisposition for a devastating disease, yet never develop the disease unless exposed to the 
environmental trigger(s) (Olden & Guthrie, 2001).  Individuals who have a mutation or 
polymorphism in genes involved in response to environmental hazards will only have an 
increased risk of disease development when they are exposed to specific environmental 
hazards (Barrett et al., 1997).  Particularly in the case of low-dose toxicants, the interactions of 
susceptibility genes with specific environmental factors are probably the dominant cause of 
any resultant human illness. Therefore, the identification of susceptibility alleles can provide a 
unique opportunity to tear apart the effects of genes and the environment on the risk of 
disease (Olden & Guthrie, 2001). However, the probability that an environmental exposure 
will cause illness is dependent on the capacity of the genetically-controlled metabolic 
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machinery and repair mechanisms of the cell to modulate adverse influences of xenobiotics 
(Olden & Guthrie, 2001).  
Therefore, risk to these individuals is influenced strongly by gene-environment interaction. 
Also, because multiple genes are involved in response to the same environmental hazard, two 
individuals with the same genetic susceptibility and environmental exposure may have 
different risks because of the interplay between genes involved in response to xenobiotics. For 
example, two individuals may both have a polymorphism in a gene that increases the rate of 
carcinogen activation but different polymorphisms in a gene that inactivates the same 
carcinogen (Barrett et al., 1997). Twin-cohort studies, the “gold standard” for distinguishing 
between the contributions of genetics versus the environment, suggest that the environment 
plays a prominent role in disease development (Olden & Guthrie, 2001).  
 
Understanding risks to human health in light of the human genome-environment interaction is 
one of the most compelling challenges in environmental public health. With approximately 
99.9% of human genomes being identical, the remaining 0.1% (or about 3 million base pairs) 
appears to dictate differences in susceptibility to environmental challenges among human 
populations (Toscano & Oehlke, 2005).  It is now apparent that most diseases are not carried 
in our genes as if these were deterministic factors of disease, but rather our genomes carry 
variations that result in differences in susceptibility to disease. With the sequencing of the 
human genome, renewed interest in understanding the role of the environment as a cause of 
human disease has re-emerged. Genes are expressed in response to the environment 
(Toscano & Oehlke, 2005) and there are two kinds of susceptibility genes; those that 
predispose to disease without exposure to environmental factors and those that increase risk 
only by interaction with environmental agents (Olden & Guthrie, 2001). Information about 
environmental risk factors should point to genes that might modify the risk, and identification 
of susceptibility genes should help identify previously unrecognized environmental risk factors 
(Olden & Guthrie, 2001).  
 
3. VARIABILITY 
Variability is an intrinsic feature of both biological and exposure measurements. Several 
biological and sampling/analytical sources of variability may influence biomarker levels and, 
therefore, taking variability factors into consideration will make the interpretation of 
biological monitoring data easier. In fact, it is important, when interpreting new biological 
monitoring data, not to “remove” biological variance but rather to uncover and explain it. In 
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other words, variability in biological monitoring may become a resource more than a 
limitation. Many of the variables that affect biological monitoring results are actually helpful 
to achieve a better indication of systemic exposure (Manno et al., 2010). Study design is 
critically important: exposed groups should be matched with respect to gender, age, smoking 
habit, alcohol consumption, nutrition and lifestyle with control (referent) groups. Inclusion 
and exclusion criteria have to be clearly defined and confounding factors (such as age, gender 
and smoking), which influence the background level of DNA damage and may bias the study, 
should be taken into consideration. Environmental and occupational monitoring relies on data 
from exposure measurement and personal monitoring, and information on dose-response 
relationships is valuable, if available (Dusinska & Collins, 2008).  
 
4. LIMITATIONS 
Biological monitoring advantages are matched by some important limitations. One of them is 
that one cannot tell from biological monitoring data what source the exposure originated 
from, e.g. whether the exposure was generated by occupational or non-occupational sources. 
In order to keep track of what source is investigated, the researcher can use questionnaires to 
get individual information, collect pre-exposure samples to establish baseline or background 
levels and/or involve “non-exposed” controls (Manno et al., 2010).  
Biomarkers may not be sufficiently specific for assessing exposure to a particulate chemical 
(e.g. hippuric acid is not very useful as an urinary biomarker of toluene exposure due to high 
background values from diet usually found in workers). It may not be easy to relate some 
exposure biomarkers to external exposure levels, and it may be even more difficult to 
establish a relationship between exposure biomarkers and a biological endpoint such as an 
adverse response or effect (Manno et al., 2010).  
Biomonitoring strategies are not useful at all if the toxic effects are local and/or acute, such as 
in the case of irritating agents. The collaboration with other disciplines has been extremely 
fruitful in developing early effect biomarkers (e.g. nephrotoxicity, neurotoxicity, etc.) or 
biomarkers that may be associated more closely with the development of pathology (e.g. 
neurobehavioural, reproductive, etc.). In routine use, however, there is a need for 
standardized, robust methodologies for comparison of test methods between different 
laboratories. Uniform protocols for establishing detection limits are necessary. Standardized 
reporting procedures and measurement units as well as an expanded database on “normal” or 
reference values are all important. Availability of biological reference materials, the 
benchmarks of accuracy, is also needed. In summary, important infrastructure that is already 
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available in other areas of routine testing is sometimes needed for a more efficient and 
effective biological monitoring in occupational health (Manno et al., 2010).  
 
 
5. GENETIC MONITORING 
During the past decades the understanding of genetics has advanced remarkably as new 
methods for identifying, manipulating, and analyzing DNA have developed. Less well 
understood, however, is the interaction between the environment and heredity, and the role 
each plays in sickness and health (U.S. Congress, 1990; Barrett et al., 1997).   
Is has long been recognized that there are substantial health risks posed by various workplace 
environments, risks often associated with exposure to harmful agents such as chemicals and 
radiations (U.S. Congress, 1990). Indeed, as early as 1938, geneticist J.B.S. Haldane discussed 
“sorting out workers according to their susceptibility to occupational hazards”. 
An occupational illness is defined by the USA Department of Labor’s Bureau of Labor Statistics 
as “any abnormal condition or disorder, other than one resulting from an occupational injury, 
caused by exposure to environmental factors associated with employment”. This includes 
acute and chronic illnesses or disease that can be caused by inhalation, absorption, ingestion, 
or direct contact (U.S. Congress, 1990). 
Genetic monitoring involves periodically examining employees to evaluate modifications of 
their genetic material, e.g., chromosomal damage or evidence of increased occurrence of 
molecular mutations – that might have evolved in the course of employment. The putative 
cause is workplace exposure to hazardous substances and the premise is that such changes 
could indicate increased risk of future illness (U.S. Congress, 1990). 
All genetic is not definitely a result of the workplace because ambient exposures, personal 
habits and lifestyle decisions (e.g., tobacco habits, alcohol consumption, etc.), and age can 
also induce changes in genetic material; genetic monitoring could detect changes that arise 
from exposures outside of the workplace. In general, current techniques are not exposure-
specific but serve merely as an indicator of recent exposure (U.S. Congress, 1990).  
Genetic monitoring could be performed on groups of employees to identify the risk for the 
exposed group as a whole, to target work areas for increased safety and health precautions, 
and to indicate a need to lower exposure levels for a group exposed to a previously unknown 
hazard (U.S. Congress, 1990). Genetic monitoring ascertains whether and individual’s genetic 
material has altered over time. Workplace genetic monitoring is designed to detect the effects 
of a toxic substance or its byproducts, and to evaluate the genetic damage caused by such a 
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substance. The objective of these techniques, ultimately, is to predict risk of disease due to 
genetic damage. When hazards are identified via genetic monitoring, prevention programs 
can be considered that will reduce exposures. This is of particular concern for certain 
occupational groups exposed to hazardous substances over many years at much higher 
concentrations than the general population (U.S. Congress, 1990).  
It is well-documented that exposure to some chemical substances and to radiation at high 
doses causes cancer and genetic mutations (changes in genetic information). Not all 
mutations, however, cause disease. The damage will be resolved in one of three ways: cell 
death, successful DNA repair, or viable mutation. It is difficult to establish the causal 
relationships between the mutation and cancer because of the long latency of human cancer. 
Nonetheless, the rationale behind the use of genetic damage assays as indicators of exposure 
is that events observed initially and at high frequencies trigger a process that may ultimately 
produce abnormal growth (neoplastic changes) in a smaller subset of cells (Figure 2). Such 
relationships between genes, mutations, and disease are becoming clearer with the 
development of molecular techniques (U.S. Congress, 1990).  
 
 
 
Figure 2 – Biological consequences of exposure to mutagenic agents. 
 
Genetic testing includes a number of technologies to detect genetic traits, changes in 
chromosomes, or changes in DNA. As used in the workplace, it encompasses two activities: 
monitoring and screening. Thus, genetic testing of employee populations involves both 
examining persons for evidence of induced change in their genetic material (monitoring) and 
methods to identify individuals with particular inherited traits or disorders (screening) (U.S. 
Congress, 1990). Periodic genetic monitoring of workers could be used to detect induced 
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genetic change that could indicate an increased risk of certain diseases, in particular cancer. 
Genetic testing to identify workplace susceptibility and predisposition to disease in essentially 
healthy people is occurring and the results have been used to making employment decisions. 
In the UK, the Human Genetic Advisory Commission in 2002 confirmed that this is a real issue 
by stating that: “(…) people should not be required to tale a genetic test for employment 
purposes (…) employers should offer a genetic test if it is known that a specific working 
environment or practice, while meeting health and safety requirement, might pose specific 
risks to individuals with particular genetic constitutions” (Bertazzi & Mutti, 2008).  
Genetic monitoring can be viewed as an extension of several types of biological monitoring in 
the workplace to detect changes or assess exposures that could be associated with increased 
exposure to occupational or non-occupational risk. Genetic screening, on the other hand, can 
be used to detect both traits that indicate a predisposition to occupational disease, as well as 
traits not associated with workplace illness (U.S. Congress, 1990).  
Certain environmental agents are known to mutate previously normal somatic cells that could, 
in some cases, cause disease (U.S. Congress, 1990). The recognition of genetic factors in 
disease presents new opportunities for detection, prevention, and treatment; being the most 
validation efforts undertaken in genetic monitoring have been designed to quantify the 
correlation of mutagenesis with carcinogenesis. 
The diseases most associated with genotoxic substances are various forms of cancer. Several 
types of mutational changes (i.e., point mutations, chromosomal rearrangements) have been 
associated with the early stage of tumour development, as well as with the following steps of 
tumour promotion and progression. 
Cancers resemble other common diseases in so far as some forms are associated with 
chromosomal anomalies, others with single mutant genes, or environmental agents. The vast 
majority, however, are best explained by a genetic-environmental interaction. Clearly, some 
individuals are predisposed to certain types of cancer given the right environmental exposure. 
There are at least 50 human genetic diseases that have been identified as having the potential 
to enhance an individual’s susceptibility to toxic or carcinogenic effects of environmental 
agents. Occupational exposures have been implicated in lung, bladder, testicular, and 
laryngeal cancers, as well leukemias. As the connections between cancer and genetics become 
clearer, so may the relevance of occupational exposure to genetic disease (U.S. Congress, 
1990).  
Gene-environment interactions will continue to play an increasingly important role in 
understanding the risk of cancer from environmental and occupational exposures. Studies 
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involving genetically sensitive populations help to clarify epidemiological data by 
strengthening the finding and providing insight into mechanisms which can lead to observed 
patterns of dose versus response. Application of these findings to risk characterization will be 
difficult; for instance, if we know a specific genotype increases the risk of developing cancer in 
a particular occupational setting, should the worker be dissuaded from taking the 
employment? Use of this information in environmental settings causes similar problems but 
provides an advantage in terms of more precise estimates of risk to the general population 
(Portier & Bell, 1998).  
 
6. SOCIAL, ETHICAL, AND LEGAL IMPLICATIONS 
Biomonitoring is one of the best, and probably the most rapidly growing tool available today 
for the prevention of health effects resulting from occupational exposure to chemicals. 
Therefore, there is a growing attention towards scientific, ethical issues and social implications 
that must include individual risk estimation, the communication of epidemiological results, 
and the translation of epidemiologic data into clinical or occupational health practice (Manno 
et al., 2010).  
The use of human biological samples implies special considerations of information, consent, 
confidentiality and follow-up as stated in the Declaration of Helsinki (www.wma.net). The 
collection of samples and personal information about health status used for research and/or 
surveillance must be preceded by a notification of the project to the ethical committee, 
including a protocol describing, e.g., the risk of the persons participating, the information (oral 
or written) given to persons participating and the way of obtaining informed consent (Watson 
& Mutti, 2004; Knudsen & Hansen, 2007).  
According to the International Code of Ethics, biomarkers must be chosen for their validity and 
relevance for protection of the health of the worker concerned, with due regard to their 
sensitivity, their specificity and their predictive value and should not be used as screening 
tests or for insurance purposes (Olden & Guthrie, 2001; Manno et al., 2010).  
Some of the most relevant ethical issues faced by those involved in biological monitoring, 
particularly for research purposes, are the following: planning the study, informed consent, 
confidentiality, communication and susceptibility (Manno et al., 2010). The information about 
exposure and susceptibility gained by biological monitoring is personal and may predict health 
impairments. Such information may therefore be discriminative and thus sensitive in relation 
to future opportunities in occupational health insurance. It is therefore of utmost importance 
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to keep all information confidential with precise guidelines on who is allowed to use the 
information (Knudsen & Hansen, 2007).   
In straightforward routine biomonitoring programs, communication of individual results 
(including their interpretation) to each worker and of collective results/interpretation to the 
employer and to the workers’ representatives would be sufficient in most cases. Finally, it is 
crucial a correct interpretation of individual or collective biomarker data requires a 
comparison of the results with appropriate reference values obtained in non-exposed but 
otherwise comparable subjects (Manno et al., 2010).   
 
The study of susceptibility in human populations poses a number of ethical challenges.  A 
special attention should be given to the ethical aspects related with the use of susceptibility 
biomarkers, namely the benefit to the worker in terms of preventive action and the cost in 
terms of their possible removal from the job. In principle, biological monitoring should not 
result in discrimination or reduction of job opportunities for the workers involved.  
The recognition of individuals who are subjected to a potentially increased risk of cancer from 
exposure, particularly occupational exposure, poses the ethical dilemma common to much of 
the present development of biomarker applications: how to prevent susceptible individuals 
from being exposed to these chemicals (Barrett et al., 1997).  
About genetic screening of workers, many critics have noted the importance of controlling 
workplace exposures instead of removing susceptible workers (“hypersusceptible”) from the 
workplace.  
Ethical considerations should always be borne in mind before biomonitoring programs are to 
be planned and implemented, particularly when new or partially validated biomarkers are 
involved. Since the primary purpose of biological monitoring is the protection of the worker’s 
health, it must be avoided that biological monitoring data, whether from exposure or effect or 
susceptibility biomarkers, could result in an adverse impact on the worker’s status of 
employment and/or quality of life (Manno et al., 2010).  
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CHAPTER 3 – BIOMARKERS  
 
 
1. BIOMARKERS – AN OVERVIEW 
 
Biomarkers have been defined by the U.S. National Academy of Sciences Committee on 
Biological Markers as an alteration in cellular or biochemical components, processes, structure 
or functions that is measurable in a biological system or sample (National Research Council, 
1987), but is not a measure of the disease, disorder or condition itself (Fergurson, 2008). A 
biomarker can be any substance, structure or process that can be monitored in tissues or 
fluids and that predicts or influences health, or assesses the incidence or biological behaviour 
of a disease. Ideally, biomarkers should be accessible (non-invasive), non-destructive and easy 
and cheap to measure. Identification of biomarkers that are on causal pathway, have a high 
probability of reflecting health or the progression to clinical disease, and have the ability to 
account for all or most of the variation in a physiological state or the preponderance of cases 
of the specified clinical outcome, have largely remained elusive, as one is never quite sure if 
they fulfill such requirements (Schulte & Mazzuckelli, 1991; Davis & Milner, 2007).   
Biological markers can contribute to quantitative risk assessment by helping to: determine the 
forms of dose-time-response relationships; assess the biologically effective dose; make 
interspecies comparison of effective dose, relative potency, and effects; resolve the 
quantitative relationships between human interindividual variability; and identify 
subpopulation that are at enhanced risk (Schulte & Mazzuckelli, 1991). Nowadays, most 
research on biomarkers is concerned with markers which will increase our ability to identify 
long-term risks due to toxicant exposure, in particular the risk of developing cancer; and 
identify early markers of toxicity in the field of environmental or ecotoxicology. For the past 
25 years, biomarkers have been used to identify biological changes due to toxic chemicals and, 
as part of an integrated approach, in the assessment of environmental health. In the future, 
many more biological markers predictive of long-term effects, such as chromosomal changes 
and DNA adducts, will be available, allowing risk assessment judgments to be made 
(Waterfield & Timbrell, 1999).   
The challenge in biomarker research is to facilitate the identification of environmental and 
genetic factors which modulate cancer risk, a challenge which must be seen in the context of 
the fact that most environmental carcinogens appear to be associated with relative risks 
which are so low as to be detectible with difficulty by classical epidemiological methods 
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(Kyrtopoulos, 2006). A goal in the use of biomarkers must be to identify adverse effects of 
chemical contaminants at the lowest levels of biological organization, so avoiding toxicological 
problems at a higher stage (Waterfield  & Timbrell  1999).  
The traditional, generally accepted classification of biomarkers divides them into three main 
categories - biomarkers of exposure, effect, and susceptibility; depending on their 
toxicological significance (Schulte & Mazzuckelli, 1991; Timbrell, 1998; Manno et al., 2010). A 
biomarker of exposure is defined as “an exogenous substance or its metabolite or the product 
of an interaction between a xenobiotic agent and some target molecule or cell that is 
measured in a compartment within an organism” (National Research Council, 1987; Manno et 
al., 2010). A biomarker of effect is a measurable biochemical, structural, functional, 
behavioural or any other kind of alteration in an organism that, according to its magnitude, 
can be associated with an established or potential health impairment or disease. A sub-class 
of biomarkers of effect is represented by biomarkers of early disease (or early biomarkers of 
disease), i.e. tests which are more closely indicative of a subclinical effect or even an early, 
reversible clinical response (Manno et al., 2010).  A biomarker of susceptibility may be defined 
as an indicator of an inherent or acquired ability of an organism to respond to the challenge of 
exposure to a chemical (Manno et al., 2010). A further discussion of biomarkers of exposure 
and of effect will be provided below. Although the different types of biomarkers are 
considered for classification purposes, as separate and alternative, in fact it is not always 
possible to attribute them to a single category. The allocation of a biomarker to one type or 
the other sometimes depends on its toxicological significance and the specific context in which 
the test is being used (Manno et al., 2010).  
With respect to prevention, the use of biomarkers to quantify interindividual variability in 
response to exposure has significant implications for carcinogenic risk assessment and 
associated regulatory actions. The assumption underlying current risk assessment models, 
that all humans respond homogeneously to a specific carcinogen or mixture of carcinogens, is 
belied by the large interindividual variation observed within human populations exposed to 
similar levels of diverse carcinogens.  
 
1.1. BIOMARKERS OF EXPOSURE 
The fundamental role of biomarkers of exposure in occupational health practice is to assess 
exposure by all routes and to complement information obtained by workplace environmental 
monitoring. For many reasons, such as being more informative, particularly at the individual 
level; biomarkers of exposure are often used, when available, as a better substitute for 
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environmental monitoring (Manno et al., 2010), often indicating exposures to environmental 
pollutants which are important to public health (Angerer et al., 2007).  
Exposure biomarkers can reflect bioavailability and be influenced by numerous parameters 
such as route of exposure, physiological characteristics of the receptor and chemical 
characteristics of the xenobiotic. Exposure biomarkers have the advantage of providing an 
integrated measure of chemical uptake, a consideration that is important in the case of agents 
that exhibit large route-dependent differences in absorption (DeCaprio, 1997; DeCaprio, 
1999). Another valuable application of exposure biomarkers is in evaluating the potential of 
intervention strategies. In either case, biomarkers can be used as endpoints, permitting a 
proof of principle to be established in advance of long-term interventions where pre-
cancerous lesions or cancer itself might be the outcome (U.S. Congress, 1990).  
Biomarkers of exposure can be divided into markers of internal dose and effective dose. The 
former gives an indication of the occurrence and extent of exposure of the organism and thus 
likely concentration of a parent compound or metabolite at the target site. The simplest 
indicator of internal dose is the blood concentration of a chemical agent measured following 
exposure. The latter is an indication of the true extent of the exposure of what is believed to 
be the target molecule, structure or cell. Both markers of internal and effective dose are 
therefore preferable to measuring external levels of the compound in question, for example in 
the workplace, as they take into account the biological variations in absorption, metabolism 
and distribution of the compound in an individual (Timbrell, 1998; Waterfield & Timbrell 
1999). 
 
1.2. BIOMARKERS OF EFFECT 
The International Programme on Chemical Safety has defined a biomarker of effect as “a 
measurable biochemical, physiological, behavioural or other alteration within an organism 
that, depending upon the magnitude, can be recognized as associated with an established or 
possible health impairment or disease”. This is a very broad definition. Biomarkers of effect 
can be elicited as a result of interaction of the organism with a host of different environmental 
factors (including chemical, physical, and biologic agents); this definition encompasses 
biomarkers of effect at the level of the whole organism, at the level of organ function, at the 
level of tissue and individual cells, and at the subcellular level (Barrett et al., 1997). 
Biomarkers of effect, which measure processed genetic damage, are sometimes used to 
define exposures; because of that, classification in more mechanistic terms, such as reversible 
(transient) genotoxic responses (exposure/dose) and irreversible (permanent) genotoxic 
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responses (effect) may be used (Albertini et al., 1996). DNA adducts are better 
representations of penetration of the agent to the target molecules of genotoxic concern than 
are protein adducts, however, the fact that DNA molecules are repaired, which must be 
considered when using DNA adducts as in vivo dosimeters, are examples of reversible 
genotoxic response (Albertini et al., 1996). Effect or irreversible genotoxic endpoints require 
host processing of DNA lesions into informational changes in the cell (e.g. mutations) and 
therefore may be relatively insensitive when used as dosimeters (Albertini et al., 1996).  
Historically and in practical terms these biomarkers are those which have been used most 
widely and routinely. They can be grouped into different categories. Hence those markers 
which are the result of pathological damage could be considered separately from markers 
which indicate a metabolic lesion (Waterfield & Timbrell, 1999).  
Other potential uses of biomarkers of effect are in monitoring of disease progression and 
prognosis, and as adjuncts to other biomarkers in providing refinements of epidemiology and 
risk assessments. At the very last, biomarkers, offer the opportunity to provide scientific 
confirmation of proposed exposure-disease pathways in vivo in human populations. 
Biomarkers of effect may be particularly useful for demonstrating the biologic influence of 
preceding susceptibility factors, for instance, genetic polymorphisms of xenobiotic-
metabolizing enzymes (Barrett et al., 1997).  
This type of biomarker indicates early biochemical or functional alterations including a wide 
array of biological responses, ranging from physiological adaptation to disease. They represent 
a heterogeneous group of indicators and have different applications depending on the 
toxicological significance. Some of them have been used for decades as indirect biological 
signs of exposure rather than markers of effect. This is because they are well and promptly 
correlated with the degree of exposure, sometimes, but not always, even at levels of exposure 
without any toxicological significance (Manno et al., 2010).  
An important group of effect biomarkers which have been developed in animals, even in vitro, 
and are now increasingly applied to occupationally exposed populations, are genotoxicity 
biomarkers in workers exposed to mutagens or genotoxic carcinogens. These tests, including 
chromosomal aberrations, micronuclei and the more recent comet assay, may be effective in 
distinguishing exposed from non-exposed subjects at high exposure. Mainly used as group 
indicators they are sensitive but not specific and in some cases difficult to interpret correctly, 
although new techniques, such as the alkaline comet assay, appear to be promising in 
distinguishing between different mechanisms of DNA damage (covalent binding versus 
oxidative stress) (Manno et al., 2010).  
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There is also growing interest in the use and identification of “non-invasive” biomarkers. 
These allow more routine sampling in human studies and may overcome ethical issues, for 
example in screening children. Thus biomarkers identified in urine, breath or saliva are 
potentially more useful than those measured in blood (Waterfield & Timbrell, 1999). Some of 
the simplest biomarkers can be very important tools in biomonitoring as they may indicate 
more subtle or complex changes taking place in response to external stressors.  
Chromosomal abnormalities can also be identified in peripheral lymphocytes and may act as 
surrogate biomarkers of changes in other tissues. Micronuclei and translocations and sister 
chromatid exchanges, which can be induced by a wide range of exposures, reflecting 
cumulative response to a variety of environmental factors are also important biomarkers in 
this field (Timbrell, 1998; Waterfield & Timbrell, 1999; Wild, 2009). Indeed, there are aspects 
of exposure assessment that are best accomplished by irreversible genotoxic endpoints 
(Albertini et al., 1996). In summary, effect biomarkers used as early predictors of clinical 
disease can improve occupational health risk assessment and contribute to implement new 
effective disease prevention policies in occupational and environmental settings, but they 
must be first validated (Manno et al., 2010). 
 
1.2.1. BIOMARKERS OF GENOTOXICITY 
Over the past decades, biomarker-based approaches have been applied in the assessment of 
exposure to genotoxic agents and increases of these biomarkers are considered early events 
associated with disease-related changes (Bonassi et al., 2011). For surrogate biomarkers to 
have disease predictability, it must be demonstrated that genotoxic events actually measured 
really mimic disease-causing genotoxic events (Albertini et al., 1996).  
Biomarkers of genotoxicity are used to measure specific occupational and environmental 
exposures or to predict the risk of disease or to monitor the effectiveness of exposure control 
procedures to genotoxic chemicals (Manno et al., 2010). Cytogenetic biomarkers are the most 
frequently used endpoint in human biomonitoring studies and are used extensively to assess 
the impact of environmental, occupational and medical factors on genomic stability (Barrett et 
al., 1997; Battershill et al., 2008). Lymphocytes, in particular, are used as a surrogate for the 
actual target tissues of genotoxic carcinogens (Barrett et al., 1997; Hagmar et al., 1998).  
Genotoxicity biomonitoring endpoints such as micronuclei, chromosomal aberrations and 8-
hydroxydeoxyguanosine (8-OHG) and DNA repair measured by comet assay are the most 
commonly used biomarkers in studies evaluating environmental or occupational risks 
associated with exposure to potential genotoxins. A review by Knudsen and Hansen (2007) on 
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the application of biomarkers of intermediate endpoints in environmental and occupational 
health concluded that micronuclei in lymphocytes provided a promising approach to assess 
health risks, but concluded that the use of chromosomal aberrations is likely to be limited by 
the laborious and sensitive procedure of the test and the lack of trained cytogeneticists. 
Nevertheless, methodologies like comet assay in peripheral blood lymphocytes, urine and 
tissues are increasingly being used as markers of oxidative DNA damage (Battershill et al., 
2008; Ersson, 2011).  
 
1.3. BIOMARKERS OF SUSCEPTIBILITY 
A biomarker of susceptibility is defined as an indicator or a measure of an inherent or acquired 
ability of an organism to respond to the challenge of exposure to a specific xenobiotic 
substance (Barrett et al., 1997; Waterfield & Timbrell 1999). Thus any variation in the 
response of an individual to identical exposures may represent some difference in 
susceptibility due either to the genetic make-up of the individual or to variables and 
environmental influences such as diet or the uptake and absorption of the xenobiotics 
(Waterfield & Timbrell, 1999).  
Biomarkers of susceptibility are concerned with factors in kinetics and dynamics of uptake and 
metabolism of exogenous chemicals. Thus the concept encompasses enzymes of activation 
and detoxification, repair enzymes, and changes in target molecules for toxic chemicals 
(Barrett et al., 1997).  
Toxicological research in experimental animals and humans over many years has revealed that 
individuals can often differ markedly in their qualitative and quantitative responses to 
chemical exposure. Such interindividual differences can be genetically mediated or can be 
result of some environmental stressor, disease process or other epigenetic factor. While these 
interindividual differences can complicate safety evaluation and risk assessment activities, 
they can also be usefully employed as biomarkers of individual susceptibility to xenobiotics 
(DeCaprio, 1997).   
 Hyper-susceptibility can be defined as a lack of capacity, beyond the limits of human 
variability, to tolerate or respond effectively to exogenous toxicants or pathogens. The 
concept of individual variability is intrinsic to the interpretation of chemical biomonitoring 
data as well as to that of any biological or clinical test. Mechanisms of susceptibility to 
chemical agents are of two kinds: toxicokinetic and toxicodynamic. Biomarkers of 
susceptibility may be of either type. A group of potential susceptibility biomarkers with a 
toxicokinetic mechanism for use in humans exposed to chemicals is represented by the in vivo 
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measurement of the specific drug metabolizing enzymes or enzyme activities involved in the 
chemicals’ activation or detoxification reactions (Manno et al., 2010).  
Interindividual variation occurs as a result of different genetically inherited background 
modified by dietary and environmental exposure and revealed by genotypic and phenotypic 
variation. Susceptibility markers are useful because they can partially explain interindividual 
variation inherent in the general population and thus provide a biological rationale for 
investigation of inherent vulnerability prior to exposure to environmental hazards (Barrett et 
al., 1997).  
Biomarkers of susceptibility do not represent stages along the dose-response mechanistic 
sequence, but instead represent conditions that alter the rate of transition between the 
stages or molecular events. The kinetics of transition is often governed by specific enzymes or 
other gene products. Consequently, determination of relative enzyme activities or the 
presence or absence of other gene products is often employed as susceptibility biomarkers. 
Enzymes involved in xenobiotic metabolism can be particularly important in the overall 
mechanism of action of xenobiotics, and genetic polymorphism in metabolic enzymatic 
activity is a common basis for interindividual differences in toxicity (DeCaprio, 1997; DeCaprio, 
1999).  
An example of xenobiotic metabolizing enzymes as susceptibility biomarkers is the 
cytochrome P450 enzyme system. This system is responsible for oxidative (i.e. Phase I) 
metabolism of a multitude of xenobiotics and endogenous molecules, primarily in the liver but 
also in others bioactivated metabolites. Another important detoxification enzyme system with 
significant use in susceptibility studies is glutathione-S-transferase (GST), which catalyses the 
conjugation (i.e. Phase II metabolism) of cellular thiol glutathione (GSH) with oxidizied 
xenobiotics (DeCaprio, 1999; Manno et al., 2010).  
In addition to enzymes involved in biotransformation, other potential susceptibility 
biomarkers have been explored or proposed in human and animal studies. These include DNA 
repair enzymes activities, nuclear and cytoplasmic receptor protein levels, oncogenes and 
corresponding gene products, tumour suppressor genes and humoral and cellular immune 
system components. 
Much hope has been vested in the development of genetic biomarkers, but for environmental 
and occupational field the research so far has not led to any routinely usable biomarkers. 
Many known genetic traits, such as polymorphisms of drug metabolism, are individually only 
weak associated with disease and many probably remain unknown, due to the requirement 
for environmental factors. Especially if the risk of disease is associated more with exposure 
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than with the genotype, limiting exposure is the only feasible approach to prevention and 
benefits all (Vähäkangas, 2008).  
These methods cannot easily identify all individuals at risk in a hazardous environment due to 
lack of understanding of the interaction of compensatory genetic and cellular mechanisms and 
complex environmental influences; to determine the role of genetic variations to explain 
interethnic differences associated with susceptibility to chemical exposures and to predict 
population vulnerability and; to improve the detection of environmental hazards by increasing 
the sensitivity of epidemiological studies which in turn will result in (i) reduction of risk 
through avoidance or limitation of chemical exposure, (ii) changes in dietary and social habits 
to improve health or reduce risk (iii) improved drug treatment to maximize response and 
minimize toxicity. Better knowledge of xenobiotic metabolism and pharmacokinetics of 
elimination of toxins will speed progress of this work (Barrett et al., 1997). Possible 
consequences of differential inter-individual and inter-ethnic susceptibilities may be related to 
(i) individual expression of clinical signs of chemical toxicity, (ii) biological monitoring data in 
exposed workers, and (iii) interpretation of results of epidemiological or molecular 
epidemiological studies (Manno et al., 2010).  
 
 
2. BIOLOGICAL PLAUSIBILITY       
 
One of the criteria for establishing association between an exposure and disease is biological 
plausibility. In this context, biomarkers may contribute by illuminating some of the 
carcinogenic steps linked to a particular risk factor. This is possibly an undervalued area where 
biomarkers can make significant contributions to cancer epidemiology. If a particular chemical 
exposure from ambient air is associated with increased risk, the additional information that 
exposed individuals have higher levels of DNA damage would add support to the exposure-
disease association (U.S. Congress, 1990). If genetic polymorphisms in carcinogen 
metabolizing or DNA repair enzymes are associated with both an increased cancer risk and 
higher levels of a biomarker on the presumed causal pathway, e.g. DNA adducts, this would 
provide support for the original association (Wild, 2009). 
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3. VALIDITY, RELIABILITY, AND PREDICTABILITY OF BIOMARKERS 
Validity has been defined as the (relative) lack of systematic measurement error when 
comparing the actual observation with a standard (reference) method, which represents the 
“truth” (U.S. Congress, 1990; Vineis, & Garte, 2008; Wild, 2009). Validity has two components, 
one is sensitivity and the other is specificity. Sensitivity is the ability to avoid false negative 
results, and it is fundamental for preventive purposes, whereas specificity, the capacity to 
avoid false positive results, is usually more important for diagnostic purposes (Manno et al., 
2010).  
In order to ensure a rational occupational risk assessment, it is important to use validated 
biomarkers. This means that before biomarkers can be routinely used for workers’ protection 
they must be tested in suitable studies. It must be demonstrated that a biomarker of exposure 
indicates the actual exposure, a biomarker of effect truly predicts the actual risk of disease 
and a biomarker of susceptibility reliably suggests a modification on the risk (Manno et al., 
2010). It must be stressed that exposure or effect biomarkers are really useful risk assessment 
tools when the metabolic fate of the compound (toxicokinetics) or the mechanisms of a 
resultant disease (toxicodynamics) are completely understood (Manno et al., 2010).  
The predictive value of an effect biomarker is the probability that a biomarker, which has 
identified a subject as having an impairment or disease, is actually correct in having done so 
(Manno et al., 2010). The predictive value mostly depends on the prevalence of the disease, 
on type of chemical being measured and on the quality of the method. Generally speaking, 
with prevalence in the reference population below 5% the negative predictive value of any 
biomarkers is high, whereas the positive predictive value is poor. The opposite occurs when 
prevalence is high. Only highly specific and sensitive biomarkers should be used when 
decisions have to be made on the worker’s job fitness or their removal from work or other 
important personal risk management issues, in order to avoid misjudgement, particularly with 
low prevalence diseases (Manno et al., 2010).  
 
The presence of long-term risks associated with human exposure to mutagenic and 
carcinogenic agents has been revealed by classic epidemiologic studies. A number of 
progressive changes occurred in workplaces, in the environment and in life-styles during the 
past few decades, this has resulted in different exposures patterns and exposures to new 
substances, and therefore new and more sensitive tools should be utilized to investigate 
cancer risk from these substances. In addition, there are aspects of metabolism and 
susceptibility previously unknown or poorly understood, such as metabolic polymorphisms, 
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which can dramatically modify individual responses to toxic and carcinogenic agents. These 
features have made the identification of etiological factors more difficult, especially for 
cancers with a long induction period, and the use of traditional epidemiologic outcomes, such 
as cancer incidence or mortality, in many cases no longer seem sufficient for the evaluation of 
cancer risk in human populations (Fenech et al., 1999b). Biomarkers that have been validated 
for their predictive value may be used for the timely identification of increased cancer risk, 
and can be used in the prevention or control of disease. The assumption underpinning the use 
of a biomarker as a surrogate of disease is that the observed relationship between exposure 
and the marker will translate into a similar relationship between exposure and disease 
(Fenech et al., 1999b).  
The advantages of using biomarkers as tools for exposure assessment are well established. 
Biomarkers are particularly useful when their toxicological significance is sufficiently 
understood, including the following:  toxicokinetic fate of the chemical or its metabolites (for 
exposure biomarkers), or the mechanism of disease/adverse effect (for effect biomarkers), or 
the modulating factors linking the chemical to the disease/adverse effect (for susceptibility 
biomarkers) (Manno et al., 2010).  
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CHAPTER 4 – GENOMIC INSTABILITY 
 
 
1. MUTAGENETICITY AND GENOTOXICITY 
 
Current evidence suggests that the mutagenic events involved in carcinogenesis are 
themselves produced by one or two broad modes of action. The first may be mediated by the 
covalent binding of a chemical or its metabolites to DNA or chromatin, or by their interference 
with DNA-related processes, such as spindle function or transcription, thereby directly 
affecting the integrity of the genome (i.e., the structure or content of DNA). The second 
mechanistic process involves chemical alterations in homeostasis that may be mediated via 
tissue necrosis, apoptosis, or cellular turnover leading indirectly to the expression of 
mutations in DNA (Waters et al., 1999).  
A genotoxic agent is a chemical or another agent that damages cellular DNA resulting in 
mutation and/or, consequently, cancer. Genotoxic substances are known to be potentially 
mutagenic or carcinogenic when inhaled, ingested or penetrate the skin. A mutagen is an 
agent that is responsible for inducing a change to the genetic material of an organism. That 
agent might be physical, chemical or biological. As many mutations may ultimately result in 
cancer (or be part of the multistep process of carcinogenesis), mutagens are typically also 
carcinogens (Friedberg et al., 2006).  
While genotoxicity is often confused with mutagenicity, all mutagens are genotoxic; however, 
not all genotoxic substances are mutagenic. The alteration can have direct or indirect effects 
on the DNA. The permanent, heritable changes can affect either somatic or germ cells, being 
the latter passed on to future generations. Mechanisms of cell defense, such as DNA repair or 
apoptosis can prevent expression of the genotoxic mutations and, consequently enabling the 
damage to be fixed and leading to mutagenesis (Friedberg et al., 2006).  
Although some carcinogens are primarily associated with genotoxic mechanisms, while others 
are considered nongenotoxic, recent knowledge indicates that many chemical carcinogens 
operate via a combination of both mechanisms with the prevailing mechanism dependent 
upon the target cell type (Waters et al., 1999). With evidence that gene mutations, gene 
amplifications, chromosomal rearrangements, and aneuploidy are associated with numerous 
types of tumours, it remains essential to identify chemicals and other agents that are capable 
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of inducing the types of genetic alterations that could damage the genes involved in 
carcinogenesis (Waters et al., 1999).  
 
Markers of general DNA damage include chromosomal aberrations, micronuclei, and sister 
chromatid exchanges, which can be induced by a wide range of exposures, reflecting 
cumulative exposure to a variety of environmental factors (U.S. Congress, 1990).  
The increasing demand for the information about health risk derived from exposure to 
complex mixtures calls for the identification of biomarkers to evaluate genotoxic effects 
associated with occupational and environmental exposure to chemicals.  
Lymphocytes are the most commonly used cells in human biomonitoring studies for the 
assessment of genetic damage, since they are easy to sample and can be used as surrogate 
cells of damaged target tissues. In fact, they circulate throughout the body, have a reasonably 
long life span, and can therefore be damaged in any specific target tissue by a toxic substance 
(Cavallo et al., 2009). In addition to lymphocytes, exfoliated cells from epithelial tissues are 
often exposed to chemical agents and have been used to evaluate genotoxic effects from 
xenobiotic exposure. The exfoliated buccal cells can be rapidly and noninvasively collected in 
large number, more easily than lymphocytes (Cavallo et al., 2009). 
 
2. OXIDATIVE DAMAGE 
 
Free radicals are unstable molecule species with an unpaired electron and are produced in 
living cells by normal metabolism and by exogenous sources such as carcinogenic compounds 
and ionizing radiations (Dizdaroglu et al., 2002; Bender, 2006).  
It is generally accepted that oxidative stress is an inevitable feature of life, induced by reactive 
forms of oxygen released during normal respiration, by the oxidative burst of the 
macrophages in response to infection, and by a variety of exogenous agents (Poulsen et al., 
1998; Volkovová et al., 2006; Valavanidis et al., 2009). Normal cellular metabolism is well 
established as the source of endogenous reactive oxygen species (ROS), and is these (normally 
non-pathogenic) cellular processes that account for the background levels of oxidative DNA 
damage detected in normal tissues (Poulsen et al., 1998; Cooke et al., 2003).  
ROS is a collective term which comprises oxygen species like oxygen (O2), superoxide anion 
(O.), hydrogen peroxide (H2O2), the hydroxyl radical (OH.), peroxyl (RO2.), alkoxyl (RO.) and 
other species that are easily converted into radicals such as hypochlorite (HOCl) and 
peroxynitrite (ONOO-) (Poulsen et al., 1998; Boiteux & Radicella, 1999).  
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Multiple exogenous and endogenous sources generate ROS in mammalian cells. The 
exogenous sources include radiation, air pollution, tobacco smoke, and a wide range of 
chemicals, whereas endogenous sources of ROS include mitochondrial respiration, 
inflammatory responses involving the immune system, apoptosis, oxidation of reduced flavin 
coenzymes, biotransformation and other metabolic processes (Collins, 1999; Marnett, 2000; 
Gedik et al., 2002; Cooke et al., 2003; Bender, 2006; Loft et al., 2008; Sedelnikova et al., 2010).  
It has been proposed that ROS and reactive nitrogen species (RNS) play a key role in human 
cancer development, especially as evidence is growing that antioxidants may prevent or delay 
the onset of some types of cancer (Wiseman & Halliwell, 1996; Mohrenweiser, 2004).  
Elevated ROS levels can create oxidative stress in a cell and chronic exposure to this stress can 
result in permanent changes in the genome. It is generally accepted that the accumulation of 
oxidative DNA lesions may promote mutagenesis, human pathogenesis and loss of 
homeostasis. High levels of oxidative stress contribute significantly to the age-related 
development of some cancers through DNA damage (Fergurson, 2008).  Lipids, proteins and 
DNA are the major target of free radicals and active oxygen species. Above all, the 
polyunsaturated fatty acids and their esters are quite susceptible to radical attack and 
oxidation (Marnett, 2000; Niki, 2000).  
Mutagenesis by ROS could contribute to the initiation of cancer, in addition to being 
important in the promotion and progression phases. ROS can have the following effects: (i) 
cause structural alterations in DNA, e.g. base pair mutations, rearrangements, deletions, 
insertions and sequence amplification. ROS can produce gross chromosomal alterations in 
addition to point mutations, and thus could be involved in the inactivation or loss of the 
second wild-type allele of a mutated proto-oncogene or tumour-suppressor gene that can 
occur during tumour promotion and progression, allowing expression of the mutated 
phenotype; (ii) affect cytoplasmic and nuclear signal transduction pathways; (iii) modulate the 
activity of the proteins and genes that respond to stress and which act to regulate the genes 
that are related to cell proliferation, differentiation and apoptosis (Wiseman & Halliwell, 
1996). However, it is important to refer that the oxidation of DNA is not only a consequence of 
the production of ROS as decreases in antioxidant defence and inhibition of repair of oxidative 
damage should also be taken into account. Xenobiotics can produce ROS, decrease 
antioxidant defences or inhibit the repair of oxidative damage (Azqueta et al., 2009).  
Oxidative damage probably constitutes the most varied class of DNA damage with at least 20 
different lesions identified. These include single or double strand breaks, single base 
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modifications, abasic sites, and DNA-protein-cross-links (Boiteux & Radicella, 1999; Lloyd & 
Phillips, 1999).  
The targets for ROS that may result in initiation of cancer, coronary heart disease and 
autoimmune disease are nucleic acids, polyunsaturated fatty acids (in cell membranes and 
plasma lipoproteins) and proteins. Both purine and pyrimidines bases in DNA are susceptible 
to chemical modifications by reactive oxygen species, resulting in the formation of derivatives 
(e.g. 8-dGuo) that, if not detected and excised by the DNA-repair mechanisms, will result in 
the incorporation of incorrect bases during DNA replication (Bender, 2006). In germline cells, 
this may result in a heritable mutation and, in somatic cells, it may initiate cancer. Radical 
damage can also cause strand breaks in DNA that accelerate the normal age-related 
shortening of telomeres (the repetitive sequences at the end of chromosomes that stabilize 
them). Polyunsaturated fatty acids are highly susceptible to oxidation, leading to the 
formation of lipid peroxides. These break down to form highly reactive dialdehydes, which 
cause chemical modification of nucleic acid bases and proteins. Amino acid side chains in 
proteins are susceptible to direct oxidation by radicals (Bender, 2006).  
Oxidative damage may play an important role in the pathogenesis of several 
neurodegenerative diseases, and growing evidence points to the involvement of free radicals 
in mediating neuronal death in these illnesses (Mecocci et al., 2002; Valavanidis et al., 2009). 
Biological systems develop enzymatic systems – superoxide dismutase, catalase, peroxidases, 
glutathione peroxidase – in combination with other antioxidants (vitamin E, glutathione, 
ascorbate) to protect against oxidative damage. In general, biological systems are in a state of 
approximate equilibrium between pro-oxidant forces and the antioxidant capacity of 
biological systems (Floyd, 1990).  
 
2.1. 8-HYDROXYDEOXYGUANOSINE (8-OHdG) 
Among free radicals, the highly reactive hydroxyl radical (.OH) causes damage to DNA and 
other biological molecules. This type of DNA damage is also called “oxidative damage to DNA” 
and is implicated in mutagenesis, carcinogenesis, and aging (Fairbairn et al., 1995; Jaruga et 
al., 2000; Dizdaroglu et al., 2002; Cooke et al., 2003; Thompson, 2004; Collins, 2004; Azqueta 
et al., 2009; Collins, 2009).  
“Oxidative stress” refers to a state where the balance is upset, either by an excessive 
production of free radicals, or by deficient antioxidant defences. In such circumstances – 
notably in a variety of diseases states – it would be expected to find an elevated level of 
oxidative damage to biomolecules (Collins, 2009).  
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The interaction of .OH with the nucleobases of the DNA strand, such as guanine, leads to the 
formation of C8-hydroxyguanine (8-OHGua) or its nucleoside form deoxyguanosine (8-
hydroxy-2’-deoxyguanosine). Initially, the reaction of the .OH addition leads to the generation 
of radical adducts then, by one electron abstraction, the 8-hydroxy-2’-deoxyguanosine (8-
OHdG) is formed (Valavanidis et al., 2009). The 8-OHdG undergoes keto-enol tautomerism, 
which favours the oxidized product 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxoG). In the 
scientific literature 8-OHdG and 8-oxodG are used for the same compound (Valavanidis et al., 
2009).  
Therefore, the most commonly base lesion, and the one most often measured as an index of 
oxidative DNA damage, is 8-hydroxyguanine (8-OHG). The popularity of 8-OHG as an indicator 
of DNA oxidation is probably attributable to the ease with which it can be measured (Collins, 
2004). It can pair A rather C, and so if it is present during replication, C > A transversions may 
result. It is sometimes measured as the nucleoside, 8-hydroxydeoxyguanosine (8-OHdG) 
(Wiseman & Halliwell, 1996; Persinger et al., 2001; Volkovová et al., 2006; Sedelnikova et al., 
2010; Ersson, 2011).   
 Oxidative DNA base damage (measured as 8-OHdG) has been detected in mitochondrial DNA 
at steady-state levels several-fold higher than in nuclear DNA (Wiseman & Halliwell, 1996; 
Collins, 1999; Sedelnikova et al., 2010). 8-OHG and 8-OHdG are the products most frequently 
measured in isolated DNA as an indicator of oxidative DNA damage (Wiseman & Halliwell, 
1996), and as a possible indicator of cancer risk (Collins, 2009) since it has a pro-mutagenic 
potential (Ersson, 2011). The European Standards Committee on Oxidative DNA Damage 
(ESCODD) was set up to examine critically the different approaches to measuring base 
oxidation in DNA, in particular 8-OHdG  (ESCODD, 2003). 8-OHdG has thus been established as 
an important biomarker of oxidative stress, of cancer risk to humans by mechanisms of 
oxygen-free radicals, of aging processes including degenerative diseases, and in general as a 
biological marker of lifestyle and the effect of diet (Valavanidis et al., 2009).  
Measurement of 8-OHdG by High Performance Liquid Chromatography (HPLC) coupled to 
electrochemical detection (ECD) is a highly sensitive method. One alternative is Gas 
Chromatography-Mass Spectrometry (GS-MS) with selected ion monitoring, which can 
measure a wide spectrum of modified DNA bases (methylated, oxidized, deaminated, etc.). 
Both methods are sufficiently sensitive to measure steady-state levels of oxidative base 
damage in human cells and tissues (Wiseman & Halliwell, 1996; Collins, 1999; Gedik et al., 
2002; Azqueta et al., 2009). Also HPLC linked to tandem mass spectrometry (HPLC-MS/MS) is 
another method that can be used (Azqueta et al., 2009). The enzyme comet assay is often 
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regarded as being less specific when measuring oxidative DNA lesions than HPLC based 
techniques because the enzymes used recognise a range of different damages. The comet 
assay using formamidopyrimidine DNA glycosylase (FPG) was included in the ESCODD trial set 
up to optimize methods for measuring background levels of oxidative damage, particularly 8-
OHG in humans. The trial concluded that the FPG-based methods seemed less prone to 
spurious oxidation than other methods including HPLC-ECD, GC-MS or HPLC-MS/MS (Collins, 
1999; Smith et al., 2006; Dusinska & Collins, 2008; Ersson, 2011).  
The ESCODD study provided a realistic estimate of the actual background level of damage in 
lymphocytes; it is likely to lie somewhere between 4.2 and 0.3 8-OHdG per 106 guanines, 
these are medians of the means from different laboratories, for HPLC and the comet assay, 
respectively  (ESCODD, 2003).  
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CHAPTER 5 – GENOTOXICITY ASSESSMENT METHODS 
 
 
 
 
1. CYTOKINESIS-BLOCK MICRONUCLEUS CYTOME ASSAY (CBMN) 
 
The cytokinesis-block micronucleus cytome (CBMN) assay is a comprehensive system for 
measuring DNA damage; cytostasis and cytotoxicity-DNA damage events are scored 
specifically in once-divided binucleated cells. The endpoints possible to be measured are 
micronuclei (MN), a biomarker of chromosome breakage and/or whole chromosome loss, 
nucleoplasmic bridges (NPB), a biomarker of DNA misrepair and/or telomere end-fusions, and 
nuclear buds (NBUD), a biomarker of elimination of amplified DNA and/or DNA repair 
complexes. Cytostatic effects are measured via the proportion of mono-, bi- and 
multinucleated cells and cytotoxicity via necrotic and/or apoptotic cell ratios (Fenech, 2006, 
2007).  
The CBMN assay has become one of the most commonly used methods for assessing 
chromosome breakage and loss in human lymphocytes both in vivo and ex vivo (Fenech et al., 
1999a; 1999b).  
In the CBMN assay, once-divided cells are recognized by their binucleated appearance after 
blocking cytokinesis with cytochalasin-B, an inhibitor of microfilament ring assembly required 
for the completion of this step (Fenech, 2007). The restriction of scoring just micronuclei in 
binucleated cells prevents confounding effects caused by suboptimal or altered cell division 
kinetics. Because of its reliability and good reproducibility, the CBMN assay has become one of 
the standard cytogenetic tests for genetic toxicology testing in human and mammalian cells 
(Fenech & Crott, 2002; Fenech, 2007) and has been extensively used to evaluate the presence 
and the extent of chromosome damage in human populations exposed to genotoxic agents in 
various occupational settings, in the environment, or as a consequence of lifestyles (Bonassi et 
al., 2011). The biological meaning of micronuclei presence in mononucleated cells indicate 
DNA damage that was present in the cells before they were put into culture with cytochalasin-
B while binucleated cells may contain pre-existing micronuclei as well as micronuclei 
expressed during culture as a result of chromosome breaks accumulated during G0 phase in 
vivo ( Kirsch-Volders & Fenech, 2001; Fenech et al., 2003).  
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CBMN assay is visualized as a “cytome” concept, that implies that every cell in the system 
studied is scored cytologically for its viability status (necrosis, apoptosis), its mitotic status 
(mononucleated, binucleated, multinucleated) and its chromosomal damage or instability 
status (presence of micronuclei, nucleoplasmic bridges, nuclear buds and number of 
centromere probe signals among nuclei or micronuclei of binucleated cells if such molecular 
tools are used in combination with the assay) (Fenech, 2007).  
The use of the CBMN assay in in vitro genetic toxicology testing is well established and in fact 
it has become an accepted standard method to assess the genotoxic hazard of chemicals 
which led to the development of a special guideline by the Organization for Economic 
Cooperation and Development (OECD), the OECD 487 guideline (Kirsch-Volders et al., 2014).  
The CBMN assay is an effective tool for the study of cellular and nuclear dysfunction caused by 
in vitro or in vivo aging, micronutrient deficiency or excess, genotoxin exposure and genetic 
defects in genome maintenance. It is also fruitful in the emerging fields of nutrigenomics and 
toxicogenomics and their combinations, as it becomes increasingly clear that nutrient status 
also impacts on sensitivity to exogenous genotoxins (Fenech, 2005, 2007).  
Many results obtained by this assay indicate the potential predictive value of the CBMN assay 
with respect to cancer risk and validate its use as a test for detecting nutritional, 
environmental and genetic factors that are potentially carcinogenic. Also it is used by 
pharmaceutical industry, human biomonitoring of genotoxic exposures and its increasing 
application in preventive medicine and nutrition and the increased investment in the 
automation of the CBMN assay are indicative of the increasing importance of this test 
(Fenech, 2007).  
The CBMN assay is also widely used in human biomonitoring of in vivo exposure to genotoxins 
and has become a standard biodosimetry method endorsed by the International Atomic 
Energy Agency and the World Health Organization (WHO) for measuring exposure to ionizing 
radiation (Vral et al., 2011).  The assay measures micronuclei and other nuclear anomalies in 
ex vivo mitogen stimulated lymphocytes from in vivo systemic exposed persons, integrating in 
this way in vivo systemic exposure of lymphocytes and in vivo/ex vivo response to the 
genotoxic stress. Its predictivity for the detection of genetic risks is supported by the fact that 
it allows measurement at the single cell level of both structural and numerical chromosome 
aberrations (Kirsch-Volders et al., 2014).   
CBMN assay is a robust assay for genetic damage with applications in ecotoxicology, nutrition, 
radiation sensitivity testing both for cancer risk assessment and optimization of radiotherapy, 
biomonitoring of human populations and importantly testing of new pharmaceuticals and 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
49 
 
other chemicals. There are expectations regarding the future development of an automated 
system that can reliably score the various end points which are possible with the CBMN assay 
(Fenech, 2007).  
There are some limitations and misconceptions regarding CBMN assay that have been 
reported in literature. The use of the CBMN assay for detecting in vivo exposure to genotoxic 
chemicals is somewhat controversial because of the extremely wide diversity of chemicals, the 
multitude of direct or indirect mechanisms of their interaction with the genome, the wide 
spectrum of DNA lesions they may induce and the variety of cellular death/survival responses 
they may trigger (Vral et al., 2011; Kirsch-Volders et al., 2014).  
Other limitation is the needing for a thorough calibration of scorers and standardization of 
scoring procedures aimed at reliably compare micronuclei frequencies among different 
laboratories and studies. One way to exclude scorer variability might be the use of an 
automatic image-analysis system, although a good correlation between visual and automatic 
scoring has been reported by experienced scorers. Automatic scoring is a useful contribution 
to the standardization of the assay and should become a quality standard for future 
biomonitoring studies with the CBMN assay (Speit et al., 2012).   
Other limitations of the CBMN assay include: (i) the exclusion of micronuclei being scored in 
non-divided cells, (ii) the micronuclei produced in vivo do not substantially contribute to 
micronuclei frequency measured in binucleated lymphocytes in the ex vivo CBMN assay, (iii) 
the sensitivity of the CBMN assay for detection of micronuclei in binucleated cells is 
diminished because cytochalasin-B is added late during the culture period so that the 
binucleated cells scored do not always represent cells that have completed one cell cycle only; 
(iv) the delay in adding cytochalasin-B means that damaged cells can be eliminated by 
apoptosis and/or DNA damage induced in vivo can be repaired prior to the production of a 
micronuclei in the presence of cytochalasin-B this may render the CBMN assay to be 
insensitive; (v) a comparison with the in vitro CBMN assay used for genotoxicity testing leads 
to the conclusion that it is unlikely that DNA damage induced in vivo is the cause of increased 
micronuclei frequencies in binucleated cells after occupational or environmental exposure to 
genotoxic chemicals (Kirsch-Volders et al., 2014).  
A recommendations for the future, is the establishment of an international network including 
several cytogenetic reference laboratories establishing and optimising International 
Standardization Organisation (ISO) standards for the conventional and automated CBMN 
assay. By creating such a network of trained laboratories using similar equipment for 
micronuclei automation and the same classifiers, standardised fixation protocols, etc., 
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comparable results can be obtained and the throughput of automated micronuclei scoring can 
be increased to allow a rapid response to large-scale radiation accidents (Vral et al., 2011).  
 
 
1.1. MICRONUCLEI (MN) 
Micronuclei originate from chromosome fragments or whole chromosomes that lag behind 
anaphase during nuclear division and are not included in the main nuclei (Fenech, 1997, 2000; 
Fenech & Crott, 2002).  
Micronuclei are small, extranuclear bodies that arise in dividing cells from acentric 
chromosome/chromatid fragments or whole chromosome/chromatid that lag behind in 
anaphase, and are not included in the daughter nuclei in telophase (Mateuca et al., 2006).  
At telophase, a nuclear envelope forms around the lagging chromosomes and fragments, 
which then uncoil and gradually assume the morphology of an interphase nucleus with the 
exception that they are smaller than the main nuclei in the cell, hence the term 
“micronucleus” (Fenech, 2000). Micronuclei harbouring chromosomal fragments may result 
from direct double strand DNA breakage, conversion of single strand breaks into double 
strand breaks after cell replication, or inhibition of DNA synthesis (Mateuca et al., 2006).   
Micronuclei can be formed via different pathways, namely from acentric chromosome or 
chromatid fragments. A small proportion of acentric chromosome fragments may simply arise 
from unrepaired double-stranded DNA breaks. Other mechanisms that could lead to 
micronuclei formation from acentric fragments include simultaneous excision repair of 
damaged (e.g. 8-OHdG) or inappropriate bases incorporated in DNA (e.g. uracil) that is in 
proximity and on opposite complementary DNA strands (Fenech et al., 2011).  
Other mechanism that may lead to micronuclei from chromosome loss events is 
hypomethylation of cytosine in centromeric and pericentromeric repeat sequences such as 
classical satellite repeats at pericentromeric regions and higher order repeats of satellite DNA 
in centromeric DNA (Fenech et al., 2011).  
Given the central role of kinetochore proteins in the engagement of chromosomes with the 
spindle, it is probable that mutations leading to defects in kinetochore and microtubule 
interaction dynamics could also be a cause of micronuclei formation due to chromosome loss 
at anaphase. Other variables that are likely to increase micronuclei from chromosome loss are 
defects in mitotic spindle assembly, mitosis check point defects and abnormal centrosome 
amplification (Fenech et al., 2011).  
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The fate of micronuclei after their formation in the micronucleated cell is poorly understood. 
Their post-mitotic fate includes: (i) elimination of the micronucleated cell as a consequence of 
apoptosis; (ii) expulsion from the cell (when the DNA within the micronuclei is not expected to 
be functional or capable of replication owing to the absence of the necessary cytoplasmic 
components); reincorporation into the main nucleus (when reincorporated chromosome may 
be indistinguishable from those of the main nucleus and might resume normal biological 
activity); (iii) retention within the cell’s cytoplasm as an extra-nuclear entity (when micronuclei 
may complete one or more rounds of DNA/chromosome replication) (Mateuca et al., 2006; 
Shimizu, 2011).  
The key advantage of the CBMN assay lies in its ability to detect both clastogenic and 
aneugenic events, leading to structural and numerical chromosomal aberrations, respectively 
(Mateuca et al., 2006). Clastogens induce micronuclei by breaking the double helix of DNA, 
thereby forming acentric fragments that are incapable of adhering to the spindle fibers and 
integrate in the daughter nuclei and are thus left out during mitosis. The same occurs to whole 
chromosomes with damaged kinetochores; they cannot attach to the microtubules that pull 
the chromatids toward the daughter cells during mitosis and thus they remain outside the 
new nuclei. This damage could be generated by chemicals reacting with proteins forming the 
kinetochores (Serrano-García & Montero-Montoya, 2001; Utani et al., 2010).   
Aneugens are chemicals that prevent the formation of the spindle apparatus during mitosis. 
These agents generate not only whole chromatids that are left out of the nuclei, thus forming 
micronuclei, but also the formation of multinucleated cells, in which each nucleus would 
contain a different number of chromosomes. These agents are also likely to induce an increase 
in mitotic figures that are clearly seen in the same slides (Serrano-García & Montero-Montoya, 
2001; Utani et al., 2010).   
With CBMN assay it is possible to distinguish between micronuclei originating from whole 
chromosomes and those originating from acentric fragments as well as to determine whether 
malsegregation of chromosomes is occurring between nuclei in a binucleated cell that may 
not contain micronuclei by using pancentromeric DNA probes (Fenech et al., 1999b; Fenech, 
2000, 2006). The use of chromosome-specific centromeric DNA probes allows both the 
determination of specific chromosome loss events resulting in micronuclei, as well as unequal 
segregation of specific chromosomes among daughter nuclei even in the absence of 
micronuclei formation (Fenech et al., 2011). Pancentromeric probes should be used only to 
distinguish between micronuclei originating from chromosome breaks (centromere negative) 
and chromosome loss (centromere positive). Chromosome-specific centromere probes should 
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be used only to measure malsegregation (owing to non-disjunction or chromosome loss) 
involving unique chromosomes (Fenech et al., 1999b; Fenech, 2000; Norppa & Falck, 2003; 
Fenech, 2006; Fenech et al., 2011). Evaluation of the mechanistic origin of individual 
micronuclei by centromere and kinetochore identification contributes to the high sensitivity 
and specificity of the method (Mateuca et al., 2006).  
It is essential to refer that there are important factors influencing the baseline micronuclei 
frequency in human lymphocytes. Age and gender are the most important demographic 
variables affecting the micronuclei index, with frequencies in females being greater than those 
in males by a factor of 1.2 to 1.6 depending on the age group (Bolognesi et al., 1999). 
Micronuclei frequency was significantly and positively correlated with age in males and 
females, and is affected by dietary factors such as folate deficiency, and plasma levels of 
vitamin B12 and homocysteine. It was also proposed that the micronuclei index can be 
influenced by the propensity of individual’s cells to undergo apoptosis and genetic factors, 
such as genetic polymorphisms (Fenech, 1998; Fenech et al., 1999b; Mateuca et al., 2006).   
In general, the formation of micronuclei is attributed to a variety of insults to the genetic 
material, which could be classified as exogenous and endogenous factors. Exogenous factors 
include radiation, chemical agents, microorganism invasion, etc. Endogenous factors include 
genetic defects, pathological changes, deficiency of essential nutritional ingredients (e.g. folic 
acid) and injuries induced by deleterious metabolic products (such as ROS) (Huang et al., 
2011).  
The hypothesis of a predictive association between the frequency of micronuclei in CBMN 
assay in lymphocytes and cancer development is supported by a number of findings: (i) an 
association between micronuclei frequency and cancer risk was inferred from mechanistic 
similarities with chromosomal aberrations, which were shown to be predictive for cancer; (ii) 
in vitro, a high concordance is observed between chromosomal aberrations and micronuclei; 
(iii) an increase in micronuclei frequency is observed in lymphocytes of cancer patients and in 
patients with syndromes that make them cancer prone such as the Bloom syndrome and 
ataxia telangiectasia; (iv) micronuclei frequency is significantly associated with the blood 
concentration of vitamins such as folate, whose deficiencies are associated with increased risk 
for some cancers; (v) a direct link between micronuclei frequencies and early stages of 
carcinogenesis, namely a significant association between increasing of micronuclei frequencies 
and low-grade and high-grade diagnostic categories of cervical carcinogenesis in women 
(Mateuca et al., 2006).  
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Formation of nuclear anomalies such as micronuclei, chromosomal rearrangements, and 
anaphase bridges (leading to breakage-fusion-bridge cycles and generation of more 
micronuclei) are events commonly seen in the early stages of carcinogenesis. Elevated levels 
of micronuclei are indicative of defects in DNA repair and chromosome segregation which 
could result in generation of daughter cells with altered gene dosage, or deregulation of gene 
expression that could lead to the evolution of the chromosome instability phenotype often 
seen in cancer. These considerations give mechanistic support to a possible causal association 
between micronuclei frequency and the risk of cancer. Study from Bonassi et al. (2007) 
observed an association between micronuclei frequency and cancer risk in non-
haematological malignancies suggested that genome damage events in lymphocytes may be 
correlated with cancer initiating events in other tissues via a common genetic, dietary, or 
environmental factor.  
Figure 3 shows the aspect of micronuclei in peripheral binucleated lymphocytes when 
observed at 1000 magnification with immersion oil in optical microscope.   
 
 
Figure 3 – Micronuclei in peripheral binucleated lymphocytes (1000X). May-Grünwald Giemsa staining 
technique. 
 
1.2. NUCLEOPLASMIC BRIDGES (NPB) 
 
Nucleoplasmic bridges occur when centromeres of dicentric chromosomes are pulled to 
opposite poles of the cell at anaphase. In the absence of breakage of the anaphase bridge, the 
nuclear membrane eventually surrounds the daughter nuclei and the anaphase bridge and in 
this manner, a nucleoplasmic bridge is formed (Fenech et al., 2011). There are various 
mechanisms that could lead to nucleoplasmic bridges formation following DNA misrepair of 
strand breaks in DNA. Typically, a dicentric chromosome and an acentric chromosome 
fragment are formed that result in the formation of a nucleoplasmic bridge and a 
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micronucleus, respectively (Fenech, 2000; Fenech & Crott, 2002; Fenech, 2006, 2007). 
Misrepair of DNA strand breaks could also lead to the formation of dicentric ring 
chromosomes and concatenated ring chromosomes which could also result in the formation 
of nucleoplasmic bridges. An alternative mechanism for dicentric chromosome and 
nucleoplasmic bridges formation is telomere end fusion caused by telomere shortening, loss 
of telomere capping proteins or defects in telomere cohesion (Thomas et al., 2003; Fenech, 
2007). The study of Rudolph et al., (2001), in models of rodent and human intestinal cancer in 
vivo, correlates with telomere length, indicating that nucleoplasmic bridges formation may 
also be used as a surrogate measure of critically short telomeres (Fenech, 2007).  
The two mechanisms of nucleoplasmic bridges formation can be distinguished in binucleated 
cytokinesis-blocked cells using telomere probes. Nucleoplasmic bridges arising from telomere 
end fusions are expected to be telomere positive if they retain telomere dysfunction due to 
loss of telomere-binding proteins without telomere attrition. In contrast, nucleoplasmic 
bridges caused by misrepair of DNA breaks has a low probability of occurring within the 
telomeric sequences and is therefore likely to be telomere negative. Furthermore, 
nucleoplasmic bridges arising from misrepair of DNA breaks are also likely to be associated 
with micronuclei originating from the acentric fragment generated during misrepair (Fenech 
et al., 2011). Nucleoplasmic bridges can break and form micronuclei (Fenech, 2006; Lindberg 
et al., 2007). About 40% of micronuclei, two or more arise from a single nucleoplasmic bridge. 
When two or more micronuclei are observed after a nucleoplasmic bridge resolution, normally 
micronuclei in each daughter cell remain (Hoffelder et al., 2004).   
 
Umegaki and Fenech (2000) validated the use of nucleoplasmic bridges as a biomarker of DNA 
damage in human WIL2-NS cells treated with hydrogen peroxide, superoxide or after co-
incubation with activated human neutrophils. Therefore, the importance of scoring 
nucleoplasmic bridges should not be underestimated because it provides direct evidence of 
genome damage resulting for misrepaired DNA breaks or telomere end fusions, which is 
otherwise not possible to deduce by scoring micronuclei only (Umegaki & Fenech, 2000; 
Fenech & Crott, 2002; Fenech, 2006). Nucleoplasmic bridges formation has been shown to be 
increased by a wide range of exposures including endogenous oxidants, ionising radiation, 
polycyclic aromatic hydrocarbons, the cigarette smoke carcinogen 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone, vanadium pentoxide, as well as deficiencies in folate and selenium 
(Fenech et al., 2011).  
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Figure 4 shows the aspect of nucleoplasmic bridges in peripheral binucleated lymphocytes 
when observed at 1000 magnification with immersion oil in optical microscope.   
 
 
Figure 4 – Nucleoplasmic bridges in peripheral binucleated lymphocytes (1000X). May-Grünwald 
Giemsa staining technique. 
 
1.3. NUCLEAR BUDS (NBUD) 
 
Nuclear buds are biomarkers of elimination of amplified DNA and/or DNA repair complexes. 
The nuclear budding process has been observed in cultures grown under strong selective 
conditions that induce gene amplification as well as under moderate folic acid deficiency 
(Fenech & Crott, 2002; Fenech, 2007). Gene amplification plays a crucial role in the malignant 
transformation of human cells as it mediates the activation of oncogenes or the acquisition of 
drug resistance (Utani et al., 2007). Studies conducted by Shimizu et al. (1998, 2000, 2005) 
showed that amplified DNA is selectively localized at specific sites of the periphery of the 
nucleus and eliminated via nuclear budding to form micronuclei during S phase of mitosis. 
Amplified DNA may be eliminated through recombination between homologous regions 
within amplified sequences forming mini-circles of acentric and atelomeric DNA (double 
minutes), which localized at distinct regions within the nucleus, or through the excision of 
amplified sequences after segregation to distinct regions of the nucleus. The process of 
nuclear budding occurs during S phase and the nuclear buds are characterized by having the 
same morphology as an micronuclei with the exception that they are linked to the nucleus by 
a narrow or wide stalk of nucleoplasmic material depending on the stage of the budding 
process (Shimizu et al., 1998, 2000, 2005). Excess of DNA may in general be expelled from the 
nucleus by the formation of nuclear buds, and subsequent micronucleation (Lindberg et al., 
2007). The duration of the nuclear budding process and the extrusion of the resulting 
micronuclei from the cell remain largely unknown (Fenech & Crott, 2002; Fenech, 2006, 2007), 
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although Utani et al. (2007) provided evidence that at least some of the cytoplasmic 
micronuclei may be eliminated from the cell by extrusion. 
Nuclear buds are also classified as tentative precursors of micronuclei, being morphologically 
similar to micronuclei, namely in shape, structure, and size; with the exception that they are 
connected to the nucleus by a narrow or wide stalk of nucleoplasmic material depending on 
the stage of the budding process (Serrano-García & Montero-Montoya, 2001; Lindberg et al., 
2007; Fenech et al., 2011). Nuclear buds may also be explained by the conventional model of 
micronuclei formation, assuming they derive from anaphase laggards that independently form 
a nuclear envelope in telophase before fully integrating into the nucleus or from remnants of 
broken anaphase bridges (Lindberg et al., 2007). The DNA in these buds is replicated and can 
subsequently be released as micronuclei in the cytoplasm. Nuclear buds have also been shown 
to be formed when a nucleoplasmic bridge between two nuclei breaks and the remnants 
shrink back towards the nuclei (Fenech et al., 2011).  
Nuclear buds originate from interstitial or terminal acentric fragments. Such nuclear buds may 
possibly represent nuclear membrane entrapment of DNA that has been left in cytoplasm 
after nuclear division or from excess DNA that is being extruded from the nucleus. Whether 
nuclear buds are also a mechanism to eliminate excess chromosomes in a hypothesized 
process known as aneuploidy, rescue remains unclear as there is only limited evidence for this 
possibility. Finally, it is also plausible that nuclear buds might occur transiently after breakage 
of nucleoplasmic bridges (Fenech et al., 2011). Figure 5 shows the aspect of micronuclei in 
peripheral binucleated lymphocytes when observed at 1000 magnification with immersion oil 
in optical microscope.   
 
 
Figure 5 – Nuclear buds in peripheral binucleated lymphocytes (1000X). May-Grünwald Giemsa staining 
technique. 
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In conclusion, the CBMN assay has evolved into an efficient “cytome” assay of DNA damage 
and misrepair, chromosomal instability, mitotic abnormalities, cell death and cytostasis, 
enabling direct and/or indirect measurement of various aspects of cellular and nuclear 
dysfunction such as: unrepaired chromosome breaks fragments and asymmetrical 
chromosome rearrangement (micronuclei or nucleoplasmic bridges accompanied by 
micronuclei originating from acentric chromosomal fragments); telomere end fusions 
(nucleoplasmic bridges with telomere signals in the middle of the bridge and possibly without 
accompanying micronuclei); malsegregation of chromosomes due to spindle or kinetochore 
defects or cell-cycle checkpoint malfunction (micronuclei containing whole chromosomes or 
asymmetrical distribution of chromosome-specific centromere signals in the nuclei of 
binucleted cells); nuclear elimination of amplified DNA and/or DNA repair complexes (nuclear 
buds); chromosomal instability phenotype and breakage-fusion-bridge cycles (simultaneous 
expression of micronuclei, nucleoplasmic bridges, and nuclear buds); DNA hypomethylation;  
altered mitotic activity and/or cytostasis and cell death by necrosis or apoptosis (ratios of 
necrotic and apoptotic cells) (Fenech, 2007).  
 
 
2. MICRONUCLEI TEST IN EXFOLIATED BUCCAL CELLS 
 
 
2.1. EXFOLIATED BUCCAL CELLS 
 
Up to 90% of cancers arise in epithelial tissues, often these tissues are the actual targets of 
carcinogens, as can be deduced by relating the sites of cancers with the exposures. Epithelial 
tissues are in immediate contact with inhaled and ingested genotoxic agents, and kidney and 
bladder cells are also in contact with metabolites of the chemicals (Tolbert et al., 1991; Fenech 
et al., 1999b; Burgaz et al., 2002; Proia, 2006; Holland et al., 2008; Kashyap & Reddy, 2012). 
Therefore, buccal cells are the first barrier for the inhalation or ingestion route and are 
capable of metabolizing proximate carcinogens to reactive products (Burgaz et al., 2002; 
Holland et al., 2008; Kashyap & Reddy, 2012).   
Exfoliated buccal cells have been effective in showing the genotoxic effects of lifestyle factors 
such as tobacco smoking, alcohol, medical treatments, such as radiotherapy as well as 
occupational and environmental exposure, namely exposure to potentially mutagenic and/or 
carcinogenic chemicals, and by studies of chemoprevention of cancer (antioxidants) and 
evaluation of malignant transformation of preneoplastic lesions with oral squamous cell 
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carcinoma (Fenech et al., 1999a; Majer et al., 2001; Burgaz et al., 2002; Proia, 2006; Fenech, 
2007; Holland et al., 2008; Thomas & Fenech, 2011; Cerqueira & Meireles 2012; Kashyap & 
Reddy, 2012). For these reasons, exfoliated cells hold strong potential as a tool for 
biomonitoring human populations exposed to genotoxic agents or undergoing preventive 
treatments, furthermore they can be easily collected from the mouth, nose, and bladder by 
non-invasive procedures.  
The buccal mucosa is a stratified squamous epithelium consisting of four distinct layers. The 
stratum corneum, or keratinized cell layer, lines the oral cavity comprising cells that are 
constantly being shed as a result of wear and tear of the surface tissue. Below this layer, lies 
the stratum granulosum, or the granular cell layer, and the stratum spinosum, or the prickle 
cell layer, containing population of differentiated, apoptotic and necrotic cells. Beneath these 
layers are the rete pegs or stratum germinativum, containing actively dividing basal cells and 
basal stem cells, which produce progeny that differentiate and maintain the profile, structure 
and integrity of the buccal mucosa (Thomas & Fenech, 2011; Cerqueira & Meireles, 2012; 
Kashyap & Reddy, 2012).  
The mucosa represents a permeability barrier for xenobiotics due mainly to the flattened 
surface cell layers and intercellular material. Cells of the epithelia are covered by mucus, 
whose main components are complexes made up of proteins and carbohydrates. Thus, soft 
tissues are well protected from chemicals and from abrasion by rough materials. 
Consequently, the detection of increased micronuclei frequencies in exfoliated epithelial cells 
requires that the genotoxic agent overwhelms the permeability barrier, reaches the basal 
layer on paracellular and/or transcellular routes, and induces DNA lesions that become 
micronuclei during cell division. These cells then have to migrate to the surface to be collected 
for the micronuclei test (Speit & Schmid, 2006).  
 
2.2. MICRONUCLEUS TEST  
 
The micronucleus test (MNT) is a cytogenetic method for measuring genetic damage, cell 
proliferation, cell differentiation and cell death in exfoliated buccal cells. This technique is 
particularly attractive as buccal cells can be collected in a minimally invasive manner. The MNT 
has been widely applied since 1980 in biomonitoring inhalation or local exposure to genotoxic 
agents. It has also been applied to investigate and evaluate the impact of nutritional status 
and lifestyle factors on DNA damage, cellular proliferation and cell death (Bolognesi et al., 
2013). The MNT has been used to measure biomarkers of DNA damage (micronuclei and/or 
nuclear buds), cytokinetic defects (binucleated cells) and proliferative potential (basal cell 
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frequency) and/or cell death (condensed chromatin, karyorrhexis, pyknotic and karyolitic cells) 
(Thomas et al., 2009; Bolognesi et al., 2013).  
The MNT is also frequently used for monitoring genetic damage in humans. The MNT with 
exfoliated epithelial cells, in particular in buccal cells, is used as a minimally invasive method 
for monitoring genotoxic effects at the site of first contact, being expected that the MNT is a 
site-specific biomarker of exposure to genotoxic agents and for cancer risk and a useful tool to 
establish human exposure limits for genotoxic substances (Majer et al., 2001; Speit et al., 
2007; Holland et al., 2008; Speit et al., 2011).  
Micronuclei are formed in damaged cells of the basal layer during cell division. These cells 
then have to migrate to the surface to be collected for the MNT.  
The use of biomarkers to identify genetic damage in individuals at higher risk of developing 
oral squamous cell carcinoma and to evaluate the malignant transformation potential of 
precancerous lesions is considered to be an important tool for cancer prevention. MNT on 
exfoliated cells from oral epithelium has been widely used for these purposes (Cerqueira & 
Meireles 2012) in all human tissues from which exfoliated cells can be obtained (Majer et al., 
2001).   
Compared with other genotoxicity assays which are currently used for human biomonitoring, 
the MNT in exfoliated buccal cells is potentially an excellent candidate to serve as such a 
biomarker having many advantages: 
(i) it is a simple and fast test system. The cells can be obtained easily and do not have to be 
cultivated. Processing and staining of the cells are less time-consuming compared to other test 
systems and can be performed in laboratories with basic equipment; (ii) the endpoint is well 
defined and can easily be recognised; (iii) cells can be fixed and stored for long periods of 
time; (iv) unlike other cytogenetic measurements, micronuclei are found in the interphase of 
the cell cycle. Therefore, all samples usually contain a sufficiently high rate of countable cells; 
(v) the simplicity of sample collection with non-invasive methods makes the test applicable to 
large sample sizes (Majer et al., 2001; Holland et al., 2008; Cerqueira & Meireles, 2012).   
The time of sampling is also an important variable to consider. As the buccal cells turn over 
every 7-21 days, it is theoretically possible to observe the genotoxic effects of an acute 
exposure approximately 7-21 days later (Shojaei, 1998; Thomas et al., 2009; Cerqueira & 
Meireles, 2012). Unlike lymphocytes which must be stimulated to undergo mitosis, and thus 
introduce problems of interpretation, epithelial cells do not need to be stimulated; 
micronuclei in exfoliated cells reflect genotoxic events that occurred in the dividing basal cell 
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layer 1 – 3 weeks earlier. Furthermore, at many sites, the technique is completely non-
invasive, and repeated sampling is acceptable (Tolbert et al., 1991).  
There is some concern regarding the staining techniques in the MNT since there are many 
false-positive results in micronuclei frequency as a result of using Romanowsky-type stains 
such as Giemsa, May-Grunwald Giemsa (MGG) and/or Leishmann’s, and Papanicolaou (Ayyad 
et al., 2006; Nersesyan et al., 2006) which leads to inaccurate assessment of DNA damage 
(Nersesyan et al., 2006). Romanowsky stains have been shown to increase the number of false 
positives as they positively stain keratin bodies that are often mistaken for micronuclei and 
are therefore not appropriate for this type of analysis (Majer et al., 2001; Holland et al., 2008; 
Thomas et al., 2009). The staining technique recommended is Feulgen because it is a DNA-
specific stain and because permanent slides can be obtained and be viewed under both 
transmitted and/or fluorescent light conditions (Nersesyan et al., 2006).  
Figure 6 shows the aspect of micronuclei in exfoliated buccal cell when observed at 1000 
magnification with immersion oil in optical microscope.   
  
 
Figure 6 – Micronuclei in exfoliated buccal cell (1000X). Feulgen staining technique without 
counterstain. 
 
 
3. COMET ASSAY 
 
Rydberg and Johanson (1978) were the first to directly quantify levels of DNA damage in 
individual cells by embedding them in agarose on slides and then lysing under mild alkali 
conditions to allow for the partial unwinding of DNA (Valverde & Rojas, 2009a). 
Östling and Johanson in 1984 developed a microgel electrophoresis technique for detecting 
DNA damage at the level of a single cell. In their technique, cells embedded in agarose were 
placed on a microscope slide, the cells were lysed by detergents and high salt, and the 
liberated DNA was electrophoresed under neutral conditions. Cells with an increased 
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frequency of DNA double-strand breaks displayed increased migration of DNA toward the 
anode. The migrating DNA was quantified by staining with ethidium bromide and by 
measuring the intensity of fluorescence at two fixed positions within the migration pattern 
using a microscope photometer. The neutral conditions used greatly limited the general utility 
of the assay though (Tice et al., 2000; Valverde & Rojas, 2009a).  
Subsequently, Singh et al. (1988) introduced a microgel technique involving electrophoresis 
under alkaline (pH>13) conditions for detecting DNA damage in single cells. At this pH, 
increased DNA migration is associated with incomplete excision repair sites, and alkali labile 
sites (Tice et al., 2000; Hartmann et al., 2003).  
Because almost all genotoxic agents induce orders of magnitude more single strand breaks 
and/or alkali labile sites than double strand breaks, this version of the assay offered greatly 
increased sensitivity for identifying genotoxic agents (Valverde & Rojas, 2009a). Two years 
later, Olive and colleagues introduced another alkaline version of this assay in which DNA is 
electrophoresed at a pH of ≈12.3. Since the introduction of alkaline (pH > 13) comet assay in 
1988, the breadth of applications and the number of investigators using this technique have 
increased almost exponentially. Compared with other genotoxicity assays, the advantages of 
the technique include: (i) its demonstrated sensitivity for detecting low levels of DNA damage; 
(ii) the requirement for small numbers of cells per sample; (iii) flexibility; (iv) low costs; (v) 
ease of application; (vi) the ability to conduct studies using relatively short time period (a few 
days) needed to complete an experiment (Tice et al., 2000).  
The comet assay or single-cell gel electrophoresis (SCGE) is a simple, sensitive method for 
detecting DNA-strand breaks. Cells embedded in agarose on a microscope slide are lysed with 
detergent and 2.5 M NaCl and fresh Triton X-100 to remove membranes and soluble cell 
constituents, including most histones, leaving the DNA, still supercoiled and attached to a 
nuclear matrix, as a nucleoid. A break in one strand of a DNA loop is enough to release the 
supercoiling, and during electrophoresis the relaxed loops are able to extend towards the 
anode (Fairbairn et al., 1995; Collins et al., 1997; Moller et al., 2000; Azqueta et al., 2009; 
Collins & Dusinska, 2009). Electrophoresis causes DNA loops containing breaks to move 
towards the anode, forming “comets” when stained and visualised by fluorescence 
microscopy. The relative content of DNA in the tail indicates the frequency of breaks (Gedik et 
al., 2002; Kumaravel & Jha, 2006; Collins & Dusinska, 2009).   
DNA strand breaks can originate from the direct modification of DNA by chemical agents or 
their metabolites; from the processes of DNA excision repair, replication, and recombination; 
or from the process of apoptosis. Direct breakage of the DNA strands occurs when ROS 
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interact with DNA. In what refers to alkaline labile sites, those can be generated by 
depurination of an adducted base of the nucleotide and a subsequent conversion of the abasic 
site to a strand break detected by alkaline treatment (pH above 13.1) (Moller et al., 2000).  
This assay was adapted to measure oxidised purines and oxidised pyrimidines by the 
incubation of the nucleoids with bacterial DNA repair enzymes (Azqueta et al., 2009), 
including formamidopyrimidine DNA glycosylase (FPG), which recognizes the oxidised purine 
8-OHdG, Endonuclease III do detect oxidised pyrimidines, T4 endonuclease V to detect UV-
induced pyrimidines dimmers, AlkA (3-methyladenine DNA glycosylase) for alkylated bases, or 
uracil DNA glycosylase, which removes misincorporated uracil from DNA (Collins & Dusinska, 
2009).  
Comet assay has become one of the standard methods for assessing DNA damage, with a wide 
range of applications, namely in genotoxicity testing, human biomonitoring and molecular 
epidemiology, ecogenotoxicology, as well as fundamental research in DNA damage and repair 
(Collins, 2004, 2009);  studying the mechanisms of action of genotoxic chemicals; investigating 
oxidative damage as a factor in disease; monitoring oxidative stress in animals or human 
subjects resulting from exercise, or diet, or exposure to environmental agents; studying the 
effects of dietary antioxidants; and monitoring environmental pollution by studying sentinel 
organisms (Dusinska & Collins, 2008; Azqueta et al., 2009a). This assay is useful for evaluating 
xenobiotic impacts based on its use of small cell samples, and its ability to evaluate DNA 
damage in non-proliferation cells such as lymphocytes. In addition, the ability to obtain 
sufficient numbers of cells for analysis from different tissues, for instance lymphocytes and 
buccal cells provides a relatively non-invasive procedure for analysis (Valverde & Rojas, 
2009a). Most of the studies assayed human blood cells because they circulate in the body, and 
the cellular, nuclear, and metabolic state of the blood cells can reflect the overall extent of 
body exposure (Valverde & Rojas, 2009). Although lymphocytes are, like all tissues, highly 
specialized, they can be seen as reflecting the overall state of the organism, insofar as they 
circulate through the whole body (Collins et al., 2008). In addition, in biomonitoring studies, 
nasal epithelial cells and buccal cells have drawn the most attention because they are cells 
from tissues that come into direct contact with ingested or inhaled compounds (Moller et al., 
2000).  
The congruence of results between the comet assay and other endpoints such micronuclei or 
sister chromatid exchanges (SCE), has been one of the principal reasons to increase the use of 
the comet assay as a biomarker for hazard assessment, particularly in monitoring the effects 
of occupational hazards (Valverde & Rojas, 2009a; 2009b).   Biological monitoring has been an 
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important tool for the surveillance of medical health programs in European countries and for 
monitoring occupational hazards in the USA (Valverde & Rojas, 2009b).  
 
3.1. FORMAMIDOPYRIMIDINE DNA GLYCOSYLASE (FPG) 
Measuring DNA strand breaks gives limited information. Breaks may represent the direct 
effect of some damaging agent, but they are generally quickly rejoined. They may in fact be 
apurinic/apyrimidinic sites (i.e. AP sites or baseless sugars), which are alkali labile and 
therefore appear as breaks. Or they may be intermediates in cellular repair, because both 
nucleotide and base excision-repair processes cut out damage and replace it with sound 
nucleotides (Collins et al., 2001; Collins, 2004). AP-sites are alkali-labile, so in principle they are 
expected to appear among the strand breaks detected in the standard alkaline comet assay. 
But it has not been convincingly demonstrated that all AP-sites are converted under these 
conditions (Azqueta et al., 2009; Johansson et al., 2010).  
To make the assay more specific as well as more sensitive, an extra step was introduced of 
digesting the nucleoids with an enzyme that recognizes a particular kind of damage and 
creates a break. FPG detects the major purine oxidation product 8-OHG as well as other 
altered purines (Moller et al., 2000; Collins et al., 2001; Collins, 2004; Collins et al., 2008).  This 
enzyme was named for its ability to recognize imidazole-ring-opened purines, or 
formamidopyrimidines, namely 8-OHdG, 2,6-diamino-4-hydroxy-5-formadopyrimidine (FaPyG) 
and 4,6-diamino-5-formamidopyrimidine (FaPyA), which occur during the spontaneous 
breakdown of damaged purines; however, a major substrate in cellular DNA is 8-OHG (Smith 
et al., 2006; Dusinska & Collins, 2008; Azqueta et al., 2009; Collins, 2009).  
A mammalian analogue of FPG, 8-Oxoguanine DNA glycosylase 1 (OGG1), has been applied in 
the comet assay, however studies performed comparing FPG and OGG1 reveals 
ineffectiveness of OGG1 (Azqueta et al., 2009). For that reason, FPG continues to be the 
enzyme of choice for oxidised purines. 
Figure 7 shows the aspect of comets observated at 400X magnification with DAPI 
fluorochrome in fluorescence microscope.   
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Figure 7 – Comets measured by Perceptive Instruments® software at 400X magnification. DAPI 
fluorescent staining technique. 
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CHAPTER 6 – INDIVIDUAL SUSCEPTIBILITY 
 
 
 
1. GENETIC SUSCEPTIBILITY 
 
Susceptibility is genetic when stemming from differences at the DNA level. Subareas of genetic 
susceptibility include: inheritable variation in carcinogen metabolizing enzymes (activation 
and detoxification); mutations of proto-oncogenes or tumour suppressor genes; hormonal and 
in immunologic factors and inherited differences in DNA adduct formation and DNA repair 
mechanisms (Ishibe & Kelsey, 1997; Vainio, 1998; Berwick & Vineis, 2000; Perera, 2000).   
Given equal exposure to the same carcinogen, individuals will vary in their internal processing 
of the agent, depending on genetic background, acquired characteristics, and other past or 
ongoing exposures (Perera, 1996).   
Individual variations in uptake of reactive chemicals, metabolism of environmental mutagens 
and repair of DNA damage, and others can affect the study outcome significantly (Au et al., 
1998). Those subjects who biotransform absorbed chemicals into effective doses even at the 
low exposure levels exhibit adverse effects comparing with the vast majority of the population 
who do not exhibit any adverse effects at the same exposure level (Mutti, 1999).  
The development of molecular techniques and data from the human genome project, have 
contributed to a better understanding of the genetic basis of the variation in environmental 
disease outcome, namely based on the inheritance of different versions of polymorphic 
metabolizing genes, such as the cytochrome P450, the GST and the N-acetyl transferase 
genes. Inheritance of “unfavourable” versions of these genes is significantly associated with 
the development of a variety of environmental cancers, such as lung and bladder cancers. 
Data suggest that inheritance of the “unfavourable” genes caused individuals to have 
increased body burden of reactive metabolites from exposure to specific environmental 
mutagens. Therefore, these individuals have significantly increased risk for environmental 
cancers (Au et al., 1998; Mutti, 1999).  
There are certain cancers, such as colon, breast and prostate cancers that are due to a genetic 
predisposition. These very strong susceptibility genes may not be influenced by environmental 
factors, but there is evidence for environmental influences in some diseases even when there 
is strong genetic predisposition. Many genes in the genome of humans and other species 
influence the impact of environmental agents on the organism. Genetic controls on the 
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uptake, activation, detoxification, or repair of environmental insults are known. The exact 
number of genes involved in the organism’s response to environmental hazards is unknown 
but could be very large (Barrett et al., 1997).  
 
1.1. SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) 
Single Nucleotide Polymorphisms (SNP) are of interest for a variety of reasons. First, a SNP, 
particularly when found in a functional gene region, may itself encode differences in protein 
form and expression, which in turn lead to disease and other, often subtler, phenotypic 
differences. Second, SNPs may mark or track the presence of other, perhaps less easily 
detected and processed genetic differences that cause phenotypes of interest. Third, they are 
useful in studying mutation rates and evolutionary history (Salisbury et al., 2003).  
Polymorphic variation in several types of genes may influence cancer susceptibility at the 
population level. In addition to the metabolism of xenobiotics, these polymorphisms can 
affect the metabolism of various dietary factors, the endogenous synthesis, metabolism and 
action of hormones, DNA repair, immune and inflammatory processes, oxidant stress, signal 
transduction and cell-cycle control (Perera, 2000).  
An example of a main contribute to interindividual susceptibility is “Phase II” detoxifying 
enzymes, such as GST and N-acetyltransferase (NAT) that may add a more substantial 
attributable risk in a carcinogen-exposed population (Perera, 1996; Ishibe & Kelsey, 1997; 
Hussain & Harris, 1998). Different sources indicated that about 40% of the population has a 
deletion at this locus which has been linked to increased risk of bladder and lung cancers 
(Perera, 2000) or approximately 50% of Caucasians have a deletion in the GSTM1 gene 
(Perera, 1996; Au et al., 1998) and in GSTT1 approximately 30% (Au et al., 1998).  
Certain combinations of metabolic polymorphisms are increasingly being linked to increased 
cancer risk. Acquired or inherited variations in the efficiency or fidelity of DNA repair can also 
influence individual susceptibility to cancer (Vineis, 1995; Perera, 2000). Common DNA 
variation, as opposed to rare mutations, could be responsible for a proportion of common 
human diseases [i.e., the common variant/common disease (CV/CD) hypothesis] (Crawford et 
al., 2005). The risks associated with single SNPs in molecular epidemiology studies are 
generally expected to be less than the risks associated with reduced repair capacity 
phenotypes assuming that the repair capacity and mutagen sensitivity phenotypes are the 
sum of the impact of multiple variants in multiple genes along a pathway (Mohrenweiser, 
2004).  
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2. GENETIC POLYMORPHISMS 
A genetic polymorphism is defined as a gene variant that is prevalent at least at a frequency of 
1% in a given population (Brooks, 2003; Thier et al., 2003). The discovery of polymorphisms in 
genes for chemical metabolisms and for DNA repair has generated tremendous interest in 
understanding the phenomenon of genetic susceptibility in populations (Au et al., 2004). 
There are several reasons why incorporating common genetic polymorphisms into 
epidemiologic studies will enhance our understanding of the relationship between 
environmental exposures and cancer: (i) by characterizing the effects of established 
carcinogens among people with particular genetic variants, one can gain mechanistic insights 
into the origins of cancer; (ii) by identifying and studying population subgroups that are 
genetically susceptible to a particular carcinogen, one can uncover the low levels of risk 
associated with certain common exposures; and (iii) by determining which susceptibility genes 
are associated with a given cancer, one can generates insights into the potential carcinogens 
acted upon by these gene products (Rothman et al., 2001; Zijno et al., 2006). Genetic 
polymorphisms may be particularly important for low exposures levels, which could influence 
the whole process of risk assessment, a process that is now starting to take individual 
variability in susceptibility into account (Garte, 2008).  
 
 
3. DNA DAMAGE REPAIR SYSTEMS 
Genes involved in DNA repair play an important role in carcinogenesis. Major research 
activities have been focused on polymorphisms in these genes as an important component of 
the susceptibility phenomenon because DNA repair activities are critically involved with 
protection of the genome and in cancer prevention (Au et al., 2004). Their primary duty is to 
maintain the integrity of the genome by removing lesions created by chemicals and other 
environmental exposures. These lesions, left unrepaired, contribute to cell death, mutation, 
chromosome damage, and carcinogenesis (Ishibe & Kelsey, 1997; Berwick & Albertini, 2008).  
At least four major, partly overlapping damage repair pathways operate in mammals – 
nucleotide excision repair (NER), base-excision repair (BER), homologous recombination (HR), 
and non homologous end joining (NHEJ) (Hoeijmakers, 2001).  
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3.1. X-RAY CROSS COMPLEMENTATION GROUP 3 (XRCC3) 
DNA double-strand breaks are considered to be particularly important because their repair is 
intrinsically more difficult than that of other types of DNA damage posing a particular threat 
to genomic integrity (Hoeijmakers, 2001; Johnson & Jasin, 2001; Khanna & Jackson, 2001). 
There are two distinct and complementary mechanisms for DNA double strand breaks repair - 
HR and NHEJ pathways (Hoeijmakers, 2001; Khanna & Jackson, 2001). HR (e.g. RAD51 gene) 
repairs double strand breaks with a template, such as a sister chromatid or homologous 
chromosome, found elsewhere in the genome, whereas NHEJ uses no repair template at all. 
NHEJ can be mutagenic; HR is more accurate and increases in S-G2 cell cycle phases. HR also 
can result in deletions and rearrangements (Berwick & Albertini, 2008). Notably, a growing 
number of mammalian proteins are related to RAD51, and some of them, such as RAD51B, 
XRCC2 and XRCC3, are involved in HR and may contribute to the maintenance of genome 
stability (Khanna & Jackson, 2001).  
The X-ray repair cross-complementing gene 3 (XRCC3) participates in DNA double-strand 
break/recombination repair and is a member of an emerging family of Rad-51-related proteins 
that participate in the HR pathway to maintain chromosome stability, repair DNA damage, and 
correct chromosome segregation in mammalian cells (Bolognesi et al., 2013; Catalán et al., 
2000b; Matullo et al., 2001; Bonassi et al., 2003; El-Zein et al., 2006; Iarmarcovai et al., 2006; 
Kirsch-Volders et al., 2006; Battershill et al., 2008; Mateuca et al., 2008). This pathway is of 
great importance in preventing chromosomal fragmentation, translocations, and deletions, 
which can lead to carcinogenesis (Winsey et al., 2000). The RAD51 paralogue XRCC3 promotes 
the HR repair of double strand breaks induced either directly or indirectly following replication 
of closely spaced single strand breaks (Mateuca et al., 2008). XRCC3 is also required for the 
assembly and stabilization of RAD51 (Winsey et al., 2000; Shen et al., 2002). In addition to 
repairing double strand-breaks, XRCC3 also plays a role in the repair of more global DNA 
damage arising from carcinogen treatment (Araujo et al., 2002). It was reported that XRCC3 
mutation causes severe chromosome instability and increased sensitivity to DNA cross-linking 
drugs (Liu et al., 1998; Brenneman et al., 2000).   
XRCC3 is on chromosome 14 (14q32.3) and its most studied polymorphism is a transition 
between cytosine and thymine in exon 7 (XRCC3-18067C> T) at codon 241 that results in the 
substitution of a threonine by a methionine (Shen et al., 2002; Bonassi et al., 2003; Wang et 
al., 2003; Battershill et al., 2008; El-Zein et al., 2008). The XRCC3 Thr241Met variation does not 
reside in the adenosine triphosphate-binding domain, the only functional domain identified in 
the resulting protein (Manuguerra et al., 2006); however, conversion from a hydroxyl amino 
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acid to one with a sulfhydryl group represents a substantial change in protein functional 
characteristics (Winsey et al., 2000). This polymorphism has been proposed as an allele of low 
penetrance associated with breast and lung cancer, acute myeloid leukemia, risk of upper 
aerodigestive tract cancer (Stich & Rosin, 1983; Ramirez & Saldanha, 2002; Wang et al., 2003; 
Au et al., 2004; El-Zein et al., 2008) and risk for melanoma skin cancer and bladder carcinoma 
(Wang et al., 2003).  
 
3.2. HUMAN 8-OXOGUANINE DNA GLYCOSYLASE 1 (OGG1) 
The cellular defense system against 8-oxoguanine (8-OHdG) mutagenesis involves BER, NER, 
mismatch repair and prevention of incorporation. BER via DNA glycosylase (OGG1) represents 
the main mechanism of protecting the integrity of the human DNA with respect to 8-OHdG. 
Repair of oxidative damage is initiated by OGG1 (Hu & Ahrendt, 2005; Jiao et al., 2007), and its 
activity is responsible for the excision of 8-OHdG and the structurally related lesion 2,6-
diamino,4-hydroxy-5-formamidopyrimidine, a hydrolytic ring-opening product of guanine. BER 
is the main guardian against damage due to cellular metabolism, including that resulting from 
reactive oxygen species, methylation, deamination and hydroxylation (Hoeijmakers, 2001). It 
is the key repair system for removing small-sized base damage that includes oxidized or 
reduced bases and non-bulky DNA adducts. BER employs DNA lesion-specific glycosylase to 
recognize and hydrolytically cleaves and removes the altered base, giving rise to an abasic site 
(Cooke et al., 2003; Au et al., 2004; Sedelnikova et al., 2010). OGG1 is considered to be the 
main enzyme responsible for the removal of 8-OHdG in humans, removing it when it is paired 
with cytosine. However, OGG1 does not release 8-OHdG when misrepaired with an adenine or 
a guanine (Boiteux & Radicella, 1999; Ersson, 2011). In general, the glycosylase mechanism of 
action acts by sliding along the DNA chain, frequently forming an “interrogation” structure 
where bases flip out from the DNA helix and are inspected by the enzyme extra-helically. 
When encountering a damaged base, it is transferred from the interrogation complex to the 
enzyme’s active site. Bifunctional glycosylases, such as OGG1 and FPG, possess both 
glycosylase and AP-lyase activity, cleaving first the glycosidic bond between the base and the 
sugar and then the DNA backbone (at the 3’-carbon of the abasic sugar). FPG also have an 
attached AP-endonuclease activity cleaving the other phosphodiester bond at the DNA 
backbone (at the 5’-carbon of the abasic sugar) (Wiseman & Halliwell, 1996; Ersson, 2011).  
Some findings indicate that the inactivation of OGG1 plays a role in the multistage process of 
carcinogenesis. The human OGG1 gene is located on chromosome 3 (3p26), and encodes a 
bifunctional DNA glycolylase endowed with a AP lyase activity. This is a region frequently lost 
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in various types of cancer, especially in small-cell lung cancers where loss of heterozygosity in 
nearly 100% of the cases can be observed. Loss of one OGG1 allele may lead to a moderate 
generation of 8-OHdG in DNA. However, loss of both alleles would abrogate OGG1 activity 
imposing an increased risk of mutagenicity on the cell due to the imbalance of oxidative 
burden and accumulation of 8-OHdG in DNA (Pilger & Rüdiger, 2006).  
The product of OGG1 gene exhibits specificity and activity for the excision of 8-OHdG (Boiteux 
& Radicella, 1999; Cooke et al., 2003; Au et al., 2004), and has a major role in the prevention 
of ROS-induced carcinogenesis (Cooke et al., 2003).   
A common polymorphism is Ser326Cys, which affects over 50% of Chinese and Japanese and 
approximately 33-41% of Caucasian population (Hu & Ahrendt, 2005). The OGG1 has a C→G 
polymorphism at position 1245 in exon 7 which causes the substitution of serine by cysteine 
at codon 326 (Kohno et al., 1998) and it is associated with increased risk for cancer 
(Macpherson et al., 2005).  
 
4. ALCOHOL DEHYDROGENASE 5 (ADH5)  
Genetic polymorphisms of metabolically relevant enzymes may lead to relevant shifts in the 
critical balance of activation and inactivation, and subsequently to altered individual disease 
susceptibility (Thier et al., 2003). To prevent the lethal and mutagenic effects of 
formaldehyde, several repair mechanisms are involved. Detoxification of formaldehyde can be 
carried out by enzymes like formaldehyde dismutase, methylformate synthase, or glutathione-
independent formaldehyde dehydrogenase (Gonzalez et al., 2006; Neuss & Speit, 2008).  
The glutathione-dependent formaldehyde dehydrogenase (FDH, also known as alcohol 
dehydrogenase 5, ADH5; EC 1.2.1.1) is the most important enzyme for the metabolic 
inactivation of formaldehyde (Just et al., 2011; NTP, 2011).  
According to the Human Genome Organization (HUGO) Gene Nomenclature Committee 
(www.genenames.org) this gene is called alcohol dehydrogenase 5 (ADH5). Previous names 
and aliases are: formaldehyde dehydrogenase (FDH); chi isozyme of ADH; ADH, class III and S-
nitrosoglutathione reductase, and even alcohol dehydrogenase 3 (ADH3) is still frequently 
used in the scientific literature (Just et al., 2011). ADH5 is composed of nine exons and eight 
introns (Hur & Edenberg, 1992), is located on chromosome 4 (4q23) (Just et al., 2011), and has 
been detected in all human tissues and at all stages of development. This enzyme is an 
important component of cellular metabolism for the elimination of formaldehyde serving as 
the prime guardian against formaldehyde (Hedberg, 2001) and offering enzymatic defence 
against both formaldehyde and nitrosative stress in human oral tissue and in epithelial cell 
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lines. Although formaldehyde is rapidly metabolized, it is an electrophile that reacts with a 
variety of endogenous molecules, including glutathione, proteins, nuclei acids, and folic acid 
(NTP, 2011). This is the only ADH identified thus far that is capable of oxidizing formaldehyde 
in a glutathione dependent reaction (Kaiser et al., 1991; Engeland et al., 1993; Lee et al., 
2003).  
ADH5 oxidizes S-hydroxymethylglutathione (which is formed spontaneously from 
formaldehyde and glutathione) to S-formylglutathione. Formation of S-
hydroxymethylglutathione efficiently counteracts the presence of free formaldehyde; a 
reaction that is determined by the fact that free glutathione is present in cells in abundance.  
S-formylglutathione is then further metabolized by S-formylglutathione hydrolase to yield 
formic acid and reduced glutathione. The activities of ADH5 are two to three orders of 
magnitude lower than those of S-glutathione hydrolase and thus the ADH5-catalysed step is 
rate-limiting. An alternative pathway involves aldehydes dehydrogenase (ALDHs) (Just et al., 
2011; NTP, 2011).  
Formaldehyde is rapidly metabolized by ADH5 and S-formyl-glutathione hydrolase to formic 
acid, which enters the one-carbon pool and can be either excreted in the urine or oxidized to 
carbon dioxide and exhaled. ADH5 has been detected in all human tissues at all stages of 
development, from embryo through adult. Although formaldehyde is rapidly metabolized, it is 
an electrophile that reacts with a variety of endogenous molecules, including glutathione, 
proteins, nucleic acids, and folic acid (Hedberg, 2001; Gonzalez et al., 2006; NTP, 2011).  
Two ADH5 polymorphisms are known: ADH5 Val309Ile, a transition of a cytosine to a thiamine 
in codon 309 that consists in the substitution of a valine by an isoleucine; and ADH5 
Asp353Glu, a transversion of an adenine to a cytosine in codon 353, that results in the 
substitution of an aspargine by a glutamine. To our knowledge, no association has been found 
between ADH5 polymorphisms and disease (Wang et al., 2010).  
 
5. VITAMIN D RECEPTOR (VDR) 
1,25(OH)2D3 is the biologically active form of vitamin D, and it exerts its effects mainly through 
binding to nuclear vitamin D receptor (VDR) and further binding to specific DNA sequences, 
namely vitamin D response elements. Through this genomic pathway, 1,25(OH)2D3 exerts 
transcriptional activation and repression of target genes by binding to the VDR (Cui & Rohan, 
2006; Polidori & Stahl, 2009).  
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The VDR (OMIM 601769) is a crucial mediator for the cellular effects of vitamin D and 
additionally it interacts with other cell-signalling pathways that influence cancer development 
(Raimondi et al., 2009; Orlow et al., 2012).   
The VDR is an intracellular hormone receptor that specifically binds the biologically active 
form of vitamin D, 1,25(OH)2D3 and interacts with specific nucleotide sequences of target 
genes to produce a variety of biologic effects. The VDR gene is located on chromosome 12q12-
q14 and several SNPs in this gene have been identified that may influence cancer risk (Kállay 
et al., 2002; Uitterlinden et al., 2004; Maruyama et al., 2006; Raimondi et al., 2009). 
Numerous studies in vitro and in vivo have shown proapoptotic and anticancer effects upon 
biding of 1,25(OH)2D3 to the VDR for many types of cancer, namely in cells derived from 
tumours of the breast, prostate, pancreas, colon, bladder, cervix, thyroid, pituitary, skin 
(squamous cell carcinoma, basal cell carcinoma and melanoma), glioma, neuroblastoma, 
leukemia and lymphoma cells (Maruyama et al., 2006; Raimondi et al., 2009). Also VDR 
polymorphisms have been implicated in several immune and inflammatory disorders, 
including mycobacterial and human immunodeficiency virus susceptibility, diabetes, psoriasis, 
and Crohn’s disease, although the precise mechanisms of action of these diverse disease-
related effects remain speculative, such as asthma and atopic risk (Raby et al., 2004).  
The involvement of VDR in multiple pathways and points of convergence within these 
pathways indicates the potential importance of VDR in the etiology of cancer (Raimondi et al., 
2009). Binding of VDR by 1,25 (OH)2D3 leads to increased differentiation and apoptosis as well 
as reduced proliferation, invasiveness, angiogenesis and metastasis (Bao et al., 2010).  
VDR polymorphisms have been identified and analysed so far mostly in Caucasians and, to a 
lesser extent, in other ethnic groups (Uitterlinden et al., 2004). The VDR gene has two sets of 
polymorphisms, one at the 3’ end of the gene involving a series of polymorphic sites and the 
other at 5’ end of the gene affecting the start codon. The 3’ polymorphisms are defined by the 
enzymes BsmI, ApaI, and TaqI, and a poly-A microsatellite, all of which are in linkage 
disequilibrium (Medeiros et al., 2002). Although neither the TaqI RFLP in exon 9 nor the linked 
BsmI and ApaI restriction fragment length polymorphism (RFLPs) in intron 8 are known to 
have functional consequences themselves, these sequence polymorphisms have been shown 
to be associated with varying levels of the circulating VDR ligand 1,25-D (Medeiros et al., 
2002).   
BsmI polymorphism which is located at the 3’ end of the gene apparently does not change the 
translated protein and has no known function on VDR. This G to A polymorphisms is located in 
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intron 8 and is linked in a haplotype with variable-length polyA sequence within the 3’-
untranslated region that has an impact on VDR mRNA stability (Shahbazi et al., 2013).  
BsmI gene polymorphism is one of the most important subtype of VDR gene polymorphisms, 
and it is genotyped as BB, Bb, or bb by polymerase chain reactions based on polymorphism at 
the BsmI restriction site (Qin et al., 2013).  
Biomonitoring and molecular epidemiology could therefore play an important role in 
identifying susceptible individuals, particularly those suffering a combination of high risk 
factors, namely a high level of exposure to chemicals, inherited cancer predisposing genes and 
a deficiency of protective factors, such as those arising, for example, from diet. Individual 
susceptibility factors can influence all stages between exposure and the onset of disease 
(Watson & Mutti, 2004). The strength of this field is that it has allowed for the investigation of 
how genes and the environment may interact either positively or negatively in humans. By 
identifying susceptible subpopulations and their association with cancer prevalence, 
epidemiologists have gained a better understanding of this heterogeneous disease, extending 
what could not be determined via traditional methods (Ishibe & Kelsey, 1997).  
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CHAPTER 7 – NUTRITIONAL RESEARCH 
 
 
 
1. NUTRITION RESEARCH 
 
Dietary habits are recognized to be an important modifiable environmental factor influencing 
cancer risk and tumour behaviour. Although some studies have estimated that about 30-40% 
of all cancers are related to dietary habits, the actual percentage is highly dependent on the 
foods consumed and the specific type of cancer (Strickland & Groopman, 1995; Davis & 
Milner, 2007; Sutandyo, 2010).  
Nutrition science has evolved into a multidisciplinary field that applies molecular biology and 
integrates individual health with the epidemiologic investigation of population health (Go et 
al., 2003). Nutritional genomics studies the functional interaction of food and its components, 
macro and micronutrients, with the genome at the molecular, cellular, and systemic level 
(Ordovas & Corella, 2004). In nutritional genomics, two terms are used: nutrigenomics and 
nutrigenetics. Nutritional genomics, defined as the interaction between nutrition and an 
individual’s genome or the response of an individual to different diets, will likely provide 
important clues about responders and non-responders (Davis & Milner, 2004).  
Nutritional genomics provides the means to develop molecular biomarkers of early, pivotal 
changes between health maintenance and disease progression (Elliott & Ong, 2002), applying 
systems biology to build models that will integrate information about intake, gene 
polymorphisms, gene expression, phenotypes, diseases, effect biomarkers and susceptibility 
biomarkers (Ordovas & Corella, 2004).   
A nutritional biomarker can be any biological specimen that indicates the nutritional status 
with respect to intake or metabolism of dietary constituents. It can be a biochemical, 
functional or clinical index of status of an essential nutrient or other dietary constituent. 
Nutritional biomarkers can have three categories depending on their use: (i) a means of 
validation of dietary instruments; (ii) surrogate indicators of dietary intake; or (iii) integrated 
measures of nutritional status for a nutrient (Potischman & Freudenheim, 2003).  
 
1.1. NUTRIGENETICS 
Nutrigenetics refers to the impact of genetic variability between individuals in their response 
to a specific dietary pattern, functional food or supplement for a specific health outcome (Bull 
& Fenech, 2008). It examines the effect of genetic variation on the interaction between diet 
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and disease. The specific fields of genome-health nutrigenomics and genome-health 
nutrigenetics are proposed on the premise that a more useful approach to the prevention of 
diseases caused by genome damage is to take into consideration. Inappropriate nutrient 
supply can cause sizeable levels of mutation or alter expression of genes required for genome 
maintenance. Genetic polymorphisms may alter the activity of genes that affect the 
bioavailability of micronutrients and/or the affinity for micronutrient cofactors in key enzymes 
involved in DNA metabolism or repair (Bull & Fenech, 2008).  
Nutrigenetics attempts to identify and characterize gene variants associated or responsible for 
differential responses to nutrients. The goal of nutrigenetics is to generate recommendations 
regarding the risks and benefits of specific diets or dietary components to the individual as a 
personalized or individualized nutrition (Ordovas & Corella, 2004). 
Genetic polymorphisms may be partially responsible for variations in individual response to 
bioactive food components (Davis & Milner, 2004). Several genetic polymorphisms have been 
identified like folate metabolism (Guerreiro et al., 2007; Carmona et al., 2008), iron 
homoeostasis, bone health, lipid metabolism, immune function and others (Elliott & Ong, 
2002), that can have significant association with nutrients in health/disease outcomes. Some 
common polymorphisms in genes involved in nutrient metabolism, metabolic activation 
and/or detoxification could establish the magnitude whether there is a positive or negative 
response to a food component (Davis & Milner, 2004). An example is the case of folate 
metabolism, there are common polymorphisms in genes that control folate metabolism that 
have been linked to conditions such as neural tube defects, Down’s syndrome, 
homocystineamia, and cancer (Elliott & Ong, 2002). If the mechanisms by which these 
polymorphisms disturb folate mechanism and alter disease risk can be elucidated, it should be 
possible to develop dietary or therapeutic strategies for “at risk” individuals to redress the 
balance. Polymorphisms have also been identified in genes involved in lipid metabolism that 
are important in determining an individual’s plasma low density lipoprotein cholesterol 
concentration, a marker of cardiovascular disease risk. It is important to consider the logistics 
and costs of routine genetic screening for many genes, the provision of appropriate 
counselling, and public attitudes and ethical issues associated with such screening in relation 
to, say, life insurance and family planning (Elliott & Ong, 2002).  
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1.2. NUTRIGENOMICS 
Nutrigenomics focuses on the effect of nutrients on the genome, proteome, metabolome, 
epigenome and transcriptome. Because it is a complex area of knowledge there are many 
different definitions regarding this concept (Ordovas & Corella, 2004). The term nutrigenomics 
emerged from the mapping of the human genome and provides researchers with the tools for 
using systems biology into exploitation of the relationship between nutrition and health (Go et 
al., 2003).  
An integrated framework that simultaneously examines genetics and associated 
polymorphisms with diet-related diseases (nutrigenetics), nutrient induced changes in DNA 
methylation and chromatin alterations (nutritional epigenomics), nutrient induced changes in 
gene expression (nutritional transcriptomics), and altered formation and/or bioactivation 
proteins (proteomics) will allow for greater understanding of the interrelationships between 
diet and cancer risk and tumour behaviour (Davis & Milner, 2004).  
Since the response to a bioactive food component may be subtle, careful attention will need 
to be given to characterizing how the quantity and timing of exposure influence small 
molecular weight cellular constituents (metabolomics). Managing this enormous amount of 
information will necessitate new and expanded approaches to bioinformatics (Davis & Milner, 
2004).  
Nutrigenomics will promote and increase understanding of how nutrition influences metabolic 
pathways and homeostatic control, how this regulation is disturbed in the early phases of diet-
related disease and the extent to which individual sensitizing genotypes contribute to such 
diseases. Eventually, nutrigenomics will lead to evidence-based dietary intervention strategies 
for restoring health and fitness for preventing diet-related disease (Afman & Müller, 2006).  
In short, nutrigenomics is the study of molecular relationships between nutritional stimuli and 
the response of the genes by application of high-throughput functional genomic technologies 
in nutrition research. Applied wisely, it will promote an increased understanding of how 
nutrition influences metabolic pathways and homeostatic control, how this regulation is 
disturbed in the early phase of a diet-related disease, and to what extend individual sensitizing 
genotypes contribute to such disease (Ordovas & Corella, 2004). Such techniques can facilitate 
the definition of optimal nutrition at the level of populations, particular groups, and 
individuals. This in turn should promote the development of new food derived treatments and 
functionally enhanced foods to improve health (Elliott & Ong, 2002).  
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2. DIET AND DNA DAMAGE 
Dietary patterns involve complex interactions of food and nutrients summarizing the total diet 
or key aspects of the diet for a population under study. In that sense it is important to focus in 
each nutrient, but also in the whole diet itself. For instance, several studies have highlighted 
the protective effect of the so call Mediterranean diet (high consumption of vegetables, 
legumes, fruits, nuts and minimally processed cereals, and mono-unsaturated lipids, 
moderately high consumption of fish, low consumption of dairy and meat products and 
regular but moderate intake of alcohol) in cancer prevention (Couto et al., 2011, 2013). Of 
major importance are also epidemiological studies on the role of environmental exposure to 
carcinogens in diet and specific cancers whose incidence is known to vary considerably among 
countries (Strickland & Groopman, 1995). The link between diet and cancer is revealed by the 
large variation in incidence and by the observed changes in incidence in those communities 
who migrated to a different geographic area and culture (Anand et al., 2008). The substantial 
increases in the risk of cancers are observed in populations migrating from low- to high-risk 
areas, suggesting that international differences in cancer incidence can be attributed primarily 
to environmental or lifestyle factors rather than genetic factors (Strickland & Groopman, 
1995; Anand et al., 2008).  
Diet can influence cancer development in several ways, namely direct action of carcinogens in 
food that can damage DNA, diet components (macro or micronutrients) that can block or 
induce enzymes involved in activation or deactivation of carcinogenic substances (Willett  & 
Giovannucci, 2006). Moreover, inadequate intake of some molecules involved in DNA 
synthesis, repair or methylation can influence mutation rate or changes in gene expression. 
Other mechanism that diet can influence DNA mutation, and consequently cancer risk, are 
energy balance and growth rates, since nutrition will influence hormone levels and growth 
factors that will influence the rate of cell division, cell cycling, and consequently influence time 
for DNA repair and/or replication of DNA lesions (Willett  & Giovannucci, 2006). High levels of 
insulin like growth factor are associated with some cancers, namely colon cancer (Pollak, 
2000).   
Several studies support the idea that diet can influence the risk of cancer; however 
information concerning the precise dietary factor that determines human cancer is an ongoing 
debate (Ames, 2001; Key et al., 2004; Anand et al., 2008; Couto et al., 2011). A lot of 
epidemiological studies, involving food frequency questionnaires, have been developed 
providing important information concerning diet and cancer, however, diet is a complex 
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composite of various nutrients (macro and micronutrients) and non-nutritive food 
constituents that makes the search for specific factors almost limitless. 
The definition of nutrient is variable and continues to evolve. A nutrient is classically defined 
as a constituent of food necessary for normal physiological function and essential nutrients 
are those required for optimal health. The postgenomic era classifies nutrient as a “fully 
characterized (physical, chemical, physiological) constituent of a diet, natural or designed, that 
serves as a significant energy yielding substrate or a precursor for the synthesis of 
macromolecules or of other components needed for normal cell differentiation, growth, 
renewal, repair, defence and/or maintenance or a required signalling molecule, cofactor or 
determinant of normal molecular structure/function and/or a promoter of cell and organ 
integrity” (Go et al., 2003).  
 
 
3. ENERGY BALANCE 
Calorie restriction (undernutrition without malnutrition) prevents a variety of cancers in 
experimental animal model. The influence of calorie restriction on carcinogenesis is effective 
in several species, for a variety of tumour types, and for both spontaneous tumours and 
chemically induced cancers (Hart et al., 1999; Hursting et al., 2003). In rodents, experiments 
with caloric restriction showed suppression in the carcinogenic action of diethylnitrosamine 
(Lagopoulos & Stalder, 1987) and also inhibition of radiation induced cancers (Gross & 
Dreyfuss, 1990).  
Calorie restriction reduces metabolic rate and oxidative stress, improves insulin sensitivity, 
and alters neuroendocrine and sympathetic nervous system function in animals (Heilbronn & 
Ravussin, 2003).  
A number of molecular processes also change with changes in energy consumption. 
Regardeless of the source and nature of DNA damage, DNA repair is better preserved and/or 
enhanced when caloric consumption decreases (Hart et al., 1999).  
The possible mechanisms associating calorie restriction to cancer prevention evolve regulation 
of cellular proliferation and apoptosis (decrease in DNA replication), reduction in metabolic 
rate, in oxidative damage and in inflammation mediators (reduction in ROS and consequent 
reduction in DNA damage) (Masoro, 2005). Inversely, the association between obesity (a 
positive energy balance) and cancer can be partially explained by alterations in hormone 
levels and metabolism that could influence cell proliferation, differentiation and apoptosis 
(Willett  & Giovannucci, 2006).  
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Moreover, it is well established that excess calorie intake, resulting in fat deposits, is a risk 
factor for cancer. Digestion, absorption, metabolism and excretion of excess nutrients require 
oxidative metabolism and produce more active oxygen species which cause DNA damage 
(Sugimura, 2000; Hwang & Bowen, 2007; Sutandyo, 2010). Since oxidative DNA damage is 
suggested to have a role in carcinogenesis, this may be one mechanism by which dietary 
change can reduce cancer risk (Djuric & Kritschevsky, 1993).  
Calorie restriction is hypothesized to lessen oxidative damage by reducing energy flux and 
metabolism, or the “rate of living”, thereby influencing the aging process. Calorie restriction is 
linked to oxidative stress, reducing it in various species, including mammals. Therefore, 
reducing metabolic rate by using calorie restriction may reduce oxygen consumption, which 
could decrease ROS formation and potentially increase life span (Heilbronn & Ravussin, 2003).  
 
4. MICRONUTRIENTS 
Micronutrients are a set of approximately 40 substances, including vitamins, essential 
minerals and other compounds required in small amounts for normal metabolism, that are 
essential for human health (Ames, 1998; Lal & Ames, 2011). Micronutrients are capable of 
acting via a number of mechanisms to block DNA damage, mutation, and carcinogenesis by 
oxygen radicals, PAHs, and other chemical carcinogens (Perera, 2000; Collins & Ferguson, 
2004). Mutations have been related to the deficit, rather than the excess, of micronutrients 
(Ferguson & Philpott, 2008).  
Epidemiological studies performed by the American Institute for Cancer Research/World 
Cancer Research Fund have also shown that individuals who consume large amounts of fruits 
and vegetables rich in micronutrients with antioxidant properties, (such as vitamin C, vitamin 
E, carotenoids and flavonoids) show a lower incidence of lung, stomach, oesophagus, breast, 
colon, liver, pancreas, endometrium, oral cavity and pharynx cancer (Prado et al., 2010; 
Sutandyo, 2010), presumably because many micronutrients are required as cofactors in DNA 
maintenance reactions, including DNA synthesis, DNA repair, DNA methylation and apoptosis 
(Ferguson, 2002).  
Micronutrient deficiency or excess can have modifying effects on genomic integrity that may 
involve nutrient-nutrient or nutrient-gene interactions and may depend on an individual’s 
genetic constitution (Fenech et al., 2005; Thomas et al., 2011). Therefore, determining the 
intake levels of micronutrients required to maintain genome stability is an essential step in the 
definition of optimal diets for the prevention of cancer and other diseases caused by genome 
damage (Fenech et al., 2005).  
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Complex gene-environment and nutrient-nutrient interactions are also risk determinants for 
most disease states. Thus, the individual’s genes, environmental exposures and physiological 
state must all be considered when determining disease risk.   
In a biological system, an antioxidant can be defined as any substance which, when present at 
low concentration in relation to oxidizable substrates, would significantly inhibit or delay 
oxidative processes, while often being oxidized itself (Wanasundara & Shahidi, 2005; Kumar, 
2011). The oxidazable substrate may be any molecule that is found in foods or biological 
materials, including carbohydrates, DNA, lipids and proteins (Wanasundara & Shahidi, 2005).   
Antioxidants delay autoxidation by inhibiting formation of free radicals or by interrupting the 
propagation of free radical by one (or more) of several mechanisms: (i) scavenging species 
that initiate peroxidation, (ii) chelating metal ions such that they are unable to generate 
reactive species or decompose lipid peroxides, (iii) quenching O2- preventing formation of 
peroxides, (iv) breaking the autoxidative chain reaction, and/or (v) reducing localized O2 
concentration (Brewer, 2011).  
Antioxidants defend against both enzymatic and non-enzymatic reactions protecting the body 
against oxidative damage. Cellular DNA may be protected against oxidation by antioxidants, 
and oxidised DNA lesions are removed by several repair systems such as base excision repair 
and nucleotide excision repair that have overlapping specificity and may interact or function 
as back-up systems (Guarnieri et al., 2008). Antioxidants may be molecules that can neutralize 
free radicals by accepting or donating electron(s) to eliminate the unpaired condition of the 
radical. The antioxidant molecules may directly react with the reactive radicals and destroy 
them, while they may become new free radicals which are less active, longer-lived and less 
dangerous than those radicals they have neutralized (Lü et al., 2010).  
Non enzymatic antioxidants are frequently added to the food to prevent lipid oxidation. 
Several lipid antioxidants can exert pro-oxidant effect towards other molecule under certain 
circumstances thus antioxidants for food and therapeutic use must be characterized carefully 
(Kumar, 2011).  
Antioxidants can be classified as primary or natural and secondary or synthetic. Natural 
antioxidants comprise enzymes, such as superoxide dismutase, catalase and glutathione 
peroxidase; they also include low molecular weight antioxidants, such as lipid and water 
soluble antioxidants (Hamid, 2010; Lü et al., 2010; Kumar, 2011).  
The antioxidant enzymes are complemented by small-molecule antioxidants, some of which 
are derived exclusively from diet and are vitamins. These small-molecule antioxidants are 
extra and intra-cellular, and include ascorbic acid (vitamin C), glutathione, and tocopherols 
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(vitamin E mostly). The mechanisms by which these antioxidants act at the molecular and 
cellular level include roles in gene expression and regulation, apoptosis, and signal 
transduction, being thus involved in fundamental metabolic and homeostatic processes (Frei, 
1999; Hamid, 2010).  
Hamid et al. (2010) classifies the natural antioxidants in three categories: mineral 
antioxidants, vitamins and phytochemicals. Mineral antioxidants are co-factor of antioxidant 
enzymes. Their absence will definitely affect metabolism of many macromolecules such as 
carbohydrates, and examples include selenium, copper, iron, zinc and manganese. Antioxidant 
vitamins are needed for most body metabolic functions; they include vitamin B, C and E 
(Cooke et al., 2003; Hamid, 2010).  
Chemoprevention is the process of using natural or synthetic compounds to block, reverse, or 
prevent the development of cancers through the action on multiple cellular mechanisms. 
Generally, these cellular mechanisms can be grouped in two: (i) Anti-mutagenesis, that 
includes the inhibition of the uptake, formation/activation of carcinogens, their detoxification, 
the blockage of carcinogen-DNA binding, and the enhancement of fidelity of DNA repair; (ii) 
Anti-proliferation/anti-progression, that includes modification of signal transduction 
pathways, inhibition of oncogene activity, and promotion of the cellular modulation of 
hormone/growth factor activity (Bartsch & Gerhäuser, 2009).  
Potential chemopreventive agents are to be found both among nutrients and non-nutrients in 
diet (Tanaka et al., 2001). Dietary components with potential cancer chemopreventive activity 
include vitamins, fibre, and minerals. If chemopreventive agents, as supplements, are to be 
suitable for the large-scale prevention of cancer in the general population, they should have 
high acceptance, low cost, oral consumability, high efficacy, no or low toxicity, and a known 
mechanism of action (Bartsch & Gerhäuser, 2009). Promising chemopreventive agents 
currently investigated in preclinical and clinical studies include naturally occurring anti-
inflammatory agents, antiestrogens, micronutrients, phytochemicals, and some synthetic 
analogues (Banakar, 2004; Bartsch & Gerhäuser, 2009).  
 
4.1. VITAMINS 
The role of vitamins in cancer chemoprevention has been increasingly under scrutiny. 
Antioxidants (vitamins A, D, E) are known to be reducing agents and these molecules are 
capable of slowing or preventing the oxidation of other molecules (Awodele et al., 2010).  
Vitamins A, D and E belong to the family of fat-soluble vitamins. Their intakes have been 
associated with reduced risk of several chronic diseases, particularly some cancers and heart 
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diseases. In contrast to water-soluble vitamins, fat-soluble vitamins are stored in the liver and 
fatty tissues and are only slowly excreted from the body. Thus, they may have deleterious or 
toxic consequences if consumed at very high levels (Jenab et al., 2009). They are at the end of 
oxidative chain reactions, removing free radicals and preventing the oxidation of unsaturated 
fats; and are clearly documented anti-genotoxic and antimutagenic potential antioxidants 
(Awodele et al., 2010).  
 
4.1.1. VITAMIN A 
Retinol (vitamin A) and its metabolites (retinoids) are important micronutrients that regulate 
many biological processes such as cellular growth and differentiation. The classical mechanism 
of action by retinoids is through activation of retinoic acid receptors (RAR) and retinoid X 
receptors (RXR) (Fritz et al., 2011; Pasquali et al., 2013). In experimental models, retinoids 
suppress the transforming effects of carcinogens, inhibit growth of premalignant cells, 
enhance differentiation of malignant cells and induce apoptosis (Stich et al., 1984a; Kristal, 
2004).  
The term vitamin A (all-trans retinol) is often used as a general term for all compounds that 
exhibit the biological activity of retinol, while the term retinoid refers to both naturally 
occurring and synthetic compounds bearing a structural resemblance to all-trans retinol. 
Biologically important oxidation products of retinol are retinal and retinoic acids that occur in 
several isomeric forms such as 11-cis retinal, 9-cis, or all-trans-retinoic acid, but the important 
biologically active form of vitamin A is retinoic acid (Polidori & Stahl, 2009).  
The oxidant activity of retinol and its derivatives is moderate; however, the compound plays a 
major role in cellular signalling, for example, as a ligand of a family of nuclear receptors 
involved in the regulation of gene expression. In vitro cell culture studies, studies on animal’s 
models, and different types of human studies; all support the idea that carotenoids and 
vitamin A play a role in the prevention of cancer (Polidori & Stahl, 2009), namely because of 
the antigenotoxic and anticarcinogenic effects of both (De Flora et al., 1999). Genotoxic 
effects include a variety of endpoints which can be evaluated both in vitro and in animal 
models, such as DNA damage, point mutation of differential specificity, numerical and 
structural chromosomal alterations and impairment of DNA repair mechanisms (De Flora et 
al., 1999).  
Vitamin A and its derivatives are essential to processes such as vision and cell differentiation, 
particularly during embryological development, as well as in carcinogenesis, glycoprotein 
synthesis, epithelial cell integrity, immune cell maintenance and human growth hormone 
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production (Kristal, 2004; Jenab et al., 2009; Polidori & Stahl, 2009; Fritz et al., 2011). 
Deficiency of this vitamin is associated with night blindness, loss of vision, xeropthalmia, 
growth retardation, foetal reabsorption, and immunodeficiency (Kristal, 2004; Polidori & 
Stahl, 2009; Fritz et al., 2011). Almost all epithelial tissues contain receptors for retinoic acid, 
and a deficiency of vitamin A has consistently been implicated as an important causal factor of 
cancers in human beings (Zhang et al., 2012). Experiments in animals have also shown that 
vitamin A deficiency predisposes to the development of squamous intraepithelial lesions 
(Zhang et al., 2012). The body obtains vitamin A from two sources: preformed vitamin A 
(retinol and retinal in the form of retinyl esters), and provitamin A carotenoids (beta-carotene, 
alpha-carotene, beta-cryptoxanthin) (Jenab et al., 2009; Fritz et al., 2011). Retinol itself is 
rarely found in foods. Preformed vitamin A is found in cod liver oil, butter, eggs, animal 
products and fortified grains. Provitamin A carotenoids are found in highly pigmented 
vegetables such as carrots, squash, tams, and green leafy vegetables. Once in the body, retinol 
is ultimately converted into retinoic acid and its isoforms, collectively known as retinoids (Fritz 
et al., 2011). 
In recent years many studies have described a protective role of vitamin A in several diseases 
related to lung development (e.g. asthma, chronic obstructive pulmonary disease, and 
parenchymal lung diseases). These studies exploit the ability of vitamin A as a scavenger of 
toxic metabolites widely known as free radicals (Pasquali et al., 2013).  
Vitamin A has been recommended in a wide range of doses for treatment of some conditions, 
mainly in the field of dermatologic disturbances and oncology (infants, children and young 
adults during leukaemia treatment). Retinoids were claimed to exert important antioxidant 
functions in biological systems, and this belief stimulated the use of retinoids as antioxidants 
and nutritional supplements in the prevention and treatment of diverse diseases (Pasquali et 
al., 2013). Preneoplastic and neoplastic diseases successfully treated with retinoids include 
oral leukoplasia, cervical dysplasia and xeroderma pigmentosum (premalignant), and acute 
promyelocitic leukemia. Modest but encouraging results have been found in the treatment of 
other cancer types including: head and neck cancer, oesophageal, cutaneous T-cell lymphoma, 
neuroblastoma and mesothelioma (Kristal, 2004; Fritz et al., 2011;). However, some studies 
observed that vitamin A may induce toxic effects to different cell types. Retinol and its 
derivatives may exert pro-oxidant effects which may cause oxidative damage, cell cycle 
disruption, and transformation and/or cell death (Pasquali et al., 2013). 
Cell culture as well as other in vitro assays confirmed that retinoids also presented cytotoxic 
and/or pro-oxidant effects, causing oxidative damage to biomolecules. The explanation could 
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be the increased lipid peroxidation by retinol, as well as the protein carbonylation, and 
decreased protein thiol content. Moreover, the activities of antioxidant enzymes, such as 
catalase and superoxide dismutase were also modulated by retinol. It is known that retinol 
auto-oxidation in vitro increases O2-. (Pasquali et al., 2013). 
The study of Pasquali et al. (2013) demonstrate that retinol causes an increase ROS/RNS 
production in human lung cancer A549 cells, which leads to NF-kB activation and decreased 
the receptor for advanced glycation end-products (RAGE) expression, this has recently been 
considered a key event in lung cancer development and progression; retinol, on the other 
hand, was previously considered an antioxidant, anticancer agent, but it has been observed to 
induce deleterious and pro-neoplastic effects. Also the review made by De Flora et al. (1999), 
concluded that the impact of supplementation with vitamin A could vary significantly, ranging 
from showing benefit to producing small but significant increases in lung cancer incidence 
amongst high risk individuals such as tobacco smokers and asbestos-exposed workers. This 
highlights the importance of just proceeds to supplementation under nutritional or medical 
specialist advice. 
Beta-Carotene and Retinol Efficacy Trial (CARET) results showed that participants receiving the 
combination of β-carotene and vitamin A had no chemopreventive benefit and had excess 
lung cancer incidence and mortality (Omenn et al., 1996). Also the Cheng & Neuhouser (2012) 
study which investigated the association between vitamin A intake and serum hydroxyvitamin 
D, showed a limited statistical evidence of the beneficial association of vitamin D with reduced 
lung cancer mortality, nevertheless this association may be diminished among those who are 
supplement users with excess circulating vitamin A or vitamin A/β-carotene (Cheng & 
Neuhouser, 2012). The study of Fritz et al. (2011) suggested that there is no evidence for an 
association between treatment and prevention of lung cancer and vitamin A and related 
retinoids. This study also enlightened important factors regarding daily supplementation of 
vitamin A, such as the increase of several parameters of oxidative stress in rat lungs (Fritz et 
al., 2011). Furthermore, data from clinical trials also indicate an increase in incidence of lung 
cancer and colorectal cancer in smokers and asbestos-exposed men that receive oral 
supplementation with vitamin A and/or beta-carotene, the same being true for cardiovascular 
disease incidence (Pasquali et al., 2013). Results obtained from Klerk et al. (1998) investigation 
suggested that retinol supplementation in subjects exposed to crocidolite (blue asbestos) may 
reduce the incidence of mesothelioma, however there was a small increase in risk of 
mesothelioma for those on β-carotene (Klerk et al., 1998), similar to what was found in the 
CARET study (Omenn et al., 1996). The study by Miyazaki et al. (2012), demonstrated a clear 
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positive association between dietary vitamin A intake and the incidence of gastric cancer in 
the general Japanese population. However this data should be critically interpreted because 
such association was enhanced by the positivity for Helicobacter pylori, a well-established 
powerful risk factor for gastric cancer. Although this study also suggested that dietary vitamin 
A was significantly associated with the incident of gastric cancer, such association was not 
observed for dietary retinol or carotenoids alone, suggesting that the combination of both 
may act as a risk factor for gastric cancer (Miyazaki et al., 2012). 
Miyazaki et al. (2012) justified their results by the autoxidation of retinoids, generating free 
radicals, which play a role in DNA damage, coupled with a higher dietary vitamin A intake 
promoting mucosal damage in the stomach. It is well known that infection with H. pylori also 
induces DNA damage in gastric mucosal cells, through oxidative stress, acting together in 
synergy. A study by Park et al. (2012) showed that dietary supplementation with vitamin A 
inhibits colon cancer metastasis to the liver, the major storage site for vitamin A and the 
target organ for colon cancer metastasis, in a mouse model. Taken together, these data 
suggest that dietary vitamin A supplementation may prove useful for reducing the number of 
metastatic tumours that develop, and thus the overall amount of cancerous tissue per liver in 
patients prone to colorectal cancer metastasis (Park et al., 2012).    
Deregulation of retinoid metabolism has been found in several cancers, including the prostate 
cancer and prostate cancer tissue is known to have a lower concentration of retinoic acid than 
a normal prostate.  Studies of multivitamin supplements, mostly using retinyl palmitate as a 
source of vitamin A, have failed to find an association with prostate cancer risk (Patterson et 
al., 1999). Finally, prospective studies based on serum retinol have revealed increased, 
decreased and no prostate cancer risk associated with higher retinol concentrations. Since 
serum retinol is homeostatically controlled, it is difficult to interpret these associations as a 
reflection of dietary retinol intake (Kristal, 2004). Neither dietary nor supplemented vitamin A 
intake is related to prostate cancer risk, and there is no evidence that they are useful as 
chemopreventive agents. Currently available synthetic retinoids will also not be useful as 
prostate cancer chemopreventive agents due to their high toxicity (Kristal, 2004).  
The results from the meta-analysis performed by Zhang et al. (2012) indicated that vitamin A 
intake is inversely associated with risk of cervical cancer; however there was no significant 
association between blood retinol level and cervical cancer risk. 
Administration of topic vitamin A revealed regression and even remission of leukoplakia, a 
white lesion of the mucosa that does not represent a histological condition but due to the 
possibility of malignant transformation, these lesions must be assessed and managed closely 
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(Epstein & Gorsky, 1999). It was observed that in hipervitaminosis A, the levels of plasma and 
tissue retinol do not correlate with the increased intake, suggesting that retinol is converted 
to several other metabolites when increasing doses are ingested (Pasquali et al., 2013). These 
data reinforce the importance of keeping retinol status within the normal physiologic range 
and the importance of carefully observing the outcome of vitamin supplementations in 
epidemiologic and experimental studies. 
 
4.1.2. VITAMIN D 
Biological and epidemiological data suggest that vitamin D levels may influence cancer 
development. Vitamin D is not a true micronutrient for most mammals, since it is primarily 
synthesized in skin cells in the presence of adequate sunlight providing UVB. Vitamin D 
deficiency, and insufficiency, has become a well-recognized problem worldwide (Polidori & 
Stahl, 2009). Besides its “classical” role in mediating calcium and phosphate homeostasis, 
1,25-dihydroxyvitamin D3 has “nonclassical” roles that include antiproliferative, 
antiangiogenic, and prodifferentiating effects in a wide range of tumour cells (Uitterlinden et 
al., 2004; Polidori & Stahl, 2009; Bao et al., 2010), it can also activate apoptotic pathways and 
inhibit cell migration, supporting claims of its potential role in cancer prevention and cure 
(Deeb et al., 2007; Raimondi et al., 2009). These effects are mediated through perturbation of 
several important cellular signalling pathways.  
There are many terms and synonyms used in the description of various compounds referred 
to broadly as vitamin D. In general, the letter D without a numeral modifier is used when a 
distinction between D2 and D3 forms is not necessary. Therefore, the common term Vitamin D 
may be inclusive of all forms of vitamin D, including ingestible forms or serum levels. Vitamin 
D2 is ergosterol, Vitamin D3 is calcitriol, 25(OH)D or 25-Hydroxyvitamin D are synonymous  of 
25-(OH) vitamin D (calcidiol)  and 1,25(OH)2D3 is 1,25(OH)2D3 or 1,25(OH)2D3 (Hines et al., 
2010).  
1,25(OH)2D3 is the biologically active form of vitamin D, and it exerts its effects mainly through 
binding to nuclear VDR and further binding to specific DNA sequences, namely vitamin D 
response elements. Through this genomic pathway, 1,25(OH)2D3 exerts transcriptional 
activation and repression of targeted genes by binding to the VDR (Cui & Rohan, 2006; Polidori 
& Stahl, 2009). Normal respiratory epithelial cells have high levels of VDR, however in lung 
cancer tissues; these components of the vitamin D pathway are suppressed, leading to a 
decrease in 1,25(OH)2D3, deterring vitamin D’s anti-proliferative function. These contrasts 
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between normal lung and malignant cells suggest that vitamin D may be important for 
maintenance of normal and anti-proliferative functions in the lung (Cheng et al., 2012). 
The study of Cheng et al. (2012) concluded that serum 25(OH)D concentrations were inversely 
associated with lung cancer mortality in non-smokers. The mechanism by which vitamin D 
reduces lung cancer risk and progression may involve modulating the immune function of lung 
epithelial cells and inhibiting tumour proliferation, angiogenesis, and metastasis. The study of 
Bao et al. (2010) higher 25(OH)D score was associated with a significantly lower risk of 
pancreatic cancer.  
There are biological reasons to suspect that the active form of vitamin D, may be related to 
ovarian cancer incidence and mortality. The study by Cook et al. (2010) demonstrated absence 
of a consistent or strong evidence to support the claim made in numerous review articles that 
vitamin D exposures reduce the risk for ovarian cancer occurrence or mortality (Cook et al., 
2010). However, Grant (2010) claims the existence of good evidence that solar UVB and 
vitamin D reduces the risk of ovarian cancer (Grant, 2010).  
 
4.1.3. VITAMIN E 
Vitamin E was first described by Evans and Bishop as an essential nutrient for reproduction in 
rats (Polidori & Stahl, 2009) and is a general term including α-, β-, δ- and γ-forms of the 
tocopherol and tocotrienol chemical classes (Jenab et al., 2009). Vitamin E has the ability to 
chemically act as a lipid based (lipoprotein and membranes) free radical chain breaking 
molecule and to exert its action by protecting the organism against the attack of those 
radicals. Vitamin E has been shown to influence cellular signalling, enzymatic activity and gene 
expression.  
The claim that vitamin E has, like vitamin A and vitamin D derivatives, cell regulatory 
properties unrelated to its radical chain breaking potential, is supported by a number of 
experimental results (Zingg & Azzi, 2004). The most potent form of natural vitamin E, α-
tocopherol, is taken up, transported and retained by the body much more efficiently than the 
other natural and synthetic derivatives (Zingg & Azzi, 2004; Singh et al., 2005). Since they all 
have equal radical chain breaking properties, it is to date still unexplained why nature 
specifically selected the α form of tocopherol, and it is an open question whether vitamin E 
deficiency syndromes could be completely prevented by supplying β-, γ- and δ-tocopherols or 
tocotrienols. On the one hand α-tocopherol has some specific characteristics, for instance the 
fully methylated chromanol-head group may be required for optimal interactions with 
enzymes and/or “α-tocopherol receptors” (Zingg & Azzi, 2004). 
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On the other hand, the β-, γ- and δ-tocopherols and the tocotrienols may have biological 
effects that interfere with normal cellular processes, so that they need to be specifically 
recognized, metabolized by the liver and later eliminated. A unique feature of δ-tocopherol is 
the location of the reactive –OH group between two methyl groups; after reacting with lipid 
peroxide the unpaired electron can delocalize over the fully substituted chromanol ring which 
is known to increase its stability and chemical reactivity (Zingg & Azzi, 2004). 
In the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study, vitamin E and β-carotene 
failed to prevent upper aerodigestive tract cancers (Wright et al., 2007). Vitamin E was 
recognized as possible blocking and suppressing agent for oesophageal cancer on account of 
its antioxidative function of scavenging electrophiles and inhibiting oxidative DNA damage 
(Yang et al., 2012).  
Yang et al. (2012) demonstrated that vitamin E and selenium supplementation was time 
selective in the chemopreventive of N-Nitrosomethylbenzymanine-induced oesophageal 
carcinogenesis. An early-stage supplementation significantly prevented cancer development, 
whereas late-stage supplementation did not show a clear benefit. Data present from the 
animal model provide further experimental support to the hypothesis that the efficacy of 
cancer chemoprevention by nutrients may time selective during the multistage of 
carcinogenesis. Tomasetti et al. (2004) observed that vitamin E analogue efficiently kills 
malignant mesothelioma cells and sensitises them to immunologic inducer of apoptosis 
tumour necrosis factor-related apoptosis-inducing ligand, showing therefore anticancer 
activity (Tomasetti et al., 2004). 
Lotan et al. (2012) found no preventative effect of selenium or vitamin E, alone or in 
combination on bladder cancer in men. The SELECT research group had previously reported no 
reduction in cancer risk following the long-term supplementation with vitamin E or selenium, 
reporting a non-significant trend for increased prostate cancer risk with vitamin E 
supplementation (Lippman et al., 2009). Gaziano et al. (2009) showed in a long-term trail of 
male physicians that neither vitamin E nor vitamin C supplementation reduced the risk of 
prostate cancer or even total cancer, namely colorectal, or other common cancers. Klein et al. 
(2011), reported that men who used vitamin E supplements were at 17% increased risk for 
cancer as compared to men taking placebo, with the increased risk for developing cancer 
being seen as soon as 3 years after enrolling in the trial.  Beilby et al. (2010) also reported null 
associations between prostate cancer and serum folate, lycopene, β-carotene, retinol and 
vitamin E. Rodriguez et al. (2004) showed lack of support for a strong role of vitamin E in 
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prostate cancer prevention, although a modest protective effect among smokers could not be 
ruled out.  
The Heart Outcomes Prevention Evaluation (HOPE) trial and the HOPE-Ongoing Outcomes 
(HOPE-TOO) studies, which administered a daily dose of natural source Vitamin E (400IU) and 
a matching placebo, concluded that in patients with vascular disease or diabetes mellitus, 
long-term vitamin E supplementation not only does not prevent cancer or major 
cardiovascular events but also may increase the risk for heart failure, therefore the 
investigators recommended that vitamin E supplements should not be used in patients with 
these diseases (Lonn et al., 2005).  Miller et al. (2005) also studied the effect of a high-dosage 
of vitamin E supplementation and concluded that a high-dosage (≥ 400 IU/d) vitamin E 
supplements may increase all-cause mortality and should therefore be avoided.  
 
4.2. OTHER MICRONUTRIENTS BY-SUBSTANCES AND CANCER 
The vitamin B9, commonly folate, is known to be involved in a wide variety of reactions within 
the cell, including DNA synthesis, repair and methylation (Wasson et al., 2008).  In vitro 
studies have shown that folic-acid deficiency causes a dose-dependent increase in uracil 
incorporation into human lymphocyte DNA, with subsequent single-strand breaks in DNA 
formed during base-excision repair. Low folate results in excessive uracil misincorporation into 
DNA, a lesion which is both mutagenic and leads to DNA strand breaks (Fenech et al., 1999b; 
Ames & Wakimoto, 2002; Cooke et al., 2002; Ames, 2004). Folate deficiency also causes 
expression of chromosomal fragile sites, chromosome breaks, micronuclei formation and 
mitochondrial DNA deletions (Duthie & Hawdon, 1998a; Fenech, 2001; Ferguson & Fenech, 
2012). Poor folic acid status in human lymphocytes in vitro is associated with increased DNA 
strand breakage, misincorporated uracil, and reduced DNA repair efficiency (Duthie & 
McMillan, 1997; Duthie & Hawdon, 1998).  
An animal study also suggested that folate supplementation at early stage (prior to the 
existence of preneoplastic lesions) could inhibit colorectal cancer formations; however, 
supplementation at a later stage could promote carcinogenesis (Fenech & Ferguson, 2001; 
Kim, 2004; Cole et al., 2007). A low folate concentration has been implicated as a potential 
promoter of carcinogenesis, for example, in colorectal cancer, lung, breast, pancreatic, gastric, 
oesophageal, cervical, brain, and prostate malignancies (Ames, 1998, 2001; Ames & 
Wakimoto, 2002; Duthie et al., 2002; Ferguson & Philpott, 2008; Beilby et al., 2010; Sutandyo, 
2010).  
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Vitamin B12 is required for the synthesis of S-adenosylmethionine, a common methyl donor 
required for the maintenance of methylation patterns in DNA that determine gene expression 
and DNA conformation. Low concentrations of S-adenosylmethionine lead to DNA 
hypomethylation, associated with abnormal gene expression and chromosomal segregation in 
specific regions such as the centromere, chromosomes 1, 9 and 16, and fragile sites (Fenech et 
al., 1999c; Milić et al., 2010). Deficiencies of vitamin B12, which is common in the population, 
also causes uracil misincorporation into human DNA and chromosome breaks by the same 
mechanism that folate deficiency, since a deficiency of vitamin B12 can mimic chemicals in 
damaging DNA by causing single and double strand breaks (Ames, 2004; Courtemanche et al., 
2004; Minnet et al., 2011). Therefore, vitamin B12 deficiency, like folic acid deficiency, causes 
uracil to accumulate in DNA, chromosome breaks, excessive uracil in DNA, micronuclei 
formation and DNA hypomethylation; an increased level in homocysteine status, an important 
risk factor for cardiovascular disease. These same defects may also play an important role in 
developmental neurological abnormalities (Fenech, 2001; Milić et al., 2010).   
Minerals can be considered to be essential micronutrients, albeit typically with a somewhat 
narrow dose range of efficacy as compared with toxicity, include iron, selenium and zinc. 
Iron is the most abundant trace element in the human body, being essential because iron 
cofactors activate enzymes involved in most of the major metabolic processes in the cell (Prá 
et al., 2012), being required in the synthesis of organic and inorganic cofactors, such as heme 
and iron-sulfur clusters. Iron is required narrow range for maintaining metabolic homeostasis 
and genome stability, and participates in oxygen transport and mitochondrial respiration as 
well as in antioxidant and nuclei acid metabolism; whereby iron deficiency leads to oxidative 
stress. Iron is extremely reactive, interacting with hydrogen peroxide, and generating hydroxyl 
radicals that can lead to DNA strand breaks and reduction in telomere length. Iron can damage 
biomolecules mainly through Fenton and Haber-Weiss chemistry, leading to the production of 
hydroxyl radicals and other ROS. Iron is capable of inducing a wide array of DNA lesions, from 
base modifications to strand breaks and adducts. Iron also seems to alter the methylation 
pattern of several genes (Prá et al., 2012). 
Iron deficiency causes decreased heme levels in the mitochondria, which results in 
dysfunctional mitochondria and neurodegeneration. Iron deficiency in mitochondria appears 
at higher iron intakes than anemia. Many reports show that inadequate iron intake causes 
cognitive dysfunction in rats and humans by altering metabolic processes such as 
mitochondrial electron transport and neurotransmitter synthesis and degradation (Ames, 
2004; Prá et al., 2011).  
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The epidemiological data on iron and cancer are mainly limited to studies of iron excess. Iron 
overload has been linked to genome instability (Prá et al., 2011, 2012). The increased risk of 
hepatic carcinoma in individuals with cirrhosis caused by haemochromatosis indicates a link 
between iron overload and cancer. Several studies have reported associations between 
increased levels of iron and colorectal cancer. But iron deficiency, as well as iron excess, leads 
to oxidative DNA damage (Ames, 2001; Ames & Wakimoto, 2002), namely being associated 
with diminished immune function and neuromuscular abnormalities (Ames, 2006).  
It is a matter of concern that current Recommended Dietary Allowances (RDA) for iron does 
not consider the concept of genomic stability (Ferguson & Fenech, 2012).  
Selenium is an important component of antioxidant enzymes, namely selenoproteins such as 
selenocysteine (Se-Cys) and selenomethionine (Se-Met), and functioning as a co-factor for the 
reduction of antioxidant enzymes, including glutathione peroxidises, thioredoxin reductases, 
and selenoprotein P, which contain molecular selenium in the form of selenocysteines within 
their active centre (Hwang & Bowen, 2007; Ferguson et al., 2012). They are involved in the 
defence of ROS, which otherwise may cause DNA damage alterations of protein function 
(Ames, 2001; Hwang & Bowen, 2007). It appears that over one third of all known 
selenoproteins are antioxidant in nature, while certain Se metabolites induce ROS. The 
antioxidant nature of selenoproteins is essential in minimising the levels of hydroperoxides 
(Ferguson et al., 2012).  
Plant foods like rice and wheat are the major dietary sources of selenium in most countries. 
Selenium supplementation has moved from the realm of correcting nutritional deficiencies to 
one of pharmacological intervention, especially in the clinical domain of cancer 
chemoprevention and in the control of heart failure (Hamid, 2010). Dietary selenium 
significantly inhibits the induction of skin, liver, colon, and mammary tumours in experimental 
animals by a number of different carcinogens, as well as the induction of mammary tumours 
by viruses (Ames, 1983).  
Populations with low selenium status have been found to have an increased risk of several 
cancers, including prostate, breast, lung and colorectal. It is possible that these levels are 
particularly important in different parts of the cancer progression, because of variable effects 
on genomic stability. For example, serum selenium levels were studied in relation to markers 
of neoplastic progression among persons with Barrett’s oesophagus (Ferguson et al., 2012). 
As with iron, selenium shows a “U” shaped curve for functionality, whereby too little is as 
damaging as too much. At optimal levels, selenium may protect against the formation of DNA 
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adducts, DNA or chromosome breakage, chromosome gain or loss, mitochondrial DNA, and 
telomere length and function (Ferguson & Fenech, 2012).  
Current dietary recommendations do not consider the concept of genome stability which is of 
concern because damage to the genome has been linked to the origin and progression of 
many diseases and is the most fundamental pathology (Prá et al., 2012). 
In 2005, Fenech suggested that the concept of recommended diet should be based on the 
prevention of genomic instability, not merely in relation to spontaneous chromosomal 
anomalies, but also in terms of genomic damage induced by chemical agents or radiation. 
Therefore, based on this proposal, the traditional concepts of mutagenicity, which were 
focused only on the interaction between gene and toxin, were enlarged to include diet as an 
influencing factor (Minozzo et al., 2010).  
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CHAPTER 8 – FORMALDEHYDE 
 
 
1. GENERAL CONSIDERATIONS 
Formaldehyde (CAS number: 50-00-0), also known as formalin, formol, and methyl aldehydes, 
is the most simple yet most reactive of all aldehydes, with the chemical formula CH2O. It is a 
colourless gas at room temperature, flammable, and has a strong pungent smell (Liteplo et al., 
2002; Pala et al., 2008; Zhang et al., 2009b). Aleksander Butlerov synthesized the chemical in 
1859, but it was August Wilhelm von Hofmann who identified it in 1867, as the product 
formed from passing methanol and air over a heated platinum spiral. This method is still the 
basis for the industrial production of formaldehyde today, in which methanol is oxidized using 
a metal catalyst. By the early 20th century, the explosion of knowledge in chemistry and 
physics, coupled with demands for more innovative synthetic products, set the scene for the 
birth of new material plastics (Zhang et al., 2009a).   
Formaldehyde is an economically important chemical with an annual production of 
approximately 46 billion pounds worldwide. According to the Report on Carcinogens (NTP, 
2011), formaldehyde ranks 25th in overall U.S. chemical production with more than 11 billion 
pounds produced each year. Formaldehyde production has increased steadily in China in 
recent years, with 7.5 million tons (16.5 billion pounds) of formaldehyde produced in 2007 
(Zhang et al., 2009a, 2010; NTP, 2011).  
Commercially, formaldehyde is manufactured as an aqueous solution called formalin, usually 
containing 37% by weight of dissolved formaldehyde. It is commonly used as a tissue 
preservative or as a bactericide in embalming fluid and medical laboratories (IARC, 2006; NTP, 
2011).  
Formaldehyde has different formulations, such as casein formaldehyde, phenolic resins, urea 
formaldehyde, melamine formaldehyde and all have played an important role in the 
production of domestic and industrial goods that have become vital to everyday life. Casein 
formaldehyde (buttons, buckles, and knitting needles); phenolic resins (electrical and 
automobile insulations and other heavy industrial products, appliances toasters and radios); 
urea formaldehyde (picnic-ware, lampshades, varnishes, laminates and adhesives); and 
melanine formaldehyde (plastics more resistant to heat, water and detergents, cups, saucers 
and other domestic items) are formaldehyde-based materials that are broadly used (Zhang et 
al., 2009a; Kim et al., 2011; NTP, 2011). It is also widely used in molding compounds, glass 
wool and rock wool insulation, decorative laminates and textile treatments. Formaldehyde is 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
96 
 
now extensively used by industries across the globe. There are regulatory decisions regarding 
formaldehyde, such as occupational exposure limits (OELs) and drinking water standards, 
which have an economic impact that runs into millions of dollars (Zang et al., 2009). 
 
2. HUMAN EXPOSURE TO FORMALDEHYDE 
Given its economic importance and widespread use, many people are exposed to 
formaldehyde environmentally and/or occupationally. Occupational exposure involves not 
only individuals employed in the direct manufacture of formaldehyde and products containing 
it, but also those in industries utilizing these products, such as construction (Liteplo et al., 
2002; Zhang et al., 2009). 
 
2.1. OCCUPATIONAL EXPOSURE AND SAFETY STANDARDS 
The U.S. Occupational Safety and Health Administration (OSHA) has estimated that 
approximately 2.1 million workers in the U.S. and many more in developing countries are 
occupationally exposed to formaldehyde. The exposed workers, commonly found in resin 
production, textiles or other industrial settings, inhale formaldehyde as a gas or absorb the 
liquid through their skin. Other exposed workers include health-care professionals, medical 
lab-specialists, morticians and embalmers, all of whom routinely handle bodies or biological 
specimens preserved with formaldehyde (Zang et al., 2009a). In occupational environments, 
formaldehyde occurs mainly as a gas; however formaldehyde particulates can be inhaled 
when paraformaldehyde or powdered resins are used or when formaldehyde adsorbs to other 
particles, such as wood dust (IARC, 2006). Occupational exposure to formaldehyde is highly 
variable and can occur in numerous industries, including the manufacture of formaldehyde 
and formaldehyde-based resins, wood composite and furniture production, plastics 
production, embalming, foundry operations, fibreglass production, construction, agriculture, 
firefighting, and histology, pathology, and biology laboratories, among others (Kim et al., 
2011; NTP, 2011). In the past, the highest continuous exposure levels were measured during 
the varnishing of furniture and wooden floors, during the finishing of textiles, in the garment 
industry, during the treatment of furs, and in certain jobs in manufactured board mills and 
foundries (NTP, 2011).  
The formaldehyde occupational exposure limits of many countries are available on the 
International Labour Organization website and through the Registry of Toxic Effects of 
Chemical Substances database (RTECS#: LP8925000) maintained by National Institute for 
Occupational Safety and Health (NIOSH) (Zang et al., 2009a). 
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The U.S. OSHA has established the following standards that have remained the same since 
1992: the permissible exposure limit (PEL) is 0.75 ppm (parts per million) in air as an 8-h time-
weighted average (8h TWA) and the short-term (15 min) exposure limit (STEL) is 2 ppm. The 
American Conference of Governmental Industrial Hygienists (ACGIH) threshold limit value 
(TLV) recommended is 0.3 ppm as an 8 h TWA. The Scientific Committee on Occupational 
Exposure Limits (SCOEL) has recommended a health-based OEL of 0.2 ppm (Bolt et al., 2010).  
 
2.1.1. PATHOLOGY ANATOMY OCCUPATIONAL SETTINGS 
Formaldehyde has been considered carcinogenic to humans, making it a subject of major 
environmental concern, namely in the occupational setting where employees in industrial and 
medical areas, in particular anatomists and medical students may be highly exposed to 
formaldehyde gas (Gulec et al., 2006). Pathology Anatomy laboratories conduct diagnosis 
based on a wide range of biological specimens removed from a subject by biopsy, surgery or 
necropsy. Formaldehyde is used as preservative, avoiding autolysis and putrefaction 
phenomena and mimetizing an in vivo state. Pathology Anatomy laboratories are mainly in 
hospitals, and are important formaldehyde occupational exposure settings, namely to 
pathologists, anatomy pathology technicians, and auxiliary staff. The professionals have 
contact with formaldehyde specifically during macroscopy exams, also known as grossing, 
working out formaldehyde solution dilutions, and discard and exchange of formalin in 
biological samples or in the processing equipment. 
 
2.2. ENVIRONMENTAL EXPOSURE AND AMBIENT LEVELS 
Formaldehyde is ubiquitous in the environment and has been detected in indoor and outdoor 
air, soil, food, treated and bottled drinking water, surface water, and groundwater (Liteplo et 
al., 2002; Kim et al., 2011; NTP, 2011). Although environmental exposure to formaldehyde 
typically occurs at much lower levels than occupational exposure, a greater number of people 
are exposed to these lower levels in their daily lives. Environmental sources of formaldehyde 
include: (i) off gassing from new mobile homes; (ii) automobile engines, especially those 
burning biofuels; (iii) smoke from cigarettes and the burning of forests and manufactured 
wood products; and (iv) various consumer products such as furniture, carpeting, fibreglass, 
permanent press fabrics, paper products and some household cleaners. Of these, the most 
significant source of global formaldehyde exposure is indoor air pollution from modern home 
furnishings and incomplete fuel combustion in older homes, where air concentrations could 
exceed occupational levels (Liteplo et al., 2002; Gulec et al., 2006; Zang et al., 2009a; NTP, 
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2011). In what concerns indoor sources of formaldehyde exposure, the most important are 
many construction materials (e.g., medium-density fiber board, particleboard, and plywood), 
which contain phenol-formaldehyde or urea-formaldehyde resin glues, and glass wool 
insulation (with similar types of binders) which are known to emit large quantities of 
formaldehyde (Liteplo et al., 2002; Kim et al., 2011; Nielsen et al., 2013). Formaldehyde is also 
formed in the early stages of residual plant decomposition in the soil and in the troposphere 
during oxidation of hydrocarbons that react with hydroxyl radicals and ozone. It ultimately 
becomes part of smog pollution.  
It has been considered carcinogenic to humans, making it a subject of major environmental 
concern, namely for employees in occupational industrial and medical settings anatomists and 
medical students in particular may be highly exposed to formaldehyde gas (Liteplo et al., 
2002; Gulec et al., 2006; Zhang et al., 2009a; NTP, 2011).  
The general population could also be exposed to formaldehyde by handling consumer 
products that contain formaldehyde as an antimicrobial agent (such as laundry detergents, 
wallpaper adhesive, or sanitizers) or from its use as a mildewcide for clothing and linens or in 
vacation homes. Although formaldehyde de per se now is rarely used in cosmetics, the use of 
formaldehyde releasers is common. An analysis of data from the U.S. Food and Drug 
Administration’s Voluntary Cosmetic Registration Program Database indicated that nearly 20% 
of cosmetic products contained formaldehyde-releasing preservatives (Kim et al., 2011; NTP, 
2011). 
Formaldehyde in food exists mostly in a bound form, and it is considered to be unstable in 
aqueous solution. Formaldehyde present in food can occur naturally or through inadvertent 
contamination; it can also be added as a preservative, disinfectant, or bacteriostatic agent and 
can result from cooking or smoking of foods. Generally, higher levels were reported in fish, 
seafood, and smoked ham, shiitake mushrooms, some Italian cheeses, and dried food (Liteplo 
et al., 2002; Norliana et al., 2009; Zhang et al., 2010; Kim et al., 2011; NTP, 2011). There have 
also been instances of formaldehyde found in fruits, vermicelli noodles, and even beer (Zhang 
et al., 2010). 
 
3. CLASSIFICATION OF FORMALDEHYDE 
The programme of the IARC “Monographs on the Evaluation of Carcinogenic Risk to Humans” 
represents a major example of hazard identification procedure (http://monographs.iarc.fr). 
For some genotoxic carcinogens the existence of a “practical” threshold is supported by 
studies on mechanisms and/or toxicokinetics. Such is the case of formaldehyde, for which a 
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No-Observable Adverse Effect Limit (NOAEL) may be established from which a health-based 
exposure limit is derived (Bertazzi & Mutti, 2008).  
The U.S. Environmental Protection Agency (EPA) classified formaldehyde as a B1 compound,  
probable human carcinogen under the conditions of unusually high or prolonged exposure, on 
basis of limited evidence in humans but with sufficient evidence in animals (US EPA, 2000).   
Formaldehyde was long considered as a probable human carcinogen (Group 2A chemical) 
based on experimental animal studies and limited evidence of human carcinogenicity. Toxic 
responses induced by formaldehyde in the respiratory tract at high airbone concentrations, 
which include ulceration, hyperplasia, and squamous metaplasia, are “considered to 
contribute to the subsequent development of cancer” (IARC, 1995). However, the IARC 
reclassified formaldehyde as a human carcinogen (Group 1) in June 2004 based on “sufficient 
epidemiological evidence that formaldehyde causes nasopharyngeal cancer in humans” (IARC, 
2006). The sufficient evidence comes from a statistically significant excess of deaths from 
nasopharyngeal cancer in the largest and most informative cohort study of industrial workers 
by the U.S. National Cancer Institute (NCI), with a strong exposure-response correlation 
between the cancer mortality rate and peak cumulative exposures (Hauptmann et al., 2004, 
2009). Collins & Lineker (2004) found an overall meta-relative risk for nasopharyngeal cancer 
also. After a thorough discussion of the epidemiologic, experimental and other relevant data, 
the IARC panel concluded that formaldehyde is a carcinogen in humans. However, it should be 
noted that some studies have argued that the IARC conclusion was premature and that the 
largest and most influential NCI study should be re-evaluated (Marsh & Youk, 2004; Marsh et 
al., 2010). Indeed, results in the literature are somewhat inconclusive. For example, Bosetti et 
al. (2008) concluded that workers and professionals exposed to formaldehyde showed no 
appreciable excess risk for oral and pharyngeal, sinonasal or lung cancers. However, for brain 
cancer and lymphohematopoietic neoplasms, there were modestly elevated risks in 
professionals, but not in industry workers. Walrath & Fraumeni, (1983) showed a slightly 
elevated mortality by cancer in embalmers, but no excess of mortality from cancers of the 
respiratory tract including the nasal passages. 
In their review, IARC also concluded that there was “strong but not sufficient evidence for a 
causal association between leukemia and occupational exposure to formaldehyde”. Much of 
the evidence for an association between formaldehyde exposure and leukemia comes from 
epidemiology studies, of which there are primarily three types: case-control studies in the 
general population, proportionate mortality studies of professionals, (e.g. funeral industry 
workers and pathologists) and cohort studies of industrial workers (Pinkerton et al., 2004; 
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Zhang et al., 2010). Zhang et al. (2009) state that formaldehyde may induce leukemia by 
damaging hematopoietic stem/progenitor cells circulating in the peripheral blood or by 
damaging the primitive pluripotent stem cells present within the nasal turbinates and/or 
olfactory mucosa. Since the previous evaluation (IARC, 2006), the NCI cohort of industrial 
workers in the USA has been updated with an additional ten years of mortality data. As in the 
previous analysis of leukemia (Hall et al., 1991), the association was stronger for myeloid 
leukemia and situations of peak exposure (Pinkerton et al., 2004; Freeman et al., 2009; NTP, 
2011).  
Other studies have argued that it is biologically implausible for formaldehyde to cause 
leukemia, being the primary arguments: (i) it is unlikely to reach the bone marrow and cause 
toxicity due to its highly reactive nature; (ii) there is no evidence that it can damage the stem 
and progenitor cells, the target cells for leukemogenesis; (iii) there is no credible experimental 
animal model for formaldehyde-induced leukemia; (iv) absence of an increase of blood 
formaldehyde levels after inhalative exposure as formaldehyde converting enzymes such as 
formaldehyde dehydrogenase and aldehydes dehydrogenase are present in many human 
tissues and also in human erytrocytes (Collins & Lineker, 2004; Heck & Casanova, 2004; 
Franks, 2005; Speit & Schmid, 2006; Neuss et al., 2010; NTP, 2011; Rhomberg et al., 2011) and 
cannot be directly related to occupation (Hayes et al., 1990). Indeed, IARC itself concluded 
“based on the data available at this time, it was not possible to identify a mechanism for the 
induction of myeloid leukemia in humans” and stated that “this is an area needing more 
research” (IARC, 2006). The last evaluation performed by IARC, concluded that there is 
“sufficient evidence in humans for the carcinogenicity of formaldehyde. Formaldehyde causes 
cancer of the nasopharynx and leukemia. Also, a positive association has been observed 
between exposure to formaldehyde and sinonasal cancer” (Baan et al., 2009; IARC, 2012).  
 
4. FORMALDEHYDE METABOLISM 
Almost every tissue in the body has the ability to breakdown formaldehyde, once absorbed it 
is usually converted to formate (a nontoxic chemical), which is excreted through the urine and 
can be exhaled via conversion to carbon dioxide (Kim et al., 2011). Formaldehyde is rapidly 
metabolized, namely in the site of first contact such as respiratory tract, where the formation 
of adducts with mucus glycoproteins can take place. By reaching blood and tissues the 
delivery of significant quantities of reactive formaldehyde to distant sites can happen (Liteplo 
et al., 2002; Heck & Casanova, 2004; NTP, 2011).   
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Formaldehyde is carcinogenic at the site of contact as a consequence of epithelial cell 
regenerative proliferation resulting from cytotoxicity and mutation (Li et al., 2007). It has been 
estimated that as much as 22 – 42% of inhaled formaldehyde may be removed by mucus flow 
(Schlosser, 1999). Thus, the fundamental issue is the dose (Heck & Casanova, 2004). A 
minimum exposure concentration is required for formaldehyde to induce a toxic response; 
actually, formaldehyde is normally present in all cells and pathways for its metabolism already 
exists in all tissues and cells examined (Heck & Casanova, 2004).   
Formaldehyde is accepted as being toxic above certain doses and the chances of harmful 
effects are increased at room temperatures because of its volatility. When ingested, 
formaldehyde is rapidly metabolized and removed from the liver (Gulec et al., 2006).  
The metabolic pathways of formaldehyde have been extensively studied (IARC, 1995), but the 
involvement of these pathways in the detoxification of formaldehyde has generally not been 
closely correlated with cytotoxicity. Cytosolic alcohol dehydrogenase, mitochondrial aldehyde 
dehydrogenase, and the GSH-dependent formaldehyde dehydrogenase are important 
pathways of formaldehyde metabolism in the hepatocyte system. Like the liver, the nasal 
mucosa is a very active metabolic system for inhaled compounds. Formaldehyde is 
metabolized by similar pathways in the nasal respiratory mucosa, which supports the 
relevance of the hepatocyte model in vivo, but owing to the many anatomical and biochemical 
differences between the two systems, the hepatocyte model can provide only qualitative 
information about formaldehyde metabolism in the tissue of interest (Teng et al., 2001; Heck 
& Casanova, 2004; Franks, 2005). Formaldehyde is also a naturally occurring compound that is 
present in human plasma at concentrations ranging from 13 to 97 µM (Heck & Casanova, 
2004). Endogenous formaldehyde and its oxidation product, formic acid, are intermediates in 
the “one-carbon-pool”, central to many biological processes, including the biosynthesis of 
purines, thymidine -  essential components of nuclei acids - the biosynthesis of certain amino 
acids, and the demethylation of a variety of important biological compounds that are central 
to cell function and survival (Zhang et al., 2010; NTP, 2011). 
Formaldehyde is an extremely reactive chemical, and reacts with monoamines or amines to 
form methylene bridges and produces covalently cross-linked complexes with proteins and 
DNA. It is also known that formaldehyde is produced by the metabolism of L-methionine, 
histamine, methanol, and methylamine (Gonzalez et al., 2006; Gulec et al., 2006; NTP, 2011). 
Graaf et al. (2009) showed that following acute formaldehyde exposure, repair and/or 
tolerance of DNA-protein crosslinks proceeds via formation of nucleotide excision repair-
dependent single-strand break intermediates and without a detectable accumulation of 
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double-strand breaks, demonstrating a differential pathway response to chronic versus acute 
formaldehyde exposures. Therefore, the relative contribution of each pathway differs 
depending on the dose and duration of exposure (Graaf et al., 2009).  
 
 
5. HEALTH EFFECTS 
Formaldehyde irritates the nose and pharynx in humans and laboratory animals under a 
variety of circumstances (IARC, 2006) and also its inhalation is associated with respiratory 
symptoms, and eye, nose and throat irritation, dry skin, tearing eyes, conjunctivitis, sneezing, 
and coughing (Zhang et al., 2009; Kim et al., 2011).  
Nasal biopsies of workers chronically exposed to formaldehyde showed chronic inflammation, 
loss of cilia, mild dysplasia, hyperplasia and squamous metaplasia, although the latter finding 
has been inconsistent and may have been confounded by others exposures, such as to wood 
dust (IARC, 2006; 2012). The cytotoxicity of formaldehyde has been confirmed in numerous in 
vitro systems (Sul et al., 2007; IARC, 2006; IARC, 2012). Irritation of the nasal and upper 
respiratory tract is also noted in animal studies. Dose-dependent pathological findings include 
inflammation, hyperplasia, degenerative changes, necrosis and squamous metaplasia (IARC 
2006; 2012). There is also some controversy regarding occupational asthma due to 
formaldehyde exposure. Asthma induced by inhaled formaldehyde may be classified as irritant 
induced asthma, as short exposures to high level formaldehyde are identified to cause a 
sudden onset of asthmatic symptoms called “Reactive airways dysfunction syndrome”. 
Because of its airways-irritating properties, it may also aggravate preexisting asthma (Kastner 
et al., 2011; Kim et al., 2011).  
Formaldehyde is a known cause of allergic contact dermatitis. Skin sensitization to 
formaldehyde has been associated with many situations of dermal exposure, including with 
formaldehyde, formaldehyde-containing resins, formaldehyde-treated fabrics, formaldehyde 
containing household products, facial tissues, and others. Its exposure has been widely 
reported to cause dermal allergic reactions in occupationally exposed nurses, doctors, and 
dentists, as well as cosmetic workers, textile workers, and construction workers (Groot et al., 
2009; Kim et al., 2011).  
Formaldehyde exposure can cause a wide range of toxic effects such as formation of DNA-
/protein cross-links, cytotoxicity, immune activation and sensory irritation (Gulec et al., 2006).  
Formaldehyde toxicity is thought to be mediated by the activation of free radical producing 
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enzymes, and also by the inhibition of free radical scavenging systems, thereby enhancing the 
production of the reactive oxygen species (Gulec et al., 2006).   
 
 
6. GENOTOXIC EFFECTS OF FORMALDEHYDE  
Formaldehyde is a direct-acting genotoxic compound and has been associated with positive 
results for almost all genetic endpoints evaluated in bacteria, yeast, fungi, plants, insects, 
nematodes, and cultured mammalian cells. It has caused base-pair gene mutations in 
Salmonella typhimurium and DNA adducts, DNA-protein crosslinks, DNA-DNA crosslinks, DNA 
single-strand breaks, unscheduled DNA synthesis, inhibition of DNA repair, gene mutations, 
cell transformation, and cytogenetics effects - chromosomal aberrations, sister chromatid 
exchanges, and micronuclei - in cultured mammalian cells (Suruda et al., 1993; Conaway et al., 
1996; Heck & Casanova, 1999; Saito et al., 2005; Orsière et al., 2006; Speit et al., 2007; Zhang 
et al., 2009a; Jiang et al., 2010; Zhang et al., 2010; Kim et al., 2011; NTP, 2011). The 
mechanism by which formaldehyde causes cancer is not completely understood and most 
likely involves several modes of action. Formaldehyde exposure is associated with key events 
related to carcinogenicity, such as DNA reactivity, gene mutation, chromosomal breakage, 
aneuploidy, epigenetic effects, glutathione depletion, oxidative stress, and cytotoxicity-
induced cellular proliferation (Saito et al., 2005; NTP, 2011). In summary, formaldehyde is 
genotoxic and induces both DNA damage and chromosome changes, frequently expressed as 
DNA-protein crosslinks. In recent years a number of reports indicate that formaldehyde can 
induce damage in circulating lymphocytes (Orsière et al., 2006; Zhang et al., 2009a). 
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CHAPTER 9 – CYTOSTATICS DRUGS 
 
 
1. ANTINEOPLASTIC DRUGS 
 
Chemical agents have a successful history of use in the treatment of illnesses and injuries, 
namely in the treatment of cancer, where they have been used for decades and were 
responsible for many advances in therapy during the past century. Many drugs with diverse 
modes of action have been synthesized and adapted for clinical use. Antineoplastic or 
cytostatics drugs are an heterogeneous group of chemicals widely used in the treatment of 
cancer and in some non-neoplasic diseases too, having in common an ability to inhibit tumour 
growth by disrupting cell division and killing actively growing cells. These drugs have 
nevertheless been proved to be also mutagens, carcinogens and teratogens (Fucic et al., 1998; 
Burgaz et al., 1999; Sessink & Bos, 1999; Bouraoui et al., 2011; Gulten et al., 2011; Buschini et 
al., 2013).  
Antineoplastic drugs include alkylating agents (e.g., cyclophosphamide, melphalan, 
chlorambucil), antimetabolites (e.g., thioguanine, 5-fluorouracil, methotrexate), antibiotics 
(e.g., doxorubicin), mitotic spindle inhibitors (e.g. vincristine), hormones (e.g., 
diethylstilbestrol), free radical generators (e.g., bleomycin) and topoisomerase inhibitors (e.g., 
irinotecan, etoposide) (Villarini et al., 2012). In general, chemicals that interact directly with 
DNA by binding covalently or by intercalating, or indirectly by interfering with DNA synthesis, 
were among the first chemotherapeutics developed. Compounds that inhibit mitotic spindle 
formation and those that affect endocrine function are also used in cancer chemotherapy 
(Jackson et al., 1996). Also, these drugs can induce reactive oxygen species that can lead to 
DNA damage and, consequently, mutations (Rombaldi et al., 2008).  
These drugs are often used in combination to achieve synergistic effects on tumour cells 
resulting from their differing modes of action. However, most if not all of these chemical 
agents are generally nonselective and, along with tumour cells, normal cells may undergo 
cytotoxic/genotoxic damage (Connor, 2006; Kopjar et al., 2006; Villarini et al., 2012). The in 
vivo exposure to antineoplastic drugs has been shown to induce different types of lesions in 
DNA, depending on the particular stage of cell cycle at the time of treatment.  
The majority of lesions occur during the DNA synthesis (S) phase, often due to misreplication. 
Both neoplasic and non-neoplasic cells attempt to repair them but, if unrepaired, DNA lesions 
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may give rise to chromatid-type aberrations during S-phase which interfere with the 
transcription and replication of DNA, resulting in cytotoxic and mutagenic effects. Growing 
evidence suggests that secondary neoplasms may arise as a complication of successful 
chemotherapy (Kopjar et al., 2006). 
Virtually all drugs have side effects associated with their use. Both patients and workers who 
handle them are at risk of suffering such effects. In addition, it is known that exposures to 
even very small concentrations of certain drugs may be hazardous for workers who handle 
them or work near them (NIOSH, 2004; Villarini et al., 2011, 2012). Accordingly, several 
antineoplastic drugs have been classified by the IARC, on the basis of epidemiological reports, 
animal carcinogenicity data, and the outcomes of in vitro genotoxicity studies, as belonging to 
the group of human carcinogens (Group 1), probable human carcinogens (Group 2A), or 
possible human carcinogens (Group 2B). In addition, investigational agents have also to be 
considered as potentially hazardous until their safety can be established.  
According to European Guidelines (Corrigendum to Directive 2004/37/EG), any use of 
carcinogenic, mutagenic or teratogenic substances, including the application in health care 
settings, are assigned to the highest risk level (Sessink & Bos, 1999; Kiffmeyer & Hadtstein, 
2007; Bouraoui et al., 2011; Gulten et al., 2011; Buschini et al., 2013).  
 
1.1. CYCLOPHOSPHAMIDE 
Cyclophosphamide (CAS no. 50-18-0) is one of the most frequently used alkylating 
antineoplastic agents for different types of tumours (Sessink et al., 1995). It is administered as 
monotherapy or in combination with other drugs to treat neoplasic and non-neoplasic 
diseases (Hedmer et al., 2008).  It is a potent alkylating agent that induces a variety of DNA 
base modifications. These DNA lesions are repaired by a set of enzymes that specifically 
recognise alkylated bases, often producing sites of base loss (Kopjar et al., 2006). 
Cyclophosphamide is carcinogenic in rats after oral or intravenous administration, producing 
benign and malignant tumours at various sites, including the bladder. It is carcinogenic in mice 
following its subcutaneous injection, also producing benign and malignant tumours at the site 
of injection and at distant sites. There was some evidence of its oncogenicity in mice and rats 
following intraperitoneal injection. The combined oral administration of cyclophosphamide 
intraperitoneally and 2-naphthylamine to mice resulted in the induction of carcinomas of the 
bladder at doses which, when given individually, did not produce bladder cancer (IARC, 1981).  
The teratogenic effects of cyclophosphamide are well established in many animal species. The 
drug can also be embryolethal at nontoxic doses to the mother (IARC, 1981). 
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Cyclophosphamide exhibited mutagenic activity in several different assays (bacteria, yeast and 
mammalian cells in vitro, and Drosophila and mice in vivo). The agent also induced 
chromosomal aberrations in mammalian cells of several species in vitro and in vivo. Moreover, 
it induced morphological transformation of mammalian cells in vitro (IARC, 1981). 
Cyclophosphamide has been widely used since the early 1950s in the treatment of malignant 
lymphoma, multiple myeloma, and cancers of the breast, ovary and lung. It has also been used 
in the treatment of certain chronic diseases, such as rheumatoid arthritis and chronic 
glomerulonephritis and other non-malignant diseases (IARC, 1981).  
Although two cases of limb reduction defects have been reported among the offspring of 
women treated with cyclophosphamide during pregnancy, no epidemiological data were 
available for assessing the embryotoxic risk to man. Increases in chromosomal aberrations and 
sister chromatid exchanges were seen in peripheral blood lymphocytes of patients treated 
with cyclophosphamide though (IARC, 1981).  
Furthermore there are many case reports of cancer, particularly bladder cancer and acute 
nonlymphocytic leukemia, following cyclophosphamide therapy (IARC, 1981). All added up, 
there appears to be sufficient evidence for the carcinogenicity of cyclophosphamide in mice 
and rats as well as in humans (IARC, 1981). Due to its reactivity with DNA and mutagenicity in 
various short-term tests, cyclophosphamide is classified as a genotoxic carcinogen (Sessink et 
al., 1995).  
 
1.2. 5 – FLUOROURACIL 
Heidelberger and co-workers began do develop pyrimidine analogs that could be used to 
inhibit uracil utilization by tumour cells. The investigators theorized that uracil analogs would 
be preferentially utilized by tumour cells, thus inhibiting tumour growth. They further 
postulated that a fluorine-substituted analogue might block the formation of thymine 
nucleotides since fluoroacetic acid is poisonous to rats, yet acetic acid is harmless 
(Heidelberger et al., 1957; Heidelberger, 1965). It was found that fluorine could be substituted 
at the 5 or 6 position of the uracil ring and that substitution at position 5 was more 
straightforward and stable. This led to the synthesis of 5-fluorouracil, an effective anticancer 
drug (Jackson et al., 1996). 5-Fluorouracil (CAS no. 51-21-8) has been used as the main 
antineoplastic agent in the treatment of gastrointestinal tumours; it is used frequently in 
combination with other agents for the treatment of a variety of solid tumours (IARC, 1981). 
Data on chromosomal aberrations produced by 5-fluorouracil, though limited, suggest that 
the drug has clastogenic potential, but no evaluation can be made so far on the carcinogenic 
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risk of 5-fluorouracil to humans (IARC, 1981, 1987). Additionally, 5-fluorouracil is one of the 
most frequently antineoplastic agents used and can be easily absorbed through the skin. 
Given these two factors, this drug can be used as an indicator of surfaces contamination and 
exposure and have been extensively discussed in other studies (Larson et al., 2003; Castiglia et 
al., 2008; Schierl et al., 2009; Hedmer & Wohlfart, 2012; Kopp et al., 2013).  
5-Fluorouracil is an antimetabolite that interferes with the production of nucleic acids, 
increasing the number of short DNA fragments by reducing the availability of essential 
nucleotide precursors and thereby also the activity of DNA polymerase (Kopjar et al., 2006). 
5-Fluorouracil was tested by intravenous administration in mice and rats and by oral 
administration in rats. No evidence of carcinogenicity was found, but the studies suffered 
from limitations regarding duration or dose (IARC, 1981; 1987).   
5-Fluorouracil can induce embryotoxic and teratogenic effects in several animal species and 
may be embryolethal in monkeys at nontoxic doses to the mother. The available experimental 
data on the mutagenicity of 5-fluorouracil are inconclusive; the agent did however induce 
transformation in a mouse cell line (IARC, 1981; 1987). 
5-Fluorouracil has been associated in a few case reports with a variety of subsequent 
neoplasms but In almost all cases the drug was given together with other agents known or 
suspected of being carcinogens, thus raising doubts on the effect of 5-fluorouracil alone. No 
epidemiological study was available to the IARC Working Group. There was no evidence for 
the carcinogenicity of 5-fluorouracil in the limited studies available in experimental animals 
and, because the data from case reports in humans were insufficient to arrive at a conclusion, 
no evaluation could be made of the carcinogenic risk of 5-fluorouracil to humans (IARC, 1981; 
1987). 
 
1.3. PACLITAXEL 
Paclitaxel (generic name Taxol) was discovered as part of the new cancer drugs screening and 
discovery program of the USA NCI in the 1960s. In this program many plant extracts were 
screened for anticancer activity, which included a crude extract from the bark of Taxus 
brevifolia (Pacific or Western yew). This crude extract showed antitumour activity against 
several cancer lines and the chemical structure of the active ingredient of the extract was 
identified as paclitaxel, being one of the most important compounds to emerge from a natural 
source (Panchagnula, 1998; Bayat et al., 2011; Al-Sharif, 2012). Paclitaxel (CAS no. 33069-62-4) 
is a well-established in vitro and in vivo antineoplastic agent approved in numerous countries 
worldwide for the first- and second-line treatment of advanced breast cancer (Panchagnula, 
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1998; Simpson & Plosker, 2004). As adjuvant therapy for early breast cancer, paclitaxel is 
approved in the USA, Japan and other countries and is generally administered sequentially to 
anthracycline-containing regimens; it has also antineoplastic activity in a wide spectrum of 
cancer types (Simpson & Plosker, 2004; Bajic et al., 2010), such as ovarian cancer, and some 
activity in head and neck cancer, gastric cancer, haematological cancer (Al-Sharif, 2012), and 
non-small-cell lung (Digue et al., 1999).  
Paclitaxel blocks the cell cycle during mitosis in the transition from prometaphase to 
metaphase since it is an antimicrotubule agent, binding specifically to the β-subunit of the 
protein tubulin promoting the assembly of microtubules (Digue et al., 1999; Cunha et al., 
2001; Simpson & Plosker, 2004). These microtubules are stable, although non-functional, 
preventing normal mitotic spindle formation and function (Cunha et al., 2001; Simpson & 
Plosker, 2004; Al-Sharif, 2012). 
This disruption of normal spindle function, which is the primary mechanism of the antitumour 
activity of paclitaxel, leads to chromosome breakage and inhibition of cell replication and 
migration. Apoptosis induction also contributes to the antitumour action of paclitaxel, 
although the mechanism by which it interrupts signal transduction pathways to promote this 
process is poorly understood (Simpson & Plosker, 2004). 
Paclitaxel is clastogenic, genotoxic, embryotoxic and fetotoxic (CCO Formulary, 2013). Can 
induce chromosome damage and aneuploidy, thereby enhancing the probability of damaged 
cells to survive (Bajic et al., 2010), also induced an increase in the frequency of micronuclei in 
the mouse bone-marrow micronucleus assay, indicating a possible carcinogenic potential of 
paclitaxel in humans(Tinwell & Ashby, 1994; Al-Sharif, 2012).  
 
2. OCCUPATIONAL EXPOSURE TO CYTOSTATICS DRUGS 
Although the potential therapeutic benefits of hazardous drugs outweigh the risks of side 
effects for ill patients, exposed health care workers risk these same side effects with no 
therapeutic benefit. The NIOSH has compiled several case studies that suggest both acute and 
long-term health effects associated to antineoplastic drug exposures, and various studies have 
associated workplace exposure with health effects such as skin rashes, hair loss, irritation, 
hypersensitivity, and headaches after reported skin contact (Kolmodin-Hedman et al., 1983; 
Stücker et al., 1990; NIOSH, 1994; Hedmer et al., 2008; Chu et al., 2011). Negative 
reproductive health outcomes are also associated with antineoplastic exposure (Kolmodin-
Hedman et al., 1983; Fransman et al., 2007; Stover & Achutan, 2011). Spontaneous abortions 
have been reported approximately twice more often among exposed pregnancies than 
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unexposed ones (Stücker et al., 1990); the same goes for congenital malformations, infertility, 
and possibly leukemia, as well as other cancers (Stücker et al., 1990; NIOSH, 1994; Froneberg, 
2006; Harrison, 2006; Kopjar et al., 2009).  
Workers may be exposed to a drug at different stages of its life cycle – from manufacture to 
transport and distribution, during its use in health care or home care settings, or at its final 
waste disposal. These workers include shipping and receiving personnel, pharmacists and 
pharmacy technicians, nursing personnel, environmental services personnel, workers in 
veterinary practices where hazardous drugs are used (NIOSH, 1994; Sessink & Bos, 1999;). 
workers employed in the synthesis and production of these products, and staffs involved in 
cleaning, transport, and disposal of hazardous drugs or contaminated material, they all may 
face health risks (Sessink & Bos, 1999; Connor, 2006; Kiffmeyer et al., 2012). The main focus of 
concern has dwelled upon the pharmacy and nursing personnel who mix and administer drugs 
and who are likely to experience the highest exposure intensity, and little attention has been 
paid to para-professional personnel, such as nursing assistants who have been assumed to be 
at a lesser risk (Kusnetz & Condon, 2003).  
Health care workers who prepare or administer hazardous drugs or who work in areas where 
these drugs are used may be exposed to these agents in the air, on work surfaces, 
contaminated clothing, medical equipment, patient excreta, and other surfaces (NIOSH, 2004; 
Kopjar et al., 2009; Mahboob et al., 2012). Exposures may occur through inhalation resulting 
from aerosolization of powder or liquid during reconstitution and spillage taking place while 
preparing or administering to patients, through skin contact, skin absorption, ingestion, or 
injection. Inhalation and skin contact/absorption are the most likely routes of exposure, but 
unintentional ingestion from hand to mouth contact and unintentional injection through a 
needle stick or sharps injury are also possible (NIOSH, 2004; Kopjar et al., 2009; Mader et al., 
2009; El-Ebiary et al., 2013). Hand contact with contaminated equipment used in preparing 
and administering these drugs, or contaminated food or cigarettes, all lead to oral ingestion. 
Furthermore, patients may excrete these drugs and their metabolic by-products in body 
wastes, exposing personnel who handle such items (Kopjar et al., 2009; El-Ebiary et al., 2011).  
Contamination of the work surfaces and also permeation of gloves to some antineoplastic 
drugs were reported already in several studies (Laffon et al., 2005; Kopjar et al., 2009; Gulten 
et al., 2011). Moreover, vaporization of spilled antineoplastic drugs may represent an 
additional route of exposure to healthcare workers through inhalation. However, contact with 
contaminated surfaces seems to have the most important role in exposure due to dermal 
absorption (Sessink & Bos, 1999; Kromhout et al., 2000; Fransman et al., 2004, 2005). 
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Therefore, the monitoring of surfaces contamination is a common way to assess occupational 
exposure, being the wipe sampling the most common method used (Hedmer et al., 2004; 
Connor, 2006; Hedmer et al., 2008) allowing for the demonstration of widespread workplace 
contamination, even when strict protocols and standard operating procedures have been 
applied (Schierl et al., 2009). 
Exposure in a hospital setting is normally due to the use of several antineoplastic drugs 
simultaneously. Nevertheless, the effects of such mixtures at the cell level and on human 
health in general are unpredictable and unique due to differences in practice of hospital 
oncology departments, in the number of patients, protection devices available, and the 
experience and safety procedures of medical staff (Kopjar et al., 2009).  
Since no occupational exposure limits have been established for airborne concentrations of 
antineoplastic drugs and for their concentration in the urine, there is no exposure level can be 
considered safe, and thus zero contamination should be the target (Sessink et al., 1992; 
Santos-Burgoa, 2006; Turci et al., 2010; Davis et al., 2011). Exposure to these compounds 
should be avoided, and safety guidelines and protective measures like wearing masks, gloves, 
gowns, caps, protective eyewear and the preparation of drugs in biological safety cabinets are 
normally available in the workplaces in order to prevent exposure (Sessink et al., 1992; Sorsa 
et al., 2006; Gulten et al., 2011).  
The growing use of complex mixtures of known and new antineoplastic drugs in cancer 
treatment, emphasize concerns about the occupational exposure and the genotoxic risks of 
workers handling such mixtures. The presence of drugs in different amounts and with 
different mechanisms of action suggests the need to study the relationship between the 
presence of genotoxic components in the mixture and the ensuing effects, taking into account 
the mechanism of action of each component de per si (Cavallo et al., 2007).  
NIOSH and U.S. OSHA have developed guidelines to protect nursing staff against 
antineoplastic drug exposure. These include (i) the use of two protective gloves and gowns 
when preparing, administering, or handling waste or excreta containing antineoplastic agents, 
(ii) training all employees who are involved in their use upon start of employment, and (iii) 
continuing education on how to handle hazardous drugs (Stover & Achutan, 2011). 
 
3. GENOTOXIC EFFECTS OF ANTINEOPLASTIC DRUGS 
Many anticancer agents have the potential to cause genetic alterations, which may lead to the 
development of cancer if they interact with proto-oncogenes or tumour suppressor genes, 
which are involved in controlling cell growth or differentiation (Moretti et al., 2011).  
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There are six broad categories of anticancer chemicals, grouped by their mode of action: (i) 
covalent DNA-binding agents, (ii) noncovalent DNA-binding agents, (iii) topoisomerase II 
inhibitors, (iv) antimetabolites, (v) mitotic spindle inhibitors, and (vi) endocrine disrupters 
(Jackson et al., 1996). Exposure to any of these genotoxic agents may initiate a sequence of 
events that leads to adverse health effects. The biological effects may vary depending on the 
drug(s), its dose, and individual genetic sensitivity/susceptibility (Kopjar et al., 2009), but it is 
difficult to assess how much drug is absorbed in the course of handling agents at the 
workplace. 
Because a safe threshold of occupational exposure cannot be defined for the majority of 
anticancer drugs, the search for appropriate monitoring parameters is an ongoing challenge. 
Although various methods of monitoring biological effects have been established, none points 
to a direct correlation between exposure level and the development of cancer, therefore they 
should be considered as an internal dosimeter in the detection of genotoxic and, presumably, 
carcinogenic risks (Bouraoui et al., 2011).  
Cytogenetic assays can be used for this goal; the conceptual basis for application is that DNA 
damage is the initial event towards pathogenesis and disease (Padjas et al., 2005; Bouraoui et 
al., 2011). Thus, cytogenetic surveillance can be viewed as an indicator enabling the early 
detection of exposure to genotoxic agents (Rekhadevi et al., 2007; Kopjar et al., 2009; 
Bouraoui et al., 2011).  
The monitoring of genotoxic risks should be done combining environmental and biological 
monitoring with procedures of biological effect monitoring (primary DNA damage and 
chromosome damage). In this integrated chemical/biotoxicological approach, the use of 
genotoxicity biomarkers measuring changes in cellular or molecular endpoints (e.g., DNA 
and/or chromosome damage) will allow us to combine environmental and biological 
monitoring with biological effect monitoring. In this context, comet assay represents a highly 
sensitive technique for detecting low levels of DNA damage in individual cells and is used in 
this thesis to accurately monitor interaction of antineoplastic drugs with DNA (biomarker of 
biologically effective dose). Among biotoxicological tests, the frequency of micronuclei in 
peripheral lymphocytes is recognized to be a predictor of cancer risks in humans, and because 
of its ability to detect both clastogenic (e.g., chromosome breakage) and aneugenic (e.g., 
spindle disruption) effects, it could have a role in occupational health surveillance programs 
for workers exposed to antineoplastic drugs to monitor long-term exposure effects (a so-
called biomarker of early/preclinical biological effects) (Villarini et al., 2012). 
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Several reports have addressed the relationship of cancer occurrence with the exposure of 
health care workers to antineoplastic drugs. A significant increased risk of leukemia has been 
reported among oncology nurses identified in the Danish cancer registry for the period 1943-
1987 (Skov et al., 1992). The same authors found an increased, but not significant, risk of 
leukemia in physicians employed for at least 6 months in a department where patients were 
treated with antineoplastic drugs (NIOSH, 2004). An association was also found in subjects 
potentially exposed to antineoplastic drugs at the employment and an elevated risk of breast 
and rectal cancer (Moretti et al., 2011). 
Past and current evidence indicates that workplace settings where anticancer drugs are 
prepared and administered to patients are themselves contaminated with the very drugs that 
have been used (Connor, 2006). To minimize the risk of occupational exposure, several 
guidelines for the handling of antineoplastic drugs and safety recommendations have been 
issued by national and international agencies. Despite the adoption of such guidelines in 
health care institutions, reports in current literature suggest that some healthcare workers do 
not follow the standards established by their employers, putting themselves at risk for 
mutagenicity, alterations in fertility, and long-term effects caused by chemotherapy agents 
(Kopjar et al., 2009). 
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CHAPTER 1 – PROCESSUAL ASPECTS 
 
1. SAMPLES 
The biological sampling took place at pathology anatomy laboratories and in pharmacy and 
nursing units at hospitals in Lisbon and the Tagus Valley region and also at Escola Superior de 
Tecnologia da Saúde de Lisboa (ESTeSL). The laboratory work was conducted in the 
laboratories of ESTeSL. 
This research involves two different occupational settings, one where workers are exposed to 
formaldehyde and another where exposure is to cytostatics. In both settings the risk of 
nuclear anomalies is evaluated by a case-control blinded study design, therefore four 
separated samples were formed comprising a sample of exposed and a sample of controls in 
regard to each occupational setting. The risk of anomalies would be assessed by comparing 
the frequency of pre-established markers in those exposed with the frequency in controls by 
means of conventional statistical procedures (e. g. Schlesselman, 1982; Woodward, 2004).  
The working places with exposure to formaldehyde were six laboratories of anatomic 
pathology, where a sample of 56 exposed workers was formed. The control group was formed 
by 85 subjects who have not been exposed to formaldehyde, namely students, teachers, and 
administrative staff of ESTeSL. As for exposure to cytostatics, the sample of cases comprised 
46 workers which have been exposed in two pharmacy laboratories and three nursing 
hospitals. The control group was formed by 46 subjects who have not been exposed to 
cytostatics, namely students, teachers, and administrative staff of ESTeSL. The samples 
distribution for both occupational settings is schematized below (Figure 8): 
 
 
 
 
 
 
 
 
 
Figure 8 – Schematization of samples distribution for a) Occupational exposure to formaldehyde, and b) 
Occupational exposure to cytostatics. 
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The sampling method could be described as convenience cluster sampling, whereby two 
laboratories were selected based on our knowledge that occupational exposure takes place 
therein. All workers in the laboratories were invited and agreed to participate in this study. 
Controls were selected based on not having been exposed to formaldehyde or cytostatics and, 
simultaneously, for being statistically comparable to the subjects exposed in regard to 
variables usually suspected of confounding effects, like age and sex.  
 
2. VARIABLES 
The variables in this study are systematized in Table 1 (occupational exposure to 
formaldehyde) and in Table 2 (occupational exposure to cytostatics).  
 
Table 1 – Variables in the study of association between occupational exposure to formaldehyde and 
genotoxicicity biomarkers, genetic polymorphisms and micronutrients.  
Variables Type of measure Scale Type of variable 
Age Quantitative Discrete Independent 
Gender Qualitative Binary  Independent 
Tobacco habits Qualitative Binary Independent 
Alcohol consumption Qualitative Binary Independent 
Formaldehyde exposure Qualitative Binary Independent 
ADH5 polymorphisms Qualitative Categorical Independent 
XRCC3 polymorphisms Qualitative Categorical Independent 
VDR polymorphisms Qualitative Categorical Independent 
Vitamins A, D and E Quantitative Discrete Independent 
Micronuclei in lymphocytes Quantitative Discrete Dependent 
Nucleoplasmic bridges Quantitative Discrete Dependent 
Nuclear buds Quantitative Discrete Dependent 
Micronucleus in buccal cells Quantitative Discrete Dependent 
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Table 2 – Variables in the study of association between occupational exposure to cytostatics and 
genotoxicicity biomarkers, genetic polymorphisms and micronutrients. 
Variables 
Type of 
measure 
Scale 
Type of 
variable 
Age Quantitative Discrete Independent 
Gender Qualitative Binary Independent 
Tobacco habits Qualitative Binary Independent 
Alcohol consumption Qualitative Binary Independent 
Cytostatics exposure Qualitative Binary Independent 
OGG1 polymorphisms Qualitative Categorical Independent 
Vitamins A and E 
Quantitative 
Discrete Independent 
FFQ intakes: retinol, vitamins B12, D and E, folate, 
iron,  selenium Quantitative 
Discrete Independent 
Micronuclei in lymphocytes Quantitative Discrete Dependent 
Nucleoplasmic bridges 
Quantitative 
Discrete Dependent 
Nuclear buds 
Quantitative 
Discrete Dependent 
% DNA in tail 
Quantitative 
Discrete Dependent 
DNA oxidative damage (FPG) 
Quantitative 
Discrete Dependent 
 
3. DATA COLLECTION INSTRUMENTS  
The data collection regarding these variables was derived from two main sources. First, 
individual questionnaires filled-in by all subjects provided information on age, sex, habits, and 
other personal traits. Second, microscopic visualization and laboratory procedures carried out 
provided information on nuclear anomalies and polymorphisms. Further details on these 
sources of information are presented next.  
 
3.1. PERSONAL QUESTIONNAIRE 
The study participants filled-in a questionnaire on individual characteristics and working 
practices. The questionnaire included questions regarding age, gender, tobacco and alcohol 
consumption habits, medication, hereditary diseases, exposure to formaldehyde, cytostatics 
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or other chemical agents, characterization of professional activity, usage of individual and 
collective protection equipment and hobbies. The questionnaire (Annex I) was validated by 
application of a pre-test in a group of subjects which was used as a pilot-sample at the 
beginning of the study. 
 
3.2. FOOD-FREQUENCY QUESTIONNAIRE 
Dietary intake was assessed using a self-administered Food Frequency Questionnaire (FFQ)  
(Lopes, 2000; Lopes et al., 2007). The FFQ included type and quantity of food intake, namely 
some food items, which allowed for the quantification of different macronutrients and 
micronutrients. The FQQ is a 3-page booklet including a list of 92 common food and beverage 
items and questions relating to food preparation and dietary habits (Annex II). Participants 
were required to indicate how often each food and beverage was usually consumed per 
month, week, or day. Average daily consumption was based on the participants’ reports on 
how often a specified serving size of each food or beverage item was consumed. This 
information, along with the nutrient composition of the food item/unit weight taken from 92 
selected items, allowed participants’ daily micronutrient and macronutrient intake to be 
calculated using the FREQUAN dietary analysis program (Baghurst and Record, 1984). The FFQ 
can be consulted in Annex II.   
 
3.3. OBSERVATION LIST 
A list of endpoint items were recorded during the microscopic visualization of slides obtained 
by the CBMN assay, micronucleus test, and comet assay. For the CBMN endpoints, the list 
included the following items: number of visualized cells, micronuclei in binuclear, 
mononuclear and multinuclear lymphocytes, nucleoplasmic bridges, and nuclear buds, and 
other observations than can be considered important (e.g. apoptosis and necrosis). The 
criteria of classification of these endpoints have been established and validated by the HUman 
MicroNucleus (HUMN) International Collaborative Project available in http://www.humn.org 
and in Fenech et al. (1999b).  
 
For the MNT, the list was organized into number of visualized cells, micronuclei, and other 
important observations, such as karyorrhectic, pyknotic and karyolitic cells according to the 
criteria for scoring nuclear abnormalities in the buccal cells described by Tolbert et al. (1991) 
and Thomas et al. (2009).    
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For the comet assay test, the observation of 50 randomly chosen comets from each gel, 
totalizing 100 comets by slide, was performed by Comet Assay IV software from Perceptive 
Instruments®, measuring parameters such as: number of scored comets, head intensity, tail 
intensity, and % DNA in tail. These parameters are described in Collins (2002).  
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CHAPTER 2 – LABORATORY PROCEEDINGS 
 
1. EXPOSURES ASSESSMENT 
 
1.1. FORMALDEYDE EXPOSURE ASSESSMENT 
The assessment of exposure to formaldehyde was based on two techniques of air monitoring 
conducted simultaneously. First, environmental samples were obtained by sampling the air 
with low flow pumps for 6 to 8 hours, during a typical working day. Formaldehyde levels were 
measured by Gas Chromatography (GC) analysis and time-weighted average (TWA8h) was 
estimated according to the NIOSH method (NIOSH 2541). 
The second method was aimed at measuring ceiling values of formaldehyde using Photo 
Ionization Detection (PID) equipment (11.7 eV lamps) with simultaneous video recording. 
Instantaneous values for formaldehyde concentration were obtained on a per second basis in 
both methods. A relationship can thus be established between worker activities and ceiling 
values, as well as to reveal the main exposure sources (McGlothlin, 2005; Viegas et al., 2010). 
Measurements and sampling were performed in a macroscopic room, provided with fume 
hoods, always near workers breath. 
 
1.2. CYTOSTATICS EXPOSURE ASSESSMENT 
Surfaces contamination was investigated in the two hospitals by wipe sampling in areas where 
antineoplastic drugs were administered, as recommended by Hedmer et al. (2004, 2008). The 
cytostatics studied were considered suitable indicators for occupational exposure to 
antineoplastic drugs because they are frequently used in preparations and have been used in 
high amounts in both hospitals considered (Castiglia et al., 2008). Sensitive analytical methods 
are already established for these drugs. In both hospitals, sampling took place in two different 
days. Regarding antineoplastic drug administration, sampling days were indicated by workers 
and services as being normal working days. Before wiping, gauzes were moistened with ethyl 
acetate. Sampling was performed by consecutive wiping to cover an area of 10x10 cm. The 
areas sampled were preparation tables, drug administration devices, chairs for drug 
administration, worktops, treatment registration tables and protection devices such as gloves 
and masks. All wipe samples were extracted as described by (Schmaus et al., 2002). The 
analysis of the samples was blinded and performed by HPLC with Diode Array Detection 
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(HPLC-DAD) with a quantification limit (LOQ) of 10 ng/cm2, in the same conditions described 
by Schmaus et al. (2002). 
 
2. LABORATORY PROCEEDINGS 
For each study sample – cases and controls – two biological matrixes were collected: 
peripheral blood obtained by venipuncture; and exfoliated epithelial cells obtained by 
scrapping the buccal mucosa with endobrush®. Epithelial cells were used exclusively for the 
MNT, whereas peripheral blood was used in many procedures, namely: CBMN assay 
(micronuclei, nucleoplasmic bridges and nuclear buds), comet assay (DNA damage and 
oxidative damage), Real-Time PCR (study of polymorphisms), HPLC (quantification of serum 
vitamins A and E), and enzyme immunoassay (quantification of serum vitamin D).  
Whole blood and exfoliated cells (buccal mucosa cells) were collected between 10 a.m. and 12 
p.m. from every subject and were processed for testing. As a considerable number of samples 
were collected in a short period of time and it was not feasible to process all samples at once, 
appropriate storage methods were required for preservation. Therefore, the whole blood was 
divided by three tubes: (i) blood tube to performed CBMN and comet assay; (ii) blood tube to 
centrifuge and separate serum; (iii) blood tube to study polymorphisms. These tubes where 
stored immediately at -20C. Regarding the first type of tubes, once the lymphocytes were 
isolated, CBMN was performed in the same day that sampling took place; and 1mL of the 
isolated lymphocytes from each sample was cryopreserved at -80C to perform comet assay. 
All samples were coded and analyzed under blind conditions. 
 
2.1. CYTOKINESIS-BLOCKED MICRONUCLEUS ASSAY (CBMN) 
The peripheral blood was obtained by venipuncture from all participating subjects and was 
divided by three tubes as follows: 10 mL of peripheral blood to 15 mL Falcon tubes with 
heparin (10U/ml blood, Sigma®), 3 mL to Kabevette serum tubes and 2 mL to Kabevette EDTA 
tubes.  
The 10 mL freshly collected blood was directly used for the CBMN assay. Lymphocytes were 
isolated using Ficoll-Paque (Amersham Biosciences) gradient and placed in RPMI 1640 culture 
medium with L-glutamine and red phenol added with 10% inactivated fetal calf serum, 50 
ug/ml streptomycin + 50U/mL penicillin, and 10 ug/mL phytohaemagglutinin. Duplicate 
cultures from each subject were incubated at 37C in a humidified 5% CO2 incubator for 44h, 
and cytochalasin-b 6 ug/mL was added to the cultures in order to prevent cytokinesis. After 
28h incubation, cells were spun onto microscope slides using a cytocentrifuge (Cyto-Tek® 
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Sakura). Smears were air-dried and double stained with May-Grünwald-Giemsa (Merck®) and 
mounted with Entellan®. Visualization was made with a Leica DM500 microscope with 
immersion oil and 1000x amplification by a single observer according to the criterion of 
scoring explained above. The figures concerning to these endpoints are presentend in chapter 
5, for micronuclei  in section 1.1, for nucleoplasmic bridges in section 1.2, and for nuclear buds 
in section 1.3.  
 
2.1.1. CRITERION OF SCORING OF CBMN 
The criteria used for scoring nuclear anomalies – micronuclei, nucleoplasmic bridges, and 
nuclear buds, are described in (Fenech et al., 2003; Fenech, 2007) as follows.  
The criteria for scoring micronuclei are: the diameter of micronuclei in human lymphocytes 
usually varies between 1/16 and 1/3 of the mean diameter of the main nuclei which 
corresponds to 1/126  and 1/9 of the area of one of the main nuclei in a binucleated cell, 
respectively; micronuclei are round or oval shape; micronuclei are non-refractile and they can 
therefore be readily distinguished from artefacts such as staining particles; micronuclei are 
not linked or connected to the main nuclei; micronuclei may touch but not overlap the nuclei 
and the micronuclear boundary should be distinguishable from the nuclear boundary; 
micronuclei usually have the same staining intensity as the main nuclei but occasionally may 
be more intense.  
The criteria for scoring nucleoplasmic bridges are: nucleoplasmic bridges are a continuous 
nucleoplasmic link between the nuclei in a binucleated cell; the width of a nucleoplasmic 
bridges may vary considerable but usually does not exceed one-fourth of the diameter of the 
nuclei within the cell; nucleoplasmic bridges should have the same staining characteristics of 
the main nuclei; on rare occasions more than one nucleoplasmic bridge may be observed 
within one binucleated cell; a binucleated cell with a nucleoplasmic bridges may or may not 
contain one or more micronuclei. 
The criteria for scoring nuclear buds are: nuclear buds are similar to micronuclei in 
appearance, except that they are connected with the nucleus via a bridge that can be slightly 
narrower than the diameter of the bud or by a much thinner bridge depending on the stage of 
the extrusion process; nuclear buds usually have the same staining intensity as micronuclei; 
occasionally, nuclear buds may appear to be located within a vacuole adjacent to the nucleus. 
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2.2. COMET ASSAY 
Isolated lymphocytes were cryopreserved following the protocols of Duthie et al. (2002) and 
Singh  & Lai,  (2009). Briefly, isolated lymphocytes suspended in RPMI medium with L-
glutamine were either centrifuged (600g, 10 min) and ressuspended in freezing mix (90% v/v 
heat-inactivated fetal calf serum and 10% v/v DMSO), frozen at -1C/min in polystyrene and 
stored at -80C. 
For analysis of DNA damage and oxidative damage a modification of the comet assay 
(originally described by (Singh et al., 1988) was used to measure the basal level of DNA 
oxidation in lymphocytes (Collins, 2009). The aliquots were rapidly thawed at 37C and 
transferred to a 15 mL Falcon tube with 2 mL of PBS (Dulbecco’s PBS, Sigma), and immediately 
centrifuged at 1800 g for 5 min to remove freezing mix. The pellets were ressuspended in PBS 
and cells were counted using a Neubauer Improved Haemocytometer. 
Thirty microliters of the cell suspension (2.0x104 cells/mL) was mixed with 140 µl of 1% low 
melting-point agarose (LM Pronadisa) in a microcentrifuge tube and added to a slide 
previously pre-coated with 1% agarose (SeaKem®), two gels per slide. The gels were covered 
with a cover slip (22x22x1.0mm) and allowed to set on a cold plate. The cover slips were 
removed and the slides immersed in lysis solution [2.5 M NaCl, 100 mM Na2EDTA, 10 mM 
TRIS, 1% Triton® X-100 (pH 10)] for 60 min. Following lysis, the slides were immersed in two 
changes of Buffer F [40 mM HEPES, 0.1 M KCl, 0.5 mM Na2EDTA and 0.2 mg/L BSA (pH 8.0)] for 
5 min, each time at 4C. FPG [kindly donated by Prof. Andrew Collins (Department of 
Nutrition, University of Oslo, Norway)] was added to the gel previously diluted in Buffer F. 
Incubation of the slides with FPG and with Buffer F was performed in a humid chamber at 
37ºC for 30 min. The reaction was stopped by placing them at 4C. 
The cover slips were removed and all the slides – lysis, Buffer F and FPG treatment - were 
placed on an electrophoresis platform, covered with electrophoresis buffer [1 mM Na2EDTA, 
0.3 M NaOH (pH 13)] and DNA was allow to unwind for 20 min before electrophoresis at 1.14 
V/cm, 300 mA for a further 20 min. DNA unwinding and electrophoresis was performed in a 
cold unit at 4C. The slides were transferred to a Coplin jar and immersed in PBS, the in 
distilled water, both for 10 min at 4C. After, dehydrate the slides in increasing ethanol 
concentrations (70%, 96% and 100%), 5 min each. The slides were dried at room temperature, 
stained with 25 µl DAPI (1 µg/mL) and visualized. Slides were scored using Zeiss AxioScope.A1 
fluorescence microscope and Comet Assay IV capture system (Perceptive Instruments) and 50 
nucleoids were scored per gel. The tail intensity, defined as the percentage of DNA migrated 
from the head of the comet into the tail, was measured from each comet scored. Tail moment 
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was not used for data analysis, as it has no recognized units. In addition, the equation used to 
calculate tail moment uses tail length, which tends to increase rapidly with concentration at 
low levels of damage. 
 
2.2.1. IMAGE ANALYSIS AND CRITERION OF SCORING 
There are three main scoring methods of comet assay results: visual scoring, semi-automated 
image analysis and automated image analysis. Results from a study performed by Azqueta et 
al. (2011) verified that all three approaches can be regarded as trustworthy and – to a large 
extent – interchangeable. 
The most important parameters to measure in comet assay are: tail length, relative 
fluorescence intensity of head and tail, normally expressed as % of DNA in tail, and tail 
moment (Collins, 2002). 
The percentage DNA in the tail is considered the parameter that can be best compared among 
laboratories. The consensus in the International Workshop on Genotoxicity Test Procedures 
was that image analysis is preferred but not required and that the parameter % tail DNA 
appeared to be the most linearly related to dose and the easiest to intuitively understand 
(Kumaravel & Jha, 2006; Hartmann  & Speit, 2009).  
The % tail DNA values are constrained to a maximum of 100 and a minimum of 0 with no 
variability at the extremes and a maximum variability at intermediate values such as 50%. The 
% tail DNA has the advantage that it can be ‘standardized’ over studies while tail length and 
moment, although consistent within the study, may not be comparable across studies (Lovell 
& Omori, 2008). Therefore, relative tail intensity is the most useful parameter, as it bears a 
linear relationship to break frequency, is relatively unaffected by threshold settings, and 
allows discrimination of damage over the widest possible range. It also gives a very clear 
indication of what the comets actually looked like (Collins, 2002; Lovell & Omori, 2008). It is 
important to refer that a satisfactory condition for the assay is that untreated control cells 
should have a background level of breaks (i.e.≈ 10% DNA in tail) and there are suggestions that 
negative control cells should have between 0 and 20% DNA as described by Lovell & Omori, 
2008.  
The figure concerning to comets image is presented in chapter 5 in section 3.1. 
 
2.3. GENETIC POLYMORPHISMS 
In order to study genetic polymorphisms in genes XRCC3, ADH5, OGG1 and VDR it is necessary 
to extract DNA from peripheral blood before using Real Time PCR to quantify the DNA in 
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study. The techniques used were: phenol-chloroform and by blood spot. It was also made a 
treatment with heparinase of the DNA of the samples from the formaldehyde study because 
they were preserved in heparin (anticoagulant) that inhibits the PCR reaction. All procedures 
are described below. 
 
2.3.1. DNA EXTRACTION  
 
2.3.1.1. DNA EXTRACTION FROM PERIPHERAL BLOOD BY PHENOL-CHLOROFORM TECHNIQUE  
Four hundred µl of peripheral blood was drawn from each sample and placed in a microtube 
with equal volume of lysis buffer (100 mM Tris-HCL pH 8; 10 mM EDTA; 100 mM NaCl; 0.1% 
SDS) plus 5 µl of proteinase K [20 mg/mL], being then incubated overnight at 56ºC. It was 
centrifuged (13.000g, 10 minutes) with phenol, phenol/chloroform and chloroform, 
respectively, with supernatant transfer to a new microtube. Finally, it was added 40 µl of 
Sodium acetate 3M pH 5.0 and 800 µl of cold absolute ethanol and refrigerated at -80C for 15 
minutes. After centrifugation (13.000g, 15 minutes) the supernatant was discarded and the 
pellet was washed with ethanol 70% and centrifuged at 4ºC (13.000g, 10 minutes). The pellet 
was dried in a coven over at 37C, ressuspended in 100 µl of ultrapure water (MiliQ), and 
stored at -20C. 
 
2.3.1.2. DNA EXTRACTION FROM BLOOD SPOT 
The whole blood previously stored at -20C was defrosted and 200 µl were dropped in 3 MM 
chromatography paper (WatmanTM) and air dried. Two samples of each biological sample were 
taken with a perforator and put in a microtube with 500 µl of ultrapure water (MiliQ). The 
perforator was disinfected between samples with ethanol 70%. Each microtube was placed in 
the vortex and kept at room temperature for 10 min, and next they were centrifuged at 
16.000 g for 2 min. The sobrenatant was eliminated and 200 µl of Chelex at 6% were added in 
the microtube and mixed in vortex. The microtubes were put at 56C for 10 min and then, 
after vortex, went for 10 more minutes at 100ºC. Finally, the microtubes were centrifugated at 
6000 g for 2 min and stored at -20C. 
 
2.3.2. TREATMENT WITH HEPARINASE I 
There are many substances that can strongly inhibit the PCR reaction, namely: proteinase K, 
phenol, quelants (EDTA), haemoglobin and other erythrocyte proteins, elevated 
concentrations of salts, and heparin.  
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In the formaldehyde occupational exposure study, heparin was used as anticoagulant in blood 
samples collected by venipuncture and it was necessary to provide a treatment with 
heparinase I.   Heparin interferes with DNA polymerase during DNA transcription and with the 
reverse transcription of RNA. The treatment with heparinase I consists in its dissolution in a 
buffer solution (20 mM Tris-HCL, pH 7.5, 50 mM NaCl, 4 mM CaCl2 and 0.01% BSA) and the 
addition of 0.83 µl of this solution plus 2 µl of ddH20 for each 7.2 µl of DNA extracted, for 2h 
at room temperature of 25C. 
 
2.3.3. STUDY OF THE POLYMORPHISMS BY REAL TIME PCR 
The genotype of the polymorphisms was studied by Real Time PCR using the iCycler iQ® 
Multicolor Real-Time PCR Detection System (BIO-RAD). The polymorphisms under examination 
were: XRCC3 Thr241Met, ADH5 Val309Ile, ADH5 Asp353Glu, OGG1 Ser241Arg, VDR BsmI, 
according to the information provided in Table 3. 
 
Table 3 – Polymorphisms studied, with the corresponding SNP ID and TaqMan SNP. 
 
 
 
 
 
 
 
The programme for Real Time PCR of the polymorphisms under study is specified in Table 4. 
 
Table 4 – Programme used to study polymorphisms by Real Time PCR. 
 
Stage Temperature (C) Time Repeats 
1º 50 2 min - 
2º 95 30 s - 
3º 95 30 s 2 
4º 95 10 min - 
5º 
92 
60 
15 s 
1 min 
50 
6º 4 - - 
 
Polymorphism SNP ID TaqMan SNP 
XRCC3 Thr241Met rs861539 C_8901525_10 
ADH5  Val309Ile rs28730628 C_61623349_10 
ADH5 Asp353Glu rs16996593 C_33249205_20 
OGG1 Ser326Cys rs1052133 C_3095552_1 
VDR BsmI rs1544410 C_8716062_10 
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The PCR reaction mixture was constituted by: 10 µl de TaqMan Universal PCR Master Mix and 
1 µl of specific primers for the polymorphisms under study, 5 µl of distilled water and 4 µl of 
DNA in study in a total volume of 20 µl. The primers and the TaqMan Universal PCR Master 
Mix were kept on ice during the preparation of the reaction solution. All reagents in the 
reaction solution were stored at -20C, except for the TaqMan Universal PCR Master Mix 
which was stored at 4C. 
 
2.4. EPITHELIAL CELLS 
Buccal cavity cells are obtained by scraping the cheeks with a tooth brush, wooden spatula, or 
a tongue depressor (Majer et al., 2001; Holland et al., 2008). The sampling of epithelial cells 
was performed by scraping the inside of both cheeks using a different brush for sampling left 
and right areas of the mouth to maximize cell sampling and to eliminate any unknown biases 
that may be caused by sampling one cheek only. It is important to note that repeated vigorous 
brushing of the same area can lead to increased collection of cells from the less differentiated 
basal layer (Thomas et al., 2009). For that purpose, buccal mucosa cells were collected with an 
endobrush®, a cytological brush; followed by a smear on two slides. The smears were fixed by 
pulverization with Mercofix®, a methanol fixative. The slides were stained by the Feulgen 
technique without counterstain and air dried. This technique allows for a highly selective 
demonstration of DNA. The reaction consists on an acid hydrolysis with nitric acid 5M aimed 
at selectively separating the purines (adenine and guanine) of the DNA molecule. The 
aldehydes groups formed in this stage stained pink by the Schiff’s reagent action. For each 
subject, two slides were done. Visualization was made in the Leica DM500 microscope with 
immersion oil and 1000x amplification by a single observer according with the observation list 
explained as follows.   
 
2.4.1. CRITERION OF SCORING  
The criterion for scoring is originally based on the description by Tolbert et al. (1992), 
intended for classifying buccal cells into categories that distinguish between “normal” cells 
and cells that are considered “abnormal” on the basis of cytological and nuclear features, 
which are indicative of DNA damage, cytokinetic failure or cell death. Only cells free smearing, 
clumping or overlapping and those containing intact nuclei should be included in the scoring. 
Therefore, some definitions of the cytological findings are (Thomas et al., 2009) as follows. 
Normal “differentiated” cells have a uniformly stained nucleus, which is oval or round in 
shape. They are distinguished from basal cells by their larger size and by their smaller nucleus-
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
131 
 
to-cytoplasm ratio. No other DNA-containing structures apart from the nucleus are observed 
in these cells, being considered to be terminally differentiated relative to basal cells, as no 
mitotic cells are observed in this population. 
Normal differentiated cells should fulfil the following parameters for being scored: (i) have an 
intact cytoplasm and relatively flat cell position on the slide; (ii) little or no overlap with 
adjacent cells; (iii) little or no debris; and (iv) nucleus normal and intact, nuclear perimeter 
smooth and distinct. The suggested criteria for identifying micronuclei are:  (i) chromatin 
intensity and staining pattern are similar to that of the main nucleus, (ii) the borders are 
distinctly recognizable indicating the presence of a nuclear membrane, (iii) the objects are 
round in the same optical plane with that of the main nucleus, (iv) and when they are 
contained within the same cytoplasm with the main nucleus (Tolbert et al., 1992). Baseline 
frequencies for micronucleated cells in the buccal mucosa are usually within the 0.5-2.5 
micronuclei /1000 cells range (Thomas et al., 2009). The latter study suggested a minimum of 
2000 differentiated cells to be scored. The figure concerning to this endpoint is presented in 
chapter 5 in section 2.2.  
 
2.5. VITAMINS QUANTIFICATION 
 
2.5.1. VITAMINS A AND E QUANTIFICATION BY HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY 
Vitamins A and E were quantified in serum samples according to Jaworowska & Bazylak 
(2008). Calibration curves were constructed from stock solutions of vitamin A (100 mM in 
methanol), vitamin E (100 mM in chloroform) and tocopheryl acetate (TA - 100 mM in 
methanol, internal standard). 
At the outset, calibration curves for each vitamin were built from successive dilutions showed 
in Table 5 for vitamins A, E and tocopheryl acetate. 
 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
132 
 
Table 5 – Range concentrations of vitamins A, E, and tocopheryl acetate to build the calibration curves. 
 
Level 
Vit. A 
(mM) 
Vit. E 
(mM) 
TA 
(mM) 
Blank 0.000 0.000 0.25 
1 0.050 0.050 0.25 
2 0.125 0.125 0.25 
3 0.250 0.250 0.25 
4 0.375 0.375 0.25 
5 0.425 0.425 0.25 
6 0.500 0.500 0.25 
 
 
The serum samples were thawed and analysed by HPLC-DAD. Before chromatography an 
extraction protocol was conducted, consisting in the addition of 400 µl of 62.5 µM TA (in 
methanol) to 200 µl of each serum sample and 330 µl n-hexane, followed by a 5-minute vortex 
homogenisation and centrifugation (13.400 g, 10 minutes). 
 
The upper phase was collected in a HPLC vial and the lower phase was re-extracted twice. The 
n-hexane extracts were pooled together and evaporated under a nitrogen stream at 37C. The 
dried extract was dissolved in 100 µl methanol and 25 µl were injected in triplicate. The 
chromatographic conditions are outlined in Table 6. 
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Table 6 – Chromatographic conditions for quantification of vitamins A and E and realizations of the 
respective calibration curves. 
 
Conditions Description 
Column Hypersil-BDS C18 
Pre-column Javelin BDS C8 
Mobile phase 100% methanol (isocratic) 
Injection volume 25 µl (no waste mode) 
Needle wash between injections Yes with methanol 
Run time 20 minutes 
Detection Wavelenght 
285 nm, Tocopheryl acetate 
290 nm, Vitamin E 
325 nm, Vitamin A 
Retention Times 
2.91 min, Vitamin A 
5.82 min, Vitamin E 
8.47 min, Tocopheryl acetate 
Total Scan 200 – 600 nm 
 
 
Data of the calibration curves obtained for vitamins A and E are showed in Table 7, with the 
respective Limit of Detection (LOD) and Limit of Quantification (LOD) and Linearity (R).  
 
Table 7 – Calibration curves data and LOD, LOQ, and Linearity (R) parameters. 
 
 
 
 
 
 
 
 
 
 [Vit A]/µM [Vit E]/µM 
Equation 
y = 605357x + 
11002 
Y=670317x + 2568 
R2 0.9999 0.9999 
LOD (nmol) 0.0154 0.01 
LOQ (nmol) 0.0468 0.04 
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2.5.2. VITAMIN D QUANTIFICATION BY IDS 25-HYDROXY VITAMIN D EIA KIT 
The IDS 25-Hydroxy Vitamin D EIA kit (Immunodiagnostic Systems Ltd) is an enzyme 
immunoassay for the quantification of 25-hydroxyvitamin D and other hydroxylated 
metabolites in human serum or plasma. 25 µl of the samples were added to a calibrator and a 
control and to 1 mL of 25-D biotin solution; 200 µl of each sample were incubated in the 
appropriate wells with antibody coated microplate in duplicate. The plate was covered with an 
adhesive plate sealer for 2h at room temperature. Later it was washed three times with 250 µl 
of wash solution (PBS containing Tween). Then 200 µl of enzyme conjugate (TMB - PBS 
containing avidin linked to horseradish peroxidase) was added and the plate was covered for 
30 minutes at room temperature. The wash step was repeated. An amount of 200 µl of TMB 
substrate was added to all wells for 30 minutes and 100 µl of HCL, in order to stop the 
reaction. The measure of the absorbance of each well was made at 450 nm (reference 650 
nm) using a microplate reader within 30 minutes after adding the stop solution. 
 
3. STATISTICAL PROCEDURES 
The deviation of variables from the normal distribution was evaluated by the Shapiro-Wilk 
goodness-of-fit test. Rejection of the null hypothesis of underlying normality usually led us to 
proceed with non-parametric procedures to compare means and check associations. 
However, parametric procedures were also commony used for descriptive purposes, some of 
them being known for their robustness to deviations from normality assumptions. For 
example, means and standard deviations were commonly used.  
The statistical procedures were aimed at investigating the association between genotoxicity 
biomarkers, herein conceptualized as dependent variables, and a selection of possible risk 
factors conceptualized as independent (explanatory) variables (Tables 1 and 2). The 
biomarkers were dichotomized (absent/present) and considered the dependent variable in 
multiple regression models, namely binary multiple logistic regression, where exposures were 
treated as independent variables. Odds ratios were computed to evaluate the risk of 
biomarkers presence and their significance was assessed.  
The biomarkers were nuclear alterations given by the endpoints studied – micronuclei, 
nucleoplasmic bridges, nuclear buds and comets. The risk factors were tobacco and alcohol 
consumption habits, diet, genetic polymorphisms (susceptibility biomarkers), vitamin serum 
levels, and dietary intakes assessed by FFQ. Spearman correlation, Mann-Whitney and 
Kruskal-Wallis tests were also used to compare groups. Multiple regression analysis was used 
solely to identify potential risk factors and not with a predictive explanatory character.  
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The analysis of genotype and allele frequency and Fisher’s exact test was made with the 
GenPop version 4.0.10 software, and all the other statistical procedures were made by using 
the Statistical Package for the Social Sciences (SPSS) version 21.0. 
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CHAPTER 1 – FORMALDEYDE OCCUPATIONAL SETTING 
 
 
1. SAMPLES  
 
Two samples were formed - the group of those occupationally exposed to formaldehyde and 
the non-exposed group (controls). The characteristics of each group regarding gender, age, 
years of exposure, tobacco, and alcohol consumption, are presented in Table 8. 
 
Table 8 – Characteristics of the samples regarding gender, age, years of exposure, tobacco and alcohol 
consumption.  
 
 Control group Exposed group 
Number of subjects 85 56 
Gender 
Females 
Males 
 
54 (64%) 
31 (36%) 
 
37 (66%) 
19 (34%) 
Age 
(mean ± standard deviation, in years) 
Range 
 
32.42 ± 8.1 
20-53 
 
 
39.45 ± 11.5 
20-61 
 
Years of exposure 
(mean ± standard deviation, in years) 
Range 
 
n.a. 
 
14.5 
1-33 
Tobacco consumption 
Non-smokers 
Smokers 
 
 
60 (70.6%) 
25 (29. 4%) 
 
 
45 (80.4%) 
11 (19.6%) 
 
Alcohol consumption 
Non-drinkers 
Drinkers 
 
 
19 (22.4%) 
66 (77.6%) 
 
 
19 (33.9%) 
37 (66.1%) 
 
           n.a. - non applicable 
 
  
2. FORMALDEHYDE EXPOSURE ASSESSMENT 
Results of formaldehyde exposure were determined using the two methods described – the 
NIOSH 2541 method (NIOSH, 1994) for average concentrations (TWA8h) and the PID method 
for ceiling concentrations. For the first exposure metric, the formaldehyde mean level of the 
56 individuals exposed was 0.16 ppm (0.04 – 0.51 ppm), a value lying below the OSHA critical 
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reference of 0.75 ppm. The mean ceiling concentration found in the laboratories was 1.14 
ppm (0.18 – 2.93 ppm), a value well above the reference of 0.3 ppm established by the ACGIH 
for ceiling concentrations. The ceiling values varied among the different tasks developed in 
histopathology laboratories. The highest formaldehyde concentration was identified during 
macroscopic specimens’ exam (Table 9). This task involves a careful observation and grossing 
of the biological specimen preserved in formaldehyde, by the pathologist or pathology 
anatomy technician, being prone to a direct and prolonged contact with formaldehyde vapors. 
Another task, jar filling, is the substitution of formaldehyde with a fresh solution in the 
recipients where it was used. The third task with high ceiling values was specimen wash, the 
washing of biological samples to remove residues that can affect macroscopy exam. Another 
task, the biopsy, is the collection of a small biological sample, usually containing the complete 
lesion and for this task the ceiling value was lower than for the macroscopic specimen exam 
(Table 9). Finally, disposal of specimen and used solutions consists in the removal of 
formaldehyde to the proper waste, and the disposal of the biological speciemens for 
incineration.  
 
 
Table 9 - Formaldehyde ceiling values (ppm) by task in the macroscopy room. 
 
Tasks Ceiling Values 
(ppm) 
Macroscopic specimen’s 
exam 
2.93  
Disposal of specimen 
and used solutions 
0.95 
Jar filling 2.51 
Specimen wash 2.28 
Biopsy exam 1.91 
 
3. GENOTOXICITY ASSESSMENT 
For all genotoxicity biomarkers under study, workers exposed to formaldehyde had 
significantly higher mean values than the controls (Table 10). 
In peripheral blood lymphocytes, significant differences (Mann-Whitney test, p<0.001) were 
observed between subjects exposed and non-exposed to formaldehyde, namely in mean MN 
(respectively, 3.96±0.53 vs 0.81±0.17), NPB (3.04±0.52 vs 0.18±0.06), and NBUD (0.98±0.27 vs 
0.07±0.03). In buccal mucosa cells, the MN mean was also significantly higher (p=0.002) in 
exposed subjects (0.96±0.28) than in controls (0.16±0.06).  
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The odds ratios (OR) indicate an increased risk for the presence of biomarkers in those 
exposed to formaldehyde, compared to non-exposed (Table 10) and they were all significant 
(p<0.001). 
 
 
Table 10 – Descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD in the studied 
population (mean ± standard error of the mean, range), p-value of the Mann-Whitney test and results 
of binary logistic regression concerning the association between exposure and genotoxicity biomarkers, 
as evaluated by the odds ratio (OR) and their confidence intervals. 
 
 MN in 
lymphocytes  
Mean ± S.E.  
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD  
Mean ± S.E. 
(range) 
MN in buccal cells 
Mean ± S.E. 
(range) 
Exposed 3.96±0.53 (0-14) 3.04±0.52 (0-15) 0.98±0.27 (0-13) 0.96±0.28 (0-9) 
Controls 0.81±0.17 (0-7) 0.18±0.06 (0-3) 0.07±0.03 (0-1) 0.16±0.06 (0-2) 
p-value1 <0.001 <0.001 <0.001 0.002 
OR 9.665 11.97 9.631 3.990 
OR CI 95% 3.81-24.52 4.59-31.20 3.12-29.70 1.38-11.58 
p-value2 <0.001 <0.001 <0.001 0.011 
1 Mann-Whitney test 
2 Binary logistic regression 
 
Regarding the impact of the duration of exposure to formaldehyde, the mean values of MN in 
lymphocytes and in buccal cells tended to increase with years of exposure (Table 11) but the 
association was not statistically significant (p>0.05). 
 
 
Table 11 –Descriptive statistics in the exposed group of MN in lymphocytes and buccal cells, NPB, and 
NBUD (mean ± standard error of the mean, range) by years of exposure to formaldehyde. 
 
Years of 
exposure 
N MN in lymphocytes 
Mean ± S.E.  
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD  
Mean ± S.E. 
(range) 
MN in buccal cells 
Mean ± S.E. 
(range) 
<5 8 2.75±0.94 
(0-8) 
5.13±1.38 
(0-10) 
1.38±0.50 
(0-3) 
0.63±0.63 
(0-5) 
6-10 19 3.05±0.78 
(0-12) 
2.42±0.67 
(0-9) 
1.53±0.73 
(0-13) 
0.63±0.33 
(0-6) 
11 – 20 12 5.50±1.32 
(0-14) 
3.33±1.44 
(0-14) 
0.33±0.19 
(0-2) 
0.83±0.46 
(0-5) 
≥ 21 15 5.00±1.15 
(0-13) 
2.33±1.04 
(0-15) 
0.73±0.25 
(0-2) 
1.20±0.80 
(0-9) 
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4. DEMOGRAPHIC AND LIFESTYLE HABITS  
Age and gender are considered the most important demographic variables affecting the MN 
index. However, the mean of all genotoxicity biomarkers (Table 12) did not differ significantly 
between men and women either in the exposed or the controls (Mann-Whitney test, p> 0.05).  
 
 
 
Table 12 –Descriptive statistics of MN in lymphocytes and buccal cells, NPB, and NBUD means by 
gender and exposure (mean ± standard error of the mean, range). There were no significant differences 
between means of the two genders either within the exposed or the controls. 
 
Groups Gender N MN in lymphocytes  
Mean ± S.E.  
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD  
Mean ± S.E. 
(range) 
MN in buccal cells 
Mean ± S.E. 
(range) 
 
 
Exposed 
Females 37 4.43±0.68 
(0-14) 
3.03±0.70 
(0-15) 
1.34±0.42 
(0-13) 
1.14±0.35 
(0-8) 
Males 19 3.47±0.88 
(0-13) 
2.95±0.82 
(0-14) 
0.42±0.16 
(0-2) 
0.74±0.50 
(0-9) 
 
 
Controls 
Females 54 0.87±0.23 
(0-7) 
0.22±0.08 
(0-3) 
0.11±0.04 
(0-1) 
0.11±0.06 
(0-2) 
Males 31 0.71±0.26 
(0-6) 
0.10±0.07 
(0-2) 
0.00 0.26±0.12 
(0-2) 
 
 
In order to examine the effect of age on biomarkers, individuals were split into exposed and 
non-exposed and, within each group, the association between age and biomarker frequency 
was studied by simple regression analysis, yielding the results in Table 13. There is a significant 
association between MN in lymphocytes and age in the exposed group, with the number of 
MNs tending to increase with age (R2= 0.206, p<0.001) as shown in Figure 9a. The regression 
coefficient (B in Table 13) indicates that a 10-year increase in age corresponds to an average 
increase of 1.55 MNs in lymphocytes. Age does not significantly account for variation in any 
other biomarker (Table 13) though.  
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Table 13 - Results of simple regression analysis of age on biomarkers by group (exposed/controls). R2 is 
the coefficient of determination; A and B are, respectively, the ordinate and the slope in the regression 
line, and p is the likelihood of B in case of no association between age and the biomarker; ** signals a 
highly significant p. 
Biomarker  R2 A B p 
MN in BN lymphocytes Exposed 0.206 -2.143 0.155 <0.001** 
Controls 0.009 1.486 -0.019 0.395 
NPB Exposed 0.000 0.705 0.000 0.999 
Controls 0.001 0.384 -0.004 0.778 
NBUD Exposed 0.013 0.015 0.009 0.403 
Controls 0.001 0.107 -0.001 0.740 
MN in Buccal Exposed 0.003 0.278 -0.003 0.671 
Controls 0.003 0.241 0.013 0.637 
 
              a)                                                                                                b) 
        
Figure 9 - Scatter plots of the number of MN in lymphocytes against age in the exposed (a) and control 
(b) groups. The slope of the regression line (dashed) in the exposed is statistically significant. 
 
 
Although the association between years of exposure and genotoxicity biomarkers, namely MN 
in lymphocytes, is not statistically significant, exposed workers with higher age tend to have 
more years of exposure, an association that was not observed in the control group. 
 
Descriptive statistics of every biomarker were decomposed by three age groups (20-30, 31-40, 
and ≥ 41 years old) in the exposed and control groups, allowing for a qualitative view of the 
same relationships (Table 14). 
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Table 14 – Age effects on descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD 
means in the studied population (mean ± standard error of the  mean, range). 
 
Groups Age N MN in lymphocytes  
Mean ± S.E.  
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD  
Mean ± S.E. 
(range) 
MN in buccal cells 
Mean ± S.E. 
(range) 
 
 
Exposed 
20-30 18 2.19±0.53 
(0-8) 
3.56±0.93 
(0-10) 
1.63±0.82 
(0-13) 
0.75±0.47 
(0-6) 
31-40 11 3.00±0.78 
(0-8) 
1.20±0.47 
(0-4) 
0.50±0.22 
(880-2) 
0.40±0.22 
(0-2) 
≥ 41 27 5.54±0.88 
(0-14) 
3.00±0.88 
(0-15) 
0.69±0.23 
(0-5) 
1.46±0.50 
(0-9) 
 
 
Controls 
20-30 36 0.47±0.16 
(0-3) 
0.14±0.07 
(0-2) 
0.08±0.05 
(0-1) 
0.19±0.96 
(0-2) 
31-40 35 1.14±0.33 
(0-7) 
0.20±0.01 
(0-3) 
0.06±0.04 
(0-1) 
0.14±0.83 
(0-2) 
≥ 41 14 0.86±0.50 
(0-6) 
0.21±0.16 
(0-2) 
0.07±0.71 
(0-1) 
0.14±0.14 
(0-2) 
 
 
 
In order to examine if gender adds a significant contribution to explain variability in 
genotoxicity biomarkers, regression analysis was repeated but now adding gender as an 
independent variable and examining whether it would improve upon the values of R2 already 
presented for age (Table 15).  
 
 
Table 15 - Results of multiple regression analysis of age and gender on biomarkers by group 
(exposed/controls). R2, new R2, and ΔR2 are, respectively, the coefficients of determination of the model 
with only age, age and gender, and the difference between them. The significance of the addition of 
gender is shown by the value of p, none being significant. 
 
  Age Age and gender 
Biomarker Group R2 New R2 ÄR2 p 
MN in BN lymphocytes Exposed 0.206 0.207 0.001 0.828 
Controls 0.009 0.014 0.005 0.574 
NPB Exposed 0.000 0.006 0.006 0.597 
Controls 0.001 0.014 0.013 0.325 
NBUD Exposed 0.013 0.040 0.027 0.244 
Controls 0.001 0.002 0.001 0.945 
MN in Buccal Exposed 0.003 0.013 0.010 0.488 
Controls 0.003 0.006 0.003 0.610 
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The results (Table 15) show that the increase in R2 due to the presence of gender in the model 
was never significant, thus gender does not help to account for the frequency of genotoxicity 
biomarkers. Table 16 allows for a further examination of descriptive statistics of biomarkers by 
groups and gender. 
 
 
Table 16 - Descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD means by 
exposition to formaldehyde, gender and age (mean ± standard error of the mean). 
 
The distribution of the genotoxicity biomarkers regarding tobacco consumption is presented 
in Table 17. Regarding smoking habits, a non-parametric analysis rejected the null hypothesis 
that biomarkers are the same for the four categories (control smokers and non-smokers, 
exposed smokers and non-smokers) (Kruskal-Wallis test, p<0.001). However, the analysis of 
the interactions between formaldehyde exposure and tobacco smoke between exposed and 
controls (Mann-Whitney test) showed that formaldehyde exposure, rather than tobacco, has a 
preponderant effect upon the determination of biomarker frequencies. In the control group, 
Groups  N MN in 
lymphocytes  
Mean ± S.E. 
 
NPB 
Mean ± S.E. 
 
NBUD  
Mean ± S.E. 
 
MN in buccal cells 
Mean ± S.E. 
 
 
 
 
 
 
Exposed 
 
Females 
20-30 
12 2.42±0.67 4.17±1.22 
 
2.00±1.07 
 
1.00±0.62 
 
Females 
31-40 
7 2.71±0.68 
 
0.86±0.46 
 
0.57±0.3 
 
0.29±0.18 
 
Females 
>41 
18 6.00±1.12 
 
3.22±1.09 
 
1.06±0.39 
 
1.44±0.55 
 
Males 
20-30 
6 1.00±0.52 3.50±1.02 
 
0.50±0.34 
 
0.00±0.0 
 
Males 
31-40 
4 3.00±1.78 
 
1.50±0.96 
 
0.25±0.25 
 
0.50±0.50 
 
Males 
>41 
9 5.33±1.45 
 
3.22±1.56 
 
0.44±0.24 
 
1.33±1.01 
 
 
 
 
 
 
Controls 
Females 
20-30 
23 0.43±0.20 0.13±0.70 
 
0.13±0.7 
 
0.13±0.10 
 
Females 
31-40 
22 1.32±0.44 0.27±0.15 
 
0.09±0.06 
 
0.14±0.10 
 
Females 
>41 
9 0.89±0.68 
 
0.33±0.24 0.11±0.11 
 
0.00±0.00 
 
Males 
20-30 
13 0.54±0.27 0.15±0.15 
 
0.00±0.00 
 
0.31±0.21 
 
Males 
31-40 
13 0.85±0.48 
 
0.08±0.08 
 
0.00±0.00 
 
0.15±0.15 
 
Males 
>41 
5 0.80±0.80 
 
0.00±0.00 
 
0.00±0.00 
 
0.40±0.40 
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non-smokers had slightly higher MN means in buccal cells in comparison with smokers; 
although the result did not reach statistical significance (Mann-Whitney test, p> 0.05). 
 
Table 17 –Descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD means (mean ± 
standard error of the mean, range) by exposition to formaldehyde and tobacco habits. 
 
Groups 
Tobacco 
consumption 
N 
MN in lymphocytes 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in buccal 
cells 
Mean ± S.E. 
(range) 
Exposed 
Non-
smokers 
44 
4.39±0.60 
(0-12) 
0.72±0.23 
(0-6) 
0.37±0.14 
(0-2) 
0.16±0.08 
(0-8) 
Smokers 11 
2.55±1.08 
(0-14) 
0.64±0.24 
(0-15) 
0.36±0.24 
(0-13) 
0.18±0.18 
(0-9) 
Controls 
Non-
smokers 
57 
0.88±0.22 
(0-6) 
0.33±0.14 
(0-3) 
0.09±0.05 
(0-1) 
0.77±0.29 
(0-2) 
Smokers 24 
0.75±0.33 
(0-7) 
 
0.13±0.13 
(0-2) 
0.00 
0.33±0.25 
(0-2) 
 
 
As for alcohol consumption, because uptake reported in enquires may differ considerably 
from real consumption, all consumers were gathered into a single entity, in contrast with non-
consumers. Nevertheless, no one acknowledged having “heavy drink habits” in the 
questionnaires. The distribuition of the genotoxicity biomarkers regarding alcohol 
consumption is presented in Table 18.   
 
Table 18 – Descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD (mean ± 
standard error of the mean, range) by alcohol consumption and exposure to formaldehyde. 
 
Groups 
Alcohol 
consumption 
N 
MN in 
lymphocytes 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in buccal 
cells 
Mean ± S.E. 
(range) 
Exposed 
Non-
drinkers 
19 
4.00±0.83 
(0-12) 
3.58±0.94 
(0-15) 
1.00±0.33 
(0-5) 
0.79±0.31 
(0-5) 
Drinkers 35 
3.95±0.68 
(0-14) 
2.76±0.63 
(0-14) 
0.97±0.38 
(0-13) 
1.05±0.39 
(0-9) 
Controls 
Non-
drinkers 
18 
0.21±0.21 
(0-4) 
0.11±0.07 
(0-1) 
0.00±0.00 
 
0.11±0.11 
(0-2) 
Drinkers 63 
0.98±0.21 
(0-7) 
 
0.20±0.07 
(0-3) 
0.09±0.04 
(0-1) 
0.18±0.07 
(0-2) 
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Overall, biomarkers in both groups – exposed and controls, did not exhibit very different mean 
frequencies among alcohol consumers and non-consumers, and these differences were 
indeed not statistically significant (Mann-Whitney test, p>0.05).  
The interaction between alcohol consumption and smoking habits was statistically significant 
(Kruskal-Wallis test, p=0.043), as subjects that do not smoke and do not drink tend to have 
lower frequencies of MN in buccal cells than those who drink and smoke, with a gradient of 
frequencies in between.   
 
 
 
5. INDIVIDUAL SUSCEPTIBILITY 
The frequencies of genotypes and alleles of the polymorphisms studied – XRCC3 Met241Thr, 
ADH5 Val309Ile and Asp353Glu, and VDR BsmI - in the two groups are shown in Table 19. No 
significant differences were observed between groups in genotype and allele frequencies for 
the four polymorphisms analyzed (Fisher’s exact tests, p > 0.05).  
 
                          Table 19 – Frequency of genotypes and alleles of XRCC3 Met241Thr, ADH5 Val309Ile and 
Asp353Glu, and VDR BsmI polymorphisms overall and by exposition group, with p-value of the Fishers’s 
exact test. 
 
Genes Genotypes All (%) 
Exposed 
(%) 
Controls (%) p-value 
XRCC3 
Met/Met 
Met/Thr 
Thr/Thr 
33 (24.3) 
49 (36.0) 
54 (39.7) 
13 (24.1) 
22 (40.7) 
19 (35.2) 
20 (24.4) 
27 (32.9) 
35 (42.7) 
0.660 
Met 
Thr 
115 
157 
48 (0.4) 
60 (0.6) 
67 (41) 
97 (59) 
0.628 
ADH5 
Val/Val 
Val/Ile 
50 (36.5) 
87 (63.5) 
21 (38.2) 
34 (61.8) 
29 (35.4) 
53 (64.6) 
0.856 
Val 
Ile 
187 
87 
76 (69.1) 
34 (30.9) 
111 (67.7) 
53 (32.3) 
0.896 
ADH5 
Asp/Asp 
Asp/Glu 
59 (43.1) 
78 (56.9) 
24 (43.6) 
31 (56.4) 
35 (42.7) 
47 (57.3) 
0.999 
Asp 
Glu 
196 
78 
79 (71.8) 
31 (28.2) 
117 (71.3) 
47 (39.7) 
0.999 
VDR 
TT 
CT 
CC 
3 (2.2) 
85 (63.0) 
47 (34.8) 
3 (5.5) 
25 (45.5) 
27 (49.0) 
0 (0.0) 
60 (75.0) 
20 (25.0) 
0.042 
T 
C 
91 
179 
31 (28.2) 
79 (71.8) 
60 (37.5) 
100 (62.5) 
0.116 
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5.1. XRCC3 MET241THR POLYMORPHISMS 
Results of binary logistic regression for both groups provided evidence for a statistically 
significant association between XRCC3 polymorphisms and NBUD. Specifically, XRCC3 
Met/Met (OR=3.975, CI95% 1.053-14.998, p = 0.042) and XRCC3 Thr/Met (OR=5.632, CI95% 
1.673-18.961, p = 0.005) are risk factors for NBUD in comparison with XRCC3 Thr/Thr. As 
shown in Table 20, lower means of NBUD were found in carriers of Thr/Thr polymorphism in 
both exposed and controls.  
 
Table 20 - Descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD (mean ± 
standard error of the mean, range) by XRCC3 Met241Thr polymorphisms and exposure, and p-value of 
the Kruskal-Wallis test. 
 
Groups XRCC3 N 
MN in 
lymphocytes 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in buccal cells 
Mean ± S.E. 
(range) 
 
 
Exposed 
Met/Met 13 
2.92±0.93 
(0-12) 
2.00±1.14 
(0-15) 
0.38±0.18 
(0-2) 
1.00±0.71 
(0-9) 
Thr/Met 22 
5.05±0.98 
(0-14) 
3.91±0.84 
(0-13) 
1.50±0.33 
(0-2) 
1.05±0.38 
(0-5) 
Thr/Thr 17 
3.88±0.85 
(0-12) 
2.82±0.94 
(0-13) 
0.24±0.95 
(0-2) 
1.06±0.49 
(0-8) 
p-value 0.372 0.156 0.002* 0.733 
 
 
Controls 
Met/Met 20 
1.15±0.46 
(0-7) 
0.25±0.12 
(0-2) 
0.2±0.09 
(0-1) 
0.25±0.14 
(0-2) 
Thr/Met 27 
0.70±0.3 
(0-6) 
0.15±0.12 
(0-3) 
0.04±0.04 
(0-1) 
0.11±0.82 
(0-2) 
Thr/Thr 35 
0.74±0.23 
(0-6) 
0.14±0.07 
(0-2) 
0.03±0.29 
(0-1) 
0.17±0.01 
(0-2) 
p-value 0.621 0.450 0.045* 0.664 
 
The Kruskal-Wallis analysis corroborates the results from binary logist regression, confirming 
statistical significant differences regarding NBUDs in both groups. In the exposed group, 
Kruskal Wallis multiple comparisons showed that Thr/Met genotype differs significantly from 
the two homozygotes (p<0.05). Also in controls, Met/Met genotype differs significantly from 
the Thr/Thr genotype (p=0.045), presenting the latter lower means of NBUDs. 
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5.2. ADH5 VAL309ILE AND ASP353GLU POLYMORPHISMS 
Descriptive statistics of the genotoxicity biomarkers by the two ADH5 polymorphisms studied 
are shown in Tables 21 and 22.  There were no individuals with homozygous genotypes (Ile/Ile  
and Glu/Glu) for the variant allele of the two ADH5 polymorphisms investigated. Results of 
binary logistic regression did not show statistically significant associations between ADH5 
polymorphisms and the genotoxicity biomarkers studied. However, a borderline significant 
association (p = 0.06) was found with NBUD, as the Asp/Asp genotype had lower means than 
the Asp/Glu genotype. There was a statistically significant difference between Val/Val and 
Val/Ile genotypes for the ADH5 Val309Ile polymorphism in MN in lymphocytes in the exposed 
group (Kruskal-Wallis test, p = 0.024) with carriers of the heterozygote genotype having higher 
mean values than the homozygotes (Table 21). 
 
Table 21 - Descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD (mean ± 
standard error of the mean, range) by ADH5 Val309Ile polymorphisms and exposure, and p-values of 
Mann-Whitney test. 
 
There were no significant associations between the genotoxicity biomarkers and the two 
genotypes available for analysis (Table 22). 
 
Groups ADH5 N 
MN in 
lymphocytes 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in buccal cells 
Mean ± S.E. 
(range) 
Exposed 
Val/Val 20 
2.57±0.65 
(0-11) 
3.19±0.89 
(0-14) 
0.62±0.28 
(0-5) 
0.95±0.41 
(0-6) 
Val/Ile 32 
4.91±0.72 
(0-14) 
3.00±0.67 
(0-15) 
0.85±0.21 
(0-5) 
1.00±0.38 
(0-9) 
p-value 0.024* 0.957 0.274 0.713 
Controls 
Val/Val 29 
0.97±0.28 
(0-6) 
0.17±0.07 
(0-1) 
0.00±0.00 
(0) 
0.14±0.10 
(0-2) 
Val/Ile 53 
0.75±0.23 
(0-7) 
0.17±0.08 
(0-3) 
0.11±0.04 
(0-1) 
0.19±0.08 
(0-2) 
p-value 0.176 0.370 0.061 0.546 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
150 
 
Table 22 - Descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD means (mean ± 
standard error of the mean, range) by ADH5 Asp353Glu polymorphisms and exposure, and p-values of 
Mann-Whitney test. 
 
5.3. VITAMIN D RECEPTOR BSMI POLYMORPHISMS  
The three possible VDR BsmI genotypes in the exposed group were regrouped in two 
genotypes, since there were only 3 carriers of the TT genotype. There were no significant 
differences between the serum concentrations of vitamin D by genotype (Mann-Whitney test, 
p>0.05). 
Concerning genotoxicity biomarkers, a significant association was found in the exposed group 
between genotype and MN in lymphocytes (Mann Whitney test, p=0.041), as carriers of the 
CT+T genotype presented higher MN means than those with CC genotype (Table 23).  
 
Table 23 - Descriptive statistics of MN in lymphocytes and buccal cells, NPB and NBUD means in the 
studied population (mean ± standard error of the mean, range) by VDR BmsI polymorphisms and 
exposure, and p-value of Mann-Whitney test. 
 
Groups VDR N 
MN in 
lymphocytes 
Mean ± S.E. 
(range) 
NPB 
Mean ± 
S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in buccal cells 
Mean ± S.E. 
(range) 
 
Exposed 
TT+CT 25 
5.11±0.83 
(0-14) 
0.93±0.29 
(0-6) 
0.37±0.12 
(0-2) 
0.07±0.07 
(0-2) 
CC 27 
2.89±0.59 
(0-12) 
0.48±0.25 
(0-6) 
0.37±0.21 
(0-5) 
0.26±0.13 
(0-2) 
p-value 0.041* 0.088 0.284 0.168 
Controls 
CT 60 
0.75±0.19 
(0-7) 
0.23±0.11 
(0-6) 
0.07±0.04 
(0-2) 
0.65±0.25 
(0-9) 
CC 20 
1.15±0.44 
(0-6) 
0.40±0.24 
(0-4) 
0.05±0.05 
(0-1) 
0.60±0.47 
(0-9) 
p-value 0.350 0.649 0.988 0.616 
Groups ADH5 N 
MN in 
lymphocytes 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in buccal cells 
Mean ± S.E. 
(range) 
Exposed 
Asp/Asp 21 
4.08±0.90 
(0-14) 
4.21±0.96 
(0-15) 
0.71±0.23 
(0-3) 
0.92±0.37 
(0-6) 
Asp/Glu 31 
3.97±0.65 
(0-12) 
2.19±0.55 
(0-14) 
0.81±0.24 
(0-5) 
1.03±0.41 
(0-9) 
p-value 0.700 0.217 0.740 0.983 
Controls 
Asp/Asp 35 
0.86±0.23 
(0-6) 
0.29±0.12 
(0-3) 
0.06±0.04 
(0-1) 
0.29±0.12 
(0-2) 
Asp/Glu 47 
0.81±0.26 
(0-7) 
0.09±0.04 
(0-1) 
0.09±0.04 
(0-1) 
0.09±0.05 
(0-2) 
p-value 0.211 0.204 0.633 0.202 
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6. MICRONUTRIENTS 
All subjects had vitamin levels within the normal range (Table 24), no significant differences 
existed in the serum levels of vitamins in the formaldehyde exposed group compared with the 
controls.  
 
Table 24 – Quantification of vitamins A, D and E in human serum in the studied population (mean ± 
standard error of the mean, range) and the biological normal limits. 
 
Vitamins Groups N 
Mean± Std. Error 
of Mean 
 
Normal range 
limits 
 
A 
(µmol/L) 
 
Exposed 46 
2.21±0.51 
(1.11 – 3.17) 
 
1.05 – 3.32 
µmol/L 
 
Controls 75 
1.79±0.29 
(1.09 – 3.03) 
D 
(nmol/L) 
Exposed 55 
66.18±4.05 
(20.8 – 141.1) 
 
25 – 137 
nmol/L Controls 81 
80.56±4.99 
(15.9 – 175.2) 
 
E 
(µmol/L) 
 
Exposed 46 
21.83±1.26 
(7.12 – 39.03) 
 
12 - 46 µmol/L 
 
Controls 78 20.06±0.77 
(2.48 – 41.21) 
 
 
The distribution of the vitamin D serum values according to the VDR genotypes is presented in 
Table 25. No statistical significant differences were found between the two genotypes in each 
exposure group. 
 
Table 25 – Distribution of the vitamin D serum values by the two VDR genotypes (mean ± standard 
error of the mean, range). 
Groups VDR N 
Vitamin D 
(nmol/L) 
Mean ± S.E. 
(range) 
Exposed 
TT+CT 
 
25 
83.80±6.21 
(15.9 – 175.2) 
CC 
 
27 
72.80±8.07 
(20.5 – 125.1) 
p-value  0.606 
Controls 
CT 60 
64.30±5.90 
(25.6 - 135.3) 
CC 20 
68.00±5.64 
(20.8 – 141.1) 
p-value  0.404 
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6.1. GENOTOXICITY BIOMARKERS AND VITAMINS A, D AND E 
In order to examine if there was any association between the frequency of biomarkers and 
any of the three vitamins under study, multiple linear regression was conducted by group 
(exposed/controls), with the frequency of each biomarker being the dependent variable and 
the vitamin levels the independent set of explanatory variables. The results indicate that none 
of the three vitamins associate with biomarkers, to the exception of NPBs in the exposed 
group (Table 26). Indeed, altogether the three vitamins account for 34.1% of variability in NPB 
in the exposed, which is highly significant (p=0.001).  
 
 
Table 26 - Results of multiple regression of biomarker frequency against the levels of a set of three 
vitamins (A, D, E) in the exposed and control groups. R2 are the coefficients of determination for each 
regression and p indicates statistical significance of the model. 
Biomarker  R2 p 
MN in lymphocytes 
Exposed 0.106 0.191 
Controls 0.042 0.456 
NPB 
Exposed 0.341 0.001** 
Controls 0.053 0.348 
NBUD 
Exposed 0.119 0.144 
Controls 0.036 0.530 
MN in Buccal cells 
Exposed 0.042 0.614 
Controls 0.025 0.680 
 
 
A closer examination of regression coefficients in the model of NPB in the exposed against 
vitamins, shows that vitamin A is by and large the major responsible for the statistical 
significance found (Table 27). Its regression coefficient (B=0.58) indicates that 1 unit increase 
in Vitamin A should, on average, correspond to an 0.58 unit increase in NPBs. Vitamin E is also 
marginally accountable for variation in NPB (p=0.17, once the effect of the other vitamins 
have been adjusted) but unlike Vitamin A, the correlation between Vitamin E and NPBs is 
negative (regression coefficient, B=-0.023). These results were confirmed by bivariate 
Spearman correlations (Table 28). 
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Table 27 - Decomposition of the model of multiple regression of NPB in the exposed. The B’s are the 
regression coefficients and p indicates its significance. 
 
NPB in the exposed 
Explanatory variables B p 
Vitamin A 0.580 <0.001** 
Vitamin D -0.001 0.848 
Vitamin E -0.023 0.170 
 
 
 
 
Table 28 – Spearman correlations between genotoxicity biomarkers (MN in lymphocytes and buccal 
cells, NPB, and NBUD) and vitamins A, D and E in the exposed (left) and the control group (right); 
Significant correlations are signaled by ** and *, respectively,  p<0.01 and p<0.05. 
 
a) Exposed                                                                                           b) Controls 
 
 
 
Biomarkers VitA VitD VitE 
MN lymphocytes 0.266 0.124 0.029 
NPB 0.557** -0.048 0.039 
NBUD -0.076 -0.106 -0.297* 
MN BC 0.121 0.018 0.191 
Biomarkers VitA VitD VitE 
MN lymphocytes -0.110 0.044 0.035 
NPB -0.082 -0.107 -0.170 
NBUD -0.157 0.069 -0.109 
MN BC -0.042 0.008 -0.109 
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CHAPTER 2 – CYTOSTATICS DRUGS OCCUPATIONAL SETTING 
 
 
1. SAMPLES 
Two samples were formed - the group of those occupationally exposed to cytostatics and the 
non-exposed group (controls). Sample characteristics such as gender distribution, age, years 
of exposure, tobacco and alcohol consumption for the control and exposed groups are shown 
in Table 29. 
 
 
 
Table 29 - Characteristics of the samples regarding gender, age, years of exposure, tobacco and alcohol 
consumption.  
 
 Control group Exposed group 
Number of subjects 46 46 
Gender 
Females  
Males  
 
34 (73.9%) 
12 (26.1%) 
 
40 (87.0%) 
6 (13.0%) 
Age  
(mean ± standard error of mean, in 
years) 
Range 
 
39.26±1.42  
 
20-61 
 
33.85±1.21  
 
24-58 
Years of exposure 
(mean ± standard error of mean, in 
years) 
Range 
 
n.a. 
 
6.62±0.94  
 
0.17 - 30 
Tobacco consumption 
Non-smokers  
Smokers  
 
 
34 (77.3%) 
10 (22.7%) 
 
 
42 (91.3%) 
4 (8.7%) 
 
Alcohol consumption 
Non-drinkers  
Drinkers  
 
 
32 (72.7%) 
12 (27.3%) 
 
 
34 (73.9%) 
12 (26.1%) 
 
               n.a. – non-applicable 
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2. CYTOSTATICS EXPOSURE ASSESSMENT 
The analytic data from exposure assessment to cystostatic drugs, namely cyclophosphamide 
(CP), 5-fluorouracil (5-FU), and paclitaxel (PTX) is presented in Table 30. 
 
Table 30 – Number of samples regarding surface contamination with cyclophosphamide (CP), 5-
fluorouracil (5-FU), paclitaxel (PTX), and respective limits of detection (LOD) and quantification (LOQ). 
 
Hospitals CP 5-FU PTX 
Samples with 
contamination 
Contamination 
with more than 
1 drug 
A 
1/67  
(1.5%) 
17/67 
(25.4%) 
17/67 
 (25.4%) 
21/67  
(31.3%) 
13/67  
(19.4%) 
B 
14/260  
(5.4%) 
18/260 
(6.9%) 
54/260  
(27.3%) 
100/260  
(38.5%) 
15/260  
(5.8%) 
Totals 
15/327  
(4.6%) 
35/327 
(10.7%) 
71/327  
(21.7%) 
121/327  
(37%) 
28/327  
(8.6%) 
LOD 
(µg/cm2) 
0.10 3.30 0.167 
 
LOQ 
(µg/cm2) 
0.30 10.00 0.50 
 
From the total of 327 analysed samples of both hospitals, 121 (37%) were positive. A sample 
was regarded as positive, when at least one of the three surrogate markers was detected. 
Considering hospital A, from the 67 samples, 21 (31.3%) were positive and 13 of them (19.4%) 
presented contamination from more than one drug. In hospital B, 100 (38.5%) out of 260 
samples were positive and 15 (5.8%) showed contamination from more than one drug.  
 
 
3. GENOTOXICITY ASSESSMENT  
 
3.1. CYTOKINESIS-BLOCK MICRONUCLEUS ASSAY 
For all genotoxicity biomarkers under study, workers occupationally exposed to cytostatics 
had significantly higher means in comparison with controls (Table 31). 
Significant differences (Mann-Whitney test, p <0.05) were observed between subjects 
exposed and non-exposed to cytostatics, namely in mean MN in binucleated lymphocytes 
(respectively, 9.83±1.28 vs 5.09±0.89), NPB (0.65±0.14 vs 0.11±0.05), and NBUD (2.43±0.37 vs 
1.37±0.32), MN in mononuclear lymphocytes (1.35±0.32 vs 0.41±0.11), multinuclear 
lymphocytes (4.09±0.78 vs 1.46±0.22). The odds ratios of binary logistic regression indicate an 
significant increased risk for the presence of biomarkers in those exposed to cytostatics, 
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compared to non-exposed (Table 31), and they were significant (p<0.05) for MN in 
binucleated cells, NPB, and NBUDs. The means MN in mono and multinucleated lymphocytes 
are increased in exposed comparing with controls, however did not reach statistical 
significance (p=0.139; p=0.819, respectively) 
 
 
Table 31 – Descriptive statistics of MN, NPB and NBUD in the two groups (mean ± standard error of the 
mean, range), p-value of the Mann-Whitney test, and results of binary logistic regression concerning 
the association between exposure and genotoxicity biomarkers, as evaluated by the odds ratio (OR). 
 
 
MN in BN 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in MONO 
Mean ± S.E. 
(range) 
MN in MULTI 
Mean ± S.E. 
(range) 
Exposed 
9.83±1.28 
(1-58) 
0.65±0.14 
(0-3) 
2.43±0.37 
(0-11) 
1.35±0.32 
(0-9) 
4.09±0.78 
(0-21) 
Controls 
5.09±0.89 
(0-34) 
0.11±0.05 
(0-1) 
1.37±0.32 
(0-13) 
0.41±0.11 
(0-3) 
1.46±0.22 
(0-6) 
p-value1 <0.001 0.001 0.006 0.027 0.044 
OR 6.667 5.770 2.893 1.894 1.111 
OR CI 
95% 
2.369-18.76 1.924-17.307 1.135-7.373 0.813-4.412 0.452-2.726 
p-value2 <0.001 0.002 0.026 0.139 0.819 
1 Mann-Whitney test 
2 Binary logistic regression 
 
 
In what concerns the influence of the duration of exposure to cytostatics, no association could 
be found between years of exposure and the presence of any of the biomarkers measured by 
CBMN assay (regression analysis slope, p>0.05). 
 
 
3.2. COMET ASSAY 
The mean of DNA damage (% DNA Tail) and oxidative DNA damage (FPG) in exposed and non-
exposed samples is shown in Table 32. No statiscally significant differences (Mann-Whitney 
test, p>0.05) were found between subjects with and without exposure. 
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Table 32 – Descriptive statistics of % DNA in tail and FPG in the studied population (mean ± standard 
error of the mean, and range), and p-value of the Mann-Whitney test. 
 
Groups Statistics % DNA in tail FPG 
Exposed 
Mean 
Std. Error 
Range 
15.18 
1.40 
1.79 – 44.5 
5.32 
0.54 
0.19 - 13.91 
Controls 
Mean 
Std. Error 
Range 
12.41 
1.24 
2.48 - 30.43 
4.59 
0.59 
0.02 - 14.46 
p-value 0.136 0.229 
 
 
3.3. CORRELATION BETWEEN THE GENOTOXICITY ASSAYS  
There were positive significant correlations between endpoints evaluated by the same 
technique.  
Regarding CBMN assay results, there was a positive correlation between MN in binucleated 
lymphocytes and MN in mononuclear lymphocytes (r=0.435, p=0.002), and multinuclear 
lymphocytes (r =0.670, p<0.001) the same between NPB and NBUDs (r=0.362, p=0.013). As for 
the comet assay, % DNA in the tail and FPG to measure oxidative damage, were correlated (r = 
0.325, p=0.002). However, correlations across the two assays – CBMN and comet assays – 
were not significant.  
 
 
4. DEMOGRAPHIC AND LIFESTYLE HABITS 
Age, gender, tobacco, and alcohol habits are possible confounding variables that can affect 
genotoxicity measurement and whose effect can be investigated by multiple regression 
analysis within the exposed and the control groups. The analysis shows that exposure to 
cytostatics was the only variable significantly affecting the DNA damage measured by CBMN 
assay, to the exception to MN in mononuclear and multinuclear lymphocytes. Gender, 
tobacco and alcohol consumption did not account for significant results (p>0.05). 
 
As Table 33 shows, genotoxicity biomarkers did not differ significantly between men and 
women within the exposed and the controls (Mann-Whitney test, p> 0.05) for the biomarkers 
measured by CBMN assay.  
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Table 33 –Descriptive statistics of MN, NPB, and NBUD by gender and exposition (mean ± standard 
error of the mean, range). There were no significant differences between means of the two genders 
either within the exposed or the controls. 
 
Groups Gender N 
MN in BN 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in 
MONO 
Mean ± S.E. 
(range) 
MN in MULTI 
Mean ± S.E. 
(range) 
 
 
Exposed 
Females 40 
9.75±1.44 
(1-58) 
0.73±0.16 
(0-3) 
2.48±0.41 
(0-11) 
1.40±0.35 
(0-9) 
3.90±0.87 
(0-21) 
Males 6 
10.33±1.94 
(6-18) 
0.17±0.17 
(0-1) 
2.17±0.79 
(0-5) 
1.00±0.68 
(0-4) 
5.33±1.65 
(0-12) 
 
 
Controls 
Females 34 
5.56±1.11 
(0-34) 
0.12±0.06 
(0-1) 
1.38±0.41 
(0-13) 
0.38±0.11 
(0-3) 
1.56±0.24 
(0-6) 
Males 12 
3.75±1.27 
(0-15) 
 
0.08±0.08 
(0-1) 
1.33±0.43 
(0-5) 
0.50±0.26 
(0-3) 
1.17±0.47 
(0-6) 
 
In what concerns DNA damage and DNA oxidative damage measured by comet assay, the 
mean of these biomarkers also did not differ significantly between genders within the exposed 
and the controls, to the exception of % DNA in tail in the control group (Table 34).  
 
 
Table 34 –Descriptive statistics of % DNA in tail and FPG means by gender and exposure (mean ± 
standard error of the mean, range).  
 
Groups Gender N 
% DNA in tail 
Mean ± S.E. 
(range) 
FPG 
Mean ± S.E. 
(range) 
 
Exposed 
Females 40 
14.84±1.38 
(1.79-31.64) 
5.31±0.61 
(0.19-13.91) 
Males 6 
17.43±5.96 
(4.61-44.50) 
5.39±1.09 
(2.38-9.65) 
 
 
Controls 
Females 34 
14.15±1.49 
(2.48-30.43) 
4.57±0.74 
(0.02-14.46) 
Males 12 
7.46±1.54 
(2.79-18.49) 
4.65±0.89 
(0.10-9.61) 
 
 
 
In order to examine the effect of age on biomarkers, individuals were split into exposed and 
non-exposed and, within each group, the association between age and biomarker frequency 
was studied by simple regression analysis, yielding the results in Table 35.  
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There is a significant association between MN in binucleated lymphocytes and age in the 
exposed group, with the number of MN tending to increase with age (R2= 0.120, p=0.018) as 
shown in Figure 10a, and in the control group (R2= 0.186, p=0.003) as shown in Figure 10b. 
Also, the MN in mononuclear lymphocytes were significantly associated with age in the 
exposed (R2= 0.087, p=0.047) and in the controls (R2= 0.164, p=0.005), as shown in Figures 11a 
and 11b, respectively. 
 
 
 
Table 35 - Results of simple regression analysis of age on biomarkers by group (exposed/controls). R2 is 
the coefficient of determination; A and B are, respectively, the ordinate and the slope in the regression 
line, and p is the likelihood of B in case of no association between age and the biomarker; ** signals a 
significant p-value. 
 
 
Biomarker  R2 A B p-value 
MN in BN lymphocytes 
Exposed 0.120 -2.586 0.367 0.018** 
Controls 0.186 -5.451 0.268 0.003** 
NPB 
Exposed 0.005 0.916 -0.008 0.657 
Controls 0.003 0.177 -0.002 0.724 
NBUD 
Exposed 0.032 4.290 -0.055 0.233 
Controls 0.016 2.487 -0.028 0.402 
MN in MONO lymphocytes 
Exposed 0.087 -1.277 0.078 0.047** 
Controls 0.164 -0.767 0.030 0.005** 
MN in MULTI lymphocytes 
Exposed 0.001 4.845 -0.022 0.819 
Controls 0.055 0.048 0.036 0.115 
% DNA in tail 
Exposed 0.029 21.863 -0.197 0.259 
Controls 0.022 7.375 0.128 0.330 
FPG 
Exposed 0.023 7.646 -0.069 0.312 
Controls 0.001 4.226 0.009 0.882 
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a)                                                                                                    b) 
 
Figure 10 - Scatter plots of the number of MN in binucleated lymphocytes against age in the exposed (a) 
and control (b) groups. The slope of the regression line (dashed) in both groups is statistically 
significant. 
 
a) b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 - Scatter plots of the number of MN in mononuclear lymphocytes against age in the exposed 
(a) and control (b) groups. The slope of the regression line (dashed) in both groups is statistically 
significant. 
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Descriptive statistics of every biomarker were stratified by three age groups (20-30, 31-40, 
and ≥ 41 years old) in the exposed and control groups, allowing for a qualitative view of the 
same relationships (Tables 36 and 37).  
 
Table 36 –Descriptive statistics of MN, NPB, NBUD, MN in mono and multinuclear lymphocytes by age 
group in exposed and controls (mean ± standard error of the mean, range).  
 
Groups Age N 
MN in BN 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in MONO 
Mean ± S.E. 
(range) 
MN in MULTI 
Mean ± S.E. 
(range) 
Exposed 
20-30 22 
8.32±0.97 
(1-19) 
0.68±0.21 
(0-3) 
2.68±0.57 
(0-13) 
0.95±0.26 
(0-4) 
3.23±0.68 
(0-10) 
31-40 15 
8.40±1.29 
(2-20) 
0.67±0.27 
(0-3) 
2.73±0.70 
(0-2) 
1.53±0.69 
(0-9) 
5.40±1.90 
(0-21) 
≥ 41 9 
15.89±5.49 
(2-58) 
0.56±0.24 
(0-2) 
1.33±0.44 
(0-5) 
2.00±0.99 
(0-9) 
4.00±1.84 
(0-17) 
Controls 
20-30 11 
2.09±1.15 
(0-13) 
0.18±0.12 
(0-1) 
1.91±1.14 
(0-13) 
0.36±0.15 
(0-1) 
0.73±0.24 
(0-2) 
31-40 12 
4.42±1.00 
(0-13) 
0.17±0.11 
(0-1) 
1.42±0.47 
(0-5) 
0.17±0.11 
(0-1) 
1.83±0.39 
(0-4) 
≥ 41 23 
6.87±1.52 
(0-34) 
0.04±0.04 
(0-1) 
1.09±0.27 
(0-5) 
0.57±0.19 
(0-3) 
1.61±0.35 
(0-6) 
 
Table 37 –Descriptive statistics of % DNA in tail and FPG by age group in the exposed and controls 
(mean ± standard error of the mean, range). 
 
Groups Age N 
% DNA in tail 
Mean ± S.E. 
(range) 
FPG 
Mean ± S.E. 
(range) 
Exposed 
20-30 22 
18.76±2.16 
(2.89-44.50) 
5.90±0.73 
(1.03-13.91) 
31-40 15 
11.36±1.73 
(1.79-24.04) 
5.21±1.09 
(0.19-12.90) 
≥ 41 9 
12.79±3.17 
(3.33-30.74) 
4.09±1.15 
(0.27-9.65) 
Controls 
20-30 11 
12.23±2.59 
(3.78-23.53) 
5.24±1.37 
(0.02-12.01) 
31-40 12 
9.88±2.73 
(2.48-30.43) 
3.48±0.89 
(0.32-11.61) 
≥ 41 23 
13.81±1.63 
(2.79-28.19) 
4.86±0.87 
(0.09-14.46) 
 
In order to examine if gender adds a significant contribution to explain variability in 
genotoxicity biomarkers, regression analysis was repeated but now adding gender as an 
independent variable and examining whether it would improve upon the values of R2 already 
presented for age (Table 38).  
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Table 38 - Results of multiple regression analysis of age and gender on biomarkers by group 
(exposed/controls). R2, new R2, and ΔR2 are, respectively, the coefficients of determination of the model 
with only age, age and gender, and the difference between them. The significance of the addition of 
gender is shown by the value of p, ** signals a significant p-value. 
 
  Age Age and gender 
Biomarker Groups R2 New R2 ΔR2 p 
MN in BN lymphocytes 
Exposed 0.120 0.122 0.002 0.061 
Controls 0.186 0.193 0.007 0.010** 
NPB 
Exposed 0.005 0.047 0.042 0.358 
Controls 0.003 0.006 0.003 0.880 
NBUD 
Exposed 0.032 0.035 0.003 0.465 
Controls 0.016 0.017 0.001 0.697 
MN in MONO lymphocytes 
Exposed 0.087 0.089 0.002 0.135 
Controls 0.164 0.179 0.015 0.014** 
MN in MULTI lymphocytes 
Exposed 0.001 0.009 0.008 0.817 
Controls 0.055 0.063 0.008 0.244 
% DNA in Tail 
Exposed 0.029 0.036 0.007 0.459 
Controls 0.022 0.135 0.113 0.044* 
FPG 
Exposed 0.023 0.023 0.000 0.604 
Controls 0.001 0.001 0.000 0.986 
 
A closer examination of regression coefficients in the model of MN in binucleated 
lymphocytes in controls against age and gender, shows that age is the major responsible for 
the statistical significance found (Table 39). Its regression coefficient (B=0.262) indicates that 1 
year increase in age should, on average, correspond to an 0.262 unit increase in MN in 
binucleated lymphocytes. The regression coefficient of gender (B=1.096) was not statistically 
significant. Figure 12a and Figure 12b show the distribution of the MN in binucleated 
lymphocytes by age and gender, for exposed and controls, respectively. 
 
Table 39 - Regression coefficients (B) of age and gender in the model of multiple regression of MN in 
binucleated lymphocytes in the controls; p indicates their significance. The full model accounts for 
19,3% of variability in the number of MN.  
 
MN in BN lymphocytes in controls 
Explanatory variables B p 
Age 0.262 0.004** 
Gender 1.096 0.560 
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a)              b)    
 
Figure 12 - Scatter plots of the number of MN in binucleated lymphocytes against age and gender in the 
exposed (a) and control (b) groups.  
 
Examination of regression coefficients in the model of MN in mononuclear lymphocytes in the 
controls against age and gender shows that age is again the major responsible for the 
statistical significance found (Table 40). Its regression coefficient (B=0.031) indicates that 1 
year increase should, on average, correspond to an 0.031 unit increase in MN in mononuclear 
lymphocytes. Figure 13a and Figure 13b show the distribution of the MN in mononuclear 
lymphocytes by age and gender, for exposed and controls, respectively. 
 
 
Table 40 - Regression coefficients (B) of age and gender in the model of multiple regression of MN in 
mononuclear lymphocytes in the controls. The B’s are the regression coefficients and p indicates their 
significance. The full model accounts for 17,9% of variability in the number of MN.  
 
MN in MONO lymphocytes in controls 
Explanatory variables B p 
Age 0.031 0.004** 
Gender -0.203 0.373 
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           a)  b) 
 
 
Figure 13 - Scatter plots of the number of MN in mononuclear lymphocytes against age and gender in 
the exposed (a) and control (b) groups. 
 
 
The examination of regression coefficients in the model of % DNA in tail in the controls against 
age and gender shows that gender is the major responsible for the statistical significance 
found (Table 41). Its regression coefficient (B=6.439) indicates that being woman increases, on 
average, 6.4 the % of DNA in tail in the control group. Figure 14a and Figure 14b show the 
distribution of the % DNA in tail by age and gender, for exposed and controls, respectively. 
 
 
Table 41 - Decomposition of the model of multiple regression of % DNA in tail the controls. The B’s are 
the regression coefficients and p indicates its significance. 
 
% DNA in Tail in controls 
Explanatory variables B p 
Age 0.091 0.469 
Gender 6.439 0.022* 
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 a)  b) 
 
 
Figure 14 - Scatter plots of % DNA in tail against age and gender in the exposed (a) and control (b) 
groups.  
 
 
Alcohol consumption and tobacco habits did not show statistically significant associations 
within genotoxicity biomarkers measured by CBMN assay for both the exposed and non 
exposed groups. In what concerns the comet assay, it was observed a positive association 
between alcohol consumption and % DNA in tail (r = 0.266, p=0.037) in the exposed group, 
indicating that alcohol consumption is associated with higher DNA damage. 
 
5. INDIVIDUAL SUSCEPTIBILITY 
 
5.1. OGG1 SER326CYS POLYMORPHISMS   
The frequencies of genotypes and alleles of the OGG1 Ser326Cys polymorphisms studied in 
the two groups are shown in Table 42. No significant differences were observed in genotypic 
and allelic frequencies in OGG1 polymorphisms under study between exposed and controls 
(Fisher’s exact test, p>0.05).  
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
167 
 
 
 
Table 42 – Frequency of genotypes and alleles of OGG1 Ser326Cys polymorphisms in the study sample, 
p-value of Fisher’s exact test. 
 
Gene Genotypes All (%) Exposed (%) Controls (%) p-value 
OGG1 
Cys/Cys 
Ser/Cys 
Ser/Ser 
9 (9.8) 
32 (34.8) 
51 (55.4) 
7 (15.2) 
14 (30.4) 
25 (54.4) 
2 (4.4) 
18 (39.1) 
26 (56.5) 
0.446 
Cys 
Ser 
50 
134 
31 (30.4) 
79 (69.6) 
22 (23.9) 
70 (76.1) 
0.409 
 
 
The descriptive statistics concerning the relationship between genotoxicity biomarkers 
provided by CBMN and comet assay and OGG1 polymorphisms studied are shown in Tables 43 
and 44. For both, there was no consistent trend regarding the variation of biomarkers with 
OGG1 polymorphisms. 
In what concerns the genotoxicity biomarkers measured by CBMN, the Kruskal-Wallis test did 
not reject the null hypothesis of equal means between the OGG1 polymorphisms. 
 
    
Table 43 – Descriptive statistics of MN, NPB, and NBUD (mean ± standard error of the mean, and range) 
by OGG1 Ser326Cys polymorphisms and exposure, p-value of the Kruskal-Wallis test. 
 
Groups OGG1 N 
MN in BN 
Mean ± S.E. 
(range) 
NPB 
Mean ± S.E. 
(range) 
NBUD 
Mean ± S.E. 
(range) 
MN in MONO 
Mean ± S.E. 
(range) 
MN in MULTI 
Mean ± S.E. 
(range) 
Exposed 
Cys/Cys 
 
7 
7.14±1.87 
(2 – 15) 
0.71±0.47 
(0 – 3) 
0.86±0.26 
(0 – 2) 
1.00±0.49 
(0 – 3) 
2.57±1.41 
(0 – 8) 
Ser/Cys 
 
14 
12.86±3.75 
(1 – 58) 
0.71±0.24 
(0 – 3) 
3.14±0.94 
(0 – 11) 
2.50±0.86 
(0 – 9) 
4.79±1.51 
(0 – 18) 
Ser/Ser 
 
25 
8.88±0.87 
(1 – 18) 
0.60±0.18 
(0 – 3) 
2.48±0.39 
(0 – 8) 
0.80±0.25 
(0 – 4) 
4.12±1.11 
(0 – 21) 
p-value 0.535 0.828 0.100 0.185 0.530 
Controls 
Cys/Cys 2 
1.50±1.50 
(0 – 3) 
0.00±0.00 
(0 – 0) 
 
1.50±0.50 
(1 - 2) 
 
0.50±0.50 
(0 – 1) 
1.00±0.00 
(1 – 1) 
Ser/Cys 18 
4.72±1.00 
(0 – 13) 
0.11±0.08 
(0 – 1) 
 
0.89±0.31 
(0 – 5) 
 
0.28±0.11 
(0 – 1) 
1.39±0.28 
(0 – 4) 
Ser/Ser 
 
26 
5.62±1.40 
(0 – 34) 
0.12±0.06 
(0 – 1) 
1.69±0.52 
(0 – 13) 
0.50±0.17 
(0 – 13) 
1.54±0.33 
(0 – 6) 
p-value 0.506 0.882 0.313 0.744 0.939 
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Also in the results provided by comet assay, no consistent trend is observed (Table 44). The 
Kruskal Wallis test did not reject the null hypothesis of equality among OGG1 polymorphisms 
in regard to the means of the two comet assay parameters.  
 
Table 44 - Descriptive statistics of % DNA Tail and FPG means in the studied population (mean ± 
standard error of the mean, and range) by OGG1 Ser326Cys polymorphisms and exposure, p-value of 
Kruskal-Wallis test. 
Groups OGG1 N 
% DNA Tail 
Mean ± S.E. 
(range) 
FPG 
Mean ± S.E. 
(range) 
Exposed 
Cys/Cys 7 
13.11±2.80 
(1.79 – 23.53) 
5.03±1.48 
(0.27 – 12.0) 
Ser/Cys 14 
13.23±1.42 
(2.48 – 28.19) 
4.97±0.72 
(0.10 – 14.46) 
Ser/Ser 25 
14.26±1.38 
(2.68 – 44.50) 
4.94±0.51 
(0.02 – 12.90) 
p-value 0.777 0.647 
Controls 
Cys/Cys 2 
14.22±9.31 
(4.91 – 23.53) 
 
7.39±4.61 
(2.78 – 12.00) 
 
Ser/Cys 18 
12.04±1.86 
(2.48 – 28.19) 
 
4.69±1.00 
(0.10 – 14.46) 
 
Ser/Ser 26 
12.52±1.74 
(2.68 – 30.43) 
 
4.30±0.73 
(0.02 – 12.69) 
 
p-value 0.906 0.682 
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6. MICRONUTRIENTS 
Most study subjects had vitamin levels within the normal range (Table 45), and no significant 
differences existed between the serum levels of vitamins in the group exposed to cytostatics 
compared to controls (Mann-Whitney test, p>0.05).  
 
 
Table 45 – Quantification of vitamins A and E in human serum in the studied population (mean ± 
standard error of the mean, range) and the biological lower limits (p-value of Mann-Whitney test). 
 
Vitamins Groups 
Mean ± Std. 
Deviation 
(range) 
 
Normal range 
limits 
 
A 
Controls 
2.36±0.82 
(1.37 – 4.08) 
 
1.05 – 3.32 
µmol/L 
 
Exposed 
3.11±0.31 
(1.06 – 11.52) 
p-value 0.204 
 
E 
Controls 
26.46±1.10 
(12.18 – 43.92) 
 
12.00 – 46.00 
µmol/L 
 
Exposed 
26.58±1.10 
(13.83 – 51.27) 
p-value 0.793 
 
 
 
6.1. GENOTOXICITY BIOMARKERS AND VITAMINS A AND E IN SERUM 
In order to examine if there was any association between the frequency of biomarkers and the  
serum vitamins A and E, multiple linear regression was conducted by group 
(exposed/controls), with the frequency of each biomarker being the dependent variable and 
the vitamin levels the independent set of explanatory variables. The results indicate that 
vitamins influence the number of NPB in the exposed, as well as NBUDs and FPG biomarkers in 
the control group (Table 46).  
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Table 46 - Results of multiple regression of biomarker frequency against the levels of a set of vitamins A 
and E in the exposed and control groups. R2 are the coefficients of determination for each regression 
and p indicates statistical significance of the model. 
 
Biomarker  R2 p 
MN in BN lymphocytes 
Exposed 0.001 0.978 
Controls 0.001 0.987 
NPB 
Exposed 0.195 0.010** 
Controls 0.031 0.505 
NBUD 
Exposed 0.081 0.169 
Controls 0.161 0.023** 
MN in MONO lymphocytes 
Exposed 0.006 0.879 
Controls 0.013 0.762 
MN in MULTI lymphocytes 
Exposed 0.049 0.347 
Controls 0.007 0.861 
% DNA in tail 
Exposed 0.001 0.988 
Controls 0.075 0.187 
FPG 
Exposed 0.055 0.305 
Controls 0.250 0.002** 
 
 
 
Table 47 shows statistically significant regression coefficients of the regression of biomarkers 
against the levels of the vitamins. In the model of NPB in the exposed against vitamins, both 
vitamins A and E significantly account for the variability in number of NPBs. Vitamin A 
coefficient (B=0.173) indicates that 1 unit increase in vitamin A should, on average, 
correspond to an 0.173 unit increase in NPBs in the exposed group. Vitamin E also accounts 
for variation in NPB (p=0.003), but unlike vitamin A, the correlation between vitamin E and 
NPBs is negative (B= -0.066). In what concerns NBUD in the control group, the vitamin E 
coefficient (B=0.096) indicates that 1 unit increase in vitamin E should, on average, correspond 
to an 0.096 unit increase in NBUDs in the control group. Finally, in the control group, the 
vitamin A coefficient (B=3.571) indicates that 1 unit increase in vitamin A should, on average, 
correspond to an 3.571 unit increase of DNA oxidative damage (FPG) in the control group. 
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Table 47 - Regression coefficients in the models of multiple regression of NPB in the exposed, and 
NBUDs and FPG in controls. The B’s are the regression coefficients and p indicates their significance. 
 
 
Biomarkers Explanatory variables B p 
NPB in Exposed 
VitA 0.173 0.028** 
VitE -0.066 0.003** 
NBUD in Controls 
VitA 0.837 0.131 
VitE 0.096 0.023** 
FPG in Controls 
VitA 3.571 >0.001** 
VitE -0.022 0.755 
 
In the exposed group, there is a significant negative correlation between vitamin E and NPB 
(Spearman’s correlation r =-0.311, p<0.05), meaning that higher serum vitamin E levels are 
associated with lower mean NPB (Table 48A).  
Vitamin E and NBUD are significantly correlated (r= 0.339, p<0.05) and so are vitamin A and 
DNA oxidative damage (r= 0.498, p<0.01) in the control group (Table 48B), meaning that 
higher levels of these vitamins are correlated with higher means of these genotoxicity 
biomarkers.  
 
Table 48 – Spearman correlations between genotoxicity biomarkers MN, NPB, and NBUD and vitamins 
A and E in (A) exposed group and (B) the control group. 
 
A – Exposed                                                                                      B – Controls 
 Vit A Vit E 
MN BN -0.032 -0.013 
NPB 0.096 -0.311* 
NBUD 0.263 0.052 
MN MONO 0.062 -0.006 
MN MULTI -0.116 -0.222 
% DNA TAIL -0.023 -0.017 
FPG 0.165 0.229 
 
** Spearman Correlation p<0.01 
* Spearman Correlation p<0.05 
 Vit A Vit E 
MN BN -0.021 0.010 
NPB 0.013 0.177 
NBUD 0.229 0.339* 
MN MONO -0.080 0.076 
MN MULTI -0.083 -0.012 
% DNA TAIL 0.228 0.161 
FPG 0.498** -0.020 
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6.2. GENOTOXICITY BIOMARKERS AND MICRONUTRIENTS MEASURED BY FFQ 
The following nutritional items were selected from the Food Frequency Questionnaire (FFQ) 
for analysis: calories, retinol, vitamin B12, folate, vitamins D and E, iron, and selenium. The 
quantification of the dietary parameters for these items is shown in Table 49.  
 
Table 49 –Dietary parameters (calories, retinol, vitamin B12, folate, vitamins D and E, iron, and 
selenium) by FFQ (mean intake per day ± standard deviation) and respective dietary reference intakes.  
 
Parameters Groups 
Mean± Std. 
Deviation 
(daily nutrient 
intake) 
 
Dietary References Intakes 
(Food and Nutrition Board, 
Institute of Medicine, National 
Academies) 
d= day 
 
Calories 
Exposed 
2652.55±188.71 
 
 
Variable by age and gender 
(kcal) Controls 
2527.40±123.07 
 
 
Retinol 
Exposed 
996.82±157.24 
 
 
Females: 500 µg/d 
Males: 625 µg/d 
 
Controls 
776.51±70.10 
 
 
Vit B12 
Exposed 
13.86±1.54 
  
2.0 µg/d 
Controls 
12.31±0.78 
 
 
Folate 
Exposed 
461.25±42.22 
  
320 µg/d 
Controls 
401.21±26.21 
 
 
Vit D 
Exposed 
5.08±0.46 
  
10 µg/d 
Controls 
4.67±0.35 
 
 
Vit E 
Exposed 
12.82±1.14 
 
 
12 mg/d 
 Controls 
11.80±0.67 
 
 
Iron 
Exposed 
20.58±1.65 
 
 
Females: 8.1 mg/d 
Males: 6 mg/d Controls 
18.82±1.07 
 
 
Selenium 
Exposed 
131.51±9.34 
  
45 µg/d 
Controls 
138.67±8.58 
 
 
In order to investigate the association between genotoxicity biomarkers and nutritional items, 
multiple linear regression was conducted by group (exposed/controls), with the frequency of 
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each biomarker being the dependent variable and the nutritional items as the independent 
set of explanatory variables. The results indicate that a significant percentage of the variability 
in % DNA in tail in the exposed group, and in FPG biomarker in the controls can be accounted 
by nutrition (Table 50).  
 
Table 50 - Results of multiple regression of biomarker frequency against a set of itens measured by the 
FFQ (calories, retinol, vitamin B12, folate, vitamins D and E, folate, iron, and selenium) in the exposed 
and control groups. R2 are the coefficients of determination for each regression and p indicates the 
statistical significance of the model. 
 
Biomarker  R2 p 
MN in BN lymphocytes 
Exposed 0.122 0.736 
Controls 0.112 0.787 
NPB 
Exposed 0.097 0.849 
Controls 0.095 0.860 
NBUD 
Exposed 0.081 0.907 
Controls 0.129 0.702 
MN in MONO lymphocytes 
Exposed 0.147 0.611 
Controls 0.213 0.296 
MN in MULTI lymphocytes 
Exposed 0.170 0.490 
Controls 0.077 0.921 
% DNA in tail 
Exposed 0.384 0.013** 
Controls 0.272 0.124 
FPG 
Exposed 0.142 0.633 
Controls 0.364 0.021** 
 
 
The model of % DNA in tail in the exposed against nutritional items showed that calories, 
folate, vitamin E and iron are responsible for the statistical significance found (Table 51). 
Calories (B=-0.011) and folate (B=-0.078) decrease DNA damage (% DNA in tail) indicates that 
1 unit increase of calories and folate intake should, on average, correspond to an 0.011 unit 
and 0.078 decrease, respectively, in % DNA in tail in the exposed group.  Vitamin E and iron 
are also accountable for variation in % DNA in tail (p=0.002 and p<0.001, respectively), but 
unlike calories and folate, the correlation between vitamin E and iron and % DNA in tail is 
positive. Vitamin E coefficient (B=1.912) indicates that 1 unit increase in Vitamin E should, on 
average, correspond to an 1.912 unit increase of % DNA in tail in the exposed group. Same 
positive correlation for iron (B=2.345), meaning that 1 unit increase of iron should, on 
average, correspond to an 2.345 unit increase of % DNA in tail in the exposed group. 
 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
174 
 
 
Table 51 – Regression coefficients (B) and their significance (p) in the model of multiple regression of % 
DNA in tail in the exposed group.  
 
Biomarkers Explanatory variables B p 
 
 
 
% DNA in Tail in Exposed 
Calories -0.011 0.013 
Folate -0.078 <0.001 
Vitamin E 1.912 0.002 
Iron 2.345 <0.001 
 
 
Regarding DNA oxidative damage (FPG) in the control group, the model showed that calories, 
retinol, and vitamin B12 are responsible for the statistical significance found (Table 52). 
Calories (B=-0.006) and vitamin B12 (B=-0.589) decrease DNA oxidative damage (FPG) as 1 unit 
increase of calories and vitamin B12 intake should, on average, correspond to an 0.006 unit 
and 0.589 decrease, respectively, in FPG in the control group. 
  
Table 52 - Regression coefficients (B) and their significance (p) in the model of multiple regression of 
FPG in the control group.  
 
Biomarkers Explanatory variables B p 
FPG in Controls 
Calories -0.006 0.002 
Retinol 0.004 0.020 
Vitamin B12 -0.589 0.006 
 
 
Bivariate Spearman correlations do not show strong associations inside both the exposed and 
non exposed group, or between groups.  In the non exposed, the majority of correlations 
between biomarkers and nutritional items were negative but with no statistical significance. A 
significant negative correlation (p<0.05) between calories intake and DNA damage (% DNA in 
tail) was found, suggesting that greater intake of calories decrease DNA damage. No statistical 
significant correlations were found in the exposed group for any genotoxicity biomarkers 
under study (Table 53A). In controls, higher vitamin E values associate with higher mean MN 
present in mononucleated lymphocytes (Table 53B). 
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Table 53 – Spearman correlations between MN, NPB, and NBUD and dietary parameters (calories, 
retinol, vitamin B12, folate, vitamins D and E, folate, iron, and selenium) in the exposed (A) and the 
control (B) groups; Significant correlations are signaled by * for p<0.05. 
 
A – Exposed  
 Calories Retinol Vit B12 Folate Vit D Vit E Iron Selenium 
MN lymp 0.004 0.135 0.136 -0.063 0.027 -0.020 -0.083 -0.053 
NPB 0.106 -0.007 -0.020 0.043 -0.021 0.069 0.065 -0.037 
NBUD -0.131 0.102 0.024 -0.102 -0.014 -0.160 -0.100 -0.148 
MN MONO 0.078 0.281 0.161 0.100 -0.053 0.007 0.073 0.006 
MN MULTI 0.012 -0.086 -0.029 -0.009 -0.001 -0.013 -0.055 -0.005 
% DNA TAIL 0.154 0.254 0.153 0.111 0.034 0.139 0.188 0.073 
FPG -0.057 0.161 0.089 -0.161 0.028 -0.100 -0.131 -0.069 
 
 
B- Non exposed 
 Calories Retinol Vit B12 Folate Vit D Vit E Iron Selenium 
MN BN -0.70 -0.255 -0.176 -0.135 -0.081 0.036 -0.130 -0.096 
NPB -0.005 0.080 -0.090 -0.071 -0.122 -0.033 -0.030 -0.143 
NBUD -0.149 -0.180 -0.216 -0.172 -0.187 -0.261 -0.138 -0.063 
MN MONO 0.175 -0.090 0.104 0.168 0.243 0.349* 0.181 0.188 
MN MULTI -0.149 -0.196 -0.093 -0.084 -0.017 -0.018 -0.158 -0.114 
% DNA TAIL -0.370* -0.042 -0.186 -0.129 -0.138 -0.162 -0.256 -0.222 
FPG 0.013 0.203 -0.086 0.187 -0.019 0.131 0.171 0.074 
 
 
The proportion of subjects who were below and above the dietary reference intake (DRI) per 
nutritional item does not appear to confound the results, as there are no significant 
differences between the exposed and the control groups in regard to such proportions (Table 
54).     
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Table 54 – Count of absolute number of subjects with measurements above dietary reference intake (≥ 
DRI) and below (< DRI), split by exposed and control group, p is from the Fisher’s exact test and were 
not computable for iron and selenium as all subjects were above DRI. 
 
Parameters Groups ≥ DRI < DRI p-value 
Retinol 
Exposed 32 14 
0.412 
Controls 30 16 
Vit B12 
Exposed 45 1 
0.500 
Controls 46 0 
Folate 
Exposed 32 14 
0.067 
Controls 24 22 
Vit D 
Exposed 3 43 
0.308 
Controls 1 45 
Vit E 
Exposed 16 30 
0.334 
Controls 19 27 
Iron 
Exposed 46 0 
n.a. 
Controls 46 0 
elenium 
Exposed 46 0 
n.a. 
Controls 46 0 
             n.a. - non-applicable 
 
6.3. CORRELATION BETWEEN TECNHIQUES 
Vitamins A and E concentrations in serum were measured by HPLC, and different nutritional 
items, such as: calories, retinol, vitamin B12, folate, vitamins D and E, iron, and selenium were 
assessed by a FFQ. Therefore, information on vitamins A (retinol) and E were available from 
both methods.  Comparing the results, no statistical significant correlations were found 
between measurements from the two methods. Correlation between vitamin A measured by 
HPLC and retinol intake measured by FFQ was positive (r=0.184), but did not reach statistical 
significance (p=0.08). Also, correlation between vitamin E measured by HPLC and intake 
measured by FFQ was positive (r=0.145) but not statistically significant (p=0.169). Scatterplots 
with the results from both measurements are shown in Figure 15a and 15b, respectively for 
vitamin A and E. 
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Figure 15 - Scatter plots of the correlation between vitamin A measured by HPLC (Vit A) and vitamin A 
measured by FFQ (TotalvitA) (a) and vitamin E measured by HPLC (Vit E) and vitamin E measured by FFQ 
(Vitamina E) (b).  
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CHAPTER 1 – FORMALDEHYDE OCCUPATIONAL SETTING 
 
 
1. FORMALDEHYDE EXPOSURE ASSESSMENT 
Long exposures to formaldehyde to which some workers are subjected for occupational 
reasons, are suspected to be associated with genotoxic effects that can be evaluated by 
biomarkers (Conaway et al., 1996; IARC, 2006; Viegas & Prista, 2007; Zhang et al., 2009b). 
Formaldehyde exposure can cause a wide range of toxic effects such as the formation of DNA-
protein crosslinks, cytotoxicity, immune activation, and sensory irritation. Formaldehyde 
toxicity is thought to be mediated by the activation of free radical producing enzymes and also 
by the inhibition of free radical scavenging systems, thereby enhancing the accumulation of 
ROS (Gulec et al., 2006), well-known DNA damaging compounds. The health effects (mostly 
cancer) which associate with formaldehyde exposure seems to be more related with peaks of 
high concentrations than with long time exposure at low levels (IARC, 2006; Pyatt et al., 2008). 
Moreover, the choice of exposure metric should be based on the mode of action of the 
chemical agent (Preller et al., 2004). These two factors contribute to explain why the 
genotoxicity biomarkers showed high values when we obtained low values for the time-
weighted exposure metric. Previously, Pyatt et al. (2008) pointed out that an important 
limitation in most previous epidemiological studies was the lack of data regarding exposure to 
peak concentrations. In those studies, health effects resulting from occupational exposure to 
formaldehyde are normally associated to exposure exclusively based on TWA concentrations. 
Until 2004 only two studies (Hauptmann et al., 2004; Pinkerton et al., 2004) presented data on 
exposure to ceiling concentrations and, as a result, obtained higher values for the relative risk 
of nasopharyngeal cancer. Hauptmann et al. (2009) found out that mortality rate from 
leukemia also increases significantly not just with number of years of activity, in this case 
embalming, but also with the increase in peak values. 
 In this study the results suggest that workers in histopathology laboratories are exposed to 
formaldehyde levels that exceed recommended exposure limits (chapter 1 of results, 2. 
formaldehyde exposure assessment section).  Macroscopic specimens’ exam, in particular, is 
the task that involves higher exposure, because it requires a greater proximity to anatomical 
species impregnated with formaldehyde, corroborating the studies of (Goyer et al., 2004; 
Orsière et al., 2006).  
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2. GENOTOXICITY ASSESSMENT 
It has been shown that a higher micronuclei frequency is directly associated with decreased 
efficiency of DNA repair and increased genome instability (Kirsch-Volders et al., 2006; Orsiére 
et al., 2006). The data has shown a significant increase of micronuclei in lymphocytes in the 
exposed group. This can be explained in light of genomic instability, understood as an 
increased amount of mutations and/or chromosomal aberrations that cytogenetically 
translate into a greater frequency of changes in chromosome number and/or structure and in 
the formation of micronuclei  (Zietkiewicz et al., 2009).  
A statistically significant association was found between formaldehyde exposure and 
biomarkers of genotoxicity, namely micronuclei in lymphocytes and buccal cells, 
nucleoplasmic bridges, and nuclear buds limits (chapter 1 of results, 3. genotoxicity 
assessment section). Chromosome damage and effects upon lymphocytes arise because 
formaldehyde escapes from sites of direct contact, such as nose or mouth, originating nuclear 
alterations in the lymphocytes of those exposed (Goyer et al., 2004; Orsière et al., 2006; 
Zhang et al., 2009b; Speit et al., 2010). Our results thus corroborate previous reports (He et 
al., 1998) that lymphocytes can be damaged by long term exposure to formaldehyde. 
Moreover, the changes in peripheral lymphocytes indicate that the cytogenetic effects 
triggered by formaldehyde can reach tissues faraway from the site of initial contact (Ye et al., 
2005). Long term exposures to high concentrations of formaldehyde indeed appear to have a 
potential for DNA damage; these effects were well demonstrated in previous experimental 
studies with animals, where local genotoxic effects followed formaldehyde exposure, namely 
DNA-protein cross links and chromosome damage (IARC, 2006). In humans, formaldehyde 
exposure is also associated with an increase in the frequency of micronuclei in buccal 
epithelial cells (Suruda et al., 1993; Burgaz et al., 2002; Speit et al., 2007), as corroborated by 
the results presented here.  
Suruda et al. (1993) claim that although changes in oral and nasal epithelial cells and 
peripheral blood cells do not indicate a direct mechanism leading to carcinogenesis, they 
present evidence that DNA alteration took place. It thus appears reasonable to conclude that 
formaldehyde is a cancer risk factor for those who are occupationally exposed in 
histopathology laboratories (IARC, 2006).   
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3. DEMOGRAPHIC AND LIFESTYLE HABITS 
In epidemiological studies, it is important to evaluate the role played by common confounding 
factors, such as gender, age, smoking and alcohol consumption, upon the association between 
disease and exposure (Bonassi et al., 2001; Iarmarcovai et al., 2008). Concerning gender, 
studies realized by Fenech et al. (1999b and Wojda et al. (2007) reported that biomarker 
frequencies were greater in females than in males by a factor of 1.2 to 1.6 depending on the 
age group. To the exception of micronuclei in the buccal cells of controls, the results 
presented here point to females having higher frequencies than males in all genotoxicity 
biomarkers, although the differences usually lacked statistical significance (chapter 1 of 
results, 4. demographic and lifestyle habits section).  Such trend is concordant with previous 
studies that reported higher micronuclei frequency in lymphocytes in females and a slightly 
higher micronuclei frequency in buccal cells in males (Holland et al., 2008) and that can be 
explained by preferential aneugenic events involving the X-chromosome. A possible 
explanation is the micronucleation of the X chromosome, which has been shown to occur in 
lymphocytes in females, both in vitro and in vivo, and that can be accounted for by the 
presence of two X chromosomes. This finding might explain the preferential micronucleation 
of the inactive X (Catalán et al., 1998, 2000a, 2000b).   
Aging in humans appears to be associated with genomic instability. Cytogenetically, ageing is 
associated with a number of gross cellular changes, including altered size and morphology, 
genomic instability and changes in expression and proliferation (Bolognesi et al., 1999; 
Zietkiewicz et al., 2009). The involvement of micronucleation in age-related chromosome loss 
has been supported by several studies showing that the rate of micronuclei formation 
increases with age, especially in women (Catalán et al., 1998).  
This study provides evidence that age and gender interact to determine the frequency of 
micronuclei in the lymphocytes of exposed subjects (chapter 1 of results, 4. demographic and 
lifestyle habits section). The higher incidence of micronuclei in both genders is more manifest 
in older age groups and the effect of gender becomes more pronounced as age increases. 
Several reports link this observation to an elevated loss of X chromosomes (Battershill et al., 
2008).  
Tobacco smoke has been epidemiologically associated to a higher risk of cancer development, 
especially in the oral cavity, larynx, and lungs, as these are places of direct contact with the 
carcinogenic tobacco’s compounds. In this study, smoking habits did not influence the 
frequency of the genotoxicity biomarkers; moreover, the frequencies of micronuclei in buccal 
cells were unexpectedly higher in exposed non-smokers than in exposed smokers, though the 
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difference was not statistically significant. In most reports, the results about the effect of 
tobacco upon the frequency of micronuclei in human lymphocytes were negative as in many 
instances smokers had lower micronuclei frequencies than non-smokers (Bonassi et al., 2003). 
In the current study, the analysis of the interaction between formaldehyde exposure and 
smoking habits indicates that exposure is preponderant in determining the frequency of 
biomarkers (chapter 1 of results, 4. demographic and lifestyle habits section). Nevertheless, 
the effect of smoking upon biomarkers remains controversial. Some studies (El-Zein et al., 
2006, 2008) reported an increased frequency of micronuclei in lymphocytes, nucleoplasmic 
bridges, and nuclear buds as a consequence of the tobacco-specific nicotine derived 
nitrosamino ketone (NNK). Still in this study no associations were observed between tobacco 
and nuclear abnormalities.   
As for alcohol consumption, it did not appear to influence the frequency of genotoxicity 
biomarkers under study, to the exception of micronuclei in lymphocytes in controls (Mann-
Whitney, p=0.011), with drinkers having higher means. Alcohol is definitely a recognized 
genotoxic agent, being cited as able to potentiate the development of carcinogenic lesions 
(Ramirez & Saldanha, 2002). In our study, drinkers in the control group had higher mean 
frequencies of all biomarkers than non-drinkers, but the differences were only significant for 
micronuclei in lymphocytes. Stich & Rosin (1983) study on alcoholic individuals, reported 
absence of significant differences concerning micronuclei frequencies in buccal cells. The same 
study (Stich & Rosin, 1983) concluded that neither alcohol nor smoking, alone, increase 
micronuclei frequency in buccal cells, but a combination of both resulted in a significant 
elevation in micronucleated cells in the buccal mucosa. However, the synergism between 
alcohol consumption and tobacco has not been observed to act upon all biomarkers and, in 
several studies of lifestyle factors, it was difficult to differentiate the effect of alcohol from 
that of smoking (Holland et al., 2008). 
The CBMN assay is a simple, practical, low cost screening technique that can be used for 
clinical prevention and management of workers subjected to occupational carcinogenic risks, 
namely exposure to a genotoxic agent such as formaldehyde. The results obtained in this 
study provide unequivocal evidence of association between occupational exposure to 
formaldehyde in histopathology laboratory workers and the presence of nuclear changes.  
Given these results, preventive actions must prioritize safety conditions for those who 
perform macroscopic exams. In general, reduction of exposure to formaldehyde in this 
occupational setting may be achieved by the use of adequate local exhaust ventilation and by 
keeping biological specimen containers closed during the macroscopic exam. Individual 
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equipment, namely masks with proper formaldehyde filters, should be provided and used by 
health care workers that handle this chemical agent. 
 
 
4. INDIVIDUAL SUSCEPTIBILITY 
Exposure to formaldehyde in occupational settings is often prolonged enough to lead to the 
accumulation of DNA damage and increased mutation risk (Mateuca et al., 2006). Previous 
studies have suggested that genetic polymorphisms in specific genes affect susceptibility to 
chromosome damage associated with environmental exposure to genotoxic agents (Umegaki 
& Fenech, 2000). Genetic polymorphisms are potentially important in micronuclei formation, 
depending on the level of exposure, biological matrix studied and ethnicity of the studied 
population (Umegaki & Fenech, 2000). Chromosomal instability and impaired cell viability 
have been correlated with XRCC3 mutations and several other genes known or thought to be 
involved in HR (Bolognesi et al., 1999; Brenneman et al., 2000), being this pathway required in 
processing DNA damage induced by formaldehyde (Zhang et al., 2010).  
In this study, we report a statistically significant association between XRCC3 Thr241Met 
polymorphism and nuclear buds, biomarkers of gene amplification (chapter 1 of results, 5.1. 
XRCC3 Met241Thr polymorphisms section). The carriers of the XRCC3 Met/Met and Thr/Met 
genotypes had higher nuclear buds frequencies than their Thr/Thr genotype counterparts. 
Gene amplification plays a crucial role on the malignant transformation of human cells as it 
mediates the activation of oncogenes or the acquisition of drug resistance (Utani et al., 2007). 
Excess DNA may be expelled from the nucleus by the formation of nuclear buds and 
subsequent micronucleation (Lindberg et al., 2007). Previous studies have described in vivo 
budding of nuclear material in cell lines where changes in chromosomal numbers were 
occurring, and the spontaneous formation of nuclear buds structures was seen as a possible 
mechanism for the loss of chromosomes and for the generation of micronuclei (Fenech et al. 
2011). Therefore, nuclear buds should also be considered genotoxic biomarkers with an origin 
comparable to that of micronuclei (Serrano-García & Montero-Montoya, 2001).  
Previous studies have shown that carriers of the XRCC3 heterozygous genotype had increased 
levels of chromatid breaks and sister-chromatid exchanges in smokers and increased DNA 
adducts in lymphocytes (Fenech et al., 1999a) suggesting that this polymorphism is associated 
with low DNA repair capacity and may increase the risk of many types of cancer (Benhamou et 
al., 2004; Han et al., 2006; Battershill et al., 2008).  Yoshihara et al. (2004) and Lindh et al. 
(2006) suggested that XRCC3 Thr241Met variants contribute to the induction of micronuclei 
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arising from chromosome loss. Carriers of the Met/Met alleles would present higher 
micronuclei frequencies than their wild-type Thr/Thr allele counterparts (Mateuca et al., 
2008). A significant increase of micronuclei frequency in the Thr/Met genotype of XRCC3 was 
reported in workers exposed to oil, indicating that this polymorphism must be taken into 
account in chronic exposure scenarios (Pérez-Cadahía et al., 2008).  
However, other studies did not find evidence for the influence of XRCC3 genotype in the 
micronuclei basal frequency (Iarmarcovai et al., 2006). The functional differences between the 
XRCC3 alleles are not entirely understood. The amino acid substitution of a threonine by a 
methionine has the potential to affect protein structure and integrity (Dhillon et al., 2011). 
Variants leading to diminished XRCC3 function may be predicted to confer an increased risk of 
cancer due to accumulated levels of DNA damage. As many genes are involved in the repair of 
DNA damage, there is also the possibility that these polymorphisms might be in linkage 
disequilibrium with other causative factors (Figueiredo et al., 2004).  
Shen et al. (2002) suggested that the Met/Met genotype may contribute to a subset of 
squamous cell carcinoma of the head and neck and Figueiredo et al. (2004) found that both 
carriers of Met/Met and Thr/Met genotypes have an increased risk for breast cancer. The 
Met/Met genotype may cause genetic instability and lead to an increased susceptibility to 
various cancers due to the inability of genotype carriers to complement the centrosome 
amplification defect and to a decrease of apoptotic rates (Lindt et al. 2006), factors that may 
prevent aberrant cells from entering apoptosis.  
A better understanding of micronuclei induction driven by genetic polymorphism affecting 
DNA repair and/or genome stability, in particular XRCC3 Thr241Met, requires larger scale 
studies and the assessment of other relevant polymorphism interacting with individual DNA 
repair capacity (Mateuca et al., 2008).  
Our study did not provide conclusive evidence that some ADH5 polymorphisms may influence 
the carrier’s capacity to protect against DNA damage (chapter 1 of results, 5.2. ADH5 Bal309Ile 
and Asp353Glu polymorphisms). A borderline association (p = 0.06) was found between the 
frequency of nuclear buds and the homozygous Asp/Asp genotype, as compared to the 
Asp/Glu heterozygous genotype. These individuals may be more prone to nuclear alterations 
following a possible alteration in formaldehyde metabolism and adduct formation. Another 
interesting result was the statistically significant difference in carriers of the Val/Ile genotype 
in comparison with Val/Val genotype of the ADH5 Val309Ile polymorphism in micronuclei in 
lymphocytes in the exposed group. The carriers of the heterozygous genotype showed higher 
means of micronuclei in lymphocytes in the exposed group but not in the control group 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
187 
 
suggesting that the carriers of Val/Ile genotype metabolize poorly formaldehyde and present 
more DNA damage. Our results are in agreement with the findings of Just et al. (2011), who 
investigated three different polymorphisms in the transcribed regions of ADH5 for inter-
individual differences against the genotoxicity of formaldehyde in the German population and 
found no biologically relevant variants. The biological significance of ADH5 polymorphisms in 
relation to disease remains uncertain.  
Regarding the VDR BsmI polymorphisms, in the exposed group we have found a significant 
association between micronuclei in lymphocytes and the genotypes studied (chapter 1 of 
results, 5.3. Vitamin D receptor BmsI polymorphisms). Carriers of the CT+T genotype have 
higher mean micronuclei in lymphocytes than CC carriers. The BsmI polymorphisms exhibit a 
heterogeneous geographical distribution. For instance, a study of Caucasian women reported 
increased risk of breast cancer with the BsmI bb (TT) genotype and low levels of vitamin D; 
whereas, BsmI BB (CC) genotype was associated to breast cancer among Hispanic and 
Taiwanese women (Lowe et al., 2005; Raimondi et al., 2009; Shahbazi et al., 2013). Studies 
corroborate the role of the TT BsmI genotype as a risk factor for a variety of pathologies, such 
as nephrolithiases, high blood pressure (Valdivielso & Fernandez, 2006),  melanoma (Denzer 
et al., 2011; Orlow et al., 2012), higher levels of antinuclear antibodies related with systemic 
lupus erythematosus (Kaleta et al., 2013), severe coronary artery disease (Schooten et al., 
1998), lower levels of calcium and more frequent type 2 diabetes mellitus (Al-Daghri et al., 
2012), lower levels of 25(OH)D and prostate cancer (Taylor et al., 1996; Ma et al., 1998; Lowe 
et al., 2005).   
Qin et al. (2013) reported, in a subgroup analysis, that the TC + TT genotypes were risk factors 
in ovarian cancer compared to CC genotype, however Mostowska et al., (2013) concluded that 
the CC genotype might be a moderate risk factor for ovarian cancer development in the Polish 
population.  
The association between SNPs in relevant genes and the frequency of micronuclei in 
lymphocytes is a valuable tool for this purpose, as the latter is one of the best-validated DNA 
damage biomarker known to be sensitive to a wide range of endogenous, environmental, and 
lifestyle factors that can harm the genome (Dhillon et al., 2011). Some genetic polymorphisms 
of xenobiotic-metabolizing enzymes have been observed to influence the level of genotoxic 
damage in humans. This may facilitate the identification of risk groups and increase the 
sensitivity of biomarkers in biomonitoring (Norppa, 2001). However, studies that report an 
association between genotypes and biomarkers, such as micronuclei, have some limitations in 
design and analysis. Common limitations are group sample size, usually too small to evaluate 
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rare polymorphisms, and the wide range of allele frequency variation for each genotype in 
different ethnic populations. The statistical analysis is often plagued with problems of lack of 
power (due to insufficient sample size) and confounding can seldom be precluded given the 
amount of potential factors involved that have not been measured (Hunter, 2005; Chung et 
al., 2010).  
Our results showed a significant statistical association between XRCC3 Thr241Met 
polymorphism and NBUD. ADH5 polymorphisms did not show significant association with the 
genotoxicity biomarkers studied, and the carriers of the CT+T genotype of the VDR BsmI 
polymorphisms have higher mean micronuclei in lymphocytes than CC carriers. Several 
association studies have recently addressed the link between DNA repair polymorphism and 
micronuclei induction, but the evidence that DNA repair polymorphisms influence micronuclei 
frequencies remains limited (Mateuca et al., 2008). Haplotype analysis – whereby all possible 
genotypes would be checked against all biomarkers – was not performed given the lack of 
association in the more global analysis and because of insufficient sample size. Any further 
sample slitting by genotype would lead to reduction in statistical power too drastic to 
proceed. 
 
5. MICRONUTRIENTS 
Vitamins, essential minerals and other components are required in small quantities in the 
human diet for efficient metabolism. However, there is no consensus regarding the level of 
micronutrients necessary to prevent DNA damage in humans. Individual characterization of 
ideal dietary intakes in order to prevent DNA damage is a fundamental goal, because the 
amount of micronutrients which prove to be protective against genome damage varies 
according to food types and a cautious choice is needed if we are to design dietary patterns 
optimized for genome health maintenance (Prado et al., 2010).  
Experimental studies reported by Bonassi et al. (2007) and Fenech (2010) support the critical 
role played by micronutrients in the preservation of genomic integrity (Lal & Ames, 2011), 
namely in the decrease of micronuclei frequencies when the subjects consume vitamin-
antioxidant mixtures (Gaziev et al., 1996). 
In the non-exposed group, there was a strong positive correlation among the genotoxicity 
biomarkers under study, namely micronuclei in lymphocytes and nucleoplasmic bridges with 
nuclear buds, and nucleoplasmic bridges and micronuclei in buccal mucosa cells. These results 
corroborate the study of Fenech & Crott (2002), where a strong cross-correlation between 
micronuclei, nucleoplasmic bridges and nuclear buds frequency suggested a common 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
189 
 
mechanism. Analogous models via other molecular pathways, such as DNA repair, can be 
developed to explain the generation of micronuclei, nucleoplasmic bridges and nuclear buds 
induction by exposure to specific genotoxic agents such as ionising radiation or other agents 
that cause double-stranded DNA breaks (Preller et al., 2004; IARC, 2006; Pyatt et al., 2008; 
Fenech, 2010).  
Our results showed a positive correlation between vitamin A and nucleoplasmic bridges, 
meaning that higher value of vitamin A increases this biomarker (chapter 1 of results, 6.1. 
genotoxicity biomarkers and vitamins A,D, and E). As nucleoplasmic bridges are biomarkers of 
chromosome rearrangement, this suggests that vitamin A promotes genomic instability, acting 
as a risk factor instead of a protective one.  
De Flora et al. (1999) verified that retinol was ineffective and some in vitro results even 
suggested it enhanced DNA damage, point mutations of differential specificity, numerical and 
structural chromosomal alterations, and impairment of DNA repair mechanisms, modulated 
by β-carotene or vitamin A. The apparently protective effect of increased retinol may be due 
to its one-step conversion to retinoic acid, which has been shown to suppress the 
inappropriate expression of NFκβ, which leads to inflammation, increased cell proliferation 
and inhibition of apoptosis, all of which may lead to an increased micronuclei expression in 
lymphocytes (Fenech et al., 2005). This result is conflicting with the findings of Gaziev et al. 
(1996) who reported that vitamin A and β-carotene enhance the antioxidant activity of cells 
and are able to reduce micronuclei frequency in human lymphocytes; however they 
supplemented subjects with a multivitamin during a 4 month period.  
Studies by (Stich et al., 1984a, 1984b) reported considerable reduction of micronuclei in 
exfoliated buccal mucosa cells following the administration of a vitamin A plus beta-carotene 
regime.  Benner et al., (1994) demonstrated a decrease in micronuclei frequencies after alpha-
tocopherol treatment. Overall, the measurement of micronuclei in exfoliated cells is suitable 
to monitor specific health risk arising from various kinds of exposure to carcinogenic hazards 
(Majer et al., 2001), our results did not find significant associations between micronuclei in 
exfoliated buccal cells and the vitamins under study. Our results can probably be explained by 
the fact that the buccal mucosal tissue cells are rapidly dividing and vitamin levels in 
desquamated buccal mucosal cells may be a poor indicator of vitamin status in the dividing 
basal cell layer where micronuclei formation occurs (Piyathilake et al., 1995).  
A considerable body of evidence indicates that vitamin E, the most potent lipid peroxyl radical 
scavenger, significantly decreases free radical induced chromosomal damages (Claycombe & 
Meydani, 2001). There are many studies that showed no effects of vitamin E upon 
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genotoxicity biomarkers, namely no correlation between micronuclei levels and vitamin E 
(Stich et al., 1984a, 1984b; Benner et al., 1994; Piyathilake et al., 1995; Fenech et al., 2005). 
Gulec et al. (2006) suggested that formaldehyde exposure of experimental animals causes 
depression in their antioxidant status due to increased lipid peroxidation, and formation of 
free radicals. Therefore, concluding that vitamin E prevents biochemical changes in the liver 
tissue and plasma of rats due to oxidative damage and cytotoxicity; it also has a protective 
effect against the administration of mutagenic chemical compounds (Awodele et al., 2010) 
and a radioprotection effect, measured by micronuclei in bone marrow and exfoliated cells 
(Konopacka et al., 1998).  Schneider et al. (2001) reported a distinctive decrease in micronuclei 
frequency after diet supplementation with vitamin E. All these studies reported on 
micronuclei levels, whereas we have found a significant association between vitamin E and 
nuclear buds (p<0.05) in the exposed group.  
Current evidence suggesting that vitamin D prevents DNA damage and regulates the cell cycle 
has been limited to studies in cultured cells and experimental animal models (Raimondi et al., 
2009). Our study did not show any association between this vitamin and the genotoxicity 
biomarkers evaluated. We also did not find significant associations between vitamin D and A 
or E. However, Sarkar et al. (2000) showed that vitamin D analogs alone, and particularly in 
combination with retinoid acid, exert antitumor effects by means of induction of cell 
differentiation, inhibition of proliferation and angiogenesis. Jones et al., (2011) also showed 
that vitamins D and E influence micronuclei frequencies significantly. 
There are some limitations, concerning the study of the association between genotoxicity 
biomarkers and vitamins, namely the small sampling size, which limits the power of statistical 
tests. Moreover, vitamin measurements were only done once in the study, and the temporal 
variation of the serum concentrations can influence the observed results. Determining the 
intake levels of micronutrients required to maintain genome stability is an essential step in the 
definition of optimal diets for the prevention of cancer and other diseases caused by genome 
damage (Fenech et al., 2005; Thomas et al., 2011). Although the presence of micronuclei is a 
strong indicator of chromosomal damage resulting from either whole chromosome loss or 
breakage, the other genotoxicity biomarkers provided by the CBMN assay should not be 
ignored because they are indicative of genomic instability. As genome damage is considered 
the most fundamental of all disease pathologies, it is essential to determine which 
micronutrients are necessary to maintain optimal genome health and who is likely to benefit 
(Thomas et al., 2011). In interpreting the data from this study, it is important to note that 
micronutrients usually exhibit metabolic dose-response effects in which both deficiency and 
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excess can be deleterious and it is probable that in a specific mixed diet, depending on the 
intake level of an individual, some of the micronutrients may be outside the intake range that 
is optimal for the prevention of genome instability (Fenech et al., 2005). 
The fact that both vitamin deficiency and excess can increase carcinogenesis is supported by 
several studies and highlights the acute need for better knowledge of dose-response 
relationships between micronutrient intake and genome health (Fenech et al., 2005). 
In conclusion, our study seems to indicate that vitamin levels may modulate direct signs of 
genotoxicity and the fact that we have measured them directly, rather than indirectly from a 
dietary questionnaire, adds strength to our results. However, is necessary to increase the size 
of the sample in order to test these and other associations. 
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CHAPTER 2 – CYTOSTATICS DRUGS OCCUPATIONAL SETTING 
 
 
1. CYTOSTATICS EXPOSURE ASSESSMENT 
Healthcare workers handling antineoplastic drugs usually implement collective and individual 
protective measures. However, contamination of the work environment is still possible, and 
the safety measures employed can be insufficient to prevent exposure. In addition, workers 
may not apply all the safety measures required for handling such substances.  
Considering surfaces contamination results, positive samples were found for all surrogate 
markers in both hospitals. These results raise concern because health effects associated to 
exposure to carcinogenic, mutagenic, and teratogenic substances usually do not depend on a 
minimum dose but rather on a prolonged exposure (Fucic, 1998; Sessink & Bos, 1999; 
Bouraoui, 2011; Buschini, 2013). Therefore, it can be concluded that there is no safety 
threshold dose concerning exposure to these drugs being appropriate to apply the ALARA 
principle: keep exposure/contamination levels “As Low As Reasonably Achievable” (Hon et al., 
2013). Widespread contamination was also observed in other studies, despite the 
implementation of safety procedures for handling antineoplastic drugs (Schmaus et al., 2002; 
Connor et al., 2006; Castiglia et al., 2008). 
Our results showed that 36% of the samples were contaminated with one cytostatic drug, and 
8.6% of the surfaces were contaminated with more than one antineoplastic drug, being most 
of these samples from the administration units (chapter 2 of results, 2. cytostatics exposure 
assessment). These results can be explained once again by the more strict safety and hygiene 
rules in preparation units when compared with administration units, eventually stemming 
from the high number of organizations that research on this field and continuously develop 
new rules and safety measures (NIOSH 2004; ISOPP 2007, among others). In this case, 
inappropriate cleaning combined with incorrect working procedures probably are contributing 
to the contamination found, a good example being the telephone handling without taking off 
the gloves. 
Our results showed that the amount of contaminated surfaces varied with the drugs 
considered. For example, it was possible to observe fewer surfaces contaminated with 
cyclophosphamide (4.6%) than with 5-fluorouracil and paclitaxel (10.7% and 26.9%, 
respectively). This can nevertheless be explained by the lower sensitivity of the 
cyclophosphamide detection method, unable to measure values below 30 µg, as compared to 
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5-fluorouracil (LOQ=1000 ng) and paclitaxel (LOQ=50 ng) (Viegas et al., 2014). Additionally, it 
seems that cyclophosphamide is rapidly degraded at room temperature disappearing more 
easily from the environment (Hedmer et al., 2004). Taking this into account, probably the 
results only represent the sampling of a one-day contamination and not what might be 
resulting from other working days. Paclitaxel, on the other hand, presented the highest 
number of contaminated surfaces (21.7%) as compared to the other two drugs (4.6% for 
cyclophosphamide and 10.7% for 5-fluorouracil) (chapter 2 of results, 2. cytostatics exposure 
assessment). Paclitaxel is characterized by low aqueous solubility and high physicochemical 
stability. These two factors combined can explain the results because this drug is probably 
more persistent on surfaces, resisting to environmental conditions and cleaning (Kopjar et al., 
2007). This brings up another important aspect that should be considered for risk assessment 
in hospital settings and alike, exposure is not to one single drug but rather to different 
antineoplastic drugs and the health effects of such mixtures are unpredictable (Fucic et al., 
1998; Cavallo et al., 2005; Kopjar et al., 2009). 
The contamination of various surfaces by antineoplastic drugs in the workplaces implies an 
increased risk for health care workers to become dermally exposed (Hedmer & Wohlfart, 
2012). 
 
2. GENOTOXICITY ASSESSMENT 
 
2.1. CBMN ASSAY 
As newly developed antineoplastic drugs are designed and introduced, in order to attack 
specific intracellular targets, their harmful effects could easily “escape” from detection by 
most standard endpoints. The CBMN should be used to accurately evaluate cytogenetic 
outcomes of such exposures (Kopjar et al., 2009). Its value in the assessment of genotoxic 
damage among occupationally exposed personnel was also confirmed in this study. The data 
obtained has shown a significant increase of micronuclei in lymphocytes in the exposed group 
in comparison with controls, on account of genomic instability, as an increased amount of 
mutations and/or chromosomal aberrations that cytogenetically translate into a greater 
frequency of changes in chromosome and in the formation of micronuclei (Zietkiewicz et al., 
2009). 
In what concerns genotoxicity assessment, our results showed statistical significant higher 
means in all genotoxicity biomarkers in the exposed as compared to control groups (p<0.05) 
(chapter 2 of results, 3.1. cytokinesis-block micronucleus assay). These results, namely those 
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concerning micronuclei frequency, are corroborated by many others studies (Fucic et al., 
1998; Deng et al., 2005; Cavallo et al., 2007; Cornetta et al., 2008; Kopjar et al., 2009; 
Bouraoui et al., 2011; El-Ebiary et al., 2011) which found significant increases of micronuclei 
frequency in workers handling antineoplastic drugs.  
The results of cytogenetic studies are often ambiguous. For example, in studies performed in 
Austria (Pilger et al., 2000) and in Sweden (Thiringer et al., 1991) no significant differences in 
micronuclei in hospital pharmacy personnel and unexposed controls were found. Also Maluf 
et al. (2000),  Hessel et al. (2001), Cavallo et al. (2005), Laffon et al. (2005) showed no 
significant micronuclei increase in those exposed to antineoplastic drugs as compared to non-
exposed. Thus it appears that research on the genotoxicity of antineoplastic drugs displays 
conflicting results; such inconsistency could be attributed to differences in the antineoplastic 
drugs handled, or the protective measures available and used effectively. Moreover, based on 
genetic bases, the human response to genotoxic xenobiotics may vary due to the presence of 
individual differences in DNA damage repairing capacity (Rekhadevi et al., 2007, El-Ebiary et 
al., 2011). 
In what concerns other endpoints measured by the CBMN assay, Kopjar et al. (2007) reported 
an increase of nucleoplasmic bridges and nuclear buds in those exposed to irinotecan, an 
antineoplastic drug. Our results also showed higher means of these biomarkers in the exposed 
group. 
For micronuclei in mono and multinucleated lymphocytes, results form binary logistic 
regression suggested that exposure can not be considered a risk factor for these two 
endpoints, however there were statistical significant differences between the exposed group 
and the controls (Mann-Whitney test, p<0.05). 
It is actually unknown to what extent mutagen exposure either leads to the formation of 
micronuclei already in vivo or to the formation of micronuclei ex vivo during cell culture as 
consequence of DNA damage which is not repaired in vivo or in vitro and persists until 
lymphocytes divide in culture (Martelli et al., 2000; Arsoy et al., 2009). Therefore, it has been 
postulated that micronuclei induced in vivo is observed in mononuclear lymphocytes, and in 
vitro damage is observed in binucleated lymphocytes. Increased frequencies in micronuclei 
can only be expected if lymphocytes with persistent damage are obtained and cultured (Arsoy 
et al., 2009). 
As for the presence of a high number of multinucleated lymphocytes, because antineoplastic 
drugs act at a diversity of cellular levels, and some groups of these drugs cause abnormalities 
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of the mitotic spindle, the presence of a considerable number of multinucleated lymphocytes 
with micronuclei was to be expected.  
We have not found evidence that the amount of years of exposure to cytostatics influenced 
the frequency of micronuclei. This result is corroborated by the studies of Thiringer et al. 
(1991), Hessel et al. (2001), Bouraoui et al. (2011), El-Ebiary et al. (2011), and Villarini et al. 
(2012) who also did not find association between years of exposure to antineoplastic drugs 
and micronuclei increase. Once again, there are controversial results regarding this matter, as 
studies by Kevekordes et al. (1998), Kasuba et al. (1999), Laffon et al. (2005), Cavallo et al. 
(2007), Rekhadevi et al. (2007), and Kopjar et al. (2009) showed an association between the 
years of exposure and the increase in micronuclei. The study by Laffon et al. (2005) reported 
this influence following 10 years of cumulative exposure. 
 
The present study confirmed surface contamination in the workplaces considered and the 
cytogenetic endpoint studied (CBMN) showed signs of a relationship with exposure. Since 
genotoxicity may be due to combined effects of all or some of the antineoplastic drugs, it is 
not possible to attribute damage to any particular agent. Results of this study as well as 
previous investigations on subjects occupationally exposed to antineoplastic drugs using 
different genotoxicity endpoints suggest that antineoplastic drugs in long-term occupational 
exposure may act as clastogens on the DNA molecule of somatic cells (Rekhadevi et al., 2007). 
 
2.2. COMET ASSAY 
The comet assay identifies injuries which are still reparable, such as single and double-strand 
DNA breaks, alkali labile lesions that are converted to strand breaks under alkaline conditions 
and single-strand breaks associated with incomplete excision repair sites (Villarini et al., 2012), 
thus providing information about recent exposures (Laffon et al., 2005). In particular, the 
comet assay with the use of enzymes, which recognizes and cuts specifically oxidized DNA 
bases allows for the evaluation of oxidative DNA damage (Collins et al., 1999). It is one of the 
most used methods in biomonitoring studies of genotoxicity on blood lymphocytes (Cavallo et 
al., 2009), and is widely used to evaluate the genotoxic effects of exposure to specific 
antineoplastic drugs in several in vitro and in vivo studies (Digue et al., 1999; Blasiak et al., 
2000; Brahnam et al., 2004). 
In what concerns comet assay, our findings suggest that occupational exposure to 
antineoplastic drugs in healthcare workers induces DNA damage but the increase compared to 
controls was not significant. The results showed higher mean DNA damage, measured by % 
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DNA in tail and oxidative DNA damage (FPG), in the lymphocytes of the exposed subjects 
compared to controls, although without reaching statistical significance (chapter 2 of results, 
3.2. comet assay). Our results are in line with studies by  Ursini et al., (2006) and Buchini et al. 
(2013), which used the alkaline comet assay of peripheral blood lymphocytes to evaluate 
biomonitoring of subjects exposed to antineoplastic drugs, and also did not reach a 
statistically significant difference between exposed and controls, or the weak significant trend 
reported by (Mader et al., 2008).  Sasaki et al. (2008) evaluated DNA damage by measuring 
comet tail moment, and there was no significant difference between exposed and control 
subjects either. A possible explanation may have to do with comet assay predominantly 
detecting single-strand breaks and alkali-labile sites, which are induced by antineoplastic 
drugs (Kopjar et al., 2009). Since both types of DNA damage are continuously and efficiently 
repaired, the measured damage level is a result of equilibrium between the amount of DNA 
damage inflicted and the speed of repair (Kopjar & Garaj-Vrhovac, 2001). Generally, the type, 
level and persistence of DNA damage in lymphocytes of exposed populations depend on the 
kind of antineoplastic drugs used as well as on the concentrations of drugs producing the 
mutagenic response (Kopjar & Garaj-Vrhovac, 2001). Also, antineoplastic drugs are well-
known cross-linking agents, which can increase the effective molecular weight of DNA, are 
thereby are known to reduce the ability of DNA containing strand breaks to migrate in an 
electric field. The presence of a cross-linking agent could have hidden an increase in DNA 
migration associated with the induction of DNA strand breaks by other genotoxic agents, with 
a higher effect in terms of DNA tail mobility (Villarini et al., 2011). 
Contrary to these findings, other researchers evaluating DNA damage in healthcare workers 
handling antineoplastic drugs were able to show a statistically significant increase in DNA 
damage on the exposed group with respect to controls with the comet assay (Ündeğer et al., 
1999; Maluf & Erdtmann, 2000; Kopjar & Garaj-Vrhovac, 2001;  Yoshida et al., 2006; Kopjar et 
al., 2007; Rekhadevi et al., 2007; Cornetta et al., 2008; Izdes et al., 2009; Kopjar et al., 2009; 
Rombaldi et al., 2009; Villarini et al., 2011). 
The comet assay and the CBMN assay detect genotoxic effects caused by different 
mechanisms. The comet assay identifies still reparable injuries such as single and double-
strand DNA breaks, alkali labile lesions that are converted to strand breaks under alkaline 
conditions and single-strand breaks associated with incomplete excision repair sites; whereas 
the CBMN assay detects injuries that survive at least one mitotic cycle and reflect unrepaired 
fixed DNA damage (Villarini et al., 2012). It is considered that, for chronic exposures, 
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micronuclei test express cumulative facts whereas comet assay provides information on 
recent exposures (Laffon et al., 2005).  
Comet assay used in biomonitoring studies reflect the current exposure (over the previous 
few weeks) and the actual levels of DNA damage present in white blood cells at the moment 
of blood sampling. The comet assay is able to sensitively reveal early, still repairable, 
moderate DNA damage, and can therefore furnish useful information on early effects induced 
by occupational exposure to low doses of xenobiotics (Kopjar et al., 2009) being 
recommended to monitor population chronically exposed to genotoxic agents combined with 
CBMN assay (Maluf & Erdtmann, 2000; Kopjar & Garaj-Vrhovac, 2001; Rekhadevi et al., 2007; 
Cornetta et al., 2008; Cavallo et al., 2009; Kopjar et al., 2009). A combination of cytogenetic 
tests and the comet assay in biomonitoring studies makes it possible to compare the relative 
sensitivities of the two test systems and, therefore, gives us a possible clue about the fraction 
of the DNA damage detected by the comet assay that will lead to fixed mutations (Milic et al., 
2010). 
Our results concerning of positive findings by micronuclei and non significant ones by comet 
assay, are corroborated by Deng et al. (2005) study performed in workers occupationally 
exposed to methotrexate, also a cytostatic drug. According to Cavallo et al. (2009), the comet 
assay seems to be more suitable for the prompt evaluation of the genotoxic effects, for 
instance, of polycyclic aromatic hydrocarbons mixtures containing volatile substances, 
whereas the micronucleus test seems more appropriate to evaluate the effects of exposure to 
antineoplastic agents. However, there are studies that observed an increase in both the comet 
assay and the micronucleus test in nurses handling antineoplastic drugs, although statistical 
significance was only seen in the comet assay, quite the opposite of our results (Maluf & 
Erdtmann, 2000; Laffon et al. 2005).  
 
3. DEMOGRAPHIC AND LIFESTYLE HABITS 
In epidemiological studies, it is important to evaluate the role played by common confounding 
factors, such as gender, age, smoking and alcohol consumption, upon the association between 
disease and exposure (Fenech et al., 1999; Bonassi et al., 2001). Concerning gender, studies by 
Fenech et al. (1999) and Ladeira et al. (2011) reported that biomarker frequencies in 
lymphocytes were greater in females in comparison with males. In our study (chapter 2 of 
results, 4. demographic and lifestyle habits),  gender was not associated with an increase in 
the frequency of micronuclei, or other of the biomarkers measured by CBMN assay, either in 
the exposed or control group, a result in agreement with Villarini et al. (2012). As for the 
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comet assay, it was found a moderate positive association in the control group, indicating that 
females have higher DNA damage. Regarding the possible influence of gender in the basal 
DNA damage measured using comet assay, studies in humans that used comet assay also 
produced divergent results. Some authors observed higher levels of basal genetic damage in 
males than in females (Bajpayee et al., 2002; Lam et al., 2002; Manikantan et al., 2009), 
whereas others have found no difference between genders (Diem et al., 2002).  
Cytogenetically, ageing is associated with a number of gross cellular changes, including altered 
size and morphology, genomic instability and changes in expression and proliferation 
(Bolognesi et al., 1999; Zietkiewicz et al., 2009). It has been shown that higher micronuclei 
frequency is directly associated with decreased efficiency in DNA repair and increased genome 
instability (Kirsch-Volders et al., 2006; Orsière et al., 2006), and it also affects the level of 
induced and basal DNA damage detected by comet assay in mammalian cells (Heuser et al., 
2008). The data obtained has shown a significant increase of micronuclei in binucleated and 
mononucleated lymphocytes in both groups, showing that micronuclei frequencies tended to 
rise with age, like in the results by Hessel et al. (2001) and Kopjar et al. (2009). The analysis of 
age and gender together corroborate the previous results, being age the factor that influence 
micronuclei in binucleated and mononucleated lymphocytes, and gender in DNA damage 
(chapter 2 of results, 4. demographic and lifestyle habits). When using the comet assay, our 
results did not reach statistical significance, unlike previous studies (Goukassian et al., 2002; 
López-Diazguerrero et al., 2005; Rossi et al., 2007; Heuser et al., 2008), where DNA damage, 
detected by comet assay, showed an increase with age. However, Manikantan et al. (2009) 
also failed to find a significant association between DNA damage and age.  
Tobacco smoke has been epidemiologically associated to a higher risk of cancer development; 
in the present study smoking habits did not affect any of the genotoxicity biomarkers 
measured by CBMN assay, either in the exposed or in the control subjects (chapter 2 of 
results, 4. demographic and lifestyle habits) being this result corroborated by Villarini et al. 
(2012).  
In the present study, smoking habits did not increase the levels of DNA damage measured by 
comet assay significantly, in either the control or the exposed subjects. Our results, which are 
in agreement with findings by Hellman et al. (1997, 1999), Wojewódzka et al., (1999) and 
Garaj-Vrhovac & Kopjar (2003) indicate that cigarette smoking is not a very potent 
confounding factor on the comet parameters measured. Some authors observed a connection 
between cigarette smoking and increased migration of human lymphocyte DNA during 
alkaline comet assay (Fuchs et al., 1995; Moller et al, 2000; Speit et al., 2003; Hininger et al., 
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2004; Manikantan et al., 2009) but our results were not significant in this regard. A possible 
explanation is that comet assay measurements may reflect both individual repair ability and 
DNA damage level. Because the damage level measured is the result of the equilibrium 
between damage infliction and repair, a low damage level as assessed experimentally in an 
individual may be the result of an actual low number of lesions or of a high efficiency of repair 
(Wojewódzka et al., 1999). 
No associations between genotoxicity assessment and alcohol consumptions were found in 
what concerns biomarkers measured by CBMN assay (chapter 2 of results, 4. demographic and 
lifestyle habits). However, a positive association in the exposed group was found, indicating 
that alcohol consumption is associated with higher DNA damage. The study from Manikantan 
et al. (2009) showed that alcoholic users had a significantly greater amount of DNA damage 
than non-users in the exposed group. Ethanol is mutagenic via its first-metabolite, 
acetaldehyde, the latter being associated with chromosomal aberrations, sister-chromatid 
exchanges and cross-links between DNA strands (Obe & Ristow, 1979). However, Philips 
(2001) found no significant evidence that ethanol is a genotoxic hazard according to the 
criteria normally applied for the purpose of classification and labelling of industrial chemicals. 
 
4. INDIVIDUAL SUSCEPTIBILITY 
OGG1 is considered to be the main enzyme responsible for the removal of 8-OHdG in humans, 
believed to play an important role in carcinogenesis because it is abundant and highly 
mutagenic. Epidemiological studies have previously related the Ser326Cys on OGG1 
polymorphism and the risk of different types of cancer, namely esophageal (Xing et al., 2001), 
orolaryngeal (Elahi et al., 2002) , lung cancer (Hu & Ahrendt, 2005), larynx colon (Pawlowska 
et al., 2009), colon cancer (Kim et al., 2003), and gastric cancer (Tekezaki et al., 2002). 
The genetic polymorphism of OGG1 at codon 326 was shown to encode serine and cystein 
aminoacids showing OGG1 Ser/Ser higher repair activity toward 8-OHdG than the OGG1 
Cys/Cys (Chen et al., 2003). In general, our results (chapter 2 of results, 5.1. OGG1 Ser326Cys 
polymorphisms) did not show a consistent trend regarding the variation of biomarkers with 
OGG1 polymorphism, and there were not statistical significant results. However, in what 
concerns micronuclei, the Ser/Ser genotype carriers presented higher means of that 
genotoxicity biomarker, unlike the study by Chen et al. (2003). Mateuca et al., (2008) 
observed also significantly lower micronuclei frequencies in carriers of the Cys/Cys genotype 
compared to the wild-type Ser/Ser carriers, being these result in line with our findings. Hu & 
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Ahrendt (2005) verified that Ser/Ser genotype was significantly associated with an increase in 
the frequency of p53 mutations among patients with non small cell lung cancer.  
As for the comet assay, the association obtained, although not statistically significant, was 
that Cys/Cys carriers presented higher levels of oxidative DNA damage in the control group. 
However, that association was not observed in the exposed group, where the Cys/Cys 
genotype revealed the lower results due to oxidative damage. Many studies reported that the 
DNA repair activity of the mutant OGG1 Cys/Cys protein is lower than that of the wild-type 
Ser/Ser protein being 8-OHdG levels in lymphocyte DNA significantly higher in homozygotes 
for the Cys326 allele than for individuals with other OGG1 genotypes.  
Aka et al. (2004) and Pawlowska et al. (2009) verified that Cys/Cys and Ser/Cys OGG1 
genotypes have less DNA repair capacity compared to the Ser/Ser OGG1 genotype. Kohno et 
al. (1998) reported that mean 8-OHdG levels were similar in peripheral leukocytes expressing 
either Ser/Ser or Cys/Cys. 
These results suggest that the effect of Ser326Cys polymorphisms on DNA repair capacity may 
differ with the type and strength of the DNA-damaging exposures and may be influenced by 
the interaction between the OGG1 polymorphism and other genetic polymorphisms (Mateuca 
et al., 2008).  The polymorphism of the OGG1 gene is worth investigation, inasmuch as a 
population with decreased enzyme activity of the OGG1 protein would be at risk of 
accumulating 8-OHdG in nuclear DNA, because of the incomplete repair of oxidatively 
damaged DNA (Tarng et al., 2001). It is important to refer that the codon 326 polymorphism 
may be in linkage disequilibrium with other functional polymorphisms in cancer-related genes 
(Hu & Ahrendt, 2005).  
Once again, the small size of our sample hampered the finding of a possible association, let 
alone a causality relationship. 
 
5. MICRONUTRIENTS 
Micronutrient deficiency or excess can have modifying effects on genomic integrity. Our 
results showed significant correlations between serum vitamins A and E and the genotoxicity 
biomarkers studied (chapter 2 of results, 6.1. genotoxicity biomarkers and vitamins A and E in 
serum).  
Vitamin A was positively correlated with nucleoplasmic bridges in the exposed group, and with 
nuclear buds and FPG in controls. As in the study by van Helden et al. (2009) on how beta-
carotene affects oxidative stress-related DNA damage in lung epithelial cells, we have also 
found an association: vitamin A can act as pro-oxidant or antioxidant, depending on the type 
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of radicals involved, and may lead to DNA oxidative damage (Alakhras et al., 2011).  The study 
by van Helsen et al. (2009) demonstrated that vitamin A enhances OH radical formation in the 
Fenton reaction.  Azqueta & Collins (2012) clearly distinguished between effects of vitamin A, 
pro-vitamin A carotenoids, and non-vitamin A carotenoids; being the latter group almost 
invariably reported to protect against DNA damage, whether endogenous or induced by 
exogenous agents, the pro-vitamin A carotenoids show a wider spectrum of effects, 
sometimes protecting and sometimes enhancing DNA damage. 
Alakhras et al. (2011) investigated the genotoxicity of all-trans retinoic acid and its steroidal 
analogue EA-4, concluding that the retinoids affected chromosome orientation during 
metaphase by inducing bipolar metaphases with non-congressed genetic material, which may 
give rise to micronuclei. 
Nucleoplasmic bridges occur when centromeres of dicentric chromosomes are pulled to 
opposite poles of the cell at anaphase and frequently fail to segregate in an orderly manner, 
instead forming bridges between the two forming nucleus. Alakhras et al. (2011) concluded 
that retinoic acid exerts cytotoxic and genotoxic activities, the mechanism of its action being 
clastogenicity and also its ability to provoke chromosome delay by defects in microtubule 
network and mitotic spindle integrity. As previously mentioned, these results are conflicting 
with the findings by Gaziev et al. (1996), where vitamin A was reported to lower micronuclei 
frequencies.  
Our results derived from the food frequency questionnaire, where retinol (vitamin A) was 
assess, found also a positive correlation between retinol and oxidative DNA damage (FPG). 
Giovannelli et al. (2002) found that a high intake of selected antioxidants (vitamin A, C, E and 
β-carotene) tended to be positively associated with oxidative DNA damage, with a borderline 
statistical significance for vitamin E, in disagreement with several studies (mostly intervention 
studies) which showed a protective effect of antioxidants with respect to DNA damage. In 
what concerns serum vitamin E, our results showed a negative significant correlation with 
nucleoplasmic bridges in the exposed group. Most studies aimed at establishing an association 
between vitamin E and genotoxicity biomarkers measured by CBMN evaluated micronuclei. 
Some report a decrease of this biomarker after vitamin E supplementation (Schneider et al., 
2001), whereas others were quite inconclusive (Stich et al., 1984a, 1984b; Benner et al., 1994; 
Piyathilake et al., 1995; Fenech et al., 2005). 
Dietary habits are recognized to be an important modifiable environmental factor influencing 
cancer risk and tumour behaviour. Our data gathered by the FFQ led to four significant 
positive correlations (chapter 2 of results, 6.2. genotoxicity biomarkers and micronutrients 
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measured by FFQ). Vitamin E was found to be positively correlated with % DNA in tail and 
micronuclei in mononuclear lymphocytes. Watters et al. (2007) also found a positive 
association of vitamin E and oxidative DNA damage in a healthy, non-smoking population of 
young adults. A possible explanation for this result stems from some evidence that in the 
presence of copper or in smokers with a fat rich diet, vitamin E can act as a strong pro-oxidant, 
nevertheless it remains an unexpected result. Duthie et al. (1996) found a positive correlation 
between DNA strand breaks and vitamin E, but the result was not interpreted as indicating any 
deleterious effect by the vitamin.  
Both iron deficiency and excess are known to contribute to oxidative stress and DNA damage. 
Our results found a positive correlation between iron and DNA damage (% DNA in tail), 
meaning that higher intake of iron associates with higher DNA damage. Oxidative lesions, and 
more specifically 8-OHdG, is one of the most prevalent lesions induced by iron containing 
substances (Prá et al., 2012), however the FPG biomarker was not statistically associated with 
iron. Iron can be mutagenic by different mechanisms, mostly involving base oxidation. There is 
sound evidence that iron deficiency increases genome instability, among other mechanisms, 
by impairing enzymes involved in antioxidant and nuclei acid metabolism (Prá et al., 2012). 
Being a transition metal, iron and its ionic forms are prone to participate in one-electron 
transfer reactions. This capacity also enables iron to generate free radicals. Under conditions 
of increased hydrogen peroxide production by activated phagocytes in the presence of Fe2+, 
very reactive hydroxyl radicals may be formed via the Fenton reaction. This can potentiate 
oxidative DNA damage (Tarng et al., 2001). 
Our results found that the amount of calories ingested was negatively correlated with both 
biomarkers assessed by comet assay, namely % DNA in tail and FPG. This was somewhat 
unexpected, as calorie restriction reduces metabolic rate and oxidative stress, meaning that 
lower calories ingestion decreases DNA damage and DNA oxidative damage (Hart et al., 1999; 
Heilbronn & Ravussin, 2003).  
A significant negative correlation was found between folate and % DNA in tail. Courtemanche 
et al. (2004) also found that folate deficiency leads to increased DNA damage in primary 
lymphocytes, and that deficiency in the physiological level of folate caused more DNA damage 
than low-dose radiation in primary T lymphocytes. On the contrary, Kapiszewska et al. (2005) 
found no correlation between (serum) folate levels and strand breaks measured using 
standard alkaline comet assay. Folate deficiency is associated with the expression of 
chromosomal fragile sites, chromosome breaks, micronucleus formation and mitochondrial 
DNA deletions (Duthie & Hawdon, 1998; Fenech, 2001; Fergurson & Fenech, 2012), increased 
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DNA strand breakage, misincorporated uracil, and reduced DNA repair efficiency (Duthie & 
McMillan, 1997; Duthie & Hawdon, 1998); however, no correlations were found between 
folate and micronuclei, as in the results of (Fenech & Rinaldi, 1998).  
 
We have found a significant negative correlation between vitamin B12 and DNA oxidative 
damage (FPG), suggesting that vitamin B12 acts like a protective factor (Ames, 2001; Ames & 
Wakimoto, 2002; Ames, 2006). Minnet et al. (2011) also found a negative correlation between 
DNA damage and vitamin B12 levels, meaning that higher levels of vitamin B12 decrease DNA 
damage, in good agreement with our results. However, our findings are specifically on DNA 
oxidative damage and not DNA damage measured by alkaline comet assay for strand breaks.  
Milic et al. (2010) did not find correlations between folate and vitamin B12, on the one hand, 
and DNA damage measured by comet assay on the other hand; however vitamin B12 showed 
a significant positive correlation with micronuclei, such as in the Everson et al. (1988) study 
where blood cell micronuclei were elevated in subjects with low levels of blood folate and 
vitamin B12. Other studies (Glória et al., 1997; Fenech et al. 1998, Fenech 1999) found 
significant negative correlations between serum vitamin B12 baseline levels and micronuclei 
frequency. As for micronuclei, our study did not find any significant correlation with vitamin 
B12. 
Comet assay allows for the study of the effects of nutrients with known anti- or pro-oxidant 
capacities on different cell types and in different concentrations. These studies have revealed 
an apparent paradox, or at least an hormetic effect, whereby many of these antioxidant 
compounds seem to protect against DNA damage at low doses while actually causing DNA 
damage at higher doses (Wasson et al., 2008). There are several possible reasons why 
significant associations are difficult to find. First, samples usually comprise mostly healthy 
persons; second, it is possible that a synergistic effect exists involving all antioxidants which is 
not seen for each individual nutrient (Watters et al., 2007). Third, it is plausible that 
associations between some of the antioxidants examined and oxidative DNA damage may be 
better captured using other measures of oxidative DNA damage. Fourth, it is possible that the 
range of antioxidant concentrations and/or oxidative DNA damage in this study was not wide 
enough to detect associations or that the associations simply do not exist (Watters et al., 
2007). Previous studies have suggested a significant moderating effect of long-term 
antioxidant supplementation on endogenous and exogenous oxidative DNA damage in 
lymphocytes, supporting the hypothesis that dietary antioxidants may protect against cancer. 
The ability to demonstrate such clear differences between subjects on placebo and on 
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supplements confirms that the comet assay is a useful tool for screening populations for 
genotoxic effects (Duthie et al., 1996). 
In conclusion, the results of this study confirm that the alkaline comet assay is applicable for 
detection of genotoxic effects induced in vivo by occupational exposure to various mutagens. 
The relative simplicity and rapidity of the method, combined with the important practical 
factor that few cells are required for the analysis, makes it attractive for biomonitoring 
purposes in human populations (Kopjar & Garaj-Vrhovac, 2001). As genotoxicity may be due 
to combined effects of all or some of the antineoplastic drugs, it is usually not possible to 
attribute the damage to any particular agent (Rekhadevi et al., 2007). The results obtained in 
our investigation, as well as studies by other authors, suggest that genotoxic damage is likely 
to occur in workers occupationally handling antineoplastic drugs. The professionals who are 
continuously exposed to these agents need to be monitored for risk behaviour, so that such 
hazardous compounds are properly managed by hospital staff (Rombaldi et al., 2009).  
We failed to find significant correlations between measurements by HPLC and FFQ. There are 
various possible explanations for lack of correlation between the measurement of vitamins A 
and E in serum by HPLC, a highly sensitive method, and the assessment of the intake values of 
these vitamins by FFQ. For instance, the FFQ was self-administered, increasing the degree of 
subjectivity to which questionnaires are usually prone. Other possible explanation is that the 
FFQ assesses the intake of vitamins based on the food items selected and their doses; the 
HPLC, on the other hand, measures vitamins in serum after metabolic processes took place, 
and the bioavailability of the vitamins differs since their intake. Both methods are valid, and 
widely used in nutritional research.  
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1. CONCLUSIONS 
Molecular epidemiology and laboratory methods, used in close association, turn out to be a 
powerful tool in the investigation of cancer related epidemiological questions.  
The use of biomarkers, in particular, allow for the identification of environmental exposures 
related to lifestyle, occupation, or ambient pollution, which are prone to promote cancer 
development (Vainio, 1998; Portier & Bell, 1999; Bartsch, 2000; Dusinska & Collins, 2008; Spitz 
& Bondy, 2010). When developing a human biomonitoring programme, it is important to use a 
combination of different biomarkers and to study a range of variables that can act as 
confounders and influence the evidence of risk from carcinogenic exposure, namely ethnicity, 
age or stage of development, gender, pre-existing health impairment and nutritional factors. 
Also, individual susceptibility should not be discarded in biomonitoring endeavours (Perera, 
2000; Perera & Weinstein, 2000; Weis et al., 2005). 
Biomarkers supply information on the various stages of the multistep process towards 
putative disease. Markers of exposure have an important role in environmental and 
occupational health; some reflect progression along a causal pathway to disease, and others 
reflect innate or acquired susceptibility to the effects of etiological agents. If unequivocal 
biomarkers of effects and biomarkers of susceptibility could be developed, the identification 
of groups of individuals at increased risk would then be possible and very helpful to preventive 
medicine (Vainio, 1998).  
The present study simulated a human biomonitoring programme in two different occupational 
settings, using biomarkers to assess genotoxic damage, and investigating possible associations 
to individual susceptibility and dietary habits.  
For both occupational settings – workers exposed to formaldehyde and workers exposed to 
cytostatics drugs – there was strong evidence for an increase of genotoxicity biomarkers in 
association with occupational exposure, revealing that both types of chemical agents studied 
promoted DNA damage. The DNA damage detected could have been caused cumulatively, as 
previously explained, and is a clear indicator of exposure to the chemical. Our results suggest 
that the safety measures adopted by workers at both occupational settings were not enough 
to avoid exposure/contamination and to prevent the health consequences of handling 
chemical agents.  
Age, gender, tobacco and alcohol habits are important variables that should be included in a 
biomonitoring study we found evidence that some of these variables can have an influence on 
the biomarkers studied, however not as dramatically as exposure to the xenobiotics in study. 
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In order to cope with confounding factors, a biomonitoring programme is also to assess 
susceptibility biomarkers and dietary habits. We provide here some evidence for the putative 
role of these variables but, like behavioural habits, their association to genotoxic biomarkers 
seems more complex and controversial than the genotoxic drugs by themselves.  
In general, our findings address the need for regular biomonitoring of personnel 
occupationally exposed to formaldehyde and cytostatics. Although biological monitoring in 
many circumstances is complicated with assay sensitivity, costs and interpretation of results, it 
should be a necessary requirement at least in cases of accidental exposure (Kopjar et al., 
2009). The risk to health is influenced by the extent of the exposure and the potency and 
toxicity of the hazardous. To provide maximum protection to workers, employers should 
assure that workers implement safety procedures and use proper protective equipment for 
handling hazardous drugs (NIOSH, 2004).         
Given the constant introduction of an increasing variety of chemical and physical agents in 
occupational settings, it is reasonable to anticipate that the risks for workers will be even 
higher in the future. However, the spectrum and specificity of biomarkers available also 
increased considerably in the recent years, allowing for a more efficient and accurate 
prediction of individual risk (Kopjar et al., 2009). To our knowledge, the current practice in 
Portuguese hospitals does not include regular monitoring of the workplace, but to ensure 
maximal occupational safety for those daily exposed, periodic biomonitoring is recommended. 
Biomonitoring studies will continue to build an understanding of the consequences of people’s 
exposure to toxic environmental chemicals. Nonetheless these data will not obviate the need 
to collect other kinds of relevant information – to monitor sources of pollution, to conduct 
surveys of toxic substances in the environment, and to study human activities and behaviours 
that contribute to exposure. Moreover, further research in toxicology and epidemiology is 
necessary before specialists can interpret the health significance of exposure biomarkers for 
the majority of environmental chemicals. As detection methods improve – enabling 
investigators to measure lower concentrations of more chemicals from smaller samples at less 
cost – scientific understanding of what the body does to the chemical (and vice versa) must 
keep pace with new environmental challenges. If this effort is successful, a full screen of 
exposure biomarkers may be a part of every routine physical exam in the not-too-distant 
future (Sexton et al., 2004). A challenge for toxicology is to utilize the available knowledge of 
the extensive genetic variation in individual susceptibility by integrating it in the evaluation of 
exposure related risk (Mohrenweiser, 2004). 
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The main conclusion of this investigation is that it is possible and necessary to implement 
human biomonitoring programmes in occupational exposure contexts. The biomonitoring 
programme should include biomarkers of exposure, effect, and susceptibility. Known possible 
confounding factors should also be addressed, namely diet and habits, into a whole integrated 
package aimed at preventing disease.  
 
2. LIMITATIONS 
Common limitations are sample size, usually too small to evaluate rare polymorphisms, and 
the wide range of allele frequency variation for each loci in different ethnic populations. The 
statistical analysis is often plagued with problems of lack of power (due to insufficient sample 
size) and confounding can seldom be precluded given the amount of potential factors involved 
that have not been measured (Hunter, 2005; Chung et al., 2010).    
The self-reported dietary data used here was subject to both random and systematic bias and 
because blood was collected at only one point in time, seasonal variability in antioxidant 
intakes could not be assessed. Nonetheless, the results using self-reported and biological 
measures of diet were comparable, and the coefficients of variation for the laboratory assays 
were within acceptable standards. 
The capacity for DNA repair activity was not measured; thus these estimates represent the 
oxidative DNA damage level only at time of collection.  
Although several covariates were controlled, residual confounding is still a concern. The fact 
that our study population consisted of generally healthy volunteers, may limit generalization. 
Finally, due to the cross-sectional nature of this study, it was not possible to examine changes 
in oxidative DNA damage over time and no conclusions concerning causality could be drawn.  
 
 
 
3. FUTURE PERSPECTIVES 
 
Molecular biomonitoring provides an opportunity to address certain issues of exposure, 
susceptibility, and risk in diet-associated human carcinogenesis (Strickland & Goopman, 1995). 
Molecular epidemiologic approaches, coupled with bioinformatics, will provide important 
evidence for the role of specific dietary mutagens in certain human cancers. Optimizing 
nutritional approaches towards the reduction of mutagenesis will require the innovative 
application of many of the newer technologies which are becoming available. Nutrition and 
food carcinogens continue to be a most challenging subject for research towards cancer 
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control (Sugimura, 2000). The interaction between diet and risk of cancer is a hugely 
important research area, and even a brief review of the literature shows that there are 
thousands of foodstuffs, micronutrients, phytochemicals and other dietary factors being 
investigated for their effect on carcinogenesis. Yet in many cases, the molecular mechanisms 
through which various nutrients might enhance or protect against carcinogenesis are still 
unknown. In this respect, the development and optimization of biomarkers suitable for use to 
investigate the molecular effects of dietary factors in human trials, animal studies and in vitro 
studies is of great importance (Ferguson & Philpott, 2008; Wasson et al., 2008).    
Although it is not possible to entirely avoid mutagenic food components or certain dietary 
regimes, rational developments of antimutagens as chemopreventive agents, coupled with 
technologies appropriate to nutrigenomics, lead to an optimistic outlook for the future 
drawing of personalized nutrition plans, aimed at protecting against diet-related mutagenesis 
(Ferguson & Philpott, 2008). 
Prevention of DNA damage and/or enhanced DNA repair activity by dietary agents constitutes 
an important strategy to prevent mutations and consequently inhibit the carcinogenic process 
(Ramos et al., 2011). With more research, we will develop a better understanding of the 
mechanisms by which specific micronutrients regulate normal cell function, and how their 
deficiencies can alter normal metabolism. “Tuning-up” human metabolism, which varies with 
genetic constitution and changes with age, could prove to be a simple and inexpensive way to 
minimize DNA damage, prevent cancer, improve health and prolong a healthy lifespan (Ames 
& Wakimoto, 2002). 
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QUESTIONÁRIO 
 
Secção I – Identificação 
 
1.1. Género: M     F  
 
1.2. Idade:· 
     
1.3. Nome: ______________________________________________________ 
(Apenas para identificação da exposição) 
 
Secção II – Historial Social 
 
2.1. Carga tabágica 
 
- Fuma ou alguma vez fumou? Sim     Não  
- Se sim, com que idade começou a fumar regularmente? ____ anos 
- Continua a fumar?   Sim     Quantos cigarros por dia?  ____ 
Não     Quando parou de fumar?   ____ 
2.2. Consumo de álcool 
Com que frequência consome álcool? __________ 
Qual a quantidade que consome? _____________ 
 
 
Secção III – Historial Ocupacional 
 
3.1. Presente Ocupação 
 
Área de Trabalho: _____________________ 
 
Função exercida: ______________________ 
 
Função exercida há ____anos 
 
Descrição do tipo de trabalho: 
_______________________________________________________________ 
_______________________________________________________________ 
 
Tempo de actividade na empresa: _________ (anos) 
 
Existe exposição ao formaldeído no seu posto de trabalho? Sim     Não  
 
Se sim passe para o ponto 3.2. 
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Se não passe para o ponto 3.3. 
 
 
3.2. Exposição ao formaldeído no local de trabalho 
 
3.2.1. Ocupações ou actividades exercidas actualmente com exposição ao formaldeído. 
 
Função exercida 
Horas 
por dia 
Dias por 
semana 
1    
2    
3    
3.2.2. Ocupações ou actividades exercidas anteriormente com exposição ao formaldeído 
 
 Função exercida Horas 
por dia 
Dias por 
semana 
De… a …. 
(anos) 
1         
2     
3     
4     
 
 
3.3. Exposição a outros produtos no local de trabalho 
Considera estar exposto a algum destes produtos? 
 
- Fenol      
- Metanol     
- Ácido acético    
- Soda cáustica    
- Ácido clorídrico   
- Hipoclorito de sódio   
(lixívia) 
- Partículas     
 
Secção IV – Susceptibilidade individual 
 
4.1. Tem, ou teve, alguma doença respiratória? Sim     Não  
Se sim, qual? __________________________________ 
Toma alguma medicação? Sim     Não  
Se sim, qual? __________________________________ 
Human Biomonitoring: Biomarkers, Individual Susceptibility, and Nutrigenetics  
 
xlv 
 
 
4.2. Tem, ou teve, alguma dificuldade respiratória? Sim     Não  
Se sim, qual? _________________________________ 
Toma alguma medicação? Sim     Não  
Se sim, qual? _________________________________ 
 
4.3. Tem, ou teve, alguma doença oncológica? Sim     Não  
Se sim, qual? _________________________________ 
Toma alguma medicação? Sim     Não  
Se sim, qual? _________________________________ 
4.4 Existem doenças oncológicas em familiares directos?  
Sim     Não  
Se sim, quais? ________________________________ 
4.5. Toma algum suplemento alimentar? 
Sim    Não    
Se sim, quais? ________________________________ 
 
4.6. Toma presentemente algum dos seguintes medicamentos? 
Sim    Não    
Se sim, quais? 
 
            Folifer 
            Neurobion 
 Folacin 
 Outro________________________________ 
 
Secção V – Equipamento de Protecção Colectiva  
 
Existem medidas de protecção colectiva? Sim     Não  
Se sim, quais?  
 Sistema de exaustão de ar?     Sim     Não  
 Sistema de insuflação de ar?   Sim     Não  
 Sistema de climatização?         Sim     Não  
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Secção VI – Equipamento de Protecção Individual 
 
Utiliza equipamento de protecção individual? Sim     Não  
Se sim, especifique: 
Botas de protecção: Sim     Não  
Luvas: Sim     Não  
Máscara das vias respiratórias: Sim     Não  
Óculos de protecção: Sim     Não  
Vestuário adequado: Sim     Não      
Protectores auriculares: Sim     Não  
Capacete: Sim     Não  
 
Secção VII – Tempos Livres 
 
Que tipo de actividades desenvolve para além da sua actividade profissional? 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________. 
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Exma. Senhor(a) 
Dr. (a designar) 
Director(a) de Serviços Farmacêuticos 
Centro Hospitalar de Lisboa Ocidental  
 
 
ASSUNTO: Exposição Profissional a Citostáticos: caracterização da exposição em Unidades 
Hospitalares Portuguesas. 
 
A Escola Superior de Tecnologia de Saúde de Lisboa, em parceria com a Escola Nacional de 
Saúde Publica, encontra-se neste momento a desenvolver um estudo sobre a Exposição 
Profissional a Citostáticos, o qual é suportado pela Autoridade para as Condições do Trabalho. 
Os citostáticos constituem um grupo farmacoterapêutico que interfere por vários mecanismos 
de acção com o DNA, levando à destruição celular. Estes agentes terapêuticos são preparados 
diariamente em Unidades Hospitalares Portuguesas, e posteriormente, usados no tratamento 
de várias doenças, nomeadamente neoplasias. A toxicidade destes medicamentos sobre o 
organismo dos indivíduos expostos manifesta-se a níveis diversos com gravidades distintas, 
incluindo efeitos adversos como a mutagénese, a teratogénese e a carcinogénese. Apesar da 
utilização de equipamentos de protecção, os operadores envolvidos na manipulação destes 
fármacos, nomeadamente os técnicos de farmácia, farmacêuticos e enfermeiros, podem estar 
expostos de forma significativa a este factor de risco. 
Estudos realizados demonstraram que a maioria das superfícies das áreas de trabalho em que 
os citostáticos são manipulados está contaminada promovendo o contacto com a pele e 
eventual absorção. No que concerne à exposição por via aérea, esta tem sido pouco estudada, 
mas julga-se poder ser uma realidade e contribuir de forma significativa para a dose absorvida. 
Embora ainda insuficiente, a investigação desenvolvida recentemente tem-se centrado na 
necessidade de desenvolver conhecimento não só sobre os efeitos para a saúde mas também, 
a enfatizar a criação de programas de prevenção e vigilância da saúde. 
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Neste contexto, pretende-se realizar um estudo em Unidades Hospitalares Portuguesas, 
aprofundando 3 vertentes essenciais: a caracterização da exposição, os critérios de avaliação 
das repercussões sobre o organismo, e os processos de organização dos programas 
preventivos. 
Este estudo que se propõe pretende contribuir para a caracterização da exposição a 
citostáticos num contexto profissional específico (salas limpas da Farmácia Hospitalar e 
Serviços de Internamento), identificando os factores que a condicionam e os eventuais efeitos 
para a saúde dos trabalhadores decorrentes dessa exposição. 
É neste sentido que vimos por este meio solicitar a V. Ex.ª autorização para que o trabalho 
possa ser realizado nos Serviços Farmacêuticos do Hospital de São Francisco Xavier, de cujo 
serviço V. Ex.ª é Directora, comprometendo-nos, naturalmente, a fornecer todos os resultados 
obtidos e as nossas próprias reflexões sobre eles, podendo os mesmos ser utilizados para os 
fins que se entenda convenientes. O estudo será ainda apresentado à Administração do 
Hospital bem como à Comissão de Ética. 
Todos os indivíduos que participem serão informados dos objectivos do estudo, sendo 
explicado que têm a possibilidade de não participar. Será solicitado o consentimento 
informado por escrito para pesquisa dos meios biológicos propostos. 
Os resultados obtidos serão facultados às Unidades Hospitalares na forma de relatório técnico 
onde constam os resultados das monitorizações ambientais e as propostas de medidas de 
eliminação e/ou controlo do risco. 
Agradecendo antecipadamente a atenção dispensada a este assunto, enviamos os melhores 
cumprimentos, 
 
P’la Equipa de Investigação 
A Coordenadora 
___________________________ 
Susana Viegas 
(susana.viegas@estesl.ipl.pt ) 
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TERMO DE CONSENTIMENTO INFORMADO 
 
 
 
A Escola Superior de Tecnologia da Saúde de Lisboa encontra-se a desenvolver um projecto de 
investigação com o tema: “Caracterização da Exposição ao Formaldeído e Conhecimento dos 
Eventuais Efeitos na Saúde”.  
Este projecto tem como objectivos primordiais a caracterização da exposição deste agente 
químico em diversas situações de trabalho, bem como a investigação de eventuais efeitos 
genotóxicos. 
De modo à concretização dos nossos objectivos, pretendemos recolher amostras de sangue 
periférico e tecido epitelial do interior da cavidade bucal a indivíduos expostos 
profissionalmente a formaldeído. 
A metodologia a utilizar é a referenciada por diversos autores, que tem como objectivo 
analisar detalhadamente a exposição dos trabalhadores ao formaldeído e, consequentemente, 
contribuir para minimizar essa exposição. 
 
Acresce-se que a privacidade assim como a completa confidencialidade dos dados obtidos 
será assegurada. 
Se tiver alguma dúvida poderá esclarece-la com as responsáveis pelo projecto. Obrigada pela 
atenção e disponibilidade. 
 
 
Eu, _______________________________________________________________ (preencha 
com o seu nome completo), dou o meu consentimento livre e informado, para participar na 
realização da colheita acima referidas, autorizando posterior uso e publicação dos dados. 
      
Data ___/___/___                                     
 
Assinatura 
 
                                                                       __________________________ 
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